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 ABSTRACT 
Large, low copy number plasmids, such as those harboring antibiotic resistance 
genes, often possess plasmid maintenance systems to ensure their persistence and 
inheritance in a bacterial population.  One example is the proteic toxin-antitoxin (TA) 
system, consisting of a toxin and an antitoxin encoded in a single operon.  When 
expressed, the antitoxin binds to and neutralizes the toxin.  However, if during cell 
division a plasmid-free daughter cell arises, the labile antitoxin is rapidly degraded, 
freeing the toxin to kill the cell.  If TA systems are prevalent and functional in clinically 
relevant bacteria, they could be exploited as a novel antimicrobial strategy: a small 
molecule capable of relieving the neutralizing effect of the antitoxin would free the toxin 
to kill the cell.  This thesis research has, in part, focused on defining the prevalence of TA 
systems in clinical isolates of vancomycin-resistant enterococci and methicillin-resistant 
S. aureus to validate TA systems as an antibacterial target.  Two TA systems, Axe-Txe 
and RelBE, were found to be common among the pathogenic bacteria surveyed and were 
therefore further investigated.  A cell-based high-throughput assay was developed to 
screen for small molecules that induce toxin-dependent cell death in E. coli expressing 
RelBE.  Additionally, mechanistic studies were performed to determine the mode of 
action by which the Txe toxin causes cell death. 
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CHAPTER 1 
ANTIBIOTIC RESISTANCE AND TOXIN-ANTITOXIN SYSTEMS IN 
CLINICALLY IMPORTANT BACTERIA 
Sections from Chapter 1 have been reproduced from “The Prevalence of Plasmids 
and Other Mobile Genetic Elements in Clinically Important Drug-resistant Bacteria, in 
Antimicrobial Resistance in Bacteria” Moritz, E.M. and P.J. Hergenrother.  2007, C.F. 
Amabile-Ceuvas, Editor.  Horizon Scientific Press:  Great Britain. p. 25-53.   
 
1.1  ANTIBACTERIAL THERAPY AND RESISTANCE 
By the mid-twentieth century antibiotics had dramatically changed the face of 
human health.  No longer were the scourges of history such as syphilis and tuberculosis 
the menace they once posed to humanity [52, 115, 148, 163, 255].  Many prominent 
scientific figures declared infectious disease all but conquered and their further study 
purely academic [197, 240].  However, this “golden age” of antibiotic is now over.  
Infectious bacteria now exist that are resistant to virtually all clinically used antibiotics, 
severely complicating treatment strategies.     
Bacterial resistance to antibiotics has become a global problem in the treatment of 
Gram-negative and Gram-positive infections.  Major nosocomial pathogens (streptococci, 
enterococci, staphylococci, and Enterobacteriaceae) are resistant to many antibiotics, 
including such stalwarts as β-lactams, quinolones, glycopeptides (particularly 
vancomycin), and macrolides.  The genetic determinants mediating resistance to these 
commonly prescribed drugs are sometimes carried on the bacterial chromosome and 
spread through cell division and clonal disseminantion.  However, they also can reside on 
mobile genetic elements (such as plasmids and transposons) that are capable of direct 
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transfer to assorted bacterial species (Figure 1.1).  This transfer of a mobile genetic 
element from one bacterium to another is often termed horizontal (or lateral) DNA 
transfer, to differentiate it from the more standard vertical DNA transfer that takes place 
during cell division.  These mobile elements often carry several antibiotic resistance 
genes, and thus their transfer results in immediate multidrug resistance in recipient 
strains.  Widespread antibiotic use has facilitated the emergence of bacteria that resist the 
preferred antibiotic treatment.  The rapid development and dissemination of antibiotic 
resistance can be partly attributed to the exchange of mobile genetic elements among 
bacterial populations. 
 
1.1.1  Mobile Genetic Elements and Antibiotic Resistance 
Direct exchange of genetic information between microbes, both within and 
outside species, allows bacterial populations to develop antibiotic resistance at a rate 
significantly greater than would be afforded by mutation of chromosomal DNA.  Thus, 
the vehicles for the dissemination of antibiotic resistance determinants (transferable 
genetic elements including plasmids, transposons, and integrons) are of considerable 
medicinal interest and importance. 
Transmissible plasmids provide a highly efficient means of horizontal gene 
transfer through a process called conjugation.  During bacterial conjugation, the cell 
surface of donor and recipient bacteria come into direct physical contact to form a bridge 
that allows transfer of conjugative plasmids from the donor to the recipient cell (Figure 
1.1A) [90, 145].  Many conjugative plasmids have been shown to confer resistance to a 
variety of antibiotics.  Perhaps even more insidious is their demonstrated capacity to 
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transfer to a wide range of bacteria [125, 176, 209, 265].  As such, conjugative plasmids 
are likely a primary factor in the emergence and increase in multidrug-resistant bacteria. 
Some plasmids are not conjugative, but rather are termed mobilizable.  Such 
plasmids can be transferred to a recipient if the conjugative functions are provided by a 
separate self-transmissible plasmid that is also harbored within the bacteria (Figure 
1.1B).  Mobilizable plasmids have not been as thoroughly studied as conjugative 
plasmids but may be equally responsible for the spread of antibiotic resistance genes and 
development of multidrug-resistant bacteria [24, 61, 74].  Thus both transmissible and 
mobilizable plasmids are transferable between bacteria; however, it should be noted that 
not all plasmids are transferable.  Plasmids are referred to as non-transmissible if they 
cannot induce conjugative mating or be mobilized into a recipient cell; these plasmids are 
not typically transferred between bacteria. 
Transposons and integrons are mobile DNA elements that can insert into the 
chromosome or plasmids of bacteria.  Transposons associated with antibiotic resistance 
fall into three major classes based on their general structure and method of insertion.  The 
first two classes consist of composite and noncomposite transposons that integrate into 
target DNA by generating direct repeats in the target sequence (Figure 1.1C).  
Composite and noncomposite transposons typically contain genes that are not essential 
for their transposition (such as antibiotic resistance genes) in between flanking terminal 
insertion sequences (composite) or inverted repeats (noncomposite).  Because 
transposition can involve excision and transfer of the entire element, such transposons are 
important in the spread of antibiotic resistance genes [79, 205].  
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Figure 1.1  Methods of genetic transfer by mobile DNA systems. 
The third class, defined as conjugative transposons, are capable of excision from 
the chromosome or a plasmid of the donor cell to transfer DNA via conjugation into a 
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recipient bacterium (Figure 1.1D).  Conjugative transposons have a broad host range and 
their transfer is not constrained to closely related bacteria; this has been demonstrated by 
the Tn916-Tn1545 family of transposons, which have been found or introduced into 50 
different species and 24 genera of bacteria encompassing both Gram-negative and Gram-
positive bacteria [46].  Transfer of a conjugative transposon begins with excision of the 
transposon from either the bacterial chromosome or plasmid DNA.  The transposon DNA 
circularizes and conjugative transfer of a single-stranded DNA copy to the recipient cell 
proceeds in a manner identical to plasmid conjugation.  A wide variety of antibiotic 
resistance genes have been discovered on large conjugative transposons, and they are 
thought to be a significant contributor to the spread and increase of antibiotic resistance 
in bacteria [31, 98, 221]. 
Finally, antibiotic resistance can also be carried and transmitted by integrons.  
These mobile genetic elements consist of an integrase gene, two promoters transcribing 
in opposite directions, and an array of other genes, which often contain antibiotic 
resistance genes (Figure 1.1E).  Integrons differ from transposons in that integrons 
possess a site-specific recombination system and do not randomly excise or insert into 
DNA regions.  Importantly, many antibiotic resistance genes have been found as part of 
integrons and such gene cassettes are capable of insertion and excision from other mobile 
genetic elements or the bacterial chromosome.  Thus, resistance determinants present on 
some transposons and plasmids may be the result of integron insertion [72]. 
In summary, plasmids are a major culprit in the resistance of bacteria to multiple 
antibiotics.  This plasmid-encoded resistance can be due to conjugative or mobilizable 
plasmids, or can be the result of the acquisition of transposons and/or integrons that have 
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integrated into the plasmid DNA.  The rapid emergence of bacterial populations resistant 
to multiple antibiotics can be therefore largely attributed to a triumvirate of mobile 
genetic elements:  plasmids, transposons and integrons. 
 
1.1.2  Examples of Antibiotic Resistance Encoded on Mobile Genetic Elements 
 The spread of antibiotic resistance determinants in some of the most clinically 
important drug-resistance pathogens can, in part, be attributed to horizontal gene transfer.  
More and more studies are helping to define the role of plasmids and transposons in the 
emergence of β-lactam and quinolone-resistant Enterobacteriaceae, vancomycin 
resistance in enterococci and staphylococci, and macrolide and tetracycline resistance in 
strepotococci.  Surveillance of clinical isolates has repeatedly identified these bacterial 
pathogens among the most frequent causes of infections in the U.S. and worldwide [23, 
85, 170, 273, 274].  Additionally, these bacteria have surfaced as difficult-to-treat 
pathogens due to the acquisition of plasmids and transposons that confer drug resistance.  
 In general, the acquisition of mobile genetic elements has allowed certain 
pathogenic bacteria to thrive in hostile, antibiotic-ridden environments.  As such, 
plasmid- and transposon-encoded resistance has reduced the effectiveness of many 
antibiotics.  However, bacteria harboring resistance-mediating mobile genetic elements 
also afford a unique opportunity and present potentially novel targets for new antibiotics.   
 
1.1.2a  Extended-spectrum β-lactamase production in Enterobacteriaceae 
 β-lactam antibiotics have long been among the most commonly prescribed 
antibacterial drugs due to their wide spectrum of activity, clinical effectiveness, and low 
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toxicity [19].  Pictured in Figure 1.2 are representative members of the different classes 
of β-lactams.   Unfortunately, the utility of β-lactam antibiotics has been tempered by the 
evolution and spread of resistance-mediating enzymes.  This is most evident in the 
treatment of infections caused by the family Enterobacteriaceae, specifically Escherichia 
coli and Klebsiella pneumoniae.  Antibiotic treatment choices have become complicated 
by the ability of these organisms to produce extended spectrum β-lactamases (ESBLs).  
ESBLs are capable of catalyzing the hydrolysis of the β-lactam bond in commonly 
prescribed β-lactam antibiotics such as broad-spectrum cephalosporins, monobactams, 
and penicillins [157].  The hydrolyzed antibiotics are ineffective as antibacterial agents. 
 
Figure 1.2  Structures of representative compounds from different β-lactam classes.  (A and B) penicillin 
class, (C) carbapenem class, (D and E) cephalosporin class, and (F) monobactam class. 
 
In 1983, a plasmid-encoded β-lactamase conferring resistance to extended-
spectrum cephalosporins was reported in Europe [128].  Since that time several hundred 
ESBLs have been characterized; the web site http://www.lahey.org/studies.webt.htm 
provides up-to-date and detailed descriptions of known ESBLs.  ESBL-producing 
organisms have spread worldwide and have emerged as significant community- and 
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hospital-acquired pathogens.  In the Enterobacteriaceae family, ESBL-producing 
organisms are often also resistant to sulfonamides, trimethoprim, fluoroquinolones, and 
aminoglycosides [21, 123, 124, 147, 155, 176].  While the genes for some β-lactamases 
reside on the chromosome, a growing cadre of ESBLs have been found to be plasmid-
encoded [121, 138, 144, 176, 229].  Such plasmids have likely facilitated the rapid spread 
and emergence of ESBLs throughout Enterobacteriaceae.   
Although a palette of ESBLs exist, the majority of clinical isolates of K. 
pneumoniae and E. coli produce one of three varieties:  SHV-type, CTX-M-type, or 
TEM-type [142, 143, 199, 213].  SHV is an abbreviation for sulfhydryl variable, and 
TEM refers to the first report of TEM-1 in E. coli isolated from a patient named 
Temoneira [54].  The majority of TEM-type ESBLs are encoded on large plasmids.  The 
transmissibility of these elements is evident in their dissemination throughout the 
Enterobacteriaceae and non-Enterobacteriaceae Gram-negative bacteria [151, 166, 188, 
196, 228].  The TEM-type ESBLs evolved from the narrow-spectrum β-lactamases TEM-
1 and TEM-2, which confers resistance to ampicillin, penicillin and first-generation 
cephalosporins.  Production of TEM-type ESBLs by a bacterium allows the cell to 
hydrolyze extended-spectrum cephalosporins and aztreonam while still retaining the 
ability to hydrolyze the classic TEM substrates mentioned above. 
 More recently, the CTX-M enzymes have been recognized as a rapidly growing 
class of ESBLs.  The CTX-M β-lactamases do not fall under the headings of TEM- or 
SHV-type ESBLs because of their greater hydrolytic activity against cefotaxime (CTX) 
and increased susceptibility to inhibitors like clavulanate, sulbactam and tazobactam.  
The CTX-M family includes more than 90 different enzyme types and five 
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subclassifications based on amino acid sequence.  In each CTX-M group a number of the 
enzymes have been found on plasmids residing within drug-resistant bacteria [25].  The 
types of plasmids CTX-M genes reside on are often conjugative and can vary greatly in 
size, ranging from 7 to 160 kb [29, 122].  CTX-M-encoding plasmids may also carry the 
genes for TEM-type and SHV-type ESBLs, and the bacterium itself will often also carry 
genes for resistance to a variety of other antibiotics.  Concern over limited treatment 
options continues to grow as reports document the rapid spread of CTX-M-producing 
strains in difficult-to-treat infections [32, 37, 144, 156].   
 Despite the major threat that ESBL production poses to the efficacy of current 
antibiotic treatments, precise information of the genetic elements responsible for ESBL 
dissemination throughout Enterobacteriaceae populations is lacking.  It is known that 
large, broad host range plasmids belonging to the incompatability groups IncA/C and 
IncL/M are commonly associated with ESBL genes [106, 121, 150, 176, 234, 259].  
Incompatibility groups consist of bacterial plasmids unable to coexist in the same cell, 
and only plasmids of different incompatibility groups can exist together in a host [177].  
It is clear that ESBL types most often carried on plasmids are easily transferred between 
bacteria, and an individual plasmid may be disseminated across whole regions.  Such a 
case was reported in Chicago hospitals and nursing homes where a large conjugal 
plasmid expressing the ESBL TEM-10 was isolated from various patients colonized or 
infected with ceftazidime-resistant E. coli or K. pneumoniae.  Plasmid analysis of the 
isolates (which were several different strain types) revealed that 17 of the 20 patients 
harbored a 54-kb plasmid that conferred resistance to ceftazidime, trimethoprim-
sulfamethoxazole, gentamicin, and tobramycin [28, 269]. 
 
 
10 
 
 In another instance, a large conjugative plasmid (180 kb) expressing the ESBL 
TEM-24 was discovered to exist in four different species of Enterobacteriaceae isolated 
from a single patient hospitalized over 4 months in an ICU in France.   The four ESBL-
producing species were Enterobacter aerogenes, Proteu mirabilis, K. pneumoniae,  and 
Providencia rettgeri, all of which contained the same 180-kb plasmid encoding TEM-24 
[151].  While it is unknown if the 54-kb and 180-kb plasmids are related, it does appear 
that ESBL-producing plasmids are often large (≥ 30 kb), conjugative, and able to transfer 
among a variety of Gram-negative bacterial species.  This commonality may allow for the 
development of tailored antibacterials for Enterobacteriaceae that are antibiotic resistant 
by virtue of plasmid-encoded ESBLs. 
 
1.1.2b  Plasmid-mediated quinolone resistance in Enterobacteriaceae 
 Quinolones and β-lactams are among the most commonly prescribed front-line 
antibiotics for treatment of infections caused by enterobacterial organisms.  While the 
prevalence of plasmid-encoded β-lactamases in Enterobacteriaceae has been documented 
(as discussed in the previous section), until recently most quinolone resistance in 
Enterobacteriaceae had been due to chromosomal mutations.  However, plasmid-
mediated quinolone resistance in Enterobaceriaceae was first discovered in 1994 and is 
now observed with increasing regularity.  Displayed in Figure 1.3 are the structures of 
representative members of the quinolone and fluoroquinolone families of antibiotics. 
 Quinolone resistance in Enterobacteriaceae typically arises through chromosomal 
mutations in the genes for DNA gyrase and topoisomerase IV, the targets of quinolone 
drugs.  Chromosomal mutations that cause increased expression of efflux pump systems 
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responsible for expelling antimicrobials and reductions in the porins that allow 
quinolones to cross the cytoplasmic membrane can also act synergistically to increase the 
level of quinolone resistance [101]. 
 
Figure 1.3  Structures of representative compounds from the (A and B) quinolone antibiotics and (C) 
fluoroquinolone antibiotics. 
 
 While chromosomally encoded quinolone resistance is common in 
Enterobacteriaceae, plasmid-mediated resistance was first discovered in 1994 in a 
clinical isolate of K. pneumoniae.  The findings, published in 1998, described a 56-kb 
plasmid encoding multidrug resistance (pMG252) that could transfer to a wide range of 
other Enterobacteriaceae and P. aeruginosa [153].  Additionally, plasmids differing from 
pMG252 were also found to confer plasmid-mediated quinolone resistance in an E. coli 
isolate, four K. pneumoniae isolates, and one Klebsiella spp. collected from the same 
institution [105].  The presence of the broad host range plasmid, pMG252, increased 
quinolone resistance in susceptible strains from eightfold to 64-fold with the highest 
transferable resistance generally to nalidixic acid.  It was also observed that acquisition of 
the quinolone resistance plasmid, which itself conferred low-level resistance, increased 
selection for higher quinolone resistance in a bacterial population, presumably by 
allowing secondary mutations to occur on the chromosome [153].  Later studies have 
shown that chromosome and plasmid-mediated quinolone resistance determinants 
together may have additive effects to further enhance resistance [152].  Plasmid pMG252 
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was initially identified because of its broad resistance to β-lactams and a multitude of 
other antibiotics such as aztreonam, ceftazidime, cefotaxime, cefoxitin, chloramphenicol, 
kanamycin, gentamicin, streptomycin, tobramycin, and trimethoprim [153].  Since then, 
plasmids encoding ESBLs and mediating multidrug resistance have been reported in such 
geographically diverse areas as the U.S., China, Europe, and Japan [149, 179, 276].  It 
has been suggested that this is the result of a genetic linkage on the plasmids between 
resistance to extended spectrum β-lactams and quinolones [110, 179, 261]. 
 The plasmid-mediated quinolone resistance determinant, now called QnrA, has 
been detected in Citrobacter freundii, E. coli, Enterobacter cloacae, Enterobacter 
sakazakii, K. pneumoniae,  and K. oxytoca, demonstrating the apparent broad host range 
of plasmids carrying a QnrA determinant [48, 101, 114, 149, 171, 200, 210, 262].  
Isolation and characterization of qnr plasmids from Enterobacteriaceae isolates has 
revealed often strong similarities with the representative qnrA-bearing plasmid, pMG252, 
in terms of their conjugative ability, large size (54 kb to greater than 180 kb), antibiotic 
resistance profile, and restriction digest pattern [201, 210, 261].  In a screen of 110 
clinical isolates of K. pneumoniae and E. coli from the U.S., Wange et al. (2004) detected 
the qnr gene in 8 (11.1%) of the K. pneumoniae strains.  Of these eight strains, seven 
carried the qnr gene on conjugative plasmids that additionally produced β-lactamases.  
Size and restriction digests showed four of the plasmids to be highly related to plasmid 
pMG252 [261].  A year later, a second survey for the qnrA gene in Enterobacteriaceae 
reported identical quinolone-resistant plasmids in four Enterobacter isolates that were 
large in size (greater than 150 kb), conjugative, and mediating resistance to the same 
range of antibiotics as pMG252 [210].  These studies suggest that the plasmids 
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responsible for quinolone resistance in Enterobacteriaceae may be closely related and 
continually selected for in the clinical setting through the use of quinolones and β-lactam 
antibiotics. 
 It was also found that qnrA-like genes reside in In4 family class 1 integrons and 
that these complex sul1-type integrons are commonly localized on plasmids carrying 
other resistance genes against antibiotics such as aminoglycosides, chloramphenicol, 
sulfonamides, quaternary ammonium compounds, and most often extended-spectrum β-
lactams [141, 149, 153, 187, 211].  The reason for the tendency of plasmid-mediated 
ESBLs and quinolone resistance to co-localize remains unclear, but it may explain the 
recent emergence of both types of drug resistance in the Enterobacteriaceae family.   
 
1.1.2c  Macrolide and tetracycline resistance in Streptococcus pneumoniae 
Streptococcus pneumoniae is an important Gram-positive bacterial pathogen 
responsible for pneumococcal infections such as bacterial pneumonia, otitis media, 
sinusitis, and bacteremia, and is one of the leading causes of illness and mortality 
worldwide [104, 178].  The emergence and spread of penicillin-resistant S. pneumoniae 
in the 1960s led physicians to use macrolides as an alternative therapeutic; however, 
during the last two decades resistance to commonly prescribed macrolides (such as 
erythromycin) has become a serious concern [2, 9, 87, 198].  The structures of several 
representative members of the  macrolide family are shown in Figure 1.4.  Unlike 
antibiotic resistance previously discussed in this chapter, streptococcal antibiotic 
resistance determinants are typically encoded on conjugative transposons instead of 
plasmids.  For example, the association of erythromycin resistance in S. pneumoniae with 
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tetracycline resistance is often due to tetracycline and macrolide resistance genes residing 
on the same highly mobile conjugative transposon, Tn1545 [46, 50, 230].  Today, 
pneumococcal strains with resistance to macrolides and tetracycline can be found in the 
U.S., Europe, and Asia [2, 11, 129, 230].  As a result of their prevalence, treatment of 
multidrug-resistant pneumococcal infections is becoming increasingly difficult 
throughout the world. 
 
Figure 1.4  Structures of representative compounds from the macrolide antibiotics.  (A) Erythromycin A, 
and its more biologically stable derivatives including (B) the 14-membered ring macrolide clarithromycin, 
(C) 15-membered ring azalide, azithromycin. 
 
Two macrolide resistance phenoytpes are predominant in clinical isolates of S. 
pneumoniae, M and MLSB [69, 208].  The M phenotype is characterized by resistance to 
primarily 14- and 15-membered macrolides through the activity of an efflux pump that is 
encoded by the mef(A) gene class [245].  The mef(A) gene is contained in either the 
chromosomal element, Tn1207.1, a defective transposon, or another chromosomal 
insertion element called the macrolide efflux genetic assembly (mega) [7].  S. 
pneumoniae strains with the M phenotype are most commonly isolated in the U.S. and 
South-East Asia [69, 233, 237].  Thus the mef(A) genes are usually located on 
conjugative elements on the chromosome, but are capable of conjugal transfer to other 
bacteria. 
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In contrast to the efflux pump that gives rise to the M phenotype, macrolide 
resistance through the MLSB phenotype is mediated by target site modification.  In this 
case, a methylase encoded by the erm(B) gene methylates the 23S rRNA, a modification 
that dramatically lowers the affinity of the macrolides for the ribosome [267].  
Methylation of 23S rRNA by the erm(B) gene product provides co-resistance to 
macrolide, lincosamide, and streptogramin B antibiotics and is often associated with 
tetracycline resistance (tet(M)) [135, 162, 230].  The frequent association of erythromycin 
and tetracycline resistance may be due to the presence of both the erm(B) and tet(M) 
genes on the same 25.3-kb conjugative transposon, Tn1545, found inserted into the 
chromosome of MLSB isolates.  The Tn1545 transposon is related to a larger class of 
transposons typified by Tn916, and is conjugative, self-transferable, and encodes tet(M)-
mediated tetracycline resistance [50].  The transferable nature of the Tn1545 transposon 
may account for the rapid emergence and spread of MLSB and tetracycline resistance 
among S. pneumoniae given the increasing occurrence of the MLSB phenotype mediated 
by Tn1545 in isolates from European and Asian countries [230, 237]. 
For example, a study from Japan examined the prevalence of the erm(B), mef(A), 
and tet(M) genes on conjugative transposons in isolates of S. pneuomoniae and found that 
the prevalence of both macrolide resistance mechanisms are roughly equal.  However, up 
to 90% of the isolates with erm(B) or mef(A) also carried a Tn1545-like element, strongly 
suggesting that such conjugative transposons have been a factor in the spread of 
pneumococcal strains resistant to macrolides in Japan [232].  In another study from Italy, 
65 erythromycin and tetracycline-resistant clinical isolates of S. pneumoniae were found 
to consist of a variety of serotypes, but 62 of the 65 strains contained the integrase gene 
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of the Tn1545 transposon family.  The extent to which the isolates were unrelated and the 
prevalence of the conjugative transposon suggests that a Tn1545-like element may be 
responsible for erythromycin and tetracycline co-resistance in the majority of 
pneumococci in Italy [162].  Other countries, such as France, Spain, Belgium, Brazil, and 
the U.S., have also seen a rise in the number of pneumococcal strains exhibiting 
erythromycin and tetracycline co-resistance, with up to 60-80% of all erythromycin-
resistant isolates also resistant to tetracycline [2, 31, 56, 63, 107, 158].  The frequent use 
of macrolides and tetracycline together and the dissemination of clones carrying both 
erythromycin and tetracycline resistance may also be major factors behind the growing 
incidence of multi-resistant pneumococci [127, 174, 230].  While the exact contribution 
of Tn1545-like transposons to the worldwide emergence of macrolide resistance among 
pneumococci is unclear, the existence of this lateral DNA transfer mechanism will only 
accelerate the incidence of antibiotic resistance among S. pneumoniae. 
 
1.2  VANCOMYCIN-RESISTANT ENTEROCOCCI 
Enterococci are natural inhabitants of the gastrointestinal tract and female urinary 
tract.  Originally thought of as benign bystanders, in the last two decades species such as 
E. faecium and E. faecalis have emerged as significant nosocomial pathogens.  
Increasingly, these bacteria are responsible for a variety of infections, particularly in 
immunocompromised patients.  Enterococci are one of the most common causes of 
surgical-site infections as well as urinary tract and bloodstream infections [99, 183, 207, 
231] and are implicated in bacterial endocarditis, intraabdominal infections, bacteremia, 
and meningitis [130].     
 
 
17 
 
Historically, enterococcal species were not considered particularly pathogenic in 
humans and serious (while rare) infections were readily treatable with antibiotics.  
However, colonization and infection with enterococcal species has become a major health 
concern in the United States; most clinical isolates are now resistant to multiple 
antibiotics, and the spread of antibiotic resistance determinants among enterococci has 
rendered some clinical strains resistant to all standard therapies, including treatment with 
vancomycin [60, 62, 146, 219].  Vancomycin is the preferred antibiotic for treating 
enterococcal infections when other therapeutic agents are no longer effective, and is 
commonly viewed as the “drug of last resort” [161].  Vancomycin exerts its antibacterial 
activity by binding the terminal D-alanyl-D-alanine dipeptide of cell wall precursors to 
inhibit peptidoglycan synthesis (Figure 1.5).   
 
Figure 1.5  Vancomycin binding to D-Ala-D-Ala termini through five hydrogen bonds to interrupt cross-
linking and cell wall synthesis. 
 
This compound has been used effectively for treating serious infections caused by 
multidrug-resistant Gram-positive bacterial infections such as enterococci, staphylococci, 
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and streptococci for over 40 years.  Vancomycin-resistant enterococci (VRE) emerged in 
the 1980s and have since rapidly spread throughout Europe and the United States [60, 62, 
136, 219, 273, 275].  In Europe, VRE is highly prevalent in domestic and farm animals 
(and humans living in these communities), while in the United States VRE thrives in 
hospitals, particularly in intensive care units [15, 116, 244, 268].  The spread of VRE in 
United States hospitals has been shown to be due to both clonal dissemination of resistant 
strains and the transferable nature of the predominant VanA and VanB gene clusters 
responsible for vancomycin resistance [15, 17, 92, 161, 268]. 
  The genes for antibiotic resistance in enterococci are typically carried on 
plasmids and highly conserved transposons.  Several vancomycin resistance genotypes 
have been described, but the VanA and VanB genotypes are by far the most common 
[268, 275].  The genes for the predominant VanA genotype, which is characterized by 
high-level inducible resistance to both vancomycin and teicoplanin, are carried on a 10.8-
kb Tn1546-like non-conjugative transposable element (see Figure 1.6) [13]. 
 
Figure 1.6  Transposon Tn1546 harbors the VanA gene cluster, which is responsible for conferring 
vancomycin resistance in enterococci.  The VanA resistance element consists of seven genes: vanR, vanS, 
vanH, vanA, vanX, vanY, and vanZ.  Teicoplanin resistance is thought to be encoded by vanZ [13]. 
 
Vancomycin resistance results from the expression of three essential genes on the 
transposon, vanA, vanH, and vanX.  The vanA gene encodes a ligase that incorporates D-
Ala-D-lactate for D-Ala-D-Ala on the terminus of the peptide precursor.  Vancomycin 
binds D-Ala-D-lactate with a much lower affinity and is thus unable to disrupt cell wall 
synthesis.  The vanH and vanX genes encode a dehydrogenase that produces D-lactate 
vanAvanH vanX vanYvanSvanR
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and a dipeptidase that cleaves D-Ala-D-Ala, respectively.  Downstream of the vanA-type 
resistance genes are orf1and orf2, which encode transposition functions [13].  Tn1546 has 
been found on a variety of enterococcal plasmids and may be moving via conjugative 
plasmids, leading to greater spread of vancomycin resistance worldwide [17, 71, 81, 92, 
168, 184, 253, 283]. 
Besides vancomycin, enterococci are often resistant to many other antibiotics 
either intrinsically or through the acquisition of plasmids or conjugative transposons; this 
results in resistance to macrolide antibiotics, chloramphenicol, tetracyclines, and some 
penicillins and streptogramins [12, 57, 88, 95, 159, 249, 282].  Thus, the added 
acquisition of vancomycin resistance severely limits effective therapeutic options for 
treating VRE infections.  In an encouraging sign, newer antibiotics such as linezolid, 
quinupristin-dalfopristin, and daptomycin have been approved for the treatment of VRE, 
thus expanding the antimicrobial repertoire for combating Gram-positive bacterial 
infections.  However, even responsible administration of these new drugs may not 
prevent the development of resistant organisms over time [10]. 
The SENTRY Antimicrobial Surveillance Program, directed by JMI laboratories, 
reports on the occurrence and antimicrobial resistance patterns of bloodstream infection 
pathogens in the United States.  During 1997-2002, the SENTRY program reported that 
Enterococcus spp. were the fourth most frequent bacterial pathogen associated with 
bloodstream infections in North America, and among the enterococci isolated from 
blood, up to 20% were resistant to vancomycin [23].  In the latest report for the years 
2002-2008, up to 33% of Enterococcus spp. tested as part of the surveillance network 
were found to be resistant to vancomycin [111].  This finding is of serious concern, 
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because vancomycin is the preferred antimicrobial treatment for such infections.  
Numerous other reports have been published documenting the emergence and prevalence 
of vancomycin-resistant E. faecium and E. faecalis strains in particular regions or hospital 
systems, and the results seem to indicate a continually growing number of VRE cases 
isolated in United States and European hospitals [43, 47, 111, 116, 212, 219, 268]. 
 
1.3  METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
One of the most problematic antibiotic-resistant bacteria is methicillin-resistant 
Staphylococcus aureus (MRSA).  S. aureus is the leading cause of bloodstream infections 
in the United States and greater than 50% of clinical strains are resistant to the β-lactam 
antibiotic, methicillin [23, 111, 219].  As a common nosocomial pathogen in the United 
States and a rising threat in community-associated bacterial illnesses, S. aureus is often 
considered to be endemic in hospitals and responsible for increased morbidity and 
mortality rates during hospitalization [99, 117, 126, 164, 186, 202, 215, 224, 241]. 
When MRSA strains were first discovered in the 1960s, several alternative 
therapies could be used instead of β-lactam antibiotics.  However, infecting strains of 
MRSA now often also carry resistance to multiple antibiotics such as macrolides, 
aminoglycosides and fluoroquinolones [14, 102, 242].  Fortunately, significant resistance 
has thus far not been observed against newer antimicrobial drugs such as linezolid, 
daptomycin, quinupristin-dalfopristin, and tigecycline [20, 118, 206, 257].   
Vancomycin therapy is the current first-line treatment for patients with an MRSA 
infection.  However, a growing number of these infections respond poorly to vancomycin 
treatment, as isolates with intermediate levels of resistance to vancomycin are becoming 
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increasingly common [76, 217, 238].  The first description of a vancomycin intermediate 
S. aureus (VISA) strain was reported in 1997 and numerous reports of VISA isolates 
worldwide have followed.  Investigation of VISA strains showed that the reduced 
susceptibility to vancomycin is due to the presence of a thickened cell wall [49, 100].  
Surprisingly, intermediate-level resistance to vancomycin was not acquired through 
genetic exchange but instead appeared to be an adaptation by S. aureus [51].   
Even more troubling are the reports of vancomycin-resistant S. aureus  (VRSA) 
strains [33-35, 119].  It was not until 2002 that the first vancomycin-resistant, oxacillin-
resistant S. aureus (VRSA) strain was identified from a patient in Michigan [33].  Since 
then several more VRSA strains have been isolated from patients in the United States, 
India and Iran [4, 34, 35, 119, 193, 195, 220, 225, 226, 248, 266].  Further investigation 
into these VRSA isolates revealed that the vanA gene had been acquired as part of a 
Tn1546-like transposable element from VRE [194, 244].  It is not uncommon for VRE 
and MRSA to co-colonize a site of infection, raising the possibility of horizontal gene 
transfer between the bacteria [78, 263].  Although plasmids within VRE harboring the 
vanA gene are unable to replicate in S. aureus, analysis of the VRSA isolates revealed 
that the Tn1546-like transposon and vanA loci stably inserted into the chromosomal or 
plasmid DNA of the S. aureus strains [44, 70, 248, 265].   
Given the critical importance of vancomycin for treatment of staphylococcal 
infections and the now-documented ability of VRE and MRSA to exchange antibiotic 
resistance determinants, the consequences of VRSA becoming prevalent in hospitals and 
the community would be devastating.  Thus, the need for new, highly effective antibiotics 
and judicious use of current antibiotics is more imperative than ever. 
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1.4  ANTIBACTERIAL TARGETS AND STRATEGIES 
The discovery of penicillin and its success in the clinic marked the beginning of 
several decades of intense antibiotic research and the further discovery of a wide range of 
natural products with antibacterial properties that could be used to treat bacterial 
infections (Figure 1.7) [192, 203].  Most antibiotics in use today were identified through 
screening libraries of natural products isolated from environmental sources such as soil 
bacteria and fungal strains [173].  However, traditional antibiotic research fueled by the 
pharmaceutical industry has diminished severely since the 1980s.  This is, in part, due to 
the increasing challenge of discovering and developing novel classes of antibiotics; since 
2000 only two new classes of antibiotics, oxazolidinones and lipopeptides, have been 
introduced [247, 285].   Many of the antibiotics approved in the last twenty years have 
been derivatives of existing antibiotic scaffolds.    
 
Figure 1.7  Timeline of Antibiotic Use and Resistance.  Bars represent the time from the introduction of an 
antibacterial compound or antibiotic class into the clinic (leftmost edge of the bar) to the time when 
resistance was reported (rightmost edge of the bar) [45, 65, 66]. 
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The methods of antibacterial drug discovery changed with the introduction of 
combinatorial chemistry and high-throughput screening to the field.  Combinatorial 
chemistry has allowed the rapid generation of compounds to populate screening libraries, 
and high-throughput screening has enabled researchers to mine synthetic compound 
collections instead of complex extracts.  Additionally, the successful sequencing of 
bacterial genomes has presented the possibility for target-based strategies to be explored 
with these screening libraries.  However, the path to antibiotic discovery has remained 
challenging even with these new tools.  High-throughput screening and target-based 
strategies could identify desperately needed new classes and methods of antibacterial 
activity, but the success of efforts in these areas has not yet been realized [189]. 
The major classes of antibiotics used in the clinic target bacteria through 
inhibition of a limited number of cellular processes, including nucleic acid synthesis, 
protein synthesis, cell wall biosynthesis, and folate synthesis (Figure 1.7) [260].  As 
resistance is observed to all classes of antibiotics with the targets listed above, new 
macromolecular targets for antibacterial therapy are urgently needed.  It is apparent that 
the “golden age” of antibiotics is over, and we are well into an era in which multidrug 
resistance is the norm, not an aberration.  Interestingly, it is not that we lack compounds 
that kill the relevant species of pathogenic bacteria; indeed, enterococci and 
staphylococci are highly susceptible to multiple antibiotics.  It is when these bacteria 
acquire the genes for resistance that they become problematic.  Numerous reports of 
clinical isolates such as vancomycin-resistant enterococci that fail to respond to all 
standard therapies have demonstrated how quickly bacteria are able to adapt or acquire 
the genes necessary to resist the traditional antibiotic classes.  Novel targets such as 
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virulence and plasmid-based gene products are only beginning to be explored as potential 
targets for new, highly specific classes of antibiotics [18, 59, 103, 251, 254].  Also being 
considered are toxin-antitoxin systems as possible antibiotic targets, as described below 
[58, 68, 271].  
 
1.5  TOXIN-ANTITOXIN SYSTEMS 
Large plasmids place a certain metabolic burden on the bacterial host, and as such 
they are typically present at a low copy number [236, 270].  How then do large plasmids 
(some of which harbor antibiotic resistance determinants) persist in bacterial populations 
in the absence of antibiotic selection?  For example, the phenomenon of “persistence” has 
been documented for VRE; humans and animals can remain colonized by enterococci for 
prolonged periods of time and the bacteria often retain vancomycin resistance even in the 
absence of antibiotic selection.  This has been observed on poultry farms in Europe after 
the ban of avoparcin, as well as in patients who, after colonization or infection with VRE, 
become persistent carriers of the bacteria [1, 26, 27, 134].  Johnsen and coworkers 
examined the fitness, stability, and persistence of a plasmid-mediated vancomycin-
resistant enterococcal strain in comparison to a plasmid-free, susceptible strain in the 
absence of vancomycin selection.  While the VRE strain did exhibit a small reduction in 
fitness compared to the plasmid-free strain in in vitro competition experiments, the 
plasmid and VanA resistance determinant were stable over 1000 generations in vitro and 
during long-term colonization in mice without antibiotic selection [113].   
Large, low copy number plasmids often possess plasmid maintenance systems 
that ensure their persistence and inheritance in a bacterial population [64, 94, 243].  One 
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class of plasmid maintenance systems are the active partitioning systems, which are 
composed of an ATPase and a DNA-binding protein that recognizes centromere-like sites 
within the partitioning loci.  Formation of the partitioning complex is responsible for the 
segregation of replicated plasmids from mid-cell to the resulting daughter cells [64].  A 
second type of plasmid maintenance systems are the plasmid multimer resolution 
systems, which resolve dimerization of plasmid copies through site-specific 
recombination [64, 243, 250].  The third class of plasmid maintenance systems are the 
Post-Segregational Killing (PSK) systems, also called Toxin-Antitoxin (TA) systems [84, 
94].  In proteic TA systems, the plasmid encodes a stable toxin together with a labile 
antitoxin.  If the cell contains the plasmid, the antitoxin is produced and inactivates the 
toxin.  However, if a plasmid-free segregant were to arise, the labile antitoxin is rapidly 
degraded and the toxin kills the cell (Figure 1.8) [3, 94].  This post-segregational killing 
by TA systems has led to them being dubbed “plasmid addiction” systems, as the cell is 
quite literally addicted to the plasmid, and will die if the plasmid is lost [84].   
 
Figure 1.8  Mechanism of plasmid addiction by a plasmid-encoded TA system. 
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Most TA systems share a very similar genetic organization.  Except in one case, 
the antitoxin is encoded upstream of the gene encoding the toxin (the gene order is 
reversed in the higBA TA system) [82, 252].  The TA genes typically form an operon and 
overlap by 1-20 nucleotides, though a spacer of up to 30 nucleotides between the two 
genes can exist [227].  Both the toxin and antitoxin genes are small and encode proteins 
that average ~100 and ~80 amino acids in length, respectively (Figure 1.9) [30, 185, 
227].  The regulatory properties of TA systems often involve the ability of the antitoxin 
to autoregulate the transcription of the TA operon by binding to upstream operator sites.  
The toxin may act as a co-repressor of transcription for the operon [82].  Additionally, a 
common feature of TA systems is for the antitoxin to have a shorter half-life than the 
toxin due to degradation by cellular proteases such as Lon and ClpXP [82].  
 
Figure 1.9  General genetic organization of a TA operon.  The typical sizes of the genes and spacing 
between the two genes are shown.  Figure taken from [227]. 
 
The first TA system to be identified was ccdAB on the F plasmid of E. coli, and 
since its discovery, a number of TA systems have been identified on a variety of plasmids 
and bacterial chromosomes [165, 180, 185, 235].  The overwhelming consensus is that 
plasmid-encoded TA systems function as plasmid maintenance systems [108].  However, 
the genes for TA systems have also been found on bacterial chromosomes, and their role 
is more unclear and controversial.   
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 The action of TA loci on chromosomes has been proposed to involve bacterial 
death and stress responses [83, 132, 133, 204, 218, 256].  One of the most well-studied 
TA systems, MazEF, was originally discovered on the E. coli chromosome [154] and 
conflicting work has shown that it may function as an irreversible mediator of cell death 
under stressful conditions [8, 131, 169] or as a modulator of translation to induce a 
reversible state of bacteriostasis in E. coli [42, 190].  The mazEF TA system consists of a 
9-kDa antitoxin (MazE) that binds to and renders inactive the 12-kDa toxin (MazF).  
MazE is a labile protein that is degraded by the ClpP protease; thus, in the absence of the 
genes encoding mazEF, the cellular MazE concentration drops rapidly, releasing MazF to 
kill or inhibit the growth of the cell [190].  The MazF toxin is an endoribonuclease that is 
specific for ACA sequences [167, 277, 281], and its degradation of mRNA is believed to 
cause the observed bacterial cell death [67].  The MazEF system has been postulated as a 
“stress-induced suicide module” [67], because it triggers cell death under conditions of 
amino acid starvation signals [3], antibiotic treatment [222], phage infection [96], 
thymine starvation [223], oxidative stress, and high temperatures [67]. However, 
conflicting research has suggested that induction of TA systems such as mazEF do not 
constitute a bacterial version of programmed cell death.  Instead, the result is a reversible 
bacteriostatic condition that allows cells to cope with environmental stresses by adjusting 
levels of energy-draining processes such as translation through toxin activation [42, 190].   
In addition to the mazEF genes, the E. coli chromosome is known to encode at least nine 
more TA systems, including chpSB, relBE, dinJ-yafQ, hicAB, prlF-yhaV, yafNO, higBA 
(ygjNM), ygiUT, and yefM-yoeB, whose regulatory roles during stressful conditions 
remain equally vague [38].  Recently it was reported that an E. coli strain with five TA 
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systems deleted from the chromosome behaved similarly to the wild-type under a variety 
of stressful conditions [256].  Thus, the role of TA systems in the E. coli stress response 
has been thrown into question, while the existence of a “point of no return” for toxin 
activation and cell death is still unresolved.    
A limited number of targets have been identified for proteic TA systems, 
including inhibition of DNA gyrase and catalysis of mRNA cleavage (Table 1.1).  The 
toxin components of the CcdAB and ParDE systems function by binding DNA gyrase 
thereby inhibiting its activity in the host cell and causing cell death. When the gyrase 
enzyme is covalently bound to DNA to introduce negative supercoils, addition of CcdB, 
ParE or quinolone antibiotics will bind and stabilize the gyrase-DNA intermediate, thus 
inhibiting DNA supercoiling.  The trapped gyrase-DNA-toxin complex formed by CcdB 
and ParE can be reversed or prevented by the respective antitoxin [16, 22, 109].   
The MazEF, RelBE, YefM-YoeB, Kis-Kid, and Phd-Doc systems have all been 
shown to inhibit protein synthesis under conditions of postsegregational killing [39, 42, 
97, 120, 167, 191, 280].  Interestingly, the translation inhibition and postsegregational 
killing effect of Phd-Doc may be dependent upon the presence of the MazEF system [97]. 
The RelBE, YefM-YoeB, Kis-Kid, and MazEF TA systems inhibit protein synthesis 
through sequence-specific mRNA cleavage.  The RelE toxin, and possibly the YoeB 
toxin, cleaves mRNA that is associated with the ribosomal A-site, essentially acting as a 
ribosome poison to halt translation [39, 191].  As mentioned above, the MazF toxin has 
been found to exhibit RNase activity by specifically cleaving ACA sequences on mRNA 
transcripts, thus blocking protein synthesis [42, 167, 280].  The Kid toxin was originally 
reported to inhibit ColE1 DNA replication in a DnaB-dependent manner [216].  Further 
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investigation has shown the Kid toxin to inhibit translation by cleaving UAH  sequences 
(where H is C, A or U) in vitro, and inhibition of ColE1 DNA replication may be an 
indirect effect of the toxin’s RNase activity [83, 278].      
 
Table 1.1  Eleven TA systems further investigated in this thesis project. 
    
1.5.1  RelBE 
The well-studied TA system, RelBE, was originally discovered on the E. coli  
chromosome and the relBE genes have been found in a wide variety of prokaryotic 
genomes [86, 185].  Similar to many proteic TA systems, the relBE TA system consists 
of a small labile antitoxin protein capable of binding the cognate toxin protein that are 
encoded together as a single operon.  Transcriptional repression of the relBE genes is 
autoregulated by the antitoxin, RelB, and the toxin, RelE, acts as a co-repressor of 
TA System Discovered On Mechanism of Toxicity
Par E. faecalis plasmid pAD1 Target unknown
Axe-Txe E. faecium plasmid pRUM Target unknown
ω−ε−ζ S. pyogenes plasmid pSM19035 Target unknown
MazEFSa S. aureus chromosome Ribonuclease
MazEF E. coli chromosome Ribonuclease
RelBE E. coli chromosome Ribonuclease
CcdAB E. coli F plasmid Gyrase poison
ParDE E. coli plasmid RK2 Gyrase poison
HigBA P. vulgaris plasmid Rts1 Ribonuclease
VagCD S. enterica virulence plasmid Ribonuclease
Phd-Doc Bacteriophage P1 Inhibits translation
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transcription when in complex with RelB [86, 139, 181].  If RelE exists in excess to 
RelB, the RelBE complex releases from the DNA and transcription of the relBE genes is 
no longer repressed (Figure 1.10) [182].   
 
Figure 1.10  Regulation of the RelBE TA system.  Figure taken from [181]. 
 
Upon forming a protein complex with the 11-kDa RelE, the 9-kDa RelB negates 
the toxin’s detrimental effect on cell growth.  The interactions between the RelB and 
RelE interface appear to be extensive and characterized by high affinity; the dissociation 
constant (KD) of RelE with a C-terminal RelB peptide is 154±15 nΜ and 0.33 nΜ with a 
full-length RelB-Cys (RelB with an extra cysteine at the C-terminus) protein [140, 181, 
246].  Activation of RelE and its ability to degrade mRNA is dependent upon Lon-
mediated degradation of the antitoxin.  RelB is a substrate for the cellular protease and 
has been shown to be protected from proteolysis by binding RelE  [36, 41, 181, 182].  
The C-terminal region of RelB appears to be responsible for counteracting the toxic 
activity of RelE; RelB peptides spanning residues 36-79, 47-79, and 52-79 are able to 
inhibit RelE activity [36, 140].  Additionally, structural data has suggested that the C-
 
 
31 
 
terminal half of RelB interacts with residues on RelE important for the toxin’s activity 
(Figure 1.11A) [140, 246].  In the archaeal RelE from P. horikoshii, mutation of Arg40, 
Leu48, Arg58, Arg65, or Arg85 to alanine moderately to completely abolished the 
activity of the toxin and several of these residues were observed to interact with the 
archaeal RelB structure (Figure 1.11B) [246].  In the E. coli RelE, a low toxicity mutant 
was generated by mutation of Arg81 and Arg83 to alanine, which are part of a positively 
charged and highly conserved cluster located adjacent to the C-terminal helix in RelE.   
Recently, a second crystal structure of an archaeal RelE from M. jannaschii was 
solved and confirmed that many of the arginine residues listed above are conserved 
across the RelE toxin family [75].  A C-terminal fragment of RelB spanning residues 47-
79 was observed to displace the C-terminal helix of RelE and directly neutralize the 
positively charged cluster in RelE, both of which are thought to be part of the toxin’s 
active site [140].           
 
Figure 1.11  Structural characterization of RelB-RelE interaction.  (A)  Ribbon representation of the 
RelER81A/R83A mutant (different RelE structural motifs are colored in blue, green, yellow, and cyan) in 
complex with the antitoxin RelBC peptide (colored in red) [140].  (B)  Residues involved in the interaction 
at the heterodimer interface between RelB (red) and RelE (green) from  P. horikoshii [246]. 
 
As mentioned above, the RelE toxin catalyzes the hydrolysis of mRNA in the 
ribosomal A site, causing inhibition of protein translation. (Figure 1.12) [93, 190, 191].  
A B
 
 
32 
 
RelE has been demonstrated to directly bind ribosomes in vitro, and this binding is 
inhibited by the addition of RelB [80].  Use of a reconstituted in vitro protein synthesis 
system demonstrated that RelE causes cleavage of mRNA codons positioned in the 
ribosomal A site and that protein synthesis inhibition could be prevented by the presence 
of excess RelB .  Both sense and stop codons were shown to be cleaved in a RelE-
dependent manner, however a strong preference was observed for cleavage of the stop 
codon UAG between the second and third bases .  Unlike several other TA systems, RelE 
was found to only degrade ribosome-associated mRNA and not free mRNA [191].  Until 
recently, it was unclear if the mechanism by which RelE mediates cleavage of mRNA in 
the ribosome occurred through direct cleavage by RelE acting as a ribonuclease or if the 
toxin stimulated the ribosome to cleave mRNA.  Neubauer and coworkers have now 
reported the crystal structures of the E. coli RelE protein bound to programmed Thermus 
thermophilus 70S ribosomes before and after mRNA cleavage.  Structural analysis 
confirmed that RelE occupies the A site of the ribosome and causes cleavage of the 
mRNA after the second base in the codon.  Additionally, their results suggest that RelE 
mediates the cleavage of mRNA and that the ribosome is required for correct orientation 
of the mRNA substrate for the cleavage reaction [172].   
The mechanism by which RelB counteracts RelE-mediated cleavage of mRNA 
may involve both the antitoxin’s binding to active-site residues in RelE as well as 
spatially preventing RelE from entering the ribosome due to the larger size of the RelBE 
complex (Figure 1.12) [140, 246, 272].  After RelE-mediated mRNA cleavage and 
neutralization of the toxin by RelB, protein synthesis is still inhibited because the 
ribosome has stalled on the damaged mRNA.  If the cell is to recover from RelE toxicity, 
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tmRNA is need to rescue the stalled ribosomes and allow recycling of the translation 
machinery (Figure 1.12).  Deletion of the gene that encodes tmRNA in E. coli increases 
the susceptibility to RelE toxicity, while a strain overexpressing tmRNA counteracted 
RelE toxicity [39]. 
 
 
Figure 1.12  RelE-mediated inhibition of translation. 
 
Like the mazEF TA system, the relBE TA system appears to be part of the 
bacterial stress response, functioning to inhibit cell growth without causing cell death, 
specifically under conditions of nutrient starvation [41].  However, the significance of 
this role is under debate, as others have reported the decrease in the rate of translation 
during amino acid starvation in a ∆relBE E. coli mutant was only slightly less than wild-
type [256]. 
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1.5.2  Axe-Txe and Other Toxin-Antitoxin Systems in Gram-Positive Bacteria 
Reports of TA systems in Gram-positive bacteria have been much rarer compared 
to the numerous studies of TA systems in Gram-negative bacteria.  Three TA systems 
that were first described in Gram-positive bacteria include par, encoded by the plasmid 
pAD1 from E. faecalis, ω−ε−ζ of plasmid pSM19035 from pathogenic bacterium S. 
pyogenes, and axe-txe, which was discovered on the multidrug resistant plasmid pRUM 
in E. faecium [89, 264, 284].  The par  system is a unique antisense RNA-regulated type I 
TA cassette that was identified on the conjugative hemolysin/bacteriocin plasmid pAD1.  
Plasmid pAD1 is a sex-pheromone responsive virulence plasmid that is representative of 
a large family of conjugative plasmids commonly found in clinical isolates of E. faecalis 
and belonging to the same incompatibility group [73].  However, the par system has been 
described only in pAD1 and not on other members of the plasmid family, suggesting it to 
be rare in enterococci.  The ω−ε−ζ system, originally described on plasmid pSM19035 of 
Streptococcus pyogenes, has also been identified in enterococci.  Plasmid encoded 
homologues of the ω−ε−ζ systems have been detected in the majority of E. faecium 
isolates from Norwegian poultry farms and appear to be linked to the vancomycin 
resistance transposable element, Tn1546 [112, 239].    
The proteic TA system, axe-txe, was discovered on the 24.8-kb nonconjugative 
plasmid pRUM from a clinical isolate of E. faecium.  The plasmid, pRUM, confers 
resistance to chloramphenicol, erythromycin, streptomycin, and streptothricin and co-
existed in the clinical strain with a 60-kb conjugative vancomycin resistance plasmid.  
Sequence analysis of pRUM suggested it arose from a variety of mobile genetic elements, 
recombination events, and smaller plasmids [89].  Recently it was shown that a genetic 
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linkage exists between pRUM-replicon type plasmids and the axe-txe genes in a 
collection of 93 E. faecium strains [214].  
While the mode of action of many of the TA systems discovered in Gram-
negative bacteria are known, the biological targets of the toxins from the Par, Axe-Txe 
and ω−ε−ζ systems have not been elucidated.  The genes of the axe-txe TA system 
epitomize the characteristic small, overlapping genetic organization common to most TA 
systems, with expected molecular masses of 9.8 and 9.6 kDa, respectively.  The Axe-Txe 
system has been shown to contribute to the segregational stability of a plasmid in E. 
faecium, as well as in Bacillus thuringiensis and E. coli.  The product of the txe gene was 
demonstrated to be toxic to E. coli, resulting in severe growth inhibition, and the 
expression of the axe gene was found to prevent the inhibitory activity of Txe, thus acting 
as a classic antitoxin to the Txe toxin [89].  However, the target of Txe toxin activity is 
unknown.   
The axe and txe genes share homology with TA modules from both Gram-positive 
and Gram-negative organisms.  In particular, Axe shares limited homology with the 
antitoxin components of the E. coli YefM-YoeB and Phd-Doc systems, while Txe has 
significant sequence similarity with the toxin component of the YefM-YoeB system 
(Figure 1.13) [89].  Little is known about the interactions between Axe and Txe, or about 
the biological target of Txe, however, both the YoeB and Doc toxins have been shown to 
inhibit protein synthesis [97, 120]. YoeB is part of the RelE toxin superfamily and is 
structurally related to the archaeal RelE monomer [75, 120].  Several mechanisms of 
action have been proposed for YoeB, including cleavage of translated mRNAs [40], 
cleavage of mRNA at purine ribonucleotides [120], and, similar to RelE, association with 
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the ribosomal A site causing mRNA cleavage [279].  Given the extensive sequence 
homology between the YoeB and Txe toxin proteins, and that mRNA cleavage has been 
shown to be the intracellular target of several TA systems, Txe may act in a similar 
manner. 
 
Figure 1.13  Alignment of the Txe and YoeB proteins.  Residues highlighted in yellow are shared between 
the two proteins, as determined by PSI-BLAST analysis [6].  The Txe protein is closely related to YoeB 
(Identity = 50/85 residues, 58.8%). 
 
1.6  TOXIN-ANTITOXIN SYSTEMS AS AN ANTIMICROBIAL TARGET 
The major antibiotics in clinical use today disrupt only a limited range of 
fundamental bacterial functions, with the most popular antibiotic targets being the 
ribosome, macromolecules involved in cell wall synthesis, and DNA gyrase [260].  In the 
search for new antimicrobial targets, one intriguing approach involves the explicit 
targeting of TA systems to exploit their innate inhibitory functions.  It has been 
postulated that activation of TA systems could be an attractive antimicrobial strategy, as a 
small molecule that releases the toxin would kill the host bacterial cell from within [5, 58, 
68, 83, 271].  Multiple experiments across the various TA systems have shown that in the 
absence of antitoxin, the toxin will rapidly kill the bacterial cell.  For example, it has been 
demonstrated that expression of the toxin alone from the RelBE, MazEF, CcdAB, and 
Axe-Txe systems results in severe growth inhibition and a decrease in viable cell counts 
[8, 53, 86, 89].  Amitai and coworkers showed that expression of MazF under the control 
of arabinose resulted in 0.5% survival two hours post-induction.  In contrast, if MazE was 
Txe  1  MIKAWSDDAWDDYLYWHEQGNKSNIKKINKLIKDIDRSPFAGLGKPEPLKH 51
YoeB 1  MKLIWSEESWDDYLYWQET-DKRIVKKINELIKDTRRTPFEGKGKPEPLKH  50
Txe  52 DLSGKWSRRITDEHRLIYRVENETIFIYSAKDHY  85
YoeB 51 NLSGFWSRRITEEHRLVYAVTDDSLLIAACRYHY 84
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co-expressed with MazF, 85% of the cells were viable two hours after induction [8].  In 
the case of RelBE, Gotfredsen and Gerdes obtained similar results when RelE was 
expressed by itself, and cell death was rescued by co-expression of the RelB antitoxin 
[86].  Thus it seems that if one were able to artificially disturb the TA interaction, then 
the freed toxin may be able to kill the bacterial cell. 
Drug-mediated toxin activation could be accomplished either through direct 
disruption of the toxin-antitoxin proteins, or through an indirect mechanism [271].  For 
example, a compound that causes toxin-dependent death via the RelBE TA system could 
conceivably work in at least three different ways (Figure 1.14).  The simplest method to 
envision is a small molecule that directly disrupts the protein-protein interactions of 
RelBE, releasing the toxin from the antitoxin to elicit its toxic effect on the cell.  A 
second, indirect, way in which the toxin could be activated is if a compound stimulates 
the degradation of the antitoxin by a cellular protease.  A key characteristic of proteic TA 
systems such as RelBE is that the antitoxin component is more susceptible to degradation 
by specific proteases, such as Lon and ClpP, than the relatively proteolytically stable 
toxin [36, 40-42, 137, 258].  A small molecule that causes the antitoxin to become more 
vulnerable to proteolysis and/or enhances the ability of cellular proteases to degrade the 
antitoxin will tip the scales in favor of free toxin.  Finally, another proposed indirect 
method for toxin activation relies on the inhibition of transcription and/or translation of 
the TA system [68, 271].  A compound that prevents synthesis of the antitoxin would 
result in pre-existing levels of the labile antitoxin to drop below the amount required to 
neutralize the toxin leading to toxin-mediated cell death.  Additionally, unknown 
pathways may exist in which a small molecule could cause toxin-dependent cell death.  
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Figure 1.14  Possible mechanisms of drug-mediated toxin activation. 
 
While TA systems potentially present an attractive target for antibacterial therapy, 
the prevalence and identity of TA systems in the most infectious bacteria must first be 
defined.  TA systems have been identified in both bacterial and archaeal hosts, including 
pathogens such as S. aureus and Enterococcus spp. [55, 77, 91, 160, 165, 175, 185, 246].  
A bioinformatics survey of 126 genomes for the distribution of the genes encoding TA 
systems has shown just how widespread and diverse the range of bacterial species are that 
harbor TA systems [185].  As more clinical isolates are confirmed to harbor genes for TA 
proteins, the more attractive therapies aimed at TA systems become.  To validate TA 
systems as an antimicrobial target, the research presented in this thesis has aimed to 
determine the prevalence of genes for TA systems in VRE and MRSA clinical isolates.  
Those systems found to occur most frequently in these clinically important bacteria 
consequently present the best targets for developing disruptors of the TA interaction.  The 
discovery that specific TA systems are prevalent in MRSA and VRE further supports the 
potential of toxin activation as a novel antibacterial strategy [165]. 
This thesis research has also further investigated two TA systems found to occur 
often in the VRE and MRSA strains studied, Axe-Txe and RelBE, to facilitate the design 
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and discovery of small-molecule toxin activators.  As mentioned earlier, the target of Txe 
toxin activity is unknown and the interactions of the Axe-Txe system are poorly 
understood.  Part of this thesis project has focused on isolating and characterizing the 
Axe-Txe system.  Additionally, studies have been aimed at peptide fragment analysis of 
RelBE to understand the minimal interactions of this TA system and identify peptidic 
disruptors of the RelBE complex.  The characterization of these TA systems and 
development of high-throughput screening methods has been directed towards the better 
understanding of key toxin-antitoxin interactions and identification of molecules capable 
of toxin activation. 
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CHAPTER 2 
PREVALENCE OF TOXIN-ANTITOXIN SYSTEMS IN VANCOMYCIN-
RESISTANT ENTEROCOCCI 
Sections from Chapter 2 have been reproduced from “Toxin-Antitoxin Systems 
Are Ubiquitous and Plasmid-Encoded in Vancomycin-Resistant Enterococci” Moritz, 
E.M. and P.J. Hergenrother.  2007, Proc Natl Acad Sci USA, 104(1):311-316. 
 
2.1  INTRODUCTION 
 Enterococci are the leading cause of surgical-site infections, the third leading 
cause of urinary tract and bloodstream infections, and are implicated in bacterial 
endocarditis, intra-abdominal infections, bacteremia, and meningitis [43, 56, 59].  The 
intrinsic resistance of enterococci to cephalosporin and aminoglycoside antibiotics 
complicates treatment strategies.  Historically, vancomycin has been effective in the 
management of enterococcal infections; however, after nearly 30 years of use, 
vancomycin-resistant enterococci (VRE) emerged in the mid-1980s.  Intensive care units 
in the U.S. have seen a dramatic increase in the percentage of enterococcal infections that 
are resistant to vancomycin, from 0.4% in 1989 to 33% in the latest SENTRY 
Antimicrobial Surveillance Program report in 2008 [38, 43].   
 As described in Chapter 1, the genes encoding the elaborate protein systems that 
mediate vancomycin resistance generally reside on mobile genetic elements within 
enterococci.  A variety of plasmid types recovered from enterococci have been found to 
encode vancomycin resistance gene clusters, and the prevalence of plasmid-encoded 
resistance in VRE appears to be ever increasing [4, 22, 23, 25, 30, 31, 38, 40, 49, 52, 68, 
69, 77, 78].  Large plasmids often have intricate mechanisms by which they maintain 
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themselves in the bacterial cell.  Some plasmids contain genes encoding post-
segregational killing “plasmid addiction” systems, which are comprised of a potent toxin 
and a labile antitoxin [27, 32].  Provided the plasmid is present, the antitoxin binds to and 
sequesters the toxin.  However, if a plasmid-free daughter cell arises, the unstable 
antitoxin is degraded, and the toxic protein kills the bacterial cell from within. 
 As discussed in Chapter 1, if toxin-antitoxin (TA) systems are prevalent and 
functional on plasmids residing in pathogenic bacteria, this would present a novel 
opportunity for antibacterial therapy.  For example, it has been suggested that small 
molecules capable of disrupting the TA interaction would free the toxin to kill the host 
[15, 20, 26].  However, both the identity and prevalence of TA systems in pathogenic 
bacteria is unknown.  In an effort to definitively link TA systems to VRE and to define 
new macromolecular targets for the treatment of these infections, the presence of TA 
systems was defined for plasmids isolated from VRE obtained from 75 different patients.   
 
2.2  CHARACTERIZATION OF THE COLLECTION OF VANCOMYCIN-
RESISTANT ENTEROCOCCI  
 A total of 75 VRE strains were obtained from five different medical centers.  The 
medical centers were:  Carle Foundation Hospital (Urbana, IL), Memorial Medical 
Center (Springfield, IL), St. Mary’s Hospital (Decatur, IL), Mount Sinai Hospital 
(Chicago, IL), and Barnes-Jewish Hospital (St. Louis, MO).  To confirm the identity of 
the strains, total DNA preparations from each strain were performed by an alkaline-lysis 
method modified from standard protocols [18].  PCR with primers specific for 
Enterococcus faecalis or Enterococcus faecium sequences revealed that 8 of the strains 
were E. faecalis, and 61 were E. faecium; 6 strains were not able to be typed by this 
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method and are denoted as Enterococcus spp. [9, 17, 42].  A complete list of the primers 
used in this study is in Table 2.1 and the features of the strains investigated in this study 
are found in Tables 2.2 and 2.3.  
 All 75 VRE strains were assessed for their susceptibility to common antibacterial 
agents using the microdilution broth method according to Clinical and Laboratory 
Standards Institute (CLSI) standards [64].  The antimicrobial agents tested included 
ampicillin, daptomycin, erythromycin, gentamicin, linezolid, quinupristin-dalfopristin, 
tetracycline, and vancomycin.  As expected, all strains were resistant to vancomycin, at 
the level of full or intermediate resistance (according to CLSI standards; Figure 2.1).  
The vast majority of the strains were also resistant to erythromycin and ampicillin, and a 
significant number were resistant to gentamicin and tetracycline.  Only a handful of 
strains showed resistance to more recent drugs targeted against Gram-positive pathogens, 
such as linezolid and quinupristin-dalfopristin, and all 75 isolates were susceptible to 
daptomycin.  The antibiotic resistance profile for each individual strain is shown in Table 
2.2.  The results from this evaluation highlight the frequency of multidrug resistance in 
VRE and the limited number of antimicrobial agents available to effectively treat 
multidrug-resistant VRE infections. 
To further characterize the vancomycin-resistance profiles in the collection of 
isolates, plasmid preparations from each strain were performed by an alkaline lysis 
method modified from standard protocols [57].  Non-degenerate primer pairs 
complementary to the vanA and vanB gene sequences were used to specifically amplify 
the predominant vancomycin-resistance determinants in enterococci [16].  PCR analysis 
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revealed that 75 of 75 of the VRE strains had plasmids with the vanA gene, and 7 of 75 
also possessed plasmids harboring the vanB gene (Table 2.3). 
 
Figure 2.1  Antibiotic resistance profiles of the 75 VRE isolates. 
 
PCR was also used to determine if three types of conjugative plasmids commonly 
found in enterococci were present in the plasmid DNA preparations of the 75 VRE 
strains.  Enterococci are known to carry at least three types of conjugative plasmids; 
pheromone-responsive plasmids, broad-host range plasmids, and pMG1-like plasmids.  
Many broad-host range plasmids in enterococci belong to the Inc18 family and often 
confer resistance to erythromycin, chloramphenicol, and vancomycin [22, 24, 34].  
Pheromone-responsive plasmids are also widely disseminated in enterococci and often 
encode virulence determinants such as cytolysin, UV light resistance, and vancomycin 
resistance [12, 44].  The pMG1-like plasmids are the most recent type of conjugative 
plasmid to have been discovered in enterococci and are often found to encode gentamicin 
and vancomycin resistance [34, 68, 69].  The plasmid DNA of all 75 VRE strains were 
probed by PCR with primers complimentary to the highly conserved rep gene of the 
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Inc18 group plasmid pAMβ1, the well-conserved aggregation substance gene from the 
pheromone-responsive plasmid pCF10, and the traA gene from pMG1-like plasmids.  
The results of this PCR analysis for each strain are listed in Table 2.3.  The genes for 
traA from pMG1 (27/75, 36%) and the pCF10 aggregation substance (17/75, 22%) were 
detected in the plasmid DNA preparations from a number of VRE isolates, while the rep 
gene of the Inc18 family of plasmids was detected in only one of the isolates.  Most of 
the VRE strains did not have any of the genes for the three known conjugative plasmid 
types by PCR (33/75, 44%), suggesting that less common or currently unknown types of 
plasmids are harbored by these clinical isolates.      
  
2.3  PRESENCE OF TOXIN-ANTITOXIN GENES ON THE PLASMIDS OF 
VANCOMYCIN-RESISTANT ENTEROCOCCI 
 
2.3.1  Presence of Toxin-Antitoxin Genes in Plasmid DNA Preparations 
 In an effort to define the prevalence of TA systems on plasmids isolated from 
VRE, PCR was used to probe the plasmid DNA preparations from the 75 clinical isolates.  
Non-degenerate primers were designed such that each primer set would specifically 
amplify the genes of one TA system [32].  These included the genes of three TA systems 
initially identified in Gram-positive organisms [ω−ε−ζ  [7, 45], axe-txe [28], and par 
[74]], and several genes representing major families of TA systems discovered in Gram-
negative bacteria [parDE [37], ccdAB [51, 70], mazEF [19], relBE [10], higBA [67], 
vagCD [55], and phd-doc [35, 46]].  The oligonucleotide sequences of all PCR primers 
used to amplify TA genes are listed in Table 2.1.  The par TA system utilizes a 
countertranscript RNA as the antitoxin, making it a “Type I” TA system [74].  The other 
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nine pairs are all “Type II” TA systems, meaning that both the toxin and antitoxin are 
proteins.  The toxin components of these systems exert their antibacterial activity through 
a variety of mechanisms, including inhibition of DNA replication, inhibition of 
translation, and direct mRNA degradation [32].  
The results of this PCR analysis of the plasmid DNA preparations are displayed in 
Figure 2.2A.  Examination of these data reveals that TA systems are ubiquitous in the 
plasmids from these VRE isolates; in fact, there is at least one plasmid-encoded TA 
system in 75 (100%) of the samples.  Most of the VRE isolates have multiple TA systems 
on their plasmids; the average number of plasmid-encoded TA systems for each VRE 
isolate was 2.7 (see Table 2.3). 
The genes for four TA systems are particularly prevalent and appear in multiple 
isolates: ω−ε−ζ (33/75, 44%), relBE (35/75, 47%), axe-txe (56/75, 75%), and mazEF 
(75/75, 100%).  The prevalence of mazEF was particularly surprising, because this TA 
combination had previously been observed on the E. coli chromosome, with only 
orthologs present on chromosomes of certain other bacteria [48].  Also, the prevalence of 
axe-txe and relBE is of significance, because the axe-txe homologue, yefM-yoeB on the E. 
coli chromosome, is considered part of the relBE superfamily of TA systems [3, 53].  
Thus, the results of the PCR screen suggest that, in addition to mazEF, members of the 
relBE TA supefamily are quite abundant in VRE; in fact, only 7 of 75 clinical isolates in 
this study do not have plasmids with either axe-txe or relBE.  See Table 2.3 for a 
complete list of the TA genes present in the total plasmid DNA preparations from the 
individual VRE isolates.   
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Figure 2.2  PCR analysis of VRE isolates.  (A) The prevalence of genes encoding vancomycin resistance 
and plasmid stability systems as assessed by PCR analysis of the total plasmid preparations from 75 VRE 
isolates.  (B) Analysis of the physical linkage between TA systems and vancomycin resistance 
determinants.  Single plasmids containing the vanA gene were isolated and probed by PCR with primers 
complementary to the genes encoding the various TA systems. 
 
DNA sequencing was performed on approximately 10% of all PCR products.  In 
every case, the sequencing data confirmed the identity of the TA system, because the 
sequenced products had >95% sequence identity with their respective reference sequence 
(ω−ε−ζ, 96% identity; relBE, 99.7%; ccdAB, 99.1% identity; axe-txe, 99.9% identity; and 
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mazEF, 98.8% identity; alignments are shown in Figures 2.6-2.10 found at the end of 
this chapter). 
The finding that both Gram-negative and Gram-positive TA systems are 
widespread among a collection of enterococci is particularly intriguing and suggests that 
TA systems may be common throughout a range bacterial species.  Thus, TA systems 
may present a novel target for antimicrobial therapy.        
 
2.3.2  Presence of Toxin-Antitoxin Genes on Plasmids Conferring Vancomycin 
Resistance  
Clinical enterococcal strains frequently contain multiple plasmids.  The 
experiments described above gave no information about whether the TA systems resided 
on the same plasmids as the vancomycin resistance genes [14, 54, 65]; therefore, a 
determination was next made about the physical linkage of the vanA resistance cluster 
with the TA systems identified.  Plasmids containing the vanA gene cluster were first 
isolated from each of the 75 VRE strains.  This was performed one of two ways.  First, all 
75 of the clinical VRE isolates were subjected to conjugative mating (broth and filter 
matings) with a plasmid-free recipient strain of E. faecium (BM4105-RF; RF, rifampicin 
and fusidic acid resistance) and subsequent selection on semisolid media containing 
vancomycin, rifampicin, and fusidic acid.  Transconjugants were obtained for 33 of 75 of 
the isolates in this manner; plasmid preparations from these transconjugants followed by 
PCR with primers specific for the vanA gene were used to confirm the presence of the 
vanA gene cluster.  For the 42 VRE strains that gave no transconjugants, the total plasmid 
DNA content was subjected to agarose gel electrophoresis, and each band was extracted 
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from the gel.  PCR with primers for the vanA gene revealed which plasmid bands 
harbored the vancomycin resistance genes. 
With a single plasmid that harbors the vanA gene cluster now in hand for each of 
the 75 different VRE isolates, these plasmids were probed by PCR for the presence of the 
various TA systems, as described above.  A summary of these results in displayed in 
Figure 2.2B, and the complete listing of individual strains is in Table 2.4.  Although 
genes for the relBE (10/75; 13%) and ω−ε−ζ (12/75; 16%) TA systems were present on a 
relatively low percentage of the plasmids harboring the vanA-resistant gene cluster, the 
genes encoding the mazEF TA system were physically linked to the vancomycin 
resistance genes in a remarkable 93% (70/75) of the isolates, and axe-txe was present on 
59% (44/75) of these vanA-containing plasmids.  As before, DNA sequencing was used 
to confirm the identity of several of these PCR products.  While there appears to be no 
definitive physical linkage between a particular TA system and plasmid-encoded 
vancomycin-resistance, TA systems are clearly widespread on plasmids isolated from 
VRE and the majority of vanA-containing plasmids encode at least one TA system. 
     
2.3.3  Controls for Chromosomal Contamination 
 Due to the prevalence of the ΤΑ  genes observed by PCR, the possibility of 
chromosomal DNA contamination from enterococci as well as E. coli was addressed.  To 
verify that the observed results were indeed due to plasmid DNA and not due to 
chromosomal DNA contamination, a plasmid-free strain of E. faecium (BM4105-RF) was 
taken through the same alkaline lysis plasmid preparation protocol.  Any DNA thus 
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isolated was probed by PCR with primers specific for the various TA systems.  In all 
cases, no amplification was observed.   
To further verify that the results observed in the PCR screens could be attributed 
to the plasmid DNA, two methods were used to eliminate contaminating chromosomal 
DNA from a number of enterococcal plasmid DNA preparations before repeating PCRs 
for the genes of various TA systems.  First, after alkaline lysis preparation, the plasmid 
content from 15 of the VRE strains was treated with a “plasmid-safe” ATP-dependent 
DNase, an enzyme that digests linear DNA but not double-stranded supercoiled DNA 
[33, 36, 50, 72].  PCR amplification of the TA systems after this treatment closely 
matched the results of the initial PCR screen (see Table 2.5).  The genes for vanA, vanB, 
and the ten different TA systems were present in most of the DNase treated samples:  
vanA (15/15), vanB (3/3), ω−ε−ζ (5/9), axe-txe (13/13), ccd (0/1), mazEF (14/15), and 
relBE (7/9), suggesting that TA loci reside on plasmid DNA.   
Second, after alkaline lysis preparation, the plasmid content from seven of the 
VRE strains was further purified by CsCl gradient ultracentrifugation.  This highly 
purified plasmid DNA was then subjected to PCR analysis for the presence of TA 
systems, and again the PCR results closely matched the results of the initial PCR screens: 
vanA (7/7), vanB (1/1), ω−ε−ζ (3/4), axe-txe (6/6), mazEF (6/7), and relBE (0/4) (see 
Table 2.6).  Instances in which the plasmid DNA is negative for a particular TA system 
after DNase treatment or CsCl-purification may be due to two reasons.  One possible 
cause for a negative result is that the genes for the TA system are encoded on the 
chromosome and not the plasmid DNA, and chromosomal contamination in the original 
plasmid preparation led to a positive result in the initial PCR screens.  A second 
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explanation for a negative PCR result is that the plasmid DNA carrying the TA system 
was nicked and/or sheared during the alkaline lysis preparations, thus making it a 
substrate for the DNase and absent from the band corresponding to supercoiled DNA in 
the CsCl density gradient.  Despite these two possibilities, these results suggest that the 
majority of the genes for the different TA systems reside on the plasmid DNA in clinical 
VRE strains.   
Finally, the flanking regions of the axe-txe genes from clinical isolates U464 and 
SL243 and the mazEF genes from clinical isolates S206 and SL243 were sequenced.  The 
DNA regions just outside the TA gene systems were found to be nearly identical to 
regions from two different enterococcal plasmids, pRUM and pPD1 (see Table 2.7 for 
DNA sequences obtained, results of BLASTN search with that sequence, and percent 
similarity to the matched database DNA) [2].  Taken together, these data suggest the TA 
loci reside on plasmid DNA in the VRE isolates.     
 
2.4  FUNCTIONALITY OF THE MAZEF SYSTEM IN ENTEROCOCCI  
 
2.4.1  Plasmid Stability Assays 
The mazEF TA system and homologous systems (parD and chpB) have been 
most extensively studied on their plasmid and chromosomal origins in enterobacteria [5, 
41, 58].  Because 100% of the VRE strains obtained for this study harbored genes for a 
plasmid-encoded mazEF TA system (Figure 2.2A), plasmid stability assays were 
performed to determine whether this plasmid addiction system was indeed functional in 
enterococci.  As a first step, plasmid stability was assessed with a transconjugate that 
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harbors a single plasmid encoding both the vanA and mazEF genes but not any of the 
other TA systems that were examined by PCR.  This plasmid, designated pS345RF, was 
found to be stable in the absence of vancomycin selection for 265 bacterial generations 
(Figure 2.3A).  However, this experiment does not conclusively show that mazEF is 
functional in VRE, because other undetected or unknown plasmid stability/maintenance 
systems may be present on this plasmid.  
 
Figure 2.3  Plasmid stability assays.  (A) Plasmid pS345RF, which has the mazEF genes as the only 
detectable TA system by PCR, was stable for 265 generations in enterococci in the absence of any 
antibiotic selection.  Plasmid stability was determined by replica plating onto selective media.  (B) Plasmid 
pAM401 was highly unstable in enterococcal strain OG1X (▲) in the absence of antibiotic selection.  
Introduction of  the mazEF loci into pAM401 increased the stability of the plasmid (■).  Error bars 
represent standard deviation from the mean (n = 3). 
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To directly determine whether the mazEF genes are functional in enterococci, the 
mazEF loci identified in VRE, consisting of the upstream promoter region and mazEF 
genes, was cloned into the unstable enterococcal vector, pAM401.  Plasmid pAM401 
(10.4 kb) is an E. coli-E. faecalis shuttle vector and contains a pACYC184 replicon for 
replication in E. coli and a pIP501 replicon for replication in E. faecalis [73, 76].  The 
shuttle vector confers chloramphenicol resistance in E. faecalis and does not carry the 
genes for any plasmid stability determinants [76].  Without antibiotic selection for the 
plasmid, pAM401 has been shown to be inherently unstable in E. faecalis; after 30 
generations only 16% of the population retain the plasmid [76].  Plasmid stability was 
measured in E. faecalis strain OG1X in the absence of antibiotic selection for the plasmid 
[76].  The new plasmid containing the mazEF loci, designated pAM401EF, was found to 
be considerably more stable than the parent vector (Figure 2.3B).  The results of these 
assays suggest that mazEF acts as a functional TA system in enterococci. 
 
2.4.2  RT-PCR Analysis 
 To confirm that the mRNA coding for the MazEF proteins was indeed being 
produced in VRE, RT-PCR was performed from total mRNA isolated from 10 of the 
VRE clinical isolates.  As displayed in Figure 2.4, all 10 isolates that had been shown to 
harbor the mazEF genes by PCR did indeed produce the mazEF transcript, as assessed by 
RT-PCR (Figure 2.4A, lanes 1-10).  This same RT-PCR analysis was also performed on 
the total RNA isolated from the plasmid-free E. faecium strain BM4105-RF, which does 
not contain the mazEF genes, and no mazEF transcript was detected (Figure 2.4A, lane 
11).  To ensure the observed RT-PCR products were not due to DNA contamination, 
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controls were conducted in which the reverse transcriptase enzyme was not added, but all 
other components (including thermostable DNA polymerase and primers for mazEF) 
were added.  Analysis shows that no amplification is observed under these conditions, 
confirming that the products seen by RT-PCR were not due to DNA contamination 
(Figure 2.4B).  Finally, RT-PCR with primers for the enterococcal elongation factor (tuf, 
encoding EF-tu of enterococci) gave the expected positive result for all strains examined 
(Figure 2.4C).  Thus, RT-PCR analysis demonstrated that the mazEF transcript is indeed 
made in VRE clinical isolates carrying the mazEF genes.  In conjunction with the results 
of the plasmid stability assays, these results strongly suggest that the MazEF system is 
functional in the VRE clinical isolates.    
 
Figure 2.4  RT-PCR analysis of 10 clinical VRE isolates (lanes 1-10) and a plasmid-free enterococcal 
strain (BM4105-RF, lane 11).  The isolates tested were U563, C27282, C31582, C531926, S177, S234, 
S345, D1, SL278, and SL518 (lanes 1-10, respectively).  (A) RT-PCR with primers complementary to 
mazEF indicated that this transcript was present in the clinical isolates but not in plasmid-free BM4105-RF.  
(B) Controls for DNA contamination, in which the reverse transcriptase was left out of the reaction mix, 
gave no amplification of mazEF.  (C) RT-PCR with primers complementary to the enterococci tuf gene 
(encoding EF-tu) gave the expected products.  Lane M contains the 100-bp DNA ladder (Invitrogen). 
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2.5  IMMUNODETECTION OF RELBE IN VANCOMYCIN-RESISTANT 
ENTEROCOCCI 
To facilitate detection of the RelBE toxin and antitoxin proteins, whose genes 
were found to be prevalent in VRE as assessed by PCR, anti-RelBE polyclonal antibodies 
were raised in rabbits through the University of Illinois Immunological Resource Center 
(see Chapter 4 for more details on expression and purification of the RelBE proteins, 
antibody generation, and Western blot development).  The cell lysates of four VRE 
clinical isolates and the plasmid-free E. faecium strain BM4105-RF, which does not 
contain the relBE genes, were separated by SDS-PAGE and transferred to an Immobilon-
P PVDF membrane (Millipore).  The membrane was probed with the anti-RelBE 
polyclonal antibody, and followed by mouse anti-rabbit IgG-horseradish peroxidase 
conjugated antiserum (Pierce).  Antibody binding was then detected with Supersignal 
West Pico Chemiluminescent substrate (Pierce) and autoradiography film.  The sizes 
expected for RelB and RelE are 9,070 Da and 11,225 Da, respectively.  For three of the 
VRE isolates and BM4105-RF, no bands were detected in the 10-15 kDa range.  
However, for VRE strain U464, a band was detected that migrated between the 10 and 15 
kDa markers (Figure 2.5A).   
To isolate the VRE protein detected by the RelBE antibody in significant 
quantities for further analysis, immunoprecipitation was performed.   RelBE antiserum 
was coupled to Affi-Gel 10 affinity media (Bio-Rad) and incubated with VRE U464 cell 
lysate.  To isolate proteins which bound selectively to the immobilized RelBE antibody, 
the slurry was thoroughly washed and then resuspended in denaturing SDS loading dye 
and analyzed by SDS-PAGE and Western blot.  A band in the 10-15 kDa range was 
detected both by Coomassie staining and western blot with the RelBE antibody (Figure 
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2.5B-C).  The Coomassie-stained band was exised from the polyacrylamide gel and 
submitted for internal sequence analysis through the University of Illinois Protein 
Sciences Facility.  Unfortunately, sequencing results were inconclusive since the ion 
scores of the best protein hits were below the threshold for indicating identity or 
extensive homology.  Thus, the identity of the protein in the band could not be 
determined with confidence.   
 
Figure 2.5  Immunodetection of RelBE.  (A)  Western blot analysis of the cell lysate of VRE isolate U464 
using RelBE antiserum.  (B) Western blot analysis and (C) Coomassie stain of proteins immunoprecipitated 
from U464 cell lysate using RelBE antiserum coupled to Affi-Gel 10 affinity media. 
 
 
2.6  CONCLUSIONS 
 Although the resistance of enterococci to vancomycin in hospital settings is a 
fairly recent phenomenon, VRE are now responsible for a large subset of nosocomial 
infections.  This upward trend in resistance is alarming:  VRE is now a major and largely 
untreatable infection, and VRE can pass the vancomycin resistance genes to the highly 
virulent methicillin-resistant S. aureus (MRSA) [21, 75].  Due to its high medical 
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relevance of VRE, an increasing number of studies have begun to explore the nature of 
plasmid-encoded vancomycin resistance.  A variety of enterococcal plasmids have been 
identifed that carry the gene clusters encoding the elaborate protein systems that mediate 
vancomycin resistance, including pheromone-responsive and highly conjugative plasmids 
[4, 22, 23, 25, 30, 31, 38, 40, 49, 52, 68, 69, 77, 78].  However, the mechanisms that 
allow these mobile genetic elements to be retained in enterococci even in the absence of 
antibiotic selection are not well understood. 
 TA systems have been identified on the chromosomes and plasmids of many 
different (mostly Gram-negative) bacteria [32].  Although the exact function of these 
chromosomal TA systems is still unclear, in some cases, they are believed to be linked to 
a bacterial stress response [1, 6, 26].  On plasmids, the function of TA systems seems 
straightforward:  to ensure faithful propagation of bacteria harboring the plasmid though 
the postsegregational killing of plasmid-free daughter cells.  Thus, it has been speculated 
that disruption of the TA interaction with pharmacological agents would unveil the active 
toxin and kill the cell from within (see Chapter 1, Section 1.6) [15, 20, 26].  However, 
many different TA systems have been described, and only recently have a few analyses 
been performed to determine their prevalence in clinically important bacteria.  A 
bioinformatics survey of 126 prokaryotic genomes has shown that the genes encoding TA 
systems are prevalent across a range of bacterial species (including archaea) [53].  In the 
survey, the genome of E. faecalis V583, the first vancomycin-resistant isolate reported in 
the United States, contained one loci belong to the relBE gene family, one loci belonging 
to the phd-doc gene family, and three loci belonging to the mazEF gene family (two of 
which were solitary toxins) [53].  The axe-txe and ω−ε−ζ TA systems have also been 
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found to be encoded in vancomycin-resistant enterococci.  The ω−ε−ζ genes have been 
discovered on the sequences of three enterococcal vancomycin-resistant plasmids isolated 
from a Norwegian poultry farm previously exposed to avoparcin as well as in a collection 
of VRE isolates from humans and animals on Norwegian poultry farms using PCR [39, 
61-63].  Recently, another PCR-based survey reported that in a collection of 93 E. 
faecium isolates (from a variety of sources including clinical, community and animal 
isolates) the genes for axe-txe and ω−ε−ζ were present in 61% of the strains and the 
occurrence of the TA systems was significantly higher in vancomycin-resistant isolates 
compared with vancomcyin-susceptible enterococci in the collection.  Thus, it is only just 
becoming clearer which TA systems are present and operational in the  most untreatable 
infections.  This lack of knowledge about the prevalence and identities of TA systems in 
clinically unmanageable bacteria has hampered compound development; indeed, to date, 
no small-molecule disruptors of any TA protein have been reported. 
 The  major findings of the survey of the plasmid content from 75 different VRE 
isolates are as follows: (i) Vancomycin resistance is plasmid encoded in the collection of 
isolates; (ii) genes encoding TA systems are ubiquitous in plasmids isolated from VRE; 
(iii) mazEF, and to a lesser extent axe-txe, relBE, and ω−ε−ζ, are common in plasmids 
from VRE isolates.  Whereas ω−ε−ζ has been previously observed on plasmids from 
Gram-positive organisms such as bacilli [8], streptococci [79], and enterococci [39], axe-
txe and par are the only other TA systems that have been found on a plasmid from a 
Gram-positive bacterium.  The axe-txe TA system was initially identified from a plasmid 
isolated from a single VRE clinical isolate, and in this strain, axe-txe was not physically 
linked with the vanA resistance element [28].  In this survey of 75 isolates, it was found 
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that the axe-txe genes are quite common on plasmids isolated from VRE (appearing in 
75% of the isolates), and in most cases, these genes reside on the same plasmid as the 
vancomycin resistance.  Similarly, ω−ε−ζ appeared quite frequently on the plasmids from 
VRE (44% of the isolates).  Interestingly, the plasmid on which axe-txe was discovered, 
pRUM, was found to make up the sequences of the flanking regions of several axe-txe 
and mazEF genes from the VRE isolates.      
The mazEF and relBE systems were both originally identified on the E. coli 
chromosome; relBE has also been found on a plasmid from E. coli [29], and the mazEF 
homologues, parD and pem, were identified on plasmids R1 and R100, respectively [5, 
47].  Thus, the finding that mazEF and relBE are common on plasmids from VRE is 
especially striking.  As mentioned above, loci resembling the mazEF and relBE genes, 
with varying degrees of homology, have been identified on the E. faecalis V583 genome 
[53].  However, the PCR products investigated from the collection of VRE clinical 
isolates show surprisingly strong sequence identity to the mazEF genes from the E. coli 
K12 genome. 
Thus, TA systems appear to be widespread on plasmids isolated from VRE.  
Further, all of those plasmids that contain the vanA resistance determinant encode at least 
one TA system.  In addition, the mazEF TA system is ubiquitous on plasmids residing the 
Gram-positive pathogen VRE (appearing in 100% of the isolates).  This high prevalence 
of mazEF suggests the encoded protein products as a logical target for tailored 
antibacterial therapy.  To determine whether mazEF is functional in these VRE isolates, 
several sets of experiments were performed.  First, the stability of a plasmid that contains 
mazEF as the only detectable TA system (plasmid pS345RF) was determined; this 
84 
 
plasmid also harbors the vanA gene.  It was observed that even in the absence of 
vancomycin, there is no detectable plasmid loss from enterococci over 265 generations of 
bacterial growth.  To directly demonstrate mazEF functionality in enterococci, the mazEF 
loci was cloned into an unstable enterococcal vector and shown to exert a stabilizing 
effect on the plasmid in enterococci.  Second, to determine whether the mazEF transcript 
is being synthesized by VRE, RT-PCR was performed on the total mRNA preparation 
from multiple VRE isolates.  It was found that the mazEF transcript is indeed being made 
when the mazEF genes are present.  While efforts to show that the MazEF proteins are 
made in enterococci were inconclusive, the plasmid stability and RT-PCR results are 
consistent with a functional mazEF in the VRE clinical isolates. 
 
2.7  MATERIALS AND METHODS 
Clinical Isolates of Enterococci.  A total of 75 clinical strains of Enterococcus 
spp., isolated from different patients over five different medical centers were collected.  
The medical centers were:  Carle Foundation Hospital (Urbana, IL), Memorial Medical 
Center (Springfield, IL), St. Mary’s Hospital (Decatur, IL), Mount Sinai Hospital 
(Chicago, IL), and Barnes-Jewish Hospital (St. Louis, MO).  The collection consisted of 
8 E. faecalis, 61 E. faecium, and 6 strains that were not able to be typed at the species 
level and are denoted as Enterococcus spp. 
Antibiotic Susceptibility Tests.  Susceptibility testing was performed in 
duplicate with the clinical isolates of enterococci by using the microdilution broth method 
as outlined by the Clinical and Laboratory Standards Institute (CLSI, formerly the 
National Committee for Clinical Laboratory Standards (NCCLS) [64].  Briefly, 
85 
 
organisms were inoculated into broth and incubated at 37°C until the culture reached the 
turbidity of the 0.5 McFarland standard.  The test medium used was cation-adjusted 
Mueller Hinton II broth (BBL) for all organisms tested.  For testing daptomycin 
susceptibility, the broth was supplemented with 50 mg/L Ca2+.  Antibiotic concentrations 
were prepared manually in the range of the minimum inhibitory concentration (MIC) 
interpretive standards for Enterococcus spp. and dispensed with a 125-µL Matrix Impact 
pipettor.  The MIC was defined as the lowest concentration of each antimicrobial agent 
that resulted in a ≥80% reduction in growth. 
Total DNA Isolation.  Total DNA from enterococci was isolated and purified by 
an alkaline-lysis method modified from standard protocols [18].  After phenol-
chloroform extraction, total DNA was precipitated by adding 100 µL of a 1:1 mixture of 
7.5 M NH4OAc and 100% ethanol on ice for 30 minutes.  Total DNA was recovered by 
removing the supernatant after centrifugation and resuspending the pellet in 10 mM 
Tris·HCl (pH 8.5) to a final volume of 100 µL. 
Plasmid DNA Isolation.  Plasmid DNA from all enterococcal strains and 
transconjugants was isolated by a modified alkaline lysis method [57].  Cell pellets were 
initially incubated with lysozyme (20 mg/mL) in 25 mM Tris/10 mM EDTA (pH 8.0), 
containing 50 mM glucose at 37°C for 1 hour.  After phenol-chloroform extraction, 
plasmid DNA was precipitated by addition of isopropanol and pelleted by centrifugation.  
The isopropanol was gently aspirated and the DNA pellet was washed with 70% ethanol.  
The plasmid DNA was again pelleted by centrifugation, the supernatant removed, and the 
pellet was resuspended in 100 µL of 10 mM Tris·HCl buffer, pH 8.5. 
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Genotypic Characterization of Enterococci by PCR.  For all clinical VRE 
isolates, PCR amplification was performed from purified total DNA or from purified 
plasmid DNA.  Oligodeoxynucleotide primer pairs were synthesized (Integrated DNA 
Technologies) that amplify the ddlE. faecalis and ddlE. faecium genes, the tuf gene, the groES 
gene, and a strongly conserved sequence in E. faecium, to identify clinical enterococci 
isolates at the genus and species level, as previously described [9, 17, 42, 66, 71].  A 
primer pair derived from the vanA gene sequence was used to amplify specifically the 
vancomycin-resistance determinant in Enterococcus, as well as a pair of PCR primers 
specific for the vanB gene sequence [16].  Primer pairs were designed based on the rep 
gene sequence of pAMβ1,  the aggregation substance gene of pCF10, and the traA gene 
of pMG1, to probe enterococcal isolates for the presence of plasmids belonging to the 
Inc18 family, pheromone-responsive type plasmids, and pMG1-like plasmids, 
respectively.  Based on the sequence alignment of the axe-txe, par, parDE, ccd, mazEF, 
relBE, higBA, vagCD, and phd-doc TA genes in the National Center for Biotechnology 
Information database, pairs of non-degenerate primers specific to each TA system were 
designed to amplify internal fragments with sizes ranging from 456 bp to 1.04 kb.  The 
sequence of primers to amplify the ω−ε−ζ gene system were identical to those previously 
reported [39]. 
 PCR amplification was performed in a final volume of 100 µL containing 1-3 µL 
of purified total DNA or plasmid DNA, 1X PCR buffer (20 mM Tris-HCl, 50 mM KCl, 
pH 8.4), 1.5 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate, 0.5 µM of each 
primer, and 2.5 U of Taq polymerase (Invitrogen).  PCR was carried out in a DNA 
thermal cycler (PTC-200, MJ Research, Inc.) with an initial denaturation step (94°C, 3 
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min), 30 cycles of denaturation (94°C, 1 min), annealing (54°C, 1 min), and extension 
(72°C, 1 min 30 s), followed by a final extension step (72°C, 10 min).  PCR amplification 
products were analyzed by agarose gel electrophoresis in 1% agarose and stained with 
ethidium bromide. 
Isolation of Plasmids Encoding Vancomycin Resistance.  Filter and broth 
matings were attempted with all clinical strains of VRE and recipient strains E. faecium 
BM4105-RF and BM4105-SS (SS, streptomycin and spectinomycin resistance), as 
described with minor modifications [11, 13].  E. faecium BM4105-RF and BM4105-SS 
are resistant to RF and SS, respectively.  To 3 mL of fresh brain-heart infusion (BHI) 
broth (BBL), equal (1 mL) volumes of donor strain and recipient strain cultures (grown 
overnight in BHI broth at 37°C) were added and further incubated for 4 hours.  The 
mating mixture was plated on BHI agar plates containing rifampicin (50 µg/mL), fusidic 
acid (20 µg/mL), and vancomycin (10 µg/mL) or streptomycin (200 µg/mL), 
spectinomycin (100 µg/mL), and vancomycin (10 µg/mL).  After incubation at 37°C for 
up to 48 hours, plates were checked for the absence (donor and recipient cultures only) or 
presence (mating mixtures) of colonies on triple selective media. 
 For filter matings, mating mixtures were filtered though a sterile membrane filter 
(pore size, 0.45 µm; MF-Millipore membrane filter HAWP 2500).  The filters were 
incubated on BHI agar plates for 24 hours at 37°C.  After mating, the cells were 
resuspended in 1 mL of BHI broth and spread on BHI agar containing rifampicin (50 
µg/mL), fusidic acid (20 µg/mL), and vancomycin (10 µg/mL) or streptomycin (200 
µg/mL), spectinomycin (100 µg/mL), and vancomycin (10 µg/mL).  The platers were 
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incubated at 37°C for 24-48 hours and checked for the absence (donor and recipient 
cultures only) or presence (mating mixtures) of colonies on triple selective media. 
 Total plasmid DNA was isolated, as described above, from clinical VRE strains 
that repeatedly failed to mate with E. faecium BM4105-RF or BM4105-SS.  This plasmid 
DNA was analyzed by agarose gel electrophoresis in 1% agarose and stained with 
ethidium bromide.  Individual bands were extracted by using the QIAquick gel extraction 
kit (Qiagen).  The vancomycin-resistance plasmid DNA was identified by PCR for the 
vanA gene.  
Sequence Analysis.  Approximately 10% of the PCR products generated from 
custom primers for the TA systems, vancomycin-resistant determinants, and species-
specific genes were submitted for DNA sequencing by the University of Illinois W. M. 
Keck Center for Comparative and Functional Genomics.  Sequence data were analyzed 
by using BioEdit, version 7.0.4.1, computer software and the BLAST database to verify 
the identity of the PCR products and sequence identity to known genes [2]. 
Plasmid-Safe DNase Treatment and Analysis.  To selectively digest 
contaminating chromosomal DNA, plasmid DNA preparations from 15 VRE strains were 
treated with Plasmid-Safe ATP-Dependent DNase (Epicentre Biotechnologies) according 
to the manufacturer’s recommendations.  In brief, 1 ug of plasmid DNA was treated with 
5 U of DNase in 25 µL reaction volumes at 37ºC for 1 hour.  The enzyme was inactivated 
at 70ºC for 30 minutes and PCR amplification was performed on treated plasmid DNA as 
described above.  PCR amplification products were analyzed by agarose gel 
electrophoresis in 1% agarose and stained with ethidium bromide. 
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Cesium Chloride (CsCl) Plasmid DNA Purification and Analysis.  Plasmid 
DNA prepared by the alkaline lysis method from seven VRE strains was further purified 
by CsCl-ethidium bromide density gradient centrifugation.  The plasmid DNA was 
resuspended in 10 mL elution buffer (10 mM Tris·HCl (pH 7.5) and then mixed with 
CsCl (1 g/mL, final concentration) and ethidium bromide (0.8 mg/mL, final 
concentration).  The DNA mixture was centrifuged in a Ti70.1 rotor for 24 to 48 hours at 
50,000 rpm until a band corresponding to the supercoiled plasmid DNA could be 
collected.  To remove ethidium bromide from the samples, DNA was extracted three 
times with a solution of n-butanol saturated with 1g/mL CsCl in elution buffer.  To 
remove the CsCl, DNA was ethanol precipitated and resuspended in 200 µL elution 
buffer.  PCR amplification was performed on CsCl purified plasmid DNA as described 
above and PCR amplification products were analyzed by agarose gel electrophoresis in 
1% agarose and stained with ethidium bromide. 
Sequence Analysis of the Flanking Regions of TA Loci.  Oligodeoxynucleotide 
primers were synthesized (Integrated DNA Technologies) that were derived from the 
ends of the axe-txe and mazEF gene sequences.  The total plasmid DNA from 7 clinical 
VRE isolates were submitted for DNA sequencing by the University of Illinois W.M. 
Keck Center for Comparative and Functional Genomics or by Nick Hermersmann at the 
University of Wisconsin (Madison) Genetics Sequencing and Genomics Services Center.  
Sequence data were analyzed by using BioEdit, version 7.0.4.1, computer software and 
the BLAST database to verify the identity of the PCR products and sequence identity to 
known genes [2]. 
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Plasmid Stability Tests.  The stability of the vancomycin-resistant plasmid in the 
transconjugant, S345RF, was studied in triplicate, as described, with some modifications 
[60].  One hundred microliters of an overnight culture of the strain grown in BHI broth 
containing 10 µg/mL vancomycin was used to inoculate 10 mL of fresh BHI broth 
containing 10 µg/mL vancomycin and grown for 4 hours.  Dilutions of the culture were 
prepared in sterile dH2O and plated onto nonselective BHI agar plates for viable counts.  
The 10-4 dilution of the culture was used to inoculate 10 mL of BHI broth without 
selection and grown overnight at 37°C.  Dilutions and viable counts were made with the 
culture as before, and a 10-4 dilution of the culture was subcultured into 10 mL of fresh 
BHI broth.  This process was repeated until 250-300 generations of growth were 
achieved.  Viable count plates containing 75-150 colonies were replica-plated onto BHI 
agar plates with and without 10 µg/mL vancomycin.  The proportion of the population 
retaining the vancomycin-resistant plasmid compared with the total number of viable 
cells was calculated in this way.  Plasmid DNA was isolated throughout the stability 
assay from selected colonies to confirm the maintenance or loss of the vancomycin-
resistant plasmid. 
 The stability of the enterococcal vector pAM401 (with and without the mazEF 
loci cloned in at the XbaI restriction site) was assessed in triplicate.  These experiments 
were performed in an analogous fashion to the experiments described with pS345RF 
above, except chloramphenicol was used to select for the cells that contained the plasmid, 
and the assay was continued for 75-95 generations of bacterial growth.  The data points at 
bacterial generation zero represent the time at which the bacteria were introduced into the 
media without antibiotic selection.  Plasmid retention was determined by replica plating; 
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generations from overnight growth on the antibiotic-free plates were not included in the 
bacterial generation count and could account for the appearance of a mixed (plasmid and 
plasmid-free) population at generation zero. 
RNA Extraction and RT-PCR Analysis.  To 10 mL of fresh BHI broth, 10 µL 
of a culture grown overnight in BHI broth was added and further incubated until 
approximately 1 x 109 cells were present.  RNA was extracted by using the RNeasy Mini 
Kit for Isolation of Total RNA from Bacteria and treated up to two times with the RNase-
Free DNase set (Qiagen).  RT-PCR was performed by using the SuperScript One-Step 
RT-PCR with Platinum Taq kit (Invitrogen).  Intragenic primers used for mRNA mazEF 
expression were designed from the E. coli K12 mazEF sequence, and the control primers 
were based on the tuf gene specific to enterococcal species [42].  Processed RNA (100 
ng) was used in RT-PCR, as well as PCRs with Platinum TaqDNA polymerase 
(Invitrogen) to detect DNA contamination.  RT-PCR was performed in a total reaction 
volume of 50 µL in a DNA thermal cycler (PTC-200; MJ Research), with an initial cycle 
at 50°C for 30 minutes for cDNA synthesis and then one cycle of denaturation at 94°C 
for 2 minutes.  PCR amplification began immediately after cDNA synthesis and 
denaturation with 35 cycles of denaturation (94°C, 30 seconds), annealing (54°C, 45 
seconds), and extension (72°C, 1 minute), followed by a final extension step (72°C, 10 
minutes).  RT-PCR amplification products were analyzed by agarose gel electrophoresis 
in 1% agarose and stained with ethidium bromide. 
RelBE Antibodies.  Anti-RelBE polyclonal antibodies were raised in rabbits 
through the University of Illinois Immunological Resource Center (IRC).  Recombinantly 
expressed and purified RelBE complex was dialyzed thoroughly into dH2O and 
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lyophilized to dryness.  Approximately 3.4 mg of lyophilized RelBE was resuspended in 
2 mL of 50 mM Tris·HCl (pH 7.5) and submitted to the IRC for antibody production.  
Western Blot Analysis.  Enterococcal strains were grown in 5 mL BHI broth to 
an OD600 of 0.4-0.6 and pelleted by centrifugation.  Cell pellets were resuspended in 50 
µL SDS loading dye buffer, sonicated for 10 seconds, and heated at 95ºC for 5 minutes.  
For each sample, 25uL was run on a 4-20% Tris·HCL precast gel (Bio-Rad) for 
approximately 1.5 hours at 100 V.  After SDS-PAGE, proteins were transferred to an 
Immobilon-P PVDF membrane (Millipore) in cold Towbin Transfer buffer (25 mM Tris, 
192 mM glycine, 20% methanol, pH 8.3) with a Bio-Rad Trans-Blot electrophoretic 
transfer apparatus for 2 hours at 45 V.  Before probing, membranes were blocked with 
Phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7H20, 
1.4 mM KH2PO4, pH 7.3) containing 5% nonfat dried milk overnight with gentle shaking 
at 4ºC.  Membranes were probed with anti-RelBE antiserum at a 1:1000 dilution in PBS, 
followed by mouse anti-rabbit IgG-horseradish peroxidase conjugated antiserum at a 
1:20,000 dilution (Pierce) in PBS with 5% nonfat dried milk.  Antibody binding was then 
detected with Supersignal West Pico Chemiluminescent substrate (Pierce), followed by 
exposure to autoradiography film and developed using a Future 2000 K automatic x-ray 
film processor (Fisher Scientific).     
Immunoprecipitation and Protein Sequence Analysis.  VRE strain U464 was 
grown in 25 mL BHI broth to an OD600 of 0.4-0.6 and pelleted by centrifugation.  The 
cell pellet was resuspended in 500 µL non-denaturing lysis buffer (1% Triton X-100, 50 
mM Tris, 300 mM NaCl, pH 7.4), frozen at -80°C and thawed, sonicated for 1 minute 
with pulses, and heated at 95ºC for 5 minutes.  RelBE antiserum was coupled to Affi-Gel 
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10 affinity media (Bio-Rad) by first thoroughly dialyzing RelBE antiserum into 100 mM 
MOPS, pH 7.5 at 4°C over approximately 48 hours with three buffer changes.  The 
dialyzed serum was centrifuged at 12,000 x g at 4°C for 10 minutes and the supernatant 
transferred to a new tube to remove aggregates.  Affi-Gel 10 beads (2 mL) were washed 
with 6 mL cold dH2O, resuspended in 500 µL 100 mM MOPs, pH 7.5, and then added to 
approximately 5 mg of dialyzed RelBE antiserium.  Coupling of the Affi-Gel 10 media 
and the RelBE antiserium was allowed to procede, protected from light, at 4°C overnight 
with gentle stirring.  Following coupling, 200 µL of 1 M ethanolamine (pH 8.0) was 
added to the slurry and allowed to continue gently stirring for 1 hour at 4°C.   
Equal volumes (500 µL) of dilution buffer (0.1% Triton X-100, 10 mM Tris, 140 
mM NaCl, pH 8.0), cell lysate, and RelBE coupled to Affi-Gel 10 media were combined 
together and gently shaken at 4°C for 1 hour.  The slurry was pelleted by centrifugation 
for 10 seconds and the supernatant removed.  The beads were washed twice with 1 mL 
dilution buffer, once with 1 mL 10 mM Tris, pH 8.0, 140 mM NaCl, and once with 1 mL 
50 mM Tris, pH 6.8, before finally being resuspended in 100 µL SDS loading dye.  The 
slurry was heated at 95ºC for 5 minutes, centrifuged for 5 minutes, and approximately 30 
µL of the supernatant was run in two separate lanes on a 4-20% Tris·HCl precast gel 
(Bio-Rad) for approximately 1.5 hours at 100 V.  After SDS-PAGE, protein from one of 
the lanes was transferred to an Immobilon-P PVDF membrane and Western blot analysis 
was carried out as described above.  Protein from the second lane was stained with 
Coomassie brilliant blue staining solution (50% methanol, 0.05% Coomassie brilliant 
blue R-250, 10% acetic acid, 40% dH2O) for 1 hour at room temperature and destained 
overnight in a solution of 50% methanol, 40% dH2O, and 10% acetic acid.  The protein 
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band of interest detected both by Western blot and Coomassie-stain was cut out from the 
Coomassie-stained polyacrylamide gel and submitted for internal sequence analysis 
through the University of Illinois Protein Sciences Facility.  Sequence analysis of 
individual peptides from the sample was performed by staff at the facility using Matrix 
Science and/or PEAKS computer software and database searching for protein 
identification. 
 
2.8  TABLES AND FIGURES 
Table 2.1  PCR primers designed for this study. * (+), sense primer; (-), antisense primer; N/A, not 
applicable. 
 
Primer Sequence (5' to 3')* Position  Accession Product  Reference 
      number size (bp)   
axe-txe (+)CTGACCCTTTCCTTACTTCCG 4937-4957 NC_005000 556 This  
(-)GGGTGAAAGGAATGGAAGCAG 5493-5473 study 
ccd (+)GTGACAGTTGACAGCGACAG 46358-46377 NC_002483 471 This 
(-)GATGTCATTTTCGCGGTGGC 46829-46810 study 
ddlE. faecalis (+)CACCTGAAGAAACAGGC 206-222 U00457 475 [16] 
(-)ATGGCTACTTCAATTTCACG 680-661 
ddlE. faecium (+)GAGTAAATCACTGAACGA  1-18 U39790 1,091 [16] 
(-)CGCTGATGGTATCGATTCAT 1091-1072 
EM1 (+)TTGAGGCAGACCAGATTGACG N/A L78127 658 [9] 
(-)TATGACAGCGACTCCGATTCC 
ω−ε−ζ (+)GTG GTT TAG GTG GCT GCA AG ORF18-19 X92945 1,044 [40] 
(-)TTA ACG AAT TAT CGG CAA GC 
groES (+)GGAATTGTTCTTGCATCCGT 67-86 AF335185 185 [67] 
(-)ACAATTAAGTATTCTACGCC 251-232 
higBA (+)GGGTGTTACTTCTGGTGTGC 194811-194830 NC_003905 530 This 
  (-)GTTCTGCTGCTGTTCGTTCG 195341-195322     study 
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Table 2.1  (cont.) 
 
Primer Sequence (5' to 3')* Position  Accession Product  Reference 
      number size (bp)   
mazEF-1 (+)CTTCGTTGCTCCTCTTGC 2908844-2908861 NC_000913 496 This 
(-)CGTTGGGGAAATTCACCG 2909340-2909323 study 
mazEF-2 (+)CAACTGTTCCTTTCTTCGTTGCTCC 2908831-2908855 NC_000913 443 This 
(-
)GATGATGAAGTGAAGATTGACCTGG 2909274-2909250 study 
par (+)CCATGCACTACTAGGCAACC 3725-3744 L01794 746 This 
(-)CTGTCTAGCAAGCAGAGTTACG 4471-4450 study 
parDE (+)CTAGCGCATTTTCCCGAC 88-105 L05507 658 This 
(-)GAAATCAGCCCTTGAGCC 746-729 study 
phd-doc (+)CCATTAACTTCCGTACCGC 2130-2148 M95666 530 This 
(-)GTCGCAGCTCCTACAGTAAG 2660-2641 study 
relBE (+)CAGAGAATGCGTTTGACCG 1643371-1643389 NC_000913 456 This 
(-)GGTGTAACTCCTTCTGAAGCG 1643827-1643807 Study 
rep (+)CTGTGCTTCATGACGGCTTG 3139-3158 AF007787 1,426 This 
(-)CGTTTTAGGGCGTTCTGC 4565-4548 study 
traA (+)GGCAAAGAGTCATTATCGCTCGG 16-38 AB081477 825 This 
(-)CATTTTCTGCCCCCTGTTCAC 841-821 study 
agg (+)GCCAATGTGGTTCCTGTTC 1738-1756 NC_006827 1,882 This 
(-)CCTGCCGCAATTCGTTCTAC 3620-3601 study 
tuf (+)TACTGACAAACCATTCATGATG N/A N/A 112 [43] 
(-)AACTTCGTCACCAACGCGAAC 
vagCD (+)CCCGGTGCAATGAACATC 12264-12281 AY517905 692 This 
(-)GTACCCGCTTCAAATTCCCG 12956-12937 study 
vanA (+)GGGAAAACGACAATTGC 176-192 M97297 732 [18] 
(-)GTACAATGCGGCCGTTA 907-891 
vanB (+)ACGGAATGGGAAGCCGA 169-185 U00456 647 [16] 
  (-)TGCACCCGATTTCGTTC 815-799       
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Table 2.2  Antimicrobial Resistance Profiles.  Hospital 1 is Carle Foundation Hospital, Hospital 2 is 
Memorial Medical Center, Hospital 3 is St. Mary’s Hospital, Hospital 4 is Mount Sinai Hospital, Hospital 5 
is Barnes Jewish Hospital.   Abbreviations:  Amp, Ampicillin; Dap, Daptomycin; Erm, Erythromycin; Gen, 
Gentamicin; Lin, Linezolid, Q-D, Quinupristin-dalfopristin; Tet,Tetracycline; Van, Vancomycin; R,  
resistant; I,  intermediate; S, sensitive. 
 
    Antimicrobial Agents 
Isolate Species Amp Dap Erm Gen Lin Q-D Tet Van 
Hospital 1 
U63 E. faecium R S R S S S R R 
U275 E. faecium R S S R S S R R 
U464 E. faecium R S R S S S R R 
U503 E. faecium R S R S S S S R 
U563 E. faecium R S R S S S R I 
  
Hospital 2 
S34 E. faecium R S R S S S R R 
S51 E. faecium R S R R S S S R 
S122 E. faecium R S R R S S S R 
S151 E. faecium R S R S S S S R 
S177 E. faecium R S R R S S S R 
S193 E. faecium R S R R S S R R 
S194 E. faecium R S R R S S R R 
S196 E. faecium R S R R S S S R 
S206 E. faecalis S S R R S R S R 
S226 E. faecium R S R R S S S R 
S234 E. faecalis S S R R S R R I 
S235 E. faecium R S R R S S R I 
S236 E. faecium R S R R S S R R 
S258 E. faecium R S I R R S R R 
S315 E. faecium R S R R S S R R 
S344 E. faecium R S R R S S S R 
S345 E. faecium S S R R S R R R 
S556 E. faecium S S R R S S S R 
S557 E. faecium R S R S S S S R 
  
Hospital 3 
D1 E. faecium R S R S S S S R 
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Table 2.2 (cont.)   
 
    Antimicrobial Agents 
Isolate Species Amp Dap Erm Gen Lin Q-D Tet Van 
Hospital 4 
C21190 E. faecium R S R R R S R R 
C21667 E. faecalis S S R R S R R R 
C27282 E. faecium R S R R S S R R 
C27569 E. faecium R S R R S S R R 
C28036 Ent. Spp. S S R R R R R R 
C28535 E. faecalis S S R R R R R R 
C29113 E. faecium R S R R R R R R 
C30280 E. faecalis S S S S S S S R 
C30296 E. faecalis S S I R R S R I 
C30465 E. faecium S S R R S R R R 
C31582 Ent. Spp. R S R R S S S R 
C33105 E. faecium R S R R S S R R 
C40105 E. faecalis S S R R S S S I 
C531926 E. faecalis R S R S R R I R 
  
Hospital 5 
SL152 E. faecium R S R R S S S R 
SL162 E. faecium R S R S S S S R 
SL166 E. faecium R S R R S S R R 
SL171 E. faecium R S R R S S S R 
SL172 E. faecium R S R S S S R R 
SL186 E. faecium S S R R S S R R 
SL234 E. faecium R S R S S S R R 
SL242 E. faecium R S R R S I R R 
SL243 E. faecium R S R R S S S R 
SL266 E. faecium R S R R S S S I 
SL270 E. faecium R S R S S S R R 
SL271 E. faecium S S R R S S R R 
SL273 E. faecium R S R R S S S R 
SL278 E. faecium R S R S S S R R 
SL285 E. faecium R S R R S S S R 
SL301 E. faecium S S R S S S S R 
SL315 E. faecium R S R R S S S R 
SL337 E. faecium R S R S S S R R 
SL365 E. faecium R S R R S S S R 
SL385 E. faecium R S R R S S S R 
SL394 E. faecium R S R S S S S R 
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Table 2.2 (cont.)   
 
    Antimicrobial Agents 
Isolate Species Amp Dap Erm Gen Lin Q-D Tet Van 
Hospital 5 
SL416 E. faecium R S R R S S R R 
SL426 E. faecium R S R S S S R I 
SL496 E. faecium R S R S S S R R 
SL518 E. faecium R S R S S S R R 
SL523 E. faecium R S R S S S R R 
SL542 E. faecium R S R S S S S R 
SL603 E. faecium R S R R S S R R 
SL633 E. faecium R S R S S S R R 
SL635 E. faecium S S R R S R R R 
SL640 E. faecium R S R R S S S R 
SL641 Ent. Spp. R S R S S S R R 
SL653 Ent. Spp. R S S S S S R I 
SL733 Ent. Spp. R S R S S S R R 
SL745 Ent. Spp. R S R S S S S I 
SL756 E. faecium R S R S R S R R 
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(-)
 
(+
) 
(-)
 
(-)
 
(-)
 
(+
) 
(+
) 
(-
) 
(-)
 
(-)
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Table 2.4  Vancomycin-Resistnat Plasmid DNA PCR Results.  Hospital 1 is Carle Foundation Hospital, 
Hospital 2 is Memorial Medical Center, Hospital 3 is St. Mary’s Hospital, Hospital 4 is Mount Sinai 
Hospital, Hospital 5 is Barnes Jewish Hospital.   SS indicates mating with BM4105SS.  RF indicates 
mating with BM4105RF.  The * symbol indicates gel extraction was used to isolate the vancomycin-
resistant plasmid. 
  Antibacterial Plasmid Stability Systems                                                       
Determinants 
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
Hospital 1     
U63RF (+) (-) (-) (+) (-) (-) (+) (+) (-) (-) (-) (-) 
U275SS (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
U464RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
U503RF (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
U563RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
Hospital 2     
S34RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S51RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S122* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S151* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S177* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S193* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S194* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S196* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S206* (+) (-) (+) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S226* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S234* (+) (+) (-) (+) (-) (-) (-) (-) (-) (-) (-) (-) 
S235* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S236* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S258* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S315* (+) (-) (+) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S344RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
S345RF (+) (+) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S556* (+) (-) (+) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S557RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
Hospital 3     
D1* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
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Table 2.4 (cont.) 
  Antibacterial Plasmid Stability Systems                                                       
Determinants 
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
Hospital 4     
C21190RF (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C21667RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C27282* (+) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
C27569RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C28036* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C28535RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C29113RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C30280* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C30296* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C30465* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C31582* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C33105* (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C40105* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C531926* (+) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
    
Hospital 5     
SL152RF (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL162RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL166RF (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL171RF (+) (-) (+) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL172* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL186* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL234* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL242* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL243* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL266* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL270* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL271* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL273RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL278* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL285* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL301RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL315* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL337RF (+) (-) (+) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL365* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL385RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL394RF (+) (-) (-) (+) (-) (-) (-) (-) (-) (-) (-) (-) 
SL416RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL426RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL496* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL518RF (+) (-) (+) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
SL523* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL542* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
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Table 2.4 (cont.) 
  Antibacterial Plasmid Stability Systems                                                       
Determinants 
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
Hospital 5     
SL603RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL633* (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL635* (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL640RF (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL641RF (+) (+) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL653RF (+) (+) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
SL733RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL745RF (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL756* (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
 
Table 2.5  Plasmid DNA PCR Results After Plasmid-Safe DNase Treatment. 
  Vancomycin Plasmid Stability Systems                                                       
  Determinants                     
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
U63 (+) (-) (-) (+) (-) (-) (+) (+) (+) (-) (-) (-) 
U63 treated (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
U563 (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
U563 treated (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
S51 (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
S51 treated (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
S206 (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
S206 treated (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
S226 (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
S226 treated (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
S345 (+) (+) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
S345 treated (+) (+) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
D1 (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
D1 treated (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
    
C21190 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C21190 treated (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
C30465 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C30465 treated (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
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Table 2.5 (cont.) 
  Vancomycin Plasmid Stability Systems                                                       
  Determinants                     
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
C33105 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
C33105 treated (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
SL152 (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL152 treated (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
SL172 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL172 treated (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
SL273 (+) (+) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL273 treated (+) (+) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
    
SL542 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
SL542 treated (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
    
SL641 (+) (+) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
SL641 treated (+) (+) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
 
Table 2.6  CsCl Purified DNA PCR Results. 
  Vancomycin Plasmid Stability Systems                                                       
  Determinants                     
Isolate vanA vanB ω/ε/ζ axe- par parDE ccd mazEF relBE higBA vagCD phd- 
        txe               doc 
S122 (+) (-) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
CsCl purified (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
  
SL270 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
CsCl purified (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
  
SL756 (+) (+) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
CsCl purified (+) (+) (-) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
  
S258 (+) (-) (+) (+) (-) (-) (-) (+) (+) (-) (-) (-) 
CsCl purified (+) (-) (-) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
  
C30296 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
CsCl purified (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
  
C31582 (+) (-) (+) (+) (-) (-) (-) (+) (-) (-) (-) (-) 
CsCl purified (+) (-) (+) (+) (-) (-) (-) (-) (-) (-) (-) (-) 
  
SL365 (+) (-) (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
CsCl purified (+) (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
 
106 
 
 I
so
la
te
Ge
ne
(s
)
Fl
an
ki
ng
 
Se
qu
en
ce
 
T
op
 m
at
ch
 a
ft
er
 B
LA
ST
N
 se
ar
ch
Si
m
ila
rit
y
A
cc
es
ss
io
n
re
gi
on
siz
e 
(b
p)
(%
)
no
. o
f m
at
ch
U
46
4
ax
e-
tx
e
N
-t
er
m
in
us
29
4
Re
gi
on
 b
et
we
en
 A
xe
 a
nd
 o
rf
8 
fr
om
 p
RU
M
 (E
. f
ae
ci
um
)
29
4/
29
4 
(1
00
%
)
A
F5
07
97
7
ax
e-
tx
e
C-
te
rm
in
us
44
2
Re
gi
on
 b
et
we
en
 o
rf
5 
an
d 
T
xe
 fr
om
 p
RU
M
  (
E.
 fa
ec
iu
m
)
44
2/
44
2 
(1
00
%
)
A
F5
07
97
7
S2
06
m
az
EF
C-
te
rm
in
us
37
0
Ge
ne
 fo
r s
ur
fa
ce
 e
xc
lu
sio
n 
pr
ot
ei
n 
se
p1
fr
om
 p
PD
1 
(E
. f
ae
ca
lis
)
36
5/
37
0 
(9
8%
)
X
96
97
6
SL
24
3
ax
e-
tx
e
N
-t
er
m
in
us
24
7
Re
gi
on
 b
et
we
en
 A
xe
 a
nd
 o
rf
8 
fr
om
 p
RU
M
 (E
. f
ae
ci
um
)
24
7/
24
7 
(1
00
%
)
A
F5
07
97
7
ax
e-
tx
e
C-
te
rm
in
us
47
6
Re
gi
on
 b
et
we
en
 o
rf
5 
an
d 
T
xe
 fr
om
 p
RU
M
  (
E.
 fa
ec
iu
m
)
47
6/
47
6 
(1
00
%
)
A
F5
07
97
7
m
az
EF
N
-t
er
m
in
us
30
2
Re
gi
on
 b
et
we
en
 o
rf
5 
an
d 
T
xe
 fr
om
 p
RU
M
  (
E.
 fa
ec
iu
m
)
30
2/
30
2 
(1
00
%
)
A
F5
07
97
7
Is
ol
at
e
Fl
an
ki
ng
Se
qu
en
ce
Se
qu
en
ce
s o
f f
la
nk
in
g 
re
gi
on
s
re
gi
on
(5
'-3
')
U
46
4
ax
e-
tx
e 
   
 
N
-t
er
m
in
us
U
46
4
ax
e-
tx
e 
   
 
C-
te
rm
in
us
S2
06
m
az
EF
   
  
C
-t
er
m
in
us
A
GT
GA
CG
T
CA
CT
T
T
T
T
GA
GT
GC
T
GG
T
A
CC
T
CA
A
A
T
CC
T
GC
T
T
T
T
T
CT
T
GG
GC
A
A
T
CA
A
T
A
A
A
T
CT
A
A
CG
CA
A
T
A
CA
CA
T
A
A
T
C
CT
GG
A
T
T
CA
CT
T
T
T
GC
CG
T
A
CT
T
CT
GC
T
T
T
A
GT
T
GC
T
GC
A
A
T
T
CT
T
T
T
T
GT
CT
CT
T
T
T
CA
T
CC
A
A
CG
T
A
A
CG
GG
T
A
A
CC
GT
T
T
A
T
T
T
CC
T
A
T
T
GC
A
A
T
T
GG
CA
T
T
A
GT
A
CT
CT
CT
CC
T
T
T
CA
T
CG
A
A
A
T
A
A
CC
CT
A
T
GA
A
A
A
A
T
A
T
GG
CT
GC
A
A
T
CA
T
CT
T
GA
A
T
A
G
T
A
GA
CT
CA
CA
A
GG
GC
T
A
A
T
A
CA
A
A
GC
GC
CA
A
A
A
GA
T
CA
A
A
CA
A
A
A
GA
A
A
CT
T
A
A
A
A
GT
T
T
T
T
GA
T
CC
T
T
A
T
T
T
T
A
T
T
T
A
CC
CT
A
GT
CA
T
T
T
A
A
A
A
A
GC
T
A
A
T
A
T
A
GC
T
T
A
GT
GT
T
GA
T
T
GT
T
A
T
T
A
A
T
GA
A
T
GT
GT
T
T
GT
T
A
CG
CG
T
A
T
T
A
CG
GA
T
A
T
A
A
GG
T
T
A
GT
A
A
A
A
T
CA
T
T
T
CT
A
A
A
GT
T
GA
GG
A
A
A
A
GT
A
A
A
T
A
T
A
A
A
T
GG
C
T
T
A
A
A
T
T
T
CA
A
CA
A
T
T
T
GA
A
GT
T
GA
A
T
A
GA
T
A
T
GT
T
A
T
A
A
T
A
CT
A
T
T
GT
A
GT
GT
GG
GA
T
GT
T
A
GT
T
A
CT
A
A
A
GG
A
T
GA
CG
CT
T
A
T
A
T
A
T
A
T
GA
CT
GA
A
T
A
GA
A
T
A
A
GC
A
A
T
A
GG
T
T
T
A
A
T
A
A
T
CT
A
T
T
T
T
A
A
A
T
T
T
T
T
T
GT
A
CT
A
GT
T
T
T
A
GT
T
A
A
T
T
A
GC
A
A
A
A
A
CA
A
CA
A
A
A
A
T
A
A
A
CT
T
CT
CA
T
A
GA
A
T
T
T
A
GC
T
A
A
A
A
A
T
T
A
A
T
GA
T
T
T
A
T
T
T
A
CA
T
A
T
T
A
A
A
T
T
T
GG
A
T
A
CA
GT
T
A
A
GT
A
A
A
A
T
T
A
T
CT
GA
A
CA
A
GA
A
A
A
GC
A
GG
CA
A
T
GG
A
T
A
A
A
GA
A
GC
A
T
T
A
GC
A
T
T
A
A
A
T
A
A
A
GT
T
T
T
CC
CT
GA
A
A
A
T
CA
A
GC
A
GA
T
G
CG
GC
A
A
A
A
GC
A
A
CG
GA
A
A
T
GA
T
CA
A
T
GT
CA
A
A
A
A
T
CC
T
A
CA
GA
A
A
A
A
CA
T
A
A
GC
A
A
CA
A
A
T
GA
GT
GA
T
T
A
T
GT
T
GT
A
GG
A
CT
T
A
T
CA
A
CG
A
CG
T
T
CG
T
GA
A
A
A
A
T
T
CG
GA
T
T
A
CA
A
A
A
GT
T
GA
A
GA
T
T
T
CT
A
A
T
CA
A
GC
CA
T
GA
A
A
T
T
T
GC
T
T
GG
GA
T
GT
T
GC
T
A
A
A
T
A
CG
A
T
A
A
T
CC
T
A
A
A
GA
A
T
A
T
GG
A
CA
T
GA
T
GT
T
A
A
T
GC
A
A
T
T
A
A
T
A
A
A
GC
A
GC
GA
A
A
GA
GA
A
T
GG
A
T
T
T
A
A
GG
A
A
T
A
T
CC
A
G
GA
GA
A
A
A
CC
GA
T
A
CG
A
A
A
A
T
CT
GA
CA
A
T
T
GG
GT
A
T
T
A
T
Ta
bl
e 
2.
7 
 T
op
 B
LA
ST
N
 m
at
ch
es
 o
f f
la
nk
in
g 
se
qu
en
ce
s.
107 
 
 
 
 
 
Is
ol
at
e
Fl
an
ki
ng
Se
qu
en
ce
Se
qu
en
ce
s o
f f
la
nk
in
g 
re
gi
on
s
re
gi
on
(5
'-3
')
SL
24
3
ax
e-
tx
e 
   
 
N
-t
er
m
in
us
SL
24
3
ax
e-
tx
e 
   
 
C
-t
er
m
in
us
SL
24
3
m
az
EF
   
  
N
-t
er
m
in
us
Ta
bl
e 
2.
7 
(c
on
t.)
CA
A
A
A
GA
T
CA
CT
A
T
T
A
A
CC
A
A
T
CG
GA
A
GT
A
A
GG
A
A
A
GG
GT
CA
GA
A
A
CT
T
A
A
A
A
GT
T
T
T
T
GA
T
CC
T
T
A
T
T
T
T
A
T
T
T
A
CC
CT
A
GT
CA
T
T
T
A
A
A
A
A
GC
T
A
A
T
A
T
A
GC
T
T
A
GT
GT
T
GA
T
T
GT
T
A
T
T
A
A
T
GA
A
T
GT
GT
T
T
GT
T
A
CG
CG
T
A
T
T
A
CG
GA
T
A
T
A
A
GG
T
T
A
GT
A
A
A
A
T
CA
T
T
T
CT
A
A
A
GT
T
GA
GG
A
A
A
A
GT
A
A
A
T
A
T
A
A
A
T
GG
CT
T
A
A
A
T
T
T
CA
A
CA
A
T
T
T
GA
A
GT
T
GA
A
T
A
GA
T
A
T
GT
T
A
T
A
A
T
A
CT
A
T
T
GT
A
GT
GT
GG
GA
T
GT
T
A
GT
T
A
CT
A
A
A
GG
A
T
GA
CG
CT
T
A
T
A
T
A
T
A
T
GA
CT
GA
GA
A
A
CT
T
A
A
A
A
GT
T
T
T
T
GA
T
CC
T
T
A
T
T
T
T
A
T
T
T
A
CC
CT
A
GT
CA
T
T
T
A
A
A
A
A
GC
T
A
A
T
A
T
A
GC
T
T
A
GT
GT
T
GA
T
T
GT
T
A
T
T
A
A
T
GA
A
T
GT
GT
T
T
GT
T
A
CG
CG
T
A
T
T
A
CG
GA
T
A
T
A
A
GG
T
T
A
GT
A
A
A
A
T
CA
T
T
T
CT
A
A
A
GT
T
GA
GG
A
A
A
A
GT
A
A
A
T
A
T
A
A
A
T
GG
CT
T
A
A
A
T
T
T
CA
A
CA
A
T
T
T
GA
A
GT
T
GA
A
T
A
GA
T
A
T
GT
T
A
T
A
A
T
A
CT
A
T
T
GT
A
GT
GT
GG
GA
T
GT
T
A
GT
T
A
CT
A
A
A
GG
A
T
GA
CG
CT
T
A
T
A
T
A
T
A
T
GA
CT
GA
A
T
A
GA
A
T
A
A
GC
A
A
T
A
GG
T
T
T
A
A
T
A
A
T
CT
A
T
T
T
T
A
A
A
T
T
T
T
T
T
GT
A
CT
A
GT
T
T
T
A
GT
T
A
A
T
T
A
GC
A
A
A
A
A
CA
A
CA
A
A
A
A
T
A
A
A
CT
T
CT
CA
T
A
GA
A
T
T
T
A
GC
T
A
A
A
A
A
T
T
A
A
T
GA
T
T
T
A
T
T
T
A
CA
T
A
T
T
A
A
A
T
T
T
GG
A
T
A
CA
GT
T
A
A
GT
A
A
T
T
T
T
T
A
T
A
T
A
T
T
GG
A
GG
A
GA
A
GT
A
A
T
GG
A
A
T
A
T
A
A
A
T
T
T
A
A
CT
T
GA
A
T
T
T
GA
A
A
GA
A
GT
A
CT
CC
CC
A
CT
T
A
T
A
A
T
T
A
A
A
A
GT
GC
T
A
T
CA
CT
T
T
T
A
GT
T
T
T
T
A
GG
A
T
A
A
A
A
A
GT
GA
CG
T
CA
CT
T
T
T
T
GA
GT
GC
T
GG
T
A
CC
T
CA
A
A
T
CC
T
GC
T
T
T
T
T
CT
T
GG
GC
A
A
T
CA
A
T
A
A
A
T
CT
A
A
CG
CA
A
T
A
CA
CA
T
A
A
T
CC
T
GG
A
T
T
CA
CT
T
T
T
GC
CG
T
A
CT
T
CT
GC
T
T
T
A
GT
T
GC
T
GC
A
A
T
T
CT
T
T
T
T
GT
CT
CT
T
T
T
CA
T
CC
A
A
CG
T
A
A
CG
GG
T
A
A
CC
GT
T
T
A
T
T
T
CC
T
A
T
T
GC
A
A
T
T
GG
CA
T
T
A
GT
A
CT
CT
CT
CC
T
T
T
C
108 
 
 
Fi
gu
re
 2
.3
 A
lig
nm
en
t 
of
 ε−
ζs
eq
ue
nc
es
.  
Th
re
e 
of
 th
e 
33
 cl
in
ic
al
 V
R
E 
st
ra
in
s i
de
nt
ifi
ed
 b
y 
PC
R
 to
 co
nt
ai
n 
th
e 
ε−ζ
ge
ne
s 
w
er
e 
su
bm
itt
ed
 fo
r D
N
A
 
se
qu
en
ci
ng
.  
U
sin
g 
a 
C
lu
st
al
W
 M
ul
tip
le
 A
lig
nm
en
t 
(B
LO
SU
M
62
 M
at
rix
) t
he
 se
qu
en
ce
s w
er
e 
al
ig
ne
d 
w
ith
 th
e 
re
fe
re
nc
e 
ε−ζ
se
qu
en
ce
 fr
om
 th
e 
S.
 
py
og
en
es
pl
as
m
id
 p
SM
19
03
5.
  B
as
es
 h
ig
hl
ig
ht
ed
 in
 b
ol
d 
on
 th
e r
ef
er
en
ce
 s
eq
ue
nc
e i
nd
ic
at
e 
th
e 
lo
ca
tio
n 
of
 th
e 
pr
im
er
s 
us
ed
 to
 P
C
R
 fo
r t
he
ε−ζ
ge
ne
s. 
10
  
  
  
  
20
  
  
  
  
30
  
  
  
  
40
  
  
  
  
50
  
  
  
  
60
  
  
  
  
70
  
  
  
  
80
  
  
  
  
90
  
  
  
 1
00
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
AT
GG
CA
GT
TA
CG
TA
TG
AA
AA
AA
CA
TT
TG
AA
AT
AG
AG
AT
CA
TT
AA
CG
AA
TT
AT
CG
GC
AA
GC
GT
TT
AT
AA
TC
GA
GT
AT
TA
AA
CT
AT
GT
TT
TG
AA
CC
AT
GA
AT
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-G
CC
GG
TT
AT
A-
TC
GA
GT
TT
TA
A-
CT
NT
GT
TT
--
GA
CC
AT
GA
AT
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-T
TT
TT
GA
GN
AT
TT
TT
TT
TC
GC
AG
CG
TT
AT
A-
TC
GA
GT
GT
TA
A-
CT
AT
GT
TT
--
GA
CC
AT
GA
AT
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-T
TT
TT
TC
GT
TA
AA
NT
TT
TT
GC
TA
GG
TT
NT
A-
TC
GA
GT
AT
TA
A-
CT
AT
GT
TT
--
GA
CC
CT
GA
AT
 
11
0 
  
  
  
12
0 
  
  
  
13
0 
  
  
  
14
0 
  
  
  
15
0 
  
  
  
16
0 
  
  
  
17
0 
  
  
  
18
0 
  
  
  
19
0 
  
  
  
20
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
TA
AA
TA
AA
AA
TG
AC
TC
TC
AA
TT
AT
TG
GA
AG
TC
AA
TT
TA
TT
AA
AC
CA
AT
TA
AA
GC
TT
GC
AA
AA
CG
TG
TA
AA
TC
TT
TT
TG
AT
TA
TT
CT
TT
AG
AA
GA
AT
TA
CA
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
TA
AA
TA
AA
AA
TG
AC
TC
TC
AA
TT
AT
TG
GA
AG
TC
AA
TT
TA
TT
AA
AC
CA
AT
TA
AA
GC
TT
GC
AA
AA
CG
TG
TA
AA
TC
TT
TT
TG
AT
TA
TT
CT
TT
AG
AA
GA
AT
TA
CA
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
TA
AA
TA
AA
AA
TG
AC
TC
TC
AA
TT
AT
TG
GA
AG
TC
AA
TT
TA
TT
AA
AC
CA
AT
TA
AA
GC
TT
GC
AA
AA
CG
TG
TA
AA
TC
TT
TT
TG
AT
TT
TT
CT
TT
AG
AA
GA
AT
TA
CA
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
TA
AA
TT
AA
AA
TG
AC
TC
TC
AA
TT
AT
TG
GA
AG
TC
AA
TT
TA
TT
AA
AC
CA
AT
TA
AA
GC
TT
GC
AA
AA
CG
TG
TA
AA
TC
TT
TT
TG
AT
TA
TT
CT
TT
AG
AA
GA
AT
TA
CA
 
21
0 
  
  
  
22
0 
  
  
  
23
0 
  
  
  
24
0 
  
  
  
25
0 
  
  
  
26
0 
  
  
  
27
0 
  
  
  
28
0 
  
  
  
29
0 
  
  
  
30
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
AG
CC
GT
TC
AT
GA
GT
AT
TG
GC
GG
TC
AA
TG
AA
TC
GT
TA
CT
CA
AA
AC
AA
GT
TT
TG
AA
TA
AA
GA
GA
AA
GT
GG
CT
TA
AT
AT
GG
CA
AA
TA
TA
GT
CA
AT
TT
TA
CT
GA
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
AG
CC
GT
TC
AT
GA
GT
AT
TG
GC
GG
TC
AA
TG
AA
TC
GT
TA
CT
CA
AA
AC
AA
GT
TT
TG
AA
TA
AA
GA
GA
AA
GT
GG
CT
TA
AT
AT
GG
CA
AA
TA
TA
GT
CA
AT
TT
TA
CT
GA
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
AG
CC
GT
TC
AT
GA
GT
AT
TG
GC
GG
TC
AA
TG
AA
TC
GT
TA
CT
CA
AA
AC
AA
GT
TT
TG
AA
TA
AA
GA
GA
AA
GT
GG
CT
TA
AT
AT
GG
CA
AA
TA
TA
GT
CA
AT
TT
TA
CT
GA
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
AG
CC
GT
TC
AT
GA
GT
AT
TG
GC
GG
TC
AA
TG
AA
TC
GT
TA
CT
CA
AA
AC
AA
GT
TT
TG
AA
TA
AA
GA
GA
AA
GT
GG
CT
TA
AT
AT
GG
CA
AA
TA
TA
GT
CA
AT
TT
TA
CT
GA
 
31
0 
  
  
  
32
0 
  
  
  
33
0 
  
  
  
34
0 
  
  
  
35
0 
  
  
  
36
0 
  
  
  
37
0 
  
  
  
38
0 
  
  
  
39
0 
  
  
  
40
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
CA
AA
CA
AT
TT
GA
GA
AT
CG
CT
TA
AA
TG
AT
AA
TT
TA
GA
AG
AA
TT
GA
TT
CA
AG
GA
AA
AA
AA
GC
GG
TT
GA
AT
CG
CC
AA
CC
GC
TT
TT
TT
AC
TT
GG
TG
GG
CA
AC
CA
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
CA
AA
CA
AT
TT
GA
GA
AT
CG
CT
TA
AA
TG
AT
AA
TT
TA
GA
AG
AA
TT
GA
TT
CA
AG
GA
AA
AA
AA
GC
GG
TT
GA
AT
CG
CC
AA
CC
GC
TT
TT
TT
AC
TT
GG
TG
GG
CA
AC
CA
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
CA
AA
CA
AT
TT
GA
GA
AT
CG
CT
TA
AA
TG
AT
AA
TT
TA
GA
AG
AA
TT
GA
TT
CA
AG
GA
AA
AA
AA
GC
GG
TT
GA
AT
CG
CC
AA
CC
GC
TT
TT
TT
AC
TT
GG
TG
GG
CA
AC
CA
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
CA
AA
CA
AT
TT
GA
GA
AT
CG
CT
TA
AA
TG
AT
AA
TT
TA
GA
AG
AA
TT
GA
TT
CA
AG
GA
AA
AA
AA
GC
GG
TT
GA
AT
CG
CC
AA
CC
GC
TT
TT
TT
AC
TT
GG
TG
GG
CA
AC
CA
 
41
0 
  
  
  
42
0 
  
  
  
43
0 
  
  
  
44
0 
  
  
  
45
0 
  
  
  
46
0 
  
  
  
47
0 
  
  
  
48
0 
  
  
  
49
0 
  
  
  
50
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
GG
GT
CA
GG
GA
AA
AC
CA
GT
TT
GC
GA
TC
AG
CA
AT
TT
TT
GA
AG
AA
AC
AC
AA
GG
GA
AT
GT
TA
TT
GT
CA
TT
GA
TA
AT
GA
TA
CC
TT
TA
AA
CA
AC
AG
CA
CC
CT
AA
TT
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
GG
GT
CA
GG
GA
AA
AC
CA
GT
TT
GC
GA
TC
AG
CA
AT
TT
TT
GA
AG
AA
AC
AC
AA
GG
GA
AT
GT
TA
TT
GT
CA
TT
GA
TA
AT
GA
TA
CC
TT
TA
AA
CA
AC
AG
CA
CC
CT
AA
TT
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
GG
GT
CA
GG
GA
AA
AC
CA
GT
TT
GC
GA
TC
AG
CA
AT
TT
TT
GA
AG
AA
AC
AC
AA
GG
GA
AT
GT
TA
TT
GT
CA
TT
GA
TA
AT
GA
TA
CC
TT
TA
AA
CA
AC
AG
CA
CC
CT
AA
TT
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
GG
GT
CA
GG
GA
AA
AC
CA
GT
TT
GC
GA
TC
AG
CA
AT
TT
TT
GA
AG
AA
AC
AC
AA
GG
GA
AT
GT
TA
TT
GT
CA
TT
GA
TA
AT
GA
TA
CC
TT
TA
AA
CA
AC
AG
CA
CC
CT
AA
TT
 
51
0 
  
  
  
52
0 
  
  
  
53
0 
  
  
  
54
0 
  
  
  
55
0 
  
  
  
56
0 
  
  
  
57
0 
  
  
  
58
0 
  
  
  
59
0 
  
  
  
60
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S
. 
p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
TT
GA
TG
AA
CT
AG
TG
AA
AC
TT
TA
TG
AA
AA
AG
AC
GT
AG
TA
AA
AC
AC
GT
TA
CC
CC
TT
AT
TC
TA
AT
CG
CA
TG
AC
AG
AA
GC
GA
TC
AT
AA
GC
CG
TT
TG
AG
CG
AT
CA
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
TT
GA
TG
AA
CT
AG
TG
AA
AC
TT
TA
TG
AA
AA
AG
AC
GT
AG
TA
AA
AC
AC
GT
TA
CC
CC
TT
AT
TC
TA
AT
CG
CA
TG
AC
AG
AA
GC
GA
TC
AT
AA
GC
CG
TT
TG
AG
CG
AT
CA
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
TT
GA
TG
AA
CT
AG
TG
AA
AC
TT
TA
TG
AA
AA
AG
AC
GT
AG
TA
AA
AC
AC
GT
TA
CC
CC
TT
AT
TC
TA
AT
CG
CA
TG
AC
AG
AA
GC
GA
TC
AT
AA
GC
CG
TT
TG
AG
CG
AT
CA
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
TT
GA
TG
AA
CT
AG
TG
AA
AC
TT
TA
TG
AA
AA
AG
AC
GT
AG
TA
AA
AC
AC
GT
TA
CC
CC
TT
AT
TC
TA
AT
CG
CA
TG
AC
AG
AA
GC
GA
TC
AT
AA
GC
CG
TT
TG
AG
CG
AT
CA
 
Fi
gu
re
 2
.6
109 
 
 F
ig
ur
e 2
.3
(c
on
t.)
61
0 
  
  
  
62
0 
  
  
  
63
0 
  
  
  
64
0 
  
  
  
65
0 
  
  
  
66
0 
  
  
  
67
0 
  
  
  
68
0 
  
  
  
69
0 
  
  
  
70
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S.
 p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
AG
GG
TA
TA
AT
TT
GG
TG
AT
CG
AA
GG
TA
CA
GG
AC
GA
AC
AA
CA
GA
CG
TT
CC
TA
TT
CA
AA
CC
GC
AA
CA
AT
GC
TT
CA
AG
CC
AA
AG
GT
TA
TG
AA
AC
AA
AA
AT
GT
AT
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
AG
GG
TA
TA
AT
TT
GG
TG
AT
CG
AA
GG
TA
CA
GG
AC
GA
AC
AA
CA
GA
CG
TT
CC
TA
TT
CA
AA
CC
GC
AA
CA
AT
GC
TT
CA
AG
CC
AA
AG
GT
TA
TG
AA
AC
AA
AA
AT
GT
AT
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
AG
GG
TA
TA
AT
TT
GG
TG
AT
CG
AA
GG
TA
CA
GG
AC
GA
AC
AA
CA
GA
CG
TT
CC
TA
TT
CA
AA
CC
GC
AA
CA
AT
GC
TT
CA
AG
CC
AA
AG
GT
TA
TG
AA
AC
AA
AA
AT
GT
AT
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
AG
GG
TA
TA
AT
TT
GG
TG
AT
CG
AA
GG
TA
CA
GG
AC
GA
AC
AA
CA
GA
CG
TT
CC
TA
TT
CA
AA
CC
GC
AA
CA
AT
GC
TT
CA
AG
CC
AA
AG
GT
TA
TG
AA
AC
AA
AA
AT
GT
AT
 
71
0 
  
  
  
72
0 
  
  
  
73
0 
  
  
  
74
0 
  
  
  
75
0 
  
  
  
76
0 
  
  
  
77
0 
  
  
  
78
0 
  
  
  
79
0 
  
  
  
80
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S.
 p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
GT
CA
TG
GC
AG
TA
CC
TA
AA
AT
CA
AC
TC
AT
AT
TT
AG
GA
AC
AA
TT
GA
AC
GA
TA
TG
AA
AC
CA
TG
TA
TG
CA
GA
TG
AT
CC
AA
TG
AC
AG
CC
AG
GG
CA
AC
AC
CA
AA
AC
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
GT
CA
TG
GC
AG
TA
CC
TA
AA
AT
CA
AC
TC
AT
AT
TT
AG
GA
AC
AA
TT
GA
AC
GA
TA
TG
AA
AC
CA
TG
TA
TG
CA
GA
TG
AT
CC
AA
TG
AC
AG
CC
AG
GG
CA
AC
AC
CA
AA
AC
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
GT
CA
TG
GC
AG
TA
CC
TA
AA
AT
CA
AC
TC
AT
AT
TT
AG
GA
AC
AA
TT
GA
AC
GA
TA
TG
AA
AC
CA
TG
TA
TG
CA
GA
TG
AT
CC
AA
TG
AC
AG
CC
AG
GG
CA
AC
AC
CA
AA
AC
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
GT
CA
TG
GC
AG
TA
CC
TA
AA
AT
CA
AC
TC
AT
AT
TT
AG
GA
AC
AA
TT
GA
AC
GA
TA
TG
AA
AC
CA
TG
TA
TG
CA
GA
TG
AT
CC
AA
TG
AC
AG
CC
AG
GG
CA
AC
AC
CA
AA
AC
 
81
0 
  
  
  
82
0 
  
  
  
83
0 
  
  
  
84
0 
  
  
  
85
0 
  
  
  
86
0 
  
  
  
87
0 
  
  
  
88
0 
  
  
  
89
0 
  
  
  
90
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S.
 p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
AA
GC
GC
AT
GA
TA
TT
GT
TG
TC
AA
AA
AC
TT
AC
CG
AC
CA
AT
TT
AG
AA
AC
CC
TT
CA
TA
AA
AC
GG
GC
TT
AT
TT
AG
CG
AT
AT
AA
GG
CT
AT
AT
AA
CA
GA
GA
AG
GA
GT
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
AA
GC
GC
AT
GA
TA
TT
GT
TG
TC
AA
AA
AC
TT
AC
CG
AC
CA
AT
TT
AG
AA
AC
CC
TT
CA
TA
AA
AC
GG
GC
TT
AT
TT
AG
CG
AT
AT
AA
GG
CT
AT
AT
AA
CA
GA
GA
AG
GA
GT
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
AA
GC
GC
AT
GA
TA
TT
GT
TG
TC
AA
AA
AC
TT
AC
CG
AC
CA
AT
TT
AG
AA
AC
CC
TT
CA
TA
AA
AC
GG
GC
TT
AT
TT
AG
CG
AT
AT
AA
GG
CT
AT
AT
AA
CA
GA
GA
AG
GA
GT
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
AA
GC
GC
AT
GA
TA
TT
GT
TG
TC
AA
AA
AC
TT
AC
CG
AC
CA
AT
TT
AG
AA
AC
CC
TT
CA
TA
AA
AC
GG
GC
TT
AT
TT
AG
CG
AT
AT
AA
GG
CT
AT
AT
AA
CA
GA
GA
AG
GA
GT
 
91
0 
  
  
  
92
0 
  
  
  
93
0 
  
  
  
94
0 
  
  
  
95
0 
  
  
  
96
0 
  
  
  
97
0 
  
  
  
98
0 
  
  
  
99
0 
  
  
  
10
00
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S.
 p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
AA
AA
CT
CT
AT
TC
AA
GT
TT
GG
AA
AC
AC
CT
TC
TA
TT
AG
TC
CA
AA
AG
AA
AC
CT
TA
GA
AA
AA
GA
AT
TG
AA
TC
GT
AA
AG
TA
TC
AG
GG
AA
AG
AA
AT
TC
AA
CC
GA
CT
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
AA
AA
CT
CT
AT
TC
AA
GT
TT
GG
AA
AC
AC
CT
TC
TA
TT
AG
TC
CA
AA
AG
AA
AC
CT
TA
GA
AA
AA
GA
AT
TG
AA
TC
GT
AA
AG
TA
TC
AG
GG
AA
AG
AA
AT
TC
AA
CC
GA
CT
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
AA
AA
CT
CT
AT
TC
AA
GT
TT
GG
AA
AC
AC
CT
TC
TA
TT
AG
TC
CA
AA
AG
AA
AC
CT
TA
GA
AA
AA
GA
AT
TG
AA
TC
GT
AA
AG
TA
TC
AG
GG
AA
AG
AA
AT
TC
AM
CC
GA
CT
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
AA
AA
CT
CT
AT
TC
AA
GT
TT
GG
AA
AC
AC
CT
TC
TA
TT
AG
TC
CA
AA
AG
AA
AC
CT
TA
GA
AA
AA
GA
AT
TG
AA
TC
GT
AA
AG
TA
TC
AG
GG
AA
AG
AA
AT
TC
AA
CC
GA
CT
 
10
10
  
  
  
10
20
  
  
  
10
30
  
  
  
10
40
  
  
  
10
50
  
  
  
10
60
  
  
  
10
70
  
  
  
10
80
  
  
  
10
90
  
  
  
11
00
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
S.
 p
yo
ge
ne
s
pS
M1
90
35
 ε−
ζ
TT
AG
AA
CG
AA
TA
GA
GC
AA
AA
AA
TG
GT
TC
TA
AA
TA
AA
CA
CC
AA
GA
GA
CA
CC
TG
AA
TT
TA
AA
GC
AA
TT
CA
AC
AA
AA
AT
TG
GA
AA
GC
TT
GC
AG
CC
AC
CT
AC
AC
U5
03
  
  
  
  
  
  
  
  
  
  
  
TT
AG
AM
CG
AA
TA
GA
GC
AA
AA
AA
TG
GT
TC
TA
AA
TA
AA
CA
CC
AA
GA
GA
CA
CC
TG
AA
TT
TA
AG
C-
-A
TT
CA
--
CA
AA
AT
NG
GA
AN
TN
CC
CC
CC
CC
CC
CC
CC
CA
 
S1
77
  
  
  
  
  
  
  
  
  
  
  
TT
AG
AA
CG
AA
TA
GA
GC
AA
AA
AA
TG
GT
TC
TA
AA
TA
AC
CN
CC
A-
GA
GA
CA
CC
TG
AN
TT
TA
AA
GC
-A
TT
CA
CC
AA
AA
AT
CG
GA
AG
--
CT
GC
CC
CC
CC
CT
AT
CA
 
S2
35
  
  
  
  
  
  
  
  
  
  
  
TT
AG
AA
CG
AA
TA
GA
GC
AA
AA
AA
TG
GT
TC
TA
AA
TA
AC
CA
CC
AA
GA
GA
CA
CC
TG
AA
TT
TA
AG
CC
-A
TT
CA
CN
AA
A-
--
TT
GG
AG
--
NT
GC
CC
CC
CC
TC
NC
CC
 
11
10
  
  
  
11
20
  
  
  
11
30
  
  
  
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
Se
qu
en
ce
 I
de
nt
it
y
S.
 p
yo
ge
ne
s
πΣ
Μ1
903
5 ε
−ζ
CA
CC
AA
TA
CC
CA
AA
AC
AC
CT
AA
AC
TT
CC
AG
GT
AT
TT
AA
 
U5
03
  
  
  
  
  
  
  
  
  
  
  
CA
AC
AA
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
95
.8
%
S1
77
  
  
  
  
  
  
  
  
  
  
  
GC
CN
AA
AA
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
96
.4
%
S2
35
  
  
  
  
  
  
  
  
  
  
  
CC
AA
AA
AA
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
95
.9
%
Fi
gu
re
 2
.6
110 
 
 
 
Fi
gu
re
 2
.4
 A
lig
nm
en
t 
of
 re
lB
E
se
qu
en
ce
s. 
 F
iv
e 
of
 th
e 3
5 
cl
in
ic
al
 V
R
E 
st
ra
in
s i
de
nt
ifi
ed
 b
y 
PC
R
 to
 c
on
ta
in
 th
e r
el
BE
ge
ne
s 
w
er
e 
su
bm
itt
ed
 fo
r D
N
A
 
se
qu
en
ci
ng
.  
U
sin
g 
a 
C
lu
st
al
W
 M
ul
tip
le
 A
lig
nm
en
t 
(B
LO
SU
M
62
 M
at
rix
) t
he
 se
qu
en
ce
s w
er
e 
al
ig
ne
d 
w
ith
 th
e 
re
fe
re
nc
e 
re
lB
E
se
qu
en
ce
 fr
om
 th
e E
. 
co
li
K
12
 ge
no
m
e.
  B
as
es
 h
ig
hl
ig
ht
ed
 in
 b
ol
d 
on
 th
e r
ef
er
en
ce
 s
eq
ue
nc
e i
nd
ic
at
e 
th
e 
lo
ca
tio
n 
of
 th
e p
rim
er
s 
us
ed
 to
 P
C
R
 fo
r t
he
 re
lB
E
ge
ne
s. 
 
10
  
  
  
  
20
  
  
  
  
30
  
  
  
  
40
  
  
  
  
50
  
  
  
  
60
  
  
  
  
70
  
  
  
  
80
  
  
  
  
90
  
  
  
 1
00
  
  
  
 1
10
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
co
li
re
lB
E
AT
GG
GT
AG
CA
TT
AA
CC
TG
CG
TA
TT
GA
CG
AT
GA
AC
TT
AA
AG
CG
CG
TT
CT
TA
CG
CC
GC
GC
TT
GA
AA
AA
AT
GG
GT
GT
AA
CT
CC
TT
CT
GA
AG
CG
CT
TC
GT
CT
CA
TG
CT
CG
AG
TA
 
S3
4 
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
GG
TG
TA
AC
TC
CT
TC
TG
AA
GC
GC
TT
CG
TC
TC
AT
GC
TC
GA
GT
A 
S1
96
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
GG
TG
TA
AC
TC
CT
TC
TG
AA
GC
GC
TT
CG
TC
TC
AT
GC
TC
GA
GT
A 
S2
34
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
GG
TG
TA
AC
TC
CT
TC
TG
AA
GC
GC
TT
CG
TC
TC
AT
GC
TC
GA
GT
A 
SL
17
1 
  
  
  
  
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-G
GT
GT
AA
NN
NC
TT
CT
GA
AG
CG
CT
TC
GT
CT
CA
TG
CT
CG
AG
TA
 
SL
75
6 
  
  
  
  
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-G
GT
GT
AA
CT
CC
TT
CT
GA
AG
CG
CT
TC
GT
CT
CA
TG
CT
CG
AG
TA
 
12
0 
  
  
  
13
0 
  
  
  
14
0 
  
  
  
15
0 
  
  
  
16
0 
  
  
  
17
0 
  
  
  
18
0 
  
  
  
19
0 
  
  
  
20
0 
  
  
  
21
0 
  
  
  
22
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
co
li
re
lB
E
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
S3
4 
  
  
  
  
  
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
S1
96
  
  
  
  
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
S2
34
  
  
  
  
 
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
SL
17
1 
  
  
  
 
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
SL
75
6 
  
  
  
 
TA
TC
GC
TG
AC
AA
TG
AA
CG
CT
TG
CC
GT
TC
AA
AC
AG
AC
AC
TC
CT
GA
GT
GA
TG
AA
GA
TG
CT
GA
AC
TT
GT
GG
AG
AT
AG
TG
AA
AG
AA
CG
GC
TT
CG
TA
AT
CC
TA
AG
CC
AG
TA
CG
TG
 
23
0 
  
  
  
24
0 
  
  
  
25
0 
  
  
  
26
0 
  
  
  
27
0 
  
  
  
28
0 
  
  
  
29
0 
  
  
  
30
0 
  
  
  
31
0 
  
  
  
32
0 
  
  
  
33
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
co
li
 r
el
BE
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
S3
4 
  
  
  
 
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
S1
96
  
  
  
  
 
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
S2
34
  
  
  
 
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
SL
17
1 
  
  
  
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
SL
75
6 
  
  
  
 
TG
AC
GC
TG
GA
TG
AA
CT
CT
GA
TG
GC
GT
AT
TT
TC
TG
GA
TT
TT
GA
CG
AG
CG
GG
CA
CT
AA
AG
GA
AT
GG
CG
AA
AG
CT
GG
GC
TC
GA
CG
GT
AC
GT
GA
AC
AG
TT
GA
AA
AA
GA
AG
CT
GG
 
34
0 
  
  
  
35
0 
  
  
  
36
0 
  
  
  
37
0 
  
  
  
38
0 
  
  
  
39
0 
  
  
  
40
0 
  
  
  
41
0 
  
  
  
42
0 
  
  
  
43
0 
  
  
  
44
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
co
li
 r
el
BE
TT
GA
AG
TA
CT
TG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
AG
GT
TA
TA
 
S3
4 
  
  
  
 
TT
GA
AG
TA
CT
TG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
AG
GT
TA
TA
 
S1
96
  
  
  
TT
GA
AG
TA
CT
NG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
AG
GT
TA
TA
 
S2
34
  
  
  
  
TT
GA
AG
TA
CT
TG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
TG
GT
TA
TA
 
SL
17
1 
  
  
  
TT
GA
AG
TA
CT
TG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
AG
GT
TA
TA
 
SL
75
6 
  
  
TT
GA
AG
TA
CT
TG
AG
TC
AC
CC
CG
GA
TT
GA
AG
CA
AA
CA
AG
CT
CC
GT
GG
TA
TG
CC
TG
AT
TG
TT
AC
AA
GA
TT
AA
GC
TC
CG
GT
CT
TC
AG
GC
TA
TC
GC
CT
TG
TA
TA
CC
AG
GT
TA
TA
 
45
0 
  
  
  
46
0 
  
  
  
47
0 
  
  
  
48
0 
  
  
  
49
0 
  
  
  
50
0 
  
  
  
51
0 
  
  
  
52
0 
  
  
  
  
  
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
Se
qu
en
ce
 I
de
nt
it
y
E
. 
co
li
 r
el
BE
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
AC
GC
AT
TC
TC
TG
A-
S3
4 
  
  
  
 
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
AC
GC
AT
TC
TC
TG
A-
10
0%
S1
96
  
  
  
  
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
AC
GC
AT
TC
TC
TG
A-
99
.8
%
S2
34
  
  
  
  
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
AC
GC
AT
TC
TC
TG
A-
99
.8
%
SL
17
1 
  
  
 
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
-C
GC
AT
TC
TC
TG
A-
99
.1
%
SL
75
6 
  
  
  
GA
CG
AG
AA
AG
TT
GT
CG
TT
TT
CG
TG
AT
TT
CT
GT
TG
GG
AA
AA
GA
GA
AC
GC
TC
GG
AA
GT
AT
AT
AG
CG
AG
GC
GG
TC
AA
AC
GC
AT
TC
TC
TG
A-
10
0%
Fi
gu
re
 2
.7
111 
 
 
 
Fi
gu
re
 2
.5
A
lig
nm
en
t 
of
 cc
dA
B
se
qu
en
ce
s. 
 T
he
 si
ng
le
 c
lin
ic
al
 V
R
E 
st
ra
in
 id
en
tif
ie
d 
by
 P
CR
 to
 c
on
ta
in
 th
e c
cd
AB
ge
ne
s 
w
as
 su
bm
itt
ed
 fo
r D
N
A
 
se
qu
en
ci
ng
.  
U
sin
g 
a 
Cl
us
ta
lW
 M
ul
tip
le
 A
lig
nm
en
t 
(B
LO
SU
M
62
 M
at
rix
) t
he
 se
qu
en
ce
 w
as
 a
lig
ne
d 
w
ith
 th
e r
ef
er
en
ce
 c
cd
AB
se
qu
en
ce
 fr
om
 th
e 
E.
 c
ol
i
F 
pl
as
m
id
.  
B
as
es
 h
ig
hl
ig
ht
ed
 in
 b
ol
d 
on
 th
e r
ef
er
en
ce
 s
eq
ue
nc
e i
nd
ic
at
e 
th
e 
lo
ca
tio
n 
of
 th
e 
pr
im
er
s 
us
ed
 to
 P
CR
 f
or
 th
e 
cc
dA
B
ge
ne
s. 
 
10
  
  
  
  
20
  
  
  
  
30
  
  
  
  
40
  
  
  
  
50
  
  
  
  
60
  
  
  
  
70
  
  
  
  
80
  
  
  
  
90
  
  
  
 1
00
  
  
  
 1
10
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
F 
pl
as
mi
d 
cc
dA
B
AT
GA
AG
CA
GC
GT
AT
TA
CA
GT
GA
CA
G-
TT
GA
CA
GC
GA
CA
GC
TA
TC
AG
TT
GC
TC
AA
GG
CA
TA
TG
AT
GT
CA
AT
AT
CT
CC
GG
TC
TG
GT
AA
GC
AC
AA
CC
AT
GC
AG
AA
TG
AA
GC
CC
 
U6
3 
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
-G
TG
AC
AG
GT
TT
GC
AG
CG
AC
AG
CT
AT
CA
GT
TG
CT
CA
AG
GC
AT
AT
GA
TG
TC
AA
TA
TC
TC
CG
GT
CT
GG
TA
AG
CA
CA
AC
CA
TG
CA
GA
AT
GA
AG
CC
C 
12
0 
  
  
  
13
0 
  
  
  
14
0 
  
  
  
15
0 
  
  
  
16
0 
  
  
  
17
0 
  
  
  
18
0 
  
  
  
19
0 
  
  
  
20
0 
  
  
  
21
0 
  
  
  
22
0
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
F 
pl
as
mi
d 
cc
dA
B
GT
CG
TC
TG
CG
TG
CC
GA
AC
GC
TG
GA
AA
GC
GG
AA
AA
TC
AG
GA
AG
GG
AT
GG
CT
GA
GG
TC
GC
CC
GG
TT
TA
TT
GA
AA
TG
AA
CG
GC
TC
TT
TT
GC
TG
AC
GA
GA
AC
AG
GG
AC
TG
GT
GA
 
U6
3 
  
  
  
  
  
  
 G
TC
GT
CT
GC
GT
GC
CG
AA
CG
CT
GG
AA
AG
CG
GA
AA
AT
CA
GG
AA
GG
GA
TG
GC
TG
AG
GT
CG
CC
CG
GT
TT
AT
TG
AA
AT
GA
AC
GG
CT
CT
TT
TG
CT
GA
CG
AG
AA
CA
GG
GA
CT
GG
TG
A 
23
0 
  
  
  
24
0 
  
  
  
25
0 
  
  
  
26
0 
  
  
  
27
0 
  
  
  
28
0 
  
  
  
29
0 
  
  
  
30
0 
  
  
  
31
0 
  
  
  
32
0 
  
  
  
33
0
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
F 
pl
as
mi
d 
cc
dA
B
AA
TG
CA
GT
TT
AA
GG
TT
TA
CA
CC
TA
TA
AA
AG
AG
AG
AG
CC
GT
TA
TC
GT
CT
GT
TT
GT
GG
AT
GT
AC
AG
AG
TG
AT
AT
TA
TT
GA
CA
CG
CC
CG
GG
CG
AC
GG
AT
GG
TG
AT
CC
CC
CT
GG
 
U6
3 
  
  
  
  
  
  
 A
AT
GC
AG
TT
TA
AG
GT
TT
AC
AC
CT
AT
AA
AA
GA
GA
GA
GC
CG
TT
AT
CG
TC
TG
TT
TG
TG
GA
TG
TA
CA
GA
GT
GA
TA
TT
AT
TG
AC
AC
GC
CC
GG
GC
GA
CG
GA
TG
GT
GA
TC
CC
CC
TG
G 
34
0 
  
  
  
35
0 
  
  
  
36
0 
  
  
  
37
0 
  
  
  
38
0 
  
  
  
39
0 
  
  
  
40
0 
  
  
  
41
0 
  
  
  
42
0 
  
  
  
43
0 
  
  
  
44
0
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
F 
pl
as
mi
d 
cc
dA
B
CC
AG
TG
CA
CG
TC
TG
CT
GT
CA
GA
TA
AA
GT
CT
CC
CG
TG
AA
CT
TT
AC
CC
GG
TG
GT
GC
AT
AT
CG
GG
GA
TG
AA
AG
CT
GG
CG
CA
TG
AT
GA
CC
AC
CG
AT
AT
GG
CC
AG
TG
TG
CC
GG
TC
 
U6
3 
  
  
  
  
  
  
 C
CA
GT
GC
AC
GT
CT
GC
TG
TC
AG
AT
AA
AG
TC
TC
CC
GT
GA
AC
TT
TA
CC
CG
GT
GG
TG
CA
TA
TC
GG
GG
AT
GA
AA
GC
TG
GC
GC
AT
GA
TG
AC
CA
CC
GA
TA
TG
GC
CA
GT
GT
GC
CG
GT
C 
45
0 
  
  
  
46
0 
  
  
  
47
0 
  
  
  
48
0 
  
  
  
49
0 
  
  
  
50
0 
  
  
  
51
0 
  
  
  
52
0 
  
  
  
  
  
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
Se
qu
en
ce
 I
de
nt
it
y
F 
pl
as
mi
d 
cc
dA
B
TC
CG
TT
AT
CG
GG
GA
AG
AA
GT
GG
CT
GA
TC
TC
AG
CC
AC
CG
CG
AA
AA
TG
A-
CA
TC
AA
AA
AC
GC
CA
TT
AA
CC
TG
AT
GT
TC
TG
GG
GA
AT
AT
AA
 
U6
3 
  
  
  
  
  
  
 T
CC
GT
TA
TC
GG
GG
AA
GA
AG
TG
GC
TG
AT
CT
CA
GC
CA
CC
GC
GA
AA
AT
GA
AC
AT
CA
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-
99
.1
%
Fi
gu
re
 2
.8
112 
 
 
 
Fi
gu
re
 2
.6
 A
lig
nm
en
t o
f a
xe
-tx
es
eq
ue
nc
es
.  S
ev
en
 o
f t
he
 5
6 c
lin
ica
l V
RE
 st
ra
in
s i
de
nt
ifi
ed
 b
y P
CR
 to
 co
nt
ai
n t
he
 a
xe
-tx
eg
en
es
 w
er
e s
ub
m
itt
ed
 fo
r D
N
A
 se
qu
en
cin
g.
  U
si
ng
 a 
Cl
us
ta
lW
 
M
ul
tip
le
 A
lig
nm
en
t (
BL
O
SU
M
62
 M
at
rix
) t
he
 se
qu
en
ce
s w
er
e a
lig
ne
d w
ith
 th
e r
ef
er
en
ce
 a
xe
-tx
es
eq
ue
nc
e f
ro
m
 th
e E
. f
ae
ci
um
pl
as
m
id
 p
RU
M
.  T
he
 p
rim
er
s u
se
d 
to
 P
CR
 fo
r t
he
 a
xe
-tx
e
ge
ne
s w
er
e l
oc
at
ed
 u
ps
tre
am
 an
d d
ow
ns
tre
am
 o
f t
he
 re
fe
re
nc
e s
eq
ue
nc
e. 
 
10
  
  
  
  
20
  
  
  
  
30
  
  
  
  
40
  
  
  
  
50
  
  
  
  
60
  
  
  
  
70
  
  
  
  
80
  
  
  
  
90
  
  
  
 1
00
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
f
ae
ci
um
pR
UM
 a
xe
-t
x
e
AT
GG
AA
GC
AG
TA
GC
TT
AT
TC
AA
AT
TT
CC
GC
CA
AA
AT
TT
AC
GT
AG
TT
AT
AT
GA
AA
CA
AG
TT
AA
TG
AG
GA
TG
CT
GA
AA
CA
CT
TA
TT
GT
AA
CA
AG
TA
AA
GA
TG
 
U2
75
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
U4
64
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
S3
4 
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
S2
06
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
S5
57
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
SL
75
6 
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
D1
  
  
  
  
  
  
  
  
  
  
  
 A
TG
GA
AG
CA
GT
AG
CT
TA
TT
CA
AA
TT
TC
CG
CC
AA
AA
TT
TA
CG
TA
GT
TA
TA
TG
AA
AC
AA
GT
TA
AT
GA
GG
AT
GC
TG
AA
AC
AC
TT
AT
TG
TA
AC
AA
GT
AA
AG
AT
G
11
0 
  
  
  
12
0 
  
  
  
13
0 
  
  
  
14
0 
  
  
  
15
0 
  
  
  
16
0 
  
  
  
17
0 
  
  
  
18
0 
  
  
  
19
0 
  
  
  
20
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
f
ae
ci
um
pR
UM
 a
xe
-t
x
e
TA
GA
AG
AT
AC
AG
TT
GT
TG
TA
TT
AT
CA
AA
AA
GA
GA
TT
AT
GA
TT
CT
AT
GC
AA
GA
AA
CG
TT
GA
GA
AC
AC
TT
TC
TA
AT
AA
TT
AC
GT
CA
TG
GA
AA
AA
AT
TC
GT
CG
 
U2
75
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
U4
64
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
S3
4 
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
S2
06
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
S5
57
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
SL
75
6 
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
D1
  
  
  
  
  
  
  
  
  
  
  
 T
AG
AA
GA
TA
CA
GT
TG
TT
GT
AT
TA
TC
AA
AA
AG
AG
AT
TA
TG
AT
TC
TA
TG
CA
AG
AA
AC
GT
TG
AG
AA
CA
CT
TT
CT
AA
TA
AT
TA
CG
TC
AT
GG
AA
AA
AA
TT
CG
TC
G
21
0 
  
  
  
22
0 
  
  
  
23
0 
  
  
  
24
0 
  
  
  
25
0 
  
  
  
26
0 
  
  
  
27
0 
  
  
  
28
0 
  
  
  
29
0 
  
  
  
30
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
f
ae
ci
um
pR
UM
 a
xe
-t
x
e
AG
GA
GA
TG
AA
CA
AT
TC
TC
CA
AA
GG
TG
CA
TT
TA
AA
AC
AC
AT
GA
CT
TA
AT
CG
AG
GT
TG
AA
TC
TG
AT
GA
TT
AA
GG
CT
TG
GT
CT
GA
TG
AT
GC
TT
GG
GA
TG
AT
TA
 
U2
75
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
U4
64
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
S3
4 
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
S2
06
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
S5
57
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
SL
75
6 
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
D1
  
  
  
  
  
  
  
  
  
  
  
 A
GG
AG
AT
GA
AC
AA
TT
CT
CC
AA
AG
GT
GC
AT
TT
AA
AA
CA
CA
TG
AC
TT
AA
TC
GA
GG
TT
GA
AT
CT
GA
TG
AT
TA
AG
GC
TT
GG
TC
TG
AT
GA
TG
CT
TG
GG
AT
GA
TT
A
31
0 
  
  
  
32
0 
  
  
  
33
0 
  
  
  
34
0 
  
  
  
35
0 
  
  
  
36
0 
  
  
  
37
0 
  
  
  
38
0 
  
  
  
39
0 
  
  
  
40
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E
. 
f
ae
ci
um
pR
UM
 a
xe
-t
x
e
TC
TT
TA
TT
GG
CA
TG
AG
CA
AG
GA
AA
CA
AA
AG
CA
AT
AT
AA
AA
AA
GA
TT
AA
CA
AG
TT
AA
TA
AA
AG
AT
AT
CG
AT
CG
TT
CC
CC
CT
TT
GC
TG
GA
TT
AG
GA
AA
AC
CT
 
U2
75
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
U4
64
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
S3
4 
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
S2
06
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
S5
57
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
SL
75
6 
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T
D1
  
  
  
  
  
  
  
  
  
  
  
 T
CT
TT
AT
TG
GC
AT
GA
GC
AA
GG
AA
AC
AA
AA
GC
AA
TA
TA
AA
AA
AG
AT
TA
AC
AA
GT
TA
AT
AA
AA
GA
TA
TC
GA
TC
GT
TC
CC
CC
TT
TG
CT
GG
AT
TA
GG
AA
AA
CC
T 
Fi
gu
re
 2
.9
113 
 
 
 
Fi
gu
re
 2
.6
(c
on
t.)
41
0 
  
  
  
42
0 
  
  
  
43
0 
  
  
  
44
0 
  
  
  
45
0 
  
  
  
46
0 
  
  
  
47
0 
  
  
  
48
0 
  
  
  
49
0 
  
  
  
50
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 f
ae
ci
um
pR
UM
 a
xe
-t
x
e
GA
GC
CA
TT
AA
AG
CA
TG
AT
TT
AT
CT
GG
AA
AA
TG
GT
CC
AG
AA
GA
AT
TA
CA
GA
TG
AA
-C
AT
AG
AC
TG
AT
AT
AT
AG
AG
TT
GA
AA
AT
GA
AA
CG
AT
AT
TT
AT
TT
AT
 
U2
75
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
U4
64
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
-G
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
S3
4 
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
S2
06
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
AT
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T
S5
57
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
SL
75
6 
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
D1
  
  
  
  
  
  
  
  
  
  
  
 G
AG
CC
AT
TA
AA
GC
AT
GA
TT
TA
TC
TG
GA
AA
AT
GG
TC
CA
GA
AG
AA
TT
AC
AG
AT
GA
A-
CA
TA
GA
CT
GA
TA
TA
TA
GA
GT
TG
AA
AA
TG
AA
AC
GA
TA
TT
TA
TT
TA
T 
51
0 
  
  
  
52
0 
..
..
|.
..
.|
..
..
|.
..
.|
. 
  
  
Se
qu
en
ce
 I
de
nt
it
y
E.
 f
ae
ci
um
pR
UM
 a
xe
-t
x
e
TC
TG
CA
AA
AG
AT
CA
CT
AT
TA
A 
U2
75
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 1
00
%
U4
64
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 9
9.
8%
S3
4 
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 1
00
%
S2
06
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 9
9.
8%
%
S5
57
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 1
00
%
SL
75
6 
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 1
00
%
D1
  
  
  
  
  
  
  
  
  
  
  
 T
CT
GC
AA
AA
GA
TC
AC
TA
TT
AA
  
  
  
  
  
 1
00
%
Fi
gu
re
 2
.9
Fi
gu
re
 2
.9
 (c
on
t.)
114 
 
 
Fi
gu
re
 2
.7
  A
lig
nm
en
t o
f m
az
EF
se
qu
en
ce
s. 
 E
ig
ht
 o
f t
he
 7
5 
cl
in
ic
al
 V
RE
 st
ra
in
s i
de
nt
ifi
ed
 b
y P
CR
 to
 co
nt
ai
n t
he
 m
az
EF
ge
ne
s w
er
e s
ub
m
itt
ed
 fo
r D
N
A
 se
qu
en
ci
ng
.  
U
sin
g a
 C
lu
st
alW
 
M
ul
tip
le
 A
lig
nm
en
t (
BL
O
SU
M
62
 M
at
rix
) t
he
 se
qu
en
ce
s w
er
e a
lig
ne
d w
ith
 th
e r
ef
er
en
ce
 m
az
EF
se
qu
en
ce
 fr
om
 th
e E
. c
ol
iK
12
 ge
no
m
e. 
 B
as
es
 h
ig
hl
ig
ht
ed
 in
 b
ol
d o
n 
th
e r
ef
er
en
ce
 se
qu
en
ce
 
in
di
ca
te
 th
e l
oc
at
io
n o
f t
he
 p
rim
er
s u
se
d 
to
 P
CR
 fo
r t
he
 m
az
EF
ge
ne
s. 
 
10
  
  
  
  
20
  
  
  
  
30
  
  
  
  
40
  
  
  
  
50
  
  
  
  
60
  
  
  
  
70
  
  
  
  
80
  
  
  
  
90
  
  
  
 1
00
  
  
  
 1
10
  
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 c
ol
i
K1
2 
ma
zE
F
AT
GA
TC
CA
CA
GT
AG
CG
TA
AA
GC
GT
TG
GG
GA
AA
TT
CA
CC
GG
CG
GT
GC
GG
AT
CC
CG
GC
TA
CG
TT
AA
TG
CA
GG
CG
CT
CA
AT
CT
GA
AT
AT
TG
AT
GA
TG
AA
GT
GA
AG
AT
TG
AC
CT
 
U6
3 
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
NT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
U4
64
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
GA
AA
TC
AC
CG
GC
GG
CG
CG
GA
TC
CC
GG
NT
AC
NT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
S1
51
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
S1
93
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
GA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
S2
06
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
S3
45
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
C2
72
82
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
C3
31
05
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
CG
TT
GG
GG
AA
AT
TC
AC
CG
GC
GG
TG
CG
GA
TC
CC
GG
CT
AC
GT
TA
AT
GC
AG
GC
GC
TC
AA
TC
TG
AA
TA
TT
GA
TG
AT
GA
AG
TG
AA
GA
TT
GA
CC
T 
12
0 
  
  
  
13
0 
  
  
  
14
0 
  
  
  
15
0 
  
  
  
16
0 
  
  
  
17
0 
  
  
  
18
0 
  
  
  
19
0 
  
  
  
20
0 
  
  
  
21
0 
  
  
  
22
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 c
ol
i
K1
2 
ma
zE
F
GG
TG
GA
TG
GC
AA
AT
TA
AT
TA
TT
GA
GC
CA
GT
GC
GT
AA
AG
AG
CC
CG
-T
AT
TT
AC
GC
TT
GC
TG
AA
CT
GG
TC
AA
CG
AC
AT
CA
CG
CC
GG
AA
AA
CC
TC
CA
CG
AG
AA
TA
TC
GA
CT
GG
 
U6
3 
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
GC
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
U4
64
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
CG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
S1
51
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
S1
93
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
S2
06
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
S3
45
  
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
C2
72
82
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
C3
31
05
  
  
  
  
  
  
 G
GT
GG
AT
GG
CA
AA
TT
AA
TT
AT
TG
AG
CC
AG
TG
CG
TA
AA
GA
GC
CC
G-
TA
TT
TA
CG
CT
TG
CT
GA
AC
TG
GT
CA
AC
GA
CA
TC
AC
GC
CG
GA
AA
AC
CT
CC
AC
GA
GA
AT
AT
CG
AC
TG
G 
23
0 
  
  
  
24
0 
  
  
  
25
0 
  
  
  
26
0 
  
  
  
27
0 
  
  
  
28
0 
  
  
  
29
0 
  
  
  
30
0 
  
  
  
31
0 
  
  
  
32
0 
  
  
  
33
0 
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 c
ol
i
K1
2 
ma
zE
F
GG
AG
AG
CC
GA
AA
GA
TA
AG
GA
AG
TC
TG
GT
AA
TG
GT
AA
GC
CG
AT
AC
GT
AC
CC
GA
TA
TG
GG
CG
AT
CT
GA
TT
TG
GG
TT
GA
TT
TT
GA
CC
CG
AC
AA
AA
GG
TA
GC
GA
GC
AA
GC
TG
GA
 
U6
3 
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
U4
64
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
S1
51
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
S1
93
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
S2
06
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
S3
45
  
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
C2
72
82
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
C3
31
05
  
  
  
  
  
  
 G
GA
GA
GC
CG
AA
AG
AT
AA
GG
AA
GT
CT
GG
TA
AT
GG
TA
AG
CC
GA
TA
CG
TA
CC
CG
AT
AT
GG
GC
GA
TC
TG
AT
TT
GG
GT
TG
AT
TT
TG
AC
CC
GA
CA
AA
AG
GT
AG
CG
AG
CA
AG
CT
GG
A 
Fi
gu
re
 2
.1
0
Fi
gu
re
 2
.1
0  
A
lig
nm
en
t o
f m
az
EF
 se
qu
en
ce
s. 
 E
ig
ht
 o
f t
he
 7
5 c
lin
ica
l V
RE
 st
ra
in
s i
de
nt
ifi
ed
 b
y P
CR
 to
 co
nt
ai
n t
he
 m
az
EF
 ge
ne
s w
er
e s
ub
m
itt
ed
 fo
r D
N
A 
se
qu
en
cin
g.
  U
si
ng
 a 
Cl
us
ta
lW
115 
 
  
Fi
gu
re
 2
.7
(c
on
t.)
34
0 
  
  
  
35
0 
  
  
  
36
0 
  
  
  
37
0 
  
  
  
38
0 
  
  
  
39
0 
  
  
  
40
0 
  
  
  
41
0 
  
  
  
42
0 
  
  
  
43
0 
  
  
  
44
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 c
ol
i
K1
2 
ma
zE
F
CA
TC
GT
CC
AG
CT
GT
TG
TC
CT
GA
GT
CC
TT
TC
AT
GT
AC
AA
CA
AC
AA
AA
CA
GG
TA
TG
TG
TC
TG
TG
TG
TT
-C
CT
TG
TA
CA
AC
GC
AA
TC
AA
AA
GG
AT
AT
CC
GT
TC
GA
AG
TT
GT
TT
 
U6
3 
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
TA
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
U4
64
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
S1
51
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
S1
93
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
S2
06
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
S3
45
  
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
C2
72
82
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
C3
31
05
  
  
  
  
  
  
 C
AT
CG
TC
CA
GC
TG
TT
GT
CC
TG
AG
TC
CT
TT
CA
TG
TA
CA
AC
AA
CA
AA
AC
AG
GT
AT
GT
GT
CT
GT
GT
GT
T-
CC
TT
GT
AC
AA
CG
CA
AT
CA
AA
AG
GA
TA
TC
CG
TT
CG
AA
GT
TG
TT
T 
45
0 
  
  
  
46
0 
  
  
  
47
0 
  
  
  
48
0 
  
  
  
49
0 
  
  
  
50
0 
  
  
  
51
0 
  
  
  
52
0 
  
  
  
53
0 
  
  
  
54
0 
  
  
  
55
0 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
E.
 c
ol
i
K1
2 
ma
zE
F
TA
TC
CG
GT
CA
GG
AA
CG
TG
AT
GG
CG
TA
GC
GT
TA
GC
TG
AT
CA
GG
TA
AA
AA
GT
AT
CG
CC
TG
GC
GG
GC
AA
GA
GG
AG
C-
AA
CG
AA
GA
AA
GG
AA
CA
GT
TG
CC
CC
AG
AG
GA
AT
TA
CA
 
U6
3 
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AN
GA
AC
GT
GA
TG
GC
AT
AG
CG
TT
AN
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CN
AG
AN
-A
TN
CA
NC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
U4
64
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
NT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
NA
TC
CA
CC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
S1
51
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
-A
GC
CA
AC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
S1
93
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
-N
GC
CA
AC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
S2
06
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
GA
GC
CA
AC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
S3
45
  
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
GA
GC
CA
AC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
C2
72
82
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
GA
GC
-A
AC
GA
AG
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-
C3
31
05
  
  
  
  
  
  
 T
AT
CC
GG
TC
AG
GA
AC
GT
GA
TG
GC
GT
AG
CG
TT
AG
CT
GA
TC
AG
GT
AA
AA
AG
TA
TC
GC
CT
GG
CG
GG
CA
AG
AG
GA
GC
-A
AC
GA
AG
A-
--
--
--
--
--
--
--
--
--
--
--
--
--
-
56
0 
  
  
  
57
0 
  
  
  
58
0 
  
  
  
 
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
..
.|
..
..
|.
.
Se
qu
en
ce
 I
de
nt
it
y
E.
 c
ol
i
K1
2 
ma
zE
F
AC
TC
AT
TA
AA
GC
CA
AA
AT
TA
AC
GT
AC
TG
AT
TG
GG
TA
G 
U6
3 
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
97
.2
%
U4
64
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
97
.4
%
S1
51
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99
.2
%
S1
93
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
98
.7
%
S2
06
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99
.4
%
S3
45
  
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99
.4
%
C2
72
82
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99
.7
%
C3
31
05
  
  
  
  
  
  
 -
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99
.4
%
Fi
gu
re
 2
.1
0
Fi
gu
re
 2
.1
0 
(c
on
t.)
116 
 
2.9  REFERENCES 
1. Aizenman, E., H. Engelberg-Kulka, and G. Glaser, An Escherichia coli 
chromosomal "addiction module" regulated by guanosine [corrected] 3',5'-
bispyrophosphate: a model for programmed bacterial cell death. Proc Natl Acad 
Sci U S A, 1996. 93(12): p. 6059-63. 
2. Altschul, S.F., W. Gish, W. Miller, E.W. Myers, and D.J. Lipman, Basic local 
alignment search tool. J Mol Biol, 1990. 215(3): p. 403-10. 
3. Anantharaman, V. and L. Aravind, New connections in the prokaryotic toxin-
antitoxin network: relationship with the eukaryotic nonsense-mediated RNA decay 
system. Genome Biol, 2003. 4(12): p. R81. 
4. Baldassarri, L., L. Bertuccini, R. Creti, G. Orefici, G. Dicuonzo, G. Gherardi, M. 
Venditti, and R. Di Rosa, Clonality among Enterococcus faecium clinical isolates. 
Microb Drug Resist, 2005. 11(2): p. 141-5. 
5. Bravo, A., G. de Torrontegui, and R. Diaz, Identification of components of a new 
stability system of plasmid R1, ParD, that is close to the origin of replication of 
this plasmid. Mol Gen Genet, 1987. 210(1): p. 101-10. 
6. Buts, L., J. Lah, M.H. Dao-Thi, L. Wyns, and R. Loris, Toxin-antitoxin modules 
as bacterial metabolic stress managers. Trends Biochem Sci, 2005. 30(12): p. 
672-9. 
7. Camacho, A.G., et al., In vitro and in vivo stability of the epsilon2zeta2 protein 
complex of the broad host-range Streptococcus pyogenes pSM19035 addiction 
system. Biol Chem, 2002. 383(11): p. 1701-13. 
8. Ceglowski, P., A. Boitsov, S. Chai, and J.C. Alonso, Analysis of the stabilization 
system of pSM19035-derived plasmid pBT233 in Bacillus subtilis. Gene, 1993. 
136(1-2): p. 1-12. 
9. Cheng, S., F.K. McCleskey, M.J. Gress, J.M. Petroziello, R. Liu, H. Namdari, K. 
Beninga, A. Salmen, and V.G. DelVecchio, A PCR assay for identification of 
Enterococcus faecium. J Clin Microbiol, 1997. 35(5): p. 1248-50. 
10. Christensen, S.K., M. Mikkelsen, K. Pedersen, and K. Gerdes, RelE, a global 
inhibitor of translation, is activated during nutritional stress. Proc Natl Acad Sci 
U S A, 2001. 98(25): p. 14328-33. 
11. Christie, P.J., R.Z. Korman, S.A. Zahler, J.C. Adsit, and G.M. Dunny, Two 
conjugation systems associated with Streptococcus faecalis plasmid pCF10: 
identification of a conjugative transposon that transfers between S. faecalis and 
Bacillus subtilis. J Bacteriol, 1987. 169(6): p. 2529-36. 
117 
 
12. Clewell, D.B., Properties of Enterococcus faecalis plasmid pAD1, a member of a 
widely disseminated family of pheromone-responding, conjugative, virulence 
elements encoding cytolysin. Plasmid, 2007. 58(3): p. 205-27. 
13. Clewell, D.B., F.Y. An, B.A. White, and C. Gawron-Burke, Streptococcus 
faecalis sex pheromone (cAM373) also produced by Staphylococcus aureus and 
identification of a conjugative transposon (Tn918). J Bacteriol, 1985. 162(3): p. 
1212-20. 
14. Coleri, A., C. Cokmus, B. Ozcan, M. Akcelik, and C. Tukel, Determination of 
antibiotic resistance and resistance plasmids of clinical Enterococcus species. J 
Gen Appl Microbiol, 2004. 50(4): p. 213-9. 
15. DeNap, J.C. and P.J. Hergenrother, Bacterial death comes full circle: targeting 
plasmid replication in drug-resistant bacteria. Org Biomol Chem, 2005. 3(6): p. 
959-66. 
16. Depardieu, F., B. Perichon, and P. Courvalin, Detection of the van Alphabet and 
Identification of Enterococci and Staphylococci at the species level by Multiplex 
PCR. J Clin Microbiol, 2004. 42: p. 5857-60. 
17. Dutka-Malen, S., S. Evers, and P. Courvalin, Detection of glycopeptide resistance 
genotypes and identification to the species level of clinically relevant enterococci 
by PCR. J Clin Microbiol, 1995. 33(1): p. 24-7. 
18. Dutka-Malen, S., R. Leclercq, V. Coutant, J. Duval, and P. Courvalin, Phenotypic 
and genotypic heterogeneity of glycopeptide resistance determinants in gram-
positive bacteria. Antimicrob Agents Chemother, 1990. 34(10): p. 1875-9. 
19. Engelberg-Kulka, H. and G. Glaser, Addiction modules and programmed cell 
death and antideath in bacterial cultures. Annu Rev Microbiol, 1999. 53: p. 43-
70. 
20. Engelberg-Kulka, H., B. Sat, M. Reches, S. Amitai, and R. Hazan, Bacterial 
programmed cell death systems as targets for antibiotics. Trends Microbiol, 2004. 
12(2): p. 66-71. 
21. Ferber, D., Microbiology. Triple-threat microbe gained powers from another bug. 
Science, 2003. 302(5650): p. 1488. 
22. Flannagan, S.E., J.W. Chow, S.M. Donabedian, W.J. Brown, M.B. Perri, M.J. 
Zervos, Y. Ozawa, and D.B. Clewell, Plasmid content of a vancomycin-resistant 
Enterococcus faecalis isolate from a patient also colonized by Staphylococcus 
aureus with a VanA phenotype. Antimicrob Agents Chemother, 2003. 47(12): p. 
3954-9. 
 
118 
 
23. Freitas, A.R., C. Novais, P. Ruiz-Garbajosa, T.M. Coque, and L. Peixe, Clonal 
expansion within clonal complex 2 and spread of vancomycin-resistant plasmids 
among different genetic lineages of Enterococcus faecalis from Portugal. J 
Antimicrob Chemother, 2009. 63(6): p. 1104-11. 
24. Garcia-Migura, L., H. Hasman, C. Svendsen, and L.B. Jensen, Relevance of hot 
spots in the evolution and transmission of Tn1546 in glycopeptide-resistant 
Enterococcus faecium (GREF) from broiler origin. J Antimicrob Chemother, 
2008. 62(4): p. 681-7. 
25. Garcia-Migura, L., E. Liebana, L.B. Jensen, S. Barnes, and E. Pleydell, A 
longitudinal study to assess the persistence of vancomycin-resistant Enterococcus 
faecium (VREF) on an intensive broiler farm in the United Kingdom. FEMS 
Microbiol Lett, 2007. 275(2): p. 319-25. 
26. Gerdes, K., S.K. Christensen, and A. Lobner-Olesen, Prokaryotic toxin-antitoxin 
stress response loci. Nat Rev Microbiol, 2005. 3(5): p. 371-82. 
27. Gerdes, K., P.B. Rasmussen, and S. Molin, Unique type of plasmid maintenance 
function: postsegregational killing of plasmid-free cells. Proc Natl Acad Sci U S 
A, 1986. 83(10): p. 3116-20. 
28. Grady, R. and F. Hayes, Axe-Txe, a broad-spectrum proteic toxin-antitoxin system 
specified by a multidrug-resistant, clinical isolate of Enterococcus faecium. Mol 
Microbiol, 2003. 47(5): p. 1419-32. 
29. Gronlund, H. and K. Gerdes, Toxin-antitoxin systems homologous with relBE of 
Escherichia coli plasmid P307 are ubiquitous in prokaryotes. J Mol Biol, 1999. 
285(4): p. 1401-15. 
30. Guardabassi, L. and A. Dalsgaard, Occurrence, structure, and mobility of 
Tn1546-like elements in environmental isolates of vancomycin-resistant 
enterococci. Appl Environ Microbiol, 2004. 70(2): p. 984-90. 
31. Hasman, H., A.G. Villadsen, and F.M. Aarestrup, Diversity and stability of 
plasmids from glycopeptide-resistant Enterococcus faecium (GRE) isolated from 
pigs in Denmark. Microb Drug Resist, 2005. 11(2): p. 178-84. 
32. Hayes, F., Toxins-antitoxins: plasmid maintenance, programmed cell death, and 
cell cycle arrest. Science, 2003. 301(5639): p. 1496-9. 
33. Hofreuter, D. and R. Haas, Characterization of Two Cryptic Helicobacter pylori 
Plasmids: a Putative Source for Horizontal Gene Transfer and Gene Shuffling. 
2002. p. 2755-2766. 
 
119 
 
34. Ike, Y., K. Tanimoto, H. Tomita, K. Takeuchi, and S. Fujimoto, Efficient transfer 
of the pheromone-independent Enterococcus faecium plasmid pMG1 (Gmr) (65.1 
kilobases) to Enterococcus strains during broth mating. J Bacteriol, 1998. 
180(18): p. 4886-92. 
35. Jensen, R.B. and K. Gerdes, Programmed cell death in bacteria: proteic plasmid 
stabilization systems. Mol Microbiol, 1995. 17(2): p. 205-10. 
36. Jeon, B.-C., S.H. Jeong, I.K. Bae, S.B. Kwon, K. Lee, D. Young, J.H. Lee, J.S. 
Song, and S.H. Lee, Investigation of a Nosocomial Outbreak of Imipenem-
Resistant Acinetobacter baumannii Producing the OXA-23 {beta}-Lactamase in 
Korea. 2005. p. 2241-2245. 
37. Jiang, Y., J. Pogliano, D.R. Helinski, and I. Konieczny, ParE toxin encoded by 
the broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase. Mol 
Microbiol, 2002. 44(4): p. 971-9. 
38. JMI. Susceptibility of Gram-Positive Pathogens.  2009  [cited; Available from: 
http://www.gp-pathogens.com/data/default.cfm. 
39. Johnsen, P.J., J.I. Osterhus, H. Sletvold, M. Sorum, H. Kruse, K. Nielsen, G.S. 
Simonsen, and A. Sundsfjord, Persistence of animal and human glycopeptide-
resistant enterococci on two Norwegian poultry farms formerly exposed to 
avoparcin is associated with a widespread plasmid-mediated vanA element within 
a polyclonal enterococcus faecium population. Appl Environ Microbiol, 2005. 
71(1): p. 159-68. 
40. Johnsen, P.J., G.S. Simonsen, O. Olsvik, T. Midtvedt, and A. Sundsfjord, 
Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide 
resistance in enterococci in the absence of antibiotic selection in vitro and in 
gnotobiotic mice. Microb Drug Resist, 2002. 8(3): p. 161-70. 
41. Kamphuis, M.B., A.M. Bonvin, M.C. Monti, M. Lemonnier, A. Munoz-Gomez, 
R.H. van den Heuvel, R. Diaz-Orejas, and R. Boelens, Model for RNA binding 
and the catalytic site of the RNase Kid of the bacterial parD toxin-antitoxin 
system. J Mol Biol, 2006. 357(1): p. 115-26. 
42. Ke, D., F.J. Picard, F. Martineau, C. Menard, P.H. Roy, M. Ouellette, and M.G. 
Bergeron, Development of a PCR assay for rapid detection of enterococci. J Clin 
Microbiol, 1999. 37(11): p. 3497-503. 
43. Koch, S., M. Hufnagel, and J. Huebner, Treatment and prevention of enterococcal 
infections--alternative and experimental approaches. Expert Opin Biol Ther, 
2004. 4(9): p. 1519-31. 
 
120 
 
44. Lim, S.K., K. Tanimoto, H. Tomita, and Y. Ike, Pheromone-responsive 
conjugative vancomycin resistance plasmids in Enterococcus faecalis isolates 
from humans and chicken feces. Appl Environ Microbiol, 2006. 72(10): p. 6544-
53. 
45. Lioy, V.S., et al., pSM19035-encoded zeta toxin induces stasis followed by death 
in a subpopulation of cells. Microbiology, 2006. 152(Pt 8): p. 2365-79. 
46. Liu, M., Y. Zhang, M. Inouye, and N.A. Woychik, Bacterial addiction module 
toxin Doc inhibits translation elongation through its association with the 30S 
ribosomal subunit. Proc Natl Acad Sci U S A, 2008. 105(15): p. 5885-90. 
47. Masuda, Y., K. Miyakawa, Y. Nishimura, and E. Ohtsubo, chpA and chpB, 
Escherichia coli chromosomal homologs of the pem locus responsible for stable 
maintenance of plasmid R100. J Bacteriol, 1993. 175(21): p. 6850-6. 
48. Mittenhuber, G., Occurrence of mazEF-like antitoxin/toxin systems in bacteria. J 
Mol Microbiol Biotechnol, 1999. 1(2): p. 295-302. 
49. Naas, T., N. Fortineau, R. Snanoudj, C. Spicq, A. Durrbach, and P. Nordmann, 
First nosocomial outbreak of vancomycin-resistant Enterococcus faecium 
expressing a VanD-like phenotype associated with a vanA genotype. J Clin 
Microbiol, 2005. 43(8): p. 3642-9. 
50. O'Neill, A.J., A.R. Larsen, R. Skov, A.S. Henriksen, and I. Chopra, 
Characterization of the Epidemic European Fusidic Acid-Resistant Impetigo 
Clone of Staphylococcus aureus. 2007. p. 1505-1510. 
51. Ogura, T. and S. Hiraga, Mini-F plasmid genes that couple host cell division to 
plasmid proliferation. Proc Natl Acad Sci U S A, 1983. 80(15): p. 4784-8. 
52. Palepou, M.F., A.M. Adebiyi, C.H. Tremlett, L.B. Jensen, and N. Woodford, 
Molecular analysis of diverse elements mediating VanA glycopeptide resistance 
in enterococci. J Antimicrob Chemother, 1998. 42(5): p. 605-12. 
53. Pandey, D.P. and K. Gerdes, Toxin-antitoxin loci are highly abundant in free-
living but lost from host-associated prokaryotes. Nucleic Acids Res, 2005. 33(3): 
p. 966-76. 
54. Paulsen, I.T., et al., Role of mobile DNA in the evolution of vancomycin-resistant 
Enterococcus faecalis. Science, 2003. 299(5615): p. 2071-4. 
55. Pullinger, G.D. and A.J. Lax, A Salmonella dublin virulence plasmid locus that 
affects bacterial growth under nutrient-limited conditions. Mol Microbiol, 1992. 
6(12): p. 1631-43. 
121 
 
56. Richards, M.J., J.R. Edwards, D.H. Culver, and R.P. Gaynes, Nosocomial 
infections in combined medical-surgical intensive care units in the United States. 
Infect Control Hosp Epidemiol, 2000. 21(8): p. 510-5. 
57. Sambrook, J. and D.W. Russel, Molecular Cloning: A Laboratory Manual. 2001, 
Cold Spring Harbor, NY: Cold Spring Harbor Lab Press. 
58. Santos Sierra, S., R. Giraldo, and R. Diaz Orejas, Functional interactions between 
chpB and parD, two homologous conditional killer systems found in the 
Escherichia coli chromosome and in plasmid R1. FEMS Microbiol Lett, 1998. 
168(1): p. 51-8. 
59. Shepard, B.D. and M.S. Gilmore, Antibiotic-resistant enterococci: the 
mechanisms and dynamics of drug introduction and resistance. Microbes Infect, 
2002. 4(2): p. 215-24. 
60. Simpson, A.E., R.A. Skurray, and N. Firth, A single gene on the staphylococcal 
multiresistance plasmid pSK1 encodes a novel partitioning system. J Bacteriol, 
2003. 185(7): p. 2143-52. 
61. Sletvold, H., P.J. Johnsen, I. Hamre, G.S. Simonsen, A. Sundsfjord, and K.M. 
Nielsen, Complete sequence of Enterococcus faecium pVEF3 and the detection of 
an omega-epsilon-zeta toxin-antitoxin module and an ABC transporter. Plasmid, 
2008. 60(1): p. 75-85. 
62. Sletvold, H., P.J. Johnsen, G.S. Simonsen, B. Aasnaes, A. Sundsfjord, and K.M. 
Nielsen, Comparative DNA analysis of two vanA plasmids from Enterococcus 
faecium strains isolated from poultry and a poultry farmer in Norway. Antimicrob 
Agents Chemother, 2007. 51(2): p. 736-9. 
63. Sorum, M., P.J. Johnsen, B. Aasnes, T. Rosvoll, H. Kruse, A. Sundsfjord, and 
G.S. Simonsen, Prevalence, persistence, and molecular characterization of 
glycopeptide-resistant enterococci in Norwegian poultry and poultry farmers 3 to 
8 years after the ban on avoparcin. Appl Environ Microbiol, 2006. 72(1): p. 516-
21. 
64. Standards, N.C.f.C.L., Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically. 2003, Wayne, PA: NCCLS. 
65. Takeuchi, K., H. Tomita, S. Fujimoto, M. Kudo, H. Kuwano, and Y. Ike, Drug 
resistance of Enterococcus faecium clinical isolates and the conjugative transfer 
of gentamicin and erythromycin resistance traits. FEMS Microbiol Lett, 2005. 
243(2): p. 347-54. 
66. Teng, L.J., P.R. Hsueh, Y.H. Wang, H.M. Lin, K.T. Luh, and S.W. Ho, 
Determination of Enterococcus faecalis groESL full-length sequence and 
application for species identification. J Clin Microbiol, 2001. 39(9): p. 3326-31. 
122 
 
67. Tian, Q.B., M. Ohnishi, A. Tabuchi, and Y. Terawaki, A new plasmid-encoded 
proteic killer gene system: cloning, sequencing, and analyzing hig locus of 
plasmid Rts1. Biochem Biophys Res Commun, 1996. 220(2): p. 280-4. 
68. Tomita, H., C. Pierson, S.K. Lim, D.B. Clewell, and Y. Ike, Possible connection 
between a widely disseminated conjugative gentamicin resistance (pMG1-like) 
plasmid and the emergence of vancomycin resistance in Enterococcus faecium. J 
Clin Microbiol, 2002. 40(9): p. 3326-33. 
69. Tomita, H., K. Tanimoto, S. Hayakawa, K. Morinaga, K. Ezaki, H. Oshima, and 
Y. Ike, Highly conjugative pMG1-like plasmids carrying Tn1546-like transposons 
that encode vancomycin resistance in Enterococcus faecium. J Bacteriol, 2003. 
185(23): p. 7024-8. 
70. Van Melderen, L., Molecular interactions of the CcdB poison with its bacterial 
target, the DNA gyrase. Int J Med Microbiol, 2002. 291(6-7): p. 537-44. 
71. Velasco, D., S. Perez, F. Pena, M.A. Dominguez, M. Cartelle, F. Molina, R. 
Moure, R. Villanueva, and G. Bou, Lack of correlation between phenotypic 
techniques and PCR-based genotypic methods for identification of Enterococcus 
spp. Diagn Microbiol Infect Dis, 2004. 49(3): p. 151-6. 
72. Wang, C., D.J. Meek, P. Panchal, N. Boruvka, F.S. Archibald, B.T. Driscoll, and 
T.C. Charles, Isolation of Poly-3-Hydroxybutyrate Metabolism Genes from 
Complex Microbial Communities by Phenotypic Complementation of Bacterial 
Mutants. 2006. p. 384-391. 
73. Weaver, K.E., K.D. Walz, and M.S. Heine, Isolation of a derivative of 
Escherichia coli-Enterococcus faecalis shuttle vector pAM401 temperature 
sensitive for maintenance in E. faecalis and its use in evaluating the mechanism of 
pAD1 par-dependent plasmid stabilization. Plasmid, 1998. 40(3): p. 225-32. 
74. Weaver, K.E., D.M. Weaver, C.L. Wells, C.M. Waters, M.E. Gardner, and E.A. 
Ehli, Enterococcus faecalis plasmid pAD1-encoded Fst toxin affects membrane 
permeability and alters cellular responses to lantibiotics. J Bacteriol, 2003. 
185(7): p. 2169-77. 
75. Weigel, L.M., et al., Genetic analysis of a high-level vancomycin-resistant isolate 
of Staphylococcus aureus. Science, 2003. 302(5650): p. 1569-71. 
76. Wirth, R., F.Y. An, and D.B. Clewell, Highly efficient protoplast transformation 
system for Streptococcus faecalis and a new Escherichia coli-S. faecalis shuttle 
vector. J Bacteriol, 1986. 165(3): p. 831-6. 
 
 
123 
 
77. Zheng, B., H. Tomita, T. Inoue, and Y. Ike, Isolation of VanB-type Enterococcus 
faecalis strains from nosocomial infections: first report of the isolation and 
identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-
type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, 
encoding erythromycin resistance and cytolysin (Hly/Bac). Antimicrob Agents 
Chemother, 2009. 53(2): p. 735-47. 
78. Zheng, B., H. Tomita, Y.H. Xiao, S. Wang, Y. Li, and Y. Ike, Molecular 
characterization of vancomycin-resistant enterococcus faecium isolates from 
mainland China. J Clin Microbiol, 2007. 45(9): p. 2813-8. 
79. Zielenkiewicz, U. and P. Ceglowski, The toxin-antitoxin system of the 
streptococcal plasmid pSM19035. J Bacteriol, 2005. 187(17): p. 6094-105. 
 
 
124 
 
CHAPTER 3 
PREVALNCE OF TOXIN-ANTITOXIN SYSTEMS IN METHICILLIN-
RESISTANT STAPHYLOCOCCUS AUREUS 
Sections from Chapter 3 have been reproduced from “The Prevalence of Toxin-
Antitoxin (TA) Genes in Clinical Isolates of Pseudomonas aeruginosa, Acinetobacter 
baumannii, and Methicillin-Resistant Staphylococcus aureus” Moritz, E.M., Williams, 
J.J., Dwyer, E.M., DiFazio, R.M., and P.J. Hergenrother.  2010, J Appl Microbiol, 
Manuscript submitted. 
 
3.1  INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) is the major cause of 
nosocomial infections in the U.S [5, 24, 34] and a rising threat in community-associated 
bacterial illnesses [33, 39, 53]. The resistance of S. aureus to antibiotics such as 
aminoglycides and fluoroquinolones has severely diminished the treatment options for 
multidrug-resistant strains [25, 67, 71].  Fortunately, significant resistance has thus far 
not been observed against newer antimicrobial drugs such as linezolid, daptomycin, and 
tigecycline [31, 32, 40, 60].  Vancomycin therapy is the current first-line treatment for 
patients with an MRSA infection; however, a growing number of these infections 
respond poorly to vancomycin treatment, as vacomycin-intermediate resistance is 
becoming increasingly common [46, 56, 61].  The rising prevalence of such multidrug-
resistant S. aureus strains both in the hospital and community setting underscores the 
continuing need for new classes of antibiotics to treat MRSA infections.   
As discussed in Chapter 2, another problematic Gram-positive nosocomial 
pathogen, vancomycin-resistant enterococci (VRE), frequently carries the genes for 
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toxin-antitoxin (TA) systems on plasmid DNA [45].  As postsegregational killing 
“plasmid addiction” systems [18, 23], TA systems are characterized by a potent toxin and 
labile antitoxin, both encoded on the plasmid DNA.  If the plasmid is present in the cell, 
the antitoxin binds to and inhibits the toxin.  However, if the plasmid is lost, the labile 
antitoxin is degraded thus releasing the more stable toxin to kill the bacterial cell.  TA 
systems may represent a novel antibacterial target based on the notion that if the toxin of 
the TA pair could be activated (either through direct TA disruption or an alternate 
mechanism) it would kill the host bacterial cell from within [1, 10, 13, 17, 38, 54, 76].  
Among the collection of clinical VRE isolates, certain TA systems were found to be 
highly prevalent (mazEF, axe-txe, relBE, and ω−ε−ζ), with the mazEF system present in 
100% of the isolates [45].  
As it has been shown that the genes encoding TA systems are ubiquitous and 
functional on plasmids in VRE, [45, 64] this raises the possibility that other pathogenic 
bacteria may also harbor the genes for TA systems.  A bioinformatics survey of 126 
prokaryotic genomes for the distribution of genes encoding TA systems has shown just 
how widespread and diverse the range of bacterial species are that harbor TA systems 
[51].  As more clinical isolates are confirmed to harbor genes for toxin-antitoxin proteins, 
the more attractive therapies aimed at TA systems become.  However, the prevalence of 
TA systems in clinical isolates of MRSA is relatively unknown.  In the current study, we 
find that genes recently discovered in S. aureus to encode a homolog of the mazEF TA 
system from E. coli [15, 16, 51] are prevalent in a collection of clinical MRSA isolates.  
The discovery that a specific TA system is prevalent in MRSA further supports the 
potential of toxin activation as a novel and broad-spectrum antibacterial strategy.  
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3.2  CHARACTERIZATION OF THE COLLECTION OF METHICILLIN-
RESISTANT S. AUREUS 
Clinical isolates of MRSA were obtained from 3 different medical centers and the 
Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for a total of 
78 strains.  The medical centers were: Carle Foundation Hospital (Urbana, IL), Memorial 
Medical Center (Springfield, IL), and Delnor Community Hospital (Geneva, IL).  To 
verify that the strains received from the three medical centers were indeed methicillin-
resistant S. aureus (MRSA), oxacillin susceptibility was tested using the agar disk 
diffusion method.  Testing revealed that all strains were resistant to oxacillin according to 
standards set by the Clinical and Laboratory Standards Institute (CLSI) [65].  Next, the 
MRSA isolates were assessed for resistance or reduced susceptibility to vancomycin.  
Microdilution broth tests verified that all of the clinical isolates were susceptible to 
vancomycin according to CLSI standards [66].   
The DNA-based typing method, MLVA, was used to assess the relatedness of the 
61 uncharacterized MRSA isolates collected from the three medical centers.  Most of the 
S. aureus isolates obtained from NARSA were not included in the MLVA because they 
had previously been characterized.  However, eight known S. aureus strains received 
from NARSA were included in the MLVA for comparison [NRS-3 is HIP5827 and NRS-
4 is HIP5836 [69], NRS-22 is USA600 [43], NRS-51 is HIP09740 [21], NRS-77 is RN1 
[49], NRS-382 is USA100, NRS-383 is USA200, and NRS-384 is USA300 [43]].   
The experimental variation between duplicate experiments was determined for the 
MLVA of five S. aureus isolates and used to establish a cutoff value of 91% for typing 
strains with identical DNA banding patterns.  Using the 91% cutoff, 46 MLVA patterns 
were defined out of the 69 strains evaluated.  The number of bands in MLVA patterns 
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ranged from four to eight bands.  When a cutoff similarity value of 75% was applied, 13 
clusters were generated from 56 strains, while 13 strains were excluded from the clusters 
and had separate positions in the dendrogram (Figure 3.1).  Isolates belonging to the 
same cluster differed by up to four bands.  The results of MLVA with the clinical S. 
aureus strains when subjected to both the 91% and 75% cutoff values reveal that the 
majority of isolates do not belong to the same clusters as the known U.S. S. aureus clones 
(USA100, USA200, USA300, and USA600) and suggest that the isolates collected from 
the Illinois area are not clonal. 
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 Figure 3.1  MLVA of the 
MRSA clinical isolates.   
The 91% cutoff value and 
75% similarity cutoff 
value are indicated by red 
and blue vertical lines, 
respectively.  The 
corresponding clusters 
generated are shown in 
matching colors alongside 
the dendrogram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
0
95908580757065605550454035302520
85. 7
83.3
88.9
62.5
49.2
100
88.9
100
92.9
85. 5
81
72.6
100
84.6
69.4
100
85. 7
80
59. 9
85. 7
93.3
82.9
100
75.6
100
85. 7
85. 7
65.9
53. 4
46.2
44
100
75
100
92.3
91.9
100
86.8
68.1
63. 6
60. 1
100
71.4
66.7
54.9
100
91.7
100
92.3
75.8
83.3
76. 9
68.5
63. 9
88.9
61.7
52.8
40.5
25.8
24.6
20.3
60
17. 6
S11
S17
S22
NRS384/USA300
S12
S20
C11
C5
S16
G14
C10
C4
S26
C3
C9
C17
C18
C21
C13
C19
C8
C7
G12
G10
G9
C6
G7
G2
G6
G8
S1
S9
S3
S8
S7
S4
NRS77
NRS4
S23
S5
G11
S19
C12
S13
S15
S2
C16
S25
G4
G5
NRS51
S24
G13
G3
S18
C14
S10
S6
NRS3
S14
S21
C20
G1
NRS382/USA100
C2
NRS383/USA200
C15
C1
NRS22/USA600
129 
 
3.3  PRESENCE OF TOXIN-ANTITOXIN GENES IN METHICILLIN-RESISTANT S. 
AUREUS  
 
3.3.1  Presence of Toxin-Antitoxin Genes in Total Plasmid DNA Preparations 
With the knowledge that the clinical isolates of S. aureus collected were indeed 
MRSA and were sufficiently diverse, an effort was made to define the prevalence of TA 
systems in plasmid preparations from MRSA.  Similar to the experiments described in 
Chapter 2 with the VRE isolates, non-degenerate PCR primers were used to amplify the 
genes of three TA systems initially identified in Gram-positive organisms [ω−ε−ζ  [6], 
axe-txe [19], and par [75]], and seven systems representing major families of TA systems 
discovered in Gram-negative bacteria [parDE [27], ccdAB [50, 73], mazEF [12], relBE 
[7], higBA [70], vagCD [55], and phd-doc [26]] [45].  The primers used to amplify the 
ω−ε−ζ, axe-txe, par, parDE, ccd, mazEF, higBA, vagCD, and phd-doc TA genes are 
identical to those used for PCR analysis of the VRE isolates and the oligonucleotide 
sequences are listed in Chapter 2, Table 2.1 [45].  The forward and reverse primers for 
the relBE TA genes were modified to the sequences 5’-CAGAGAATGCGTTTGACCG-
3’ and 5’-CGCTGACAATGAACGCTTGCC-3’, respectively.   
Plasmid DNA was prepared from each of the 78 MRSA strains by the alkaline 
lysis method; however, this method is prone to chromosomal DNA contamination.  Thus, 
steps were taken to eliminate contaminating genomic DNA in hopes of determining the 
location (plasmid or chromosome) of the TA genes.  DNA isolated using the alkaline 
lysis method was treated with Plasmid-Safe DNase (Epicentre Biotechnologies), which 
selectively digests linear dsDNA but not supercoiled dsDNA.  This enzyme has been 
used in several studies to effectively destroy sheared genomic DNA present in plasmid 
DNA solutions [22, 30, 42, 45].  PCR analysis after Plasmid-Safe DNase treatment 
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revealed that the following three TA systems were present in multiple isolates: ccdAB 
(35/78, 44%), mazEF (24/78, 30%), and relBE (20/78, 25%) (see Table 3.1).  However, 
for the TA systems ω−ε−ζ, axe-txe, par, parDE, higBA, vagCD and phd-doc, no product 
was observed by PCR after treatment, suggesting that these TA loci were not present on 
plasmid DNA.   
To verify that the input DNA for PCR did not contain any chromosomal DNA, 
PCR was carried out using previously described primers to amplify two housekeeping 
genes from S. aureus that are encoded on the chromosome; glycerol kinase (glp) and 
guanylate kinase (gmk) [14].  The total plasmid DNA of four MRSA isolates (C5, G13, 
S22 and NRS24) were treated with Plasmid-Safe DNase and then probed by PCR for the 
glp and gmk products.  For all four samples, the housekeeping gene PCR products were 
amplified, suggesting that the Plasmid-Safe DNase did not effectively digest 
chromosomal DNA.  In light of these results, it was decided that the total genomic DNA 
of the 78 MRSA strains would be used in the PCR screen since it would be difficult to 
isolate plasmid DNA free of chromosomal DNA from the clinical isolates.   
 
3.3.2  Presence of Toxin-Antitoxin Genes in Genomic DNA Preparations 
The primers used to amplify the ω−ε−ζ, axe-txe, par, parDE, ccd, mazEF, relBE, 
higBA, vagCD, and phd-doc TA genes from the plasmid DNA preparations were also 
used to probe total DNA preparations of the 78 MRSA isolates.  Additionally, non-
degenerate PCR primers were designed to amplify the genes for a mazEF homolog 
observed on the S. aureus COL genome, mazEFSa [15, 16].  The initial round of PCRs 
revealed that 100% of the samples contained at least one TA system and that total DNA 
preparations of most MRSA isolates had multiple TA systems.  Specifically, the genes 
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for six different TA systems were detected by PCR in the collection of strains:  ω−ε−ζ 
(16/78, 20%), axe-txe (48/78, 61%), ccdAB (73/78, 93%), mazEF (77/78, 98%), relBE 
(78/78, 100%), and mazEFSa (78/78, 100%) (see Table 3.2).  However, subsequent PCRs 
failed to consistently amplify products for all of the TA systems except the mazEFSa 
genes.  Thus, PCR results were designated as positive if a distinct band could be seen at 
the expected size on an agarose gel and repeated in triplicate.   
To further investigate the negative PCR results seen with most of the TA systems, 
Southern blot hybridization was performed with PstI-digested total DNA of five MRSA 
isolates (C3, C4, C5, S7, and S8).  Dioxigenin-labeled relBE and mazEF PCR products 
were used as probes and E. coli DH5α PstI-digested total DNA was included as a 
positive control.  In agreement with the latter PCR results, the relBE and mazEF genes 
were not detected by Southern blot analysis in the five MRSA isolates. 
The final result for the 78 MRSA strains was the confirmed detection of the genes 
for the mazEFSa TA system in all of the isolates by PCR (78/78, 100%).  DNA 
sequencing was performed on >10% of the PCR products to confirm the identity of the 
amplified TA system.  Sequenced PCR products revealed strong sequence identity for the 
mazEFSa results (98.5 – 99.7%) to the reference TA gene sequences from the S. aureus 
COL genome (mazEFSa alignments are shown in Figure 3.6 at the end of this chapter).    
The PCR results for the mazEFSa TA sequence, however, did not give any 
information as to whether the genes were located on a plasmid or the chromosome of the 
MRSA isolates.  Fortunately, the sequences directly upstream and downstream of the 
mazEFSa TA genes are highly conserved (99-100% identity) among the 16 S. aureus 
completed genomes in the National Center for Biotechnology Information (NCBI) 
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Genome database.  Thus, primers were designed to amplify the sequences between the 
rbsU and mazFSa genes and the alr and mazESa genes (See Figure 3.2).  If the genes for 
the mazEFSa TA system detected in all of the MRSA isolates by PCR are also located on 
the chromosome between the rbsU and alr genes, PCR products should be generated. 
 
Figure 3.2  In all 16 completed genomes of S. aureus, the mazEFSa genes are flanked by rbsU and alr, 
which encode a sigma factor B regulator and alanine racemase, respectively.  Primers were designed to 
amplify the sequences from the rbsU gene to the mazFSa gene and from the mazESa gene to the alr gene. 
 
 PCR analysis revealed that in 100% of the isolates (78/78), the sequences 
upstream and downstream of the mazEFSa genes were identical to the sequences flanking 
the mazEFSa genes in the 16 S. aureus genomes in the NCBI database.  Thus, these 
results suggest that the mazEFSa genes detected in the MRSA clinical isolates reside on 
the chromosome as well.  DNA sequencing was performed on >10% of the PCR products 
to confirm the identity of the amplified sequence.  Sequenced PCR products revealed a 
strong sequence identity for the rbsU-mazFSa and mazESa-alr results (91.7 – 98.5%) to 
the reference sequence from the S. aureus COL genome (alignments are shown in 
Figures 3.7-3.8 at the end of this chapter).   
   
3.3.3  Controls for E. coli Contamination 
 To ensure that the observed results were specific to the MRSA isolates and not 
due to E. coli chromosomal contamination, several PCR-based contamination controls 
were conducted.  First, the total DNA of S. aureus strain USA_300 was isolated and 
probed by PCR for the eleven TA systems originally investigated in the PCR screen.  The 
rbsU alrmazFSa mazESa
753 bp product 566 bp product
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genome of the USA_300 strain has been sequenced and should only contain the genes for 
the mazEFSa system and none of the ten other TA systems.  In agreement with the 
published genome sequence of USA_300, only the  mazEFSa genes were amplified by 
PCR.  Second, a media-only overnight “culture” was taken through the total DNA 
preparation protocol.  Any DNA thus isolated was probed by PCR for the eleven TA 
systems, and, in all cases, no amplification was observed.  Finally, PCR was performed 
with the 9 MRSA isolates (C1-C6, C21, S1 and S14) using primers for the E. coli 16S 
rRNA gene to detect any low levels of E. coli DNA present in the MRSA total DNA 
preparations [59].  In all cases, no amplification was observed suggesting that there was 
no E. coli chromosomal contamination in the total DNA samples isolated from the 
MRSA isolates.  While these results do not explain the initial positive PCR results for so 
many of the TA systems, they do demonstrate that the total DNA preparations used for 
the final PCR results were sufficiently free of contaminating DNA. 
 
3.4  ASSESSING THE FUNCTIONALITY OF TOXIN-ANTITOXIN SYSTEMS IN 
METHICILLIN-RESISTANT S. AUREUS   
 
3.4.1  Immunodetection of MazEF in Methicillin-Resistant S. aureus 
 Before the final results of the PCR screen for TA systems were known and the 
initial results suggested that the 78 MRSA isolates carried the genes for the E. coli 
mazEF TA system, Western blot analysis was attempted using an anti-MazEF polyclonal 
antibody with the clinical isolates.  Anti-MazEF polyclonal antibodies were generated in 
a manner identical to the methods used to generate anti-RelBE polyclonal antibodies 
described in Chapter 2, section 2.5.  The cell lysates of all 78 MRSA clinical isolates 
were separated by SDS-PAGE and transferred to Immobilon-P PVDF membranes 
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(Millipore).  Membranes were probed with the anti-MazEF polyclonal antibody, and 
followed by mouse anti-rabbit IgG-horseradish peroxidase conjugated antiserum (Pierce).  
Antibody binding was then detected with Supersignal West Pico Chemiluminescent 
substrate (Pierce) and autoradiography film.  The sizes expected for MazE and MazF are 
9,350 Da and 12,090 Da, respectively.  For forty-one of the MRSA isolates, no bands 
were detected in the 10-15 kDa range.  However, for the remaining thirty-seven MRSA 
strains, a single band was detected that migrated between the 10 and 15 kDa markers (see 
Figure 3.3A for Western blot results with 13 of the MRSA isolates).   
To isolate the MRSA protein detected by the MazEF antibody in significant 
quantities for further analysis, immunoprecipitation was performed.   MazEF antiserum 
was coupled to Affi-Gel 10 affinity media (Bio-Rad) and incubated with MRSA C6 or 
NRS17 cell lysates.  To isolate proteins which bound selectively to the immobilized 
MazEF antibody, the slurry was thoroughly washed and then resuspended in denaturing 
SDS loading dye and analyzed by SDS-PAGE and Western blot.  A single band in the 
10-15 kDa range was detected  for both strains by Coomassie staining and one or two 
bands by Western blot with the MazEF antibody (Figure 3.3B). 
The cell lysate of MRSA clinical isolate C6 was also analyzed by 2-D gel 
electrophoresis and Western blot to detect the MazEF proteins.  The Protein Sciences 
Facility at the University of Illinois performed 2-D gel electrophoresis analysis in 
duplicate.  For the first dimension, isoelectric focusing (IEF) of the lysate was carried out 
using an immobilized pH gradient (IPG) strip with a linear pH range of 3.0-10.0.  After 
separating proteins in the lysate according to differences in isoelectric points, protein 
were separated based on molecular weight for the second dimension by SDS-PAGE.  One 
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of the 2-D gels was stained with Coomassie Blue to detect all of the proteins in the 
sample.  The second gel was transferred to a PVDF membrane and probed with the anti-
MazEF polyclonal antibody as before to specifically detect the MazEF proteins (Figure 
3.3C).  The pI of MazE is 4.72 and the pI of MazF is 8.49.  Unfortunately, the cell lysate 
did not separate well by IEF and SDS-PAGE and the anti-MazEF polyclonal antibody 
bound non-specifically to many proteins, rendering the results of the 2-D gel analysis 
inconclusive.       
The Coomassie-stained band detected from the immunoprecipiation of the C6 
isolate was cut out from the polyacrylamide gel and submitted for internal sequence 
analysis through the University of Illinois Protein Sciences Facility.  Sequencing results 
revealed the band in the 10-15 kDa range to be the 30S ribosomal protein S8 from S. 
aureus, which is 14.7 kDa, and not either of the MazEF proteins.   This result is in 
agreement with the final PCR results, in which the mazEF genes from E. coli were not 
detected in the 78 MRSA isolates.  
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Figure 3.3  Immunodetection of MazEF.  (A)  Western blots of the cell lysates of 13 MRSA isolates using 
MazEF antiserum.  (B) Western blots and Coomassie-staining of proteins immunoprecipitated from C6 and 
N17 cell lysates using MazEF antiserum coupled to Affi-Gel 10 affinity media.  (C)  Western blot and 
Coomassie-staining of C6 cell lysate separated by 2-D gel electrophoresis.  M indicates lane containing 
marker of protein standards. 
A
15 kDa
10 kDa
15 kDa
10 kDa
N3 N17 N18 N21 N22 N23
C1 C2 C3 C4 C5 C6 C7
B
15 kDa
10 kDa
15 kDa
10 kDa
15 kDa
10 kDa
15 kDa
10 kDa
C6
C6
N17
N17
Coomassie-
stained gels
Anti-MazEF 
Western blots
C
14 kDa
31 kDa
3.5 kDa
55 kDa
14 kDa
31 kDa
3.5 kDa
55 kDa
6 kDa
Anti-MazEF 
Western blot
Coomassie-
stained 2-D gel
M
M
M
M
M
M
M
M pH 3 pH 10
pH 3 pH 10
137 
 
3.4.2  RT-PCR Analysis 
In order to determine if the mazEFSa system is transcribed in MRSA, RT-PCR 
was performed with the total RNA isolated from nine MRSA isolates determined by PCR 
analysis with total DNA to contain the mazEFSa genes.  As shown in Figure 3.4A, the 
mazEFSa transcript was detected from the total RNA of all nine MRSA strains probed by 
RT-PCR.   
 
Figure 3.4  RT-PCR analysis of 9 clinical MRSA isolates (lanes 1-10).  (A) RT-PCR with primers 
complementary to mazEFSa indicates that this transcript is present in the clinical isolates.  (B) Controls for 
DNA contamination, in which the reverse transcriptase is left out of the reaction mix, give no amplification 
of mazEFSa.   
 
To rule out DNA contamination as the source of the RT-PCR products, controls 
were performed in which no reverse transcriptase enzyme was added to the reaction, but 
all other components (including thermostable DNA polymerase and primers for mazEFSa) 
were kept the same.  For all nine samples, no amplification products were observed under 
these conditions, confirming that the products seen by RT-PCR were due to the presence 
of the mazEFSa transcript in MRSA isolates carrying the mazEFSa genes and not DNA 
contamination (see Figure 3.4B). 
 
 
S3S1N26N17N4G3G1C16C8
S3S1N26N17N4G3G1C16C8
A
B
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3.5  CONCLUSIONS 
 The presumed role of TA systems residing on plasmid DNA is to ensure the stable 
inheritance and maintenance of the plasmid in a bacterial population by postsegregational 
killing of any plasmid-free cells that arise.  The function of TA loci on bacterial 
chromosomes is unclear but it has been proposed that TA systems are involved in 
bacterial stress and death responses [17, 35, 37, 54, 57, 72].  Conflicting work has shown 
that the MazEF system in E. coli may function as an irreversible mediator of cell death 
under stressful conditions [3, 36, 47] or as a modulator of translation to induce a 
reversible state of bacteriostasis [8, 52].  In addition to the mazEF genes, the E. coli 
chromosome is known to encode at least four more TA systems, including chpBIK, 
relBE, dinJ-yafQ, and yefM-yoeB, whose regulatory roles during stressful conditions 
remain equally vague.  
A bioinformatics survey of 126 prokaryotic genomes identified TA loci belonging 
to known TA gene families on the completed genomes of three S. aureus strains [51].  
The genomes of all three S. aureus strains each contained two loci belonging to the relBE 
gene family and one locus belonging to the mazEF gene family [51].  The relB genes 
identified in the three S. aureus strains share 34-44% protein sequence identity with the 
YefM antitoxin of E. coli and belong to the PhD/YefM superfamily of antitoxins, which 
also includes RelB.  The relE genes identified share 31-52% protein sequence identity 
with the YoeB toxin of E. coli, which belongs to the RelE toxin superfamily [51].   
The mazEF genes identified in the three S. aureus strains share limited homology 
with the mazEF genes from E. coli (12% and 20% protein sequence identity to MazE and 
MazF, respectively), but have been demonstrated to be a TA module in S. aureus [15].  
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The MazEFSa TA system was also identified on the S. aureus COL genome when primer 
extension experiments revealed two additional ORFS, SA2059 (mazESa) and SA2058 
(mazFSa), were cotranscribed with the sigB operon upstream during early growth strages 
[63].  The toxin,  MazFSa, is a sequence-specific endoribonuclease and inhibits cell 
growth when expressed in both E. coli and S. aureus (Figure 3.5) [16, 77].  MazFSa 
cleavage of mRNA occurs preferentially  at the 5’ side of the first U or 3’ side of the 
second U residue of VUUV’ sequences (where V and V’are A, C, or G and may or may 
not be identical) both in vitro and in vivo [15].  Interestingly, the MazFSa toxin was shown 
to cleave mRNA transcripts selectively in vivo, avoiding cleavage of transcripts of 
virulence regulators and essential gene products [16].  This observation supports the idea 
that the  MazFSa toxin inhibits cell growth and causes cell stasis rather than immediate 
cell death. 
 
Figure 3.5  Reduction of CFUs (colony forming units) with S. aureus ALC6094 by overexpression of 
MazFSa-His6.  Cultures were grown to an OD650 of 0.45 and MazFSa-His6 expression was induced with 1 
mM IPTG.  At various timepoints, aliquots were withdrawn, serially diluted and spread onto selective 
media to determine the CFU counts.  Figure taken from [16]. 
 
In the collection of MRSA strains, the mazEFSa genes were discovered to be 
present in 100% (78/78) of the isolates and the transcript to be made in the 9 isolates 
analyzed.  As mentioned above, the MazEFSa system is cotranscribed with the alternative 
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transcription factor, σΒ, under certain stress conditions [11, 15, 63].  Thus, it will be 
interesting to determine how the role of TA systems found on the chromosomes of 
MRSA and other clinically important bacteria compares with the stress-related functions 
of the more well-studied TA systems, RelBE and MazEF, in E. coli.   
It has been suggested that activation of TA systems could be an attractive 
antimicrobial strategy, as a compound that released the toxin would result in host 
bacterial cell death [1, 10, 13, 17].  This drug-mediated toxin activation could be 
achieved either through direct disruption of the toxin-antitoxin proteins, or through an 
indirect mechanism [76].  Bioinformatics studies have revealed that a variety of 
homologues of the known TA systems exist in a multitude of bacterial and archaeal hosts, 
including S. aureus strains [9, 15, 20, 41, 44, 48, 51, 68].  While the presence of TA 
systems in microorganisms whose genomes have been sequenced has been established, 
the prevalence of TA systems in clinically relevant isolates is largely unknown.  Given 
the results of the study described in Chapter 2 showing that TA systems are ubiquitous in 
VRE [45], and the current study showing that the MazEFSa TA system is highly prevalent 
in MRSA, it appears that these important bacterial pathogens would indeed be susceptible 
to TA-based antibacterial strategies. 
 
3.6  MATERIALS AND METHODS 
Clinical Isolates of S. aureus.  Clinical isolates of MRSA were obtained from 3 
different medical centers and the Network on Antimicrobial Resistance in 
Staphylococcus aureus (NARSA) for a total of 78 strains.  The medical centers were: 
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Carle Foundation Hospital (Urbana, IL), Memorial Medical Center (Springfield, IL), and 
Delnor Community Hospital (Geneva, IL).   
Antibiotic Susceptibility Tests.  Oxacillin susceptibility testing for S. aureus 
strains was performed using the agar disk diffusion method as outlined by the Clinical 
and Laboratory Standards Institute (CLSI), formerly the National Committee for Clinical 
Laboratory Standards (NCCLS) [65].  Testing for reduced susceptibility to vancomycin 
and vancomycin resistance in S. aureus strains was performed using the microdilution 
broth method as outlined by the CLSI [66]. 
Plasmid DNA Isolation.  Plasmid DNA from staphylococci was isolated by a 
modified alkaline lysis method [62].  Cell pellets were initially incubated with 50 µg/mL 
lysostaphin (Sigma) in 25 mM Tris, 10 mM EDTA (pH 8.0), containing 50 mM glucose 
at 37°C for 30 minutes.  After phenol-chloroform extraction, plasmid DNA was 
precipitated by addition of isopropanol and pelleted by centrifugation at maximum speed 
for 5 minutes.  The isopropanol was gently removed and 70% ethanol was added to the 
DNA pellet.  The plasmid DNA was again pelleted by centrifugation, the supernatant 
removed, and the pellet was resuspended in 50 µL of 10 mM Tris-HCl buffer, pH 8.0. 
Total DNA Isolation.  Total DNA from all S. aureus strains was prepared using a 
modified isolation method from standard protocols [4, 29].  Briefly, cell pellets were 
resuspended in 50 mM Tris/10 mM EDTA (pH 8.0), containing 1% SDS, 300 µg/mL 
proteinase K, 50 µg/mL lysostaphin, and 60 µg/mL RNase A.  The suspension was 
incubated at 37ºC for a minimum of 1 hour, followed by phenol-chloroform extraction.  
Total DNA was precipitated by the addition of isopropanol and pelleted by 
centrifugation.  The isopropanol was subsequently removed, 70% ethanol was added and 
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the DNA was again pelleted by centrifugation.  Once the ethanol was removed, DNA 
samples were dissolved in 10 mM Tris-HCl buffer (pH 8.0).   
MLVA.  To assess the clonality of the clinical MRSA isolates basic molecular 
typing was performed by the PCR-based multiple-locus variable number of tandem 
repeats analysis (MLVA) method as previously described [58].  For MRSA, a minor 
modification was made to the reported protocol, in that a greater amount of Taq 
polyermase was added to the PCR mix (0.25 units per µL) and 6 µL of PCR products 
were analyzed in 1.8% Low-Range Ultra agarose (Biorad) for 3 hours at 6.5 V/cm.  TIFF 
files of the MLVA gel images were visually evaluated with BioNumerics software 
(Applied Maths) and a dendrogram of banding patterns was constructed using the Dice 
coefficient and the unweighted-pair group method using average linkages (UPGMA).   
Plasmid-Safe DNase Treatment.  To selectively digest contaminating 
chromosomal DNA, plasmid DNA isolated via the alkaline lysis method (described 
above) was treated with Plasmid-Safe ATP-Dependent DNase (Epicentre 
Biotechnologies) according to the manufacturer’s recommendations.  Approximatley 1 
µg of plasmid DNA was treated with 5 U of DNase in 25 µL reaction volumes at 37ºC 
for 1 hour.  The enzyme in the sample was the inactivated by incubation at 70ºC for 30 
minutes, and no further purification of the treated DNA was performed before carrying-
out PCR amplification. 
PCR Analysis.  For the clinical MRSA isolates, PCR amplification was 
performed with Plasmid-Safe DNase-treated plasmid DNA and purified total DNA 
preparations.  The primers used to amplify the axe-txe, par, parDE, ccd, mazEF, higBA, 
vagCD, and phd-doc TA genes were identical to those previously used for PCR analysis 
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of clinical VRE isolates [45].  The oligonucleotide sequences of the modified forward 
and reverse primers for the relBE TA genes were 5’CAG AGA ATG CGT TTG ACC G3’ 
and 5’CGC TGA CAA TGA ACG CTT GCC3’, respectively.  The oligonucelotide 
sequences of the forward and reverse primers designed to amplify the mazEFSa TA genes 
were 5’ ATC ATC GGA TAA GTA CGT CAG TTT3’ and 5’ AGA AGG ATA TTC ACA 
AAT GGC TGA3’, respectively.  The sequences of primers used to amplify the ω−ε−ζ, 
TA system were identical to those reported [28].  The oligonucelotide sequences of the 
forward and reverse primers designed to amplify the sequence from the rbsU gene to 
mazFSa gene were 5’GTC TTG AAC ACA TCT TCA CGC G3’ and 5’GCG AAA ATA 
CCG ACA CAT GTA GAG3’, respectively.  The oligonucelotide sequences of the 
forward and reverse primers designed to amplify the sequence from the mazESa gene to 
alr gene were 5’GCT TCG TTC GCT AGG GAG AG3’ and 5’CTA CAA GCG GGT GAG 
TCT GTA AG3’, respectively.  Most PCRs were carried out in a DNA thermal cycler 
(PTC-200, MJ Research, Inc.) under reaction conditions as described previously [45].  
Amplification of the mazEFSa genes required a lowering of the annealing temperature to 
49°C.  PCR for the E. coli 16S rRNA genes was performed using previously described 
primers, ECA75F and ECR619R, and followed the reactions conditions to those reported 
with minor modifications [59].  Briefly, a hot start was not used in the thermal cycling 
program.  Instead, 1.5 U of Taq polymerase (Invitrogen) was added last to the reaction 
mixture and PCR was carried out in a DNA thermal cycler (PTC-200, MJ Research, Inc.) 
with an initial denaturation step (94°C, 3 minutes), 40 cycles of denaturation (94°C, 45 
seconds) and annealing-extension (72°C, 45 seconds), followed by a final extension step 
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(72°C, 10 minutes).  PCR amplified products were analyzed by agarose gel 
electrophoresis in 1% agarose and stained with ethidium bromide. 
Sequencing Analysis.  Approximately 10% of the PCR products generated from 
custom primers for the TA systems were submitted for DNA sequencing by the 
University of Illinois W.M. Keck Center for Comparative and Functional Genomics.  
Sequence data was analyzed using BioEdit version 7.0.4.1 computer software and the 
BLAST database to verify the identity of PCR products and sequence identity to known 
genes [2]. 
Southern Blot Analysis.  MRSA total DNA preparations were digested overnight 
with PstI (New England Biolabs) and the DNA fragments were separated on a 0.8% 
agarose gel by electrophoresis.  The gel was placed in denaturation solution (0.5 M 
NaOH, 1.5 M NaCl) and gently shaken at room temperature for 30 minutes.  Following 
denaturation, the gel was briefly rinsed with dH2O, soaked in neutralization solution (0.5 
M Tris-HCl, pH 7.5, 1.5 M NaCl) with gentle shaking for 30 minutes, and then 
equilibrated in 20X SSC (3M NaCl, 0.3 M sodium citrate, pH 7.0) for 30 minutes at room 
temperature.  The gel was transferred overnight at room temperature to a Nytran 
Supercharge nylon membrane (Whatman) using the TurboBlotter system (Whatman) for 
rapid downward capillary transfer according to the manufacturer’s instructions.  After 
overnight transfer, the membrane was washed for 5 minutes with 2X SSC (pH 7.0) fixed 
with Ultraviolet light (254 nm) for 1 minute, rinsed briefly with dH2O, and allowed to 
air-dry. 
 Probes for relBE and mazEF were synthesized and labeled with digoxigenin-
dUTP using the PCR DIG Probe Synthesis Kit (Roche Diagnostics) and purified by gel 
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extraction with the QIAquick Gel Extraction Kit (Qiagen).  DIG-labeled probes were 
hybridized to the membrane in DIG Easy Hyb (Roche Diagnostics) (2 µL probe solution 
per mL of hybridization buffer) overnight (16-18 hours) at 42°C with gentle shaking.  
After hybridization, the membrane was washed twice at room temperature with low 
stringency buffer (2X SSC, 0.1% SDS) for 5 minutes each, and then twice at 68°C with 
pre-warmed high stringency buffer (0.1X SSC, 0.1% SDS) for 15 minutes each.  DIG 
detection was carried out using the DIG Wash and Block Buffer set (Roche Diagnostics), 
according to manufacturer’s instructions, and incubation with Anti-Digoxigenin-POD 
(peroxidase) Fab fragments (Roche Diagnostics) in 1X phosphate-buffered saline (1X 
PBS), pH 7.5, containing 1% 1X Blocking Solution at room temperature for 1 hour.  The 
membrane was subsequently washed twice with 1X PBS, pH 7.5, and detected with 
Supersignal West Pico Chemiluminescent substrate (Pierce).  Membranes were exposed 
to autoradiography film and developed using a Future 2000 K automatic x-ray film 
processor (Fisher).        
MazEF Antibodies.  Anti-MazEF polyclonal antibodies were raised in rabbits 
through the University of Illinois Immunological Resource Center (IRC).  Another 
member of the Hergenrother lab, Nora Wang, recombinantly expressed and purified the 
MazEF complex, dialyzed the protein thoroughly into dH2O and lyophilized to dryness.  
Lyophilized MazEF was resuspended in 2 mL of 50 mM Tris·HCl (pH 7.5) and 
submitted to the IRC for antibody production.  
Western Blot Analysis.  MRSA strains were grown in 5 mL BHI broth to an 
OD600 of 0.4-0.6, pelleted by centrifugation, and frozen at -80°C.  Cell pellets were 
thawed and resuspended in 50 µL SDS loading dye buffer, sonicated for 10 seconds, and 
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heated at 95ºC for 5 minutes.  The cell suspensions were frozen at -80°C once more and 
thawed before analyzing by SDS-PAGE.  For each sample, 25 µL was run on a 4-20% 
Tris·HCl precast gel (Bio-Rad) for approximately 1.5 hours at 100 V.  After SDS-PAGE, 
proteins were transferred to an Immobilon-P PVDF membrane (Millipore) in cold 
Towbin Transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) with a 
Bio-Rad Trans-Blot electrophoretic transfer apparatus for 2 hours at 45 V.  Before 
probing, membranes were blocked with 1X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4·7H20, 1.4 mM KH2PO4, pH 7.3) containing 5% nonfat dried milk overnight 
with gentle shaking at 4ºC.  The following day, membranes were washed three times with 
1X PBS at room temperature and then probed with anti-MazEF antiserum at a 1:500 or 
1:1000 dilution in 1X PBS for 1 hour.  This was followed by addition of mouse anti-
rabbit IgG-horseradish peroxidase conjugated antiserum at a 1:20,000 dilution (Pierce) in 
1X PBS with 5% nonfat dried milk for 1 hour.  Membranes were again washed three 
times with 1X PBS at room temperature and antibody binding was detected with 
Supersignal West Pico Chemiluminescent substrate (Pierce).  Membranes were exposed 
to autoradiography film and developed using a Future 2000 K automatic x-ray film 
processor (Fisher).     
Immunoprecipitation and Protein Sequence Analysis.  MRSA strains C6 and 
NRS17 were grown in 5 mL BHI broth to an OD600 of 0.4-0.6, pelleted by centrifugation, 
and frozen at -80°C.  Thawed cell pellets were resuspended in 100 µL non-denaturing 
lysis buffer (1% Triton X-100, 50 mM Tris, 300 mM NaCl, pH 7.4), frozen again at -
80°C and thawed, sonicated for 30 seconds with pulses, and heated at 95ºC for 5 minutes.  
Cell lysates were then stored at -80°C til use.  MazEF antiserum was coupled to Affi-Gel 
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10 affinity media (Bio-Rad) by first thoroughly dialyzing 5 mL MazEF antiserum into 1 
L 100 mM MOPS, pH 7.5 at 4°C over approximately 24 hours with three buffer changes.  
The dialyzed serum was centrifuged at 12,000 × g at 4°C for 10 minutes and the 
supernatant transferred to a new tube to remove aggregates.  Affi-Gel 10 beads (2 mL) 
were washed three times with cold dH2O and the moist gel media was added to 
approximately 5 mg of dialyzed MazEF antiserum.  Coupling of the Affi-Gel 10 media 
and the MazEF antiserum was allowed to proceed, protected from light, at 4°C overnight 
with gentle stirring.  Following coupling, 100 µL of 1 M ethanolamine (pH 8.0) was 
added to the slurry and allowed to continue gently stirring for 1 hour at 4°C.   
Cell lysates were thawed and resuspended in 200 µL dilution buffer (0.1% Triton 
X-100, 10 mM Tris, 140 mM NaCl, pH 8.0) and combined with an equal volume of 
MazEF coupled to Affi-Gel 10 media and gently shaken at 4°C for 1 hour.  The slurry 
was pelleted by centrifugation for 10 seconds and the supernatant removed.  The beads 
were washed twice with 1 mL dilution buffer, once with 1 mL 10 mM Tris, pH 8.0, 140 
mM NaCl, and once with 1 mL 50 mM Tris, pH 6.8, before being resuspended in 50 µL 
SDS loading dye.  The slurry was heated at 95ºC for 5 minutes, centrifuged for 5 minutes, 
and 25 µL of the supernatant was run in two separate lanes on a 4-20% Tris·HCl precast 
gel (Bio-Rad) for approximately 1.5 hours at 100 V.   
After SDS-PAGE, protein from one of the lanes was transferred to an Immobilon-
P PVDF membrane and Western blot analysis was carried out as described above.  
Protein from the second lane was stained with Coomassie brilliant blue staining solution 
(50% methanol, 0.05% Coomassie brilliant blue R-250, 10% acetic acid, 40% dH2O) for 
1 hour at room temperature and destained overnight in a solution of 50% methanol, 40% 
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dH2O, and 10% acetic acid.  The protein band of interest detected both by Western blot 
and Coomassie-staining was cut out from the Coomassie-stained polyacrylamide gel and 
submitted for internal sequence analysis through the University of Illinois Protein 
Sciences Facility.  Sequence analysis of individual peptides from the sample was 
performed by staff at the facility using Matrix Science and/or PEAKS computer software 
and database searching for protein identification. 
2-D Gel Electrophoresis Analysis.  MRSA strain C6 was grown in 25 mL BHI 
broth to an OD600 of 0.4-0.6, pelleted by centrifugation, and frozen at -80°C.  The thawed 
cell pellet was resuspendend in 250 µL SDS loading dye buffer and turned over to the 
University of Illinois Protein Sciences Facility for 2-D gel electrophoresis analysis.  IEF 
was carried out using 11 cm IPG strips with a linear pH range of 3.0 to 10.0, followed by 
SDS-PAGE using 12% Bis-Tris precast polyacrylamide gels (Bio-Rad).  After SDS-
PAGE, the proteins on one of the gels was transferred to an Immobilon-P PVDF 
membrane and Western blot analysis was carried out as described above.  Proteins on the 
second gel were stained with Coomassie brilliant blue staining solution as described 
above.    
RNA Extraction and RT-PCR Analysis.  Cultures of MRSA were grown in 
BHI broth until approximately 1 x 109 cfu/mL were present, at which point 1 mL aliquots 
were pelleted by centrifugation and frozen at -80°C.  Total RNA was extracted from 
bacteria following an RNA isolation protocol adapted from Vandecasteele et al. [74].   
Cell pellets comprising approximately 1 x 109 cfu were thawed and resuspended in 500 
µL acidified phenol-chloroform (5:1) (pH 4.7) (Sigma) and kept at room temperature for 
5 minutes.  Next, 500 µL NAES buffer (50 mM sodium acetate, pH 5.1, 10 mM EDTA, 
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1% SDS) was added to the cell suspension and inverted repeatedly for 5 minutes at room 
temperature.  The solution was transferred to a FastRNA tube-blue (Bio101) containing 
Lysing Matrix B, vortexed at maximum speed for 5 minutes, and centrifuged at 11,000 × 
g for 5.5 minutes at room temperature.  RNA was precipitated from the supernatant 
fraction (~450 µL) by mixing with 520 µL isopropanol and 35 µL 3 M sodium acetate 
and centrifuged at 11,000 × g for 5.5 minutes.  The pellet was washed with ice-cold 70% 
ethanol, centrifuged 5 minutes at 4°C, allowed to dry at room temperature, and 
resuspended in 50 µL RNase-free autoclaved dH2O overnight at 4°C. 
To remove genomic DNA contamination, MRSA total RNA samples were treated 
twice with RNase-Free DNase (Qiagen) according to the on-column DNase treatment 
protocol with some modifications.  DNase treatment was carried out for at least 1 hour at 
room temperature (instead of 15 minutes) with twice the amount of DNase 
recommended.  RNA was eluted with 50 µL RNase-free autoclaved dH2O.  Yields of 
DNA-free total RNA from MRSA were very low, with average final concentrations of 
10-20 ng/µL.  
RT-PCR was performed using the SuperScript One-Step RT-PCR with Platinum 
Taq kit (Invitrogen).  The primers used to amplify the mazEFSa sequence for RT-PCR are 
the same as those designed for PCR analysis.  The extracted total RNA (up to 40 ng) was 
used in RT-PCR, as well as PCR with Platinum Taq DNA polymerase (Invitrogen) to 
detect DNA contamination.  Reverse transcription and PCR amplification were carried 
out in a DNA thermal cycler (PTC-200, MJ Research, Inc.) under reaction conditions as 
described previously [45], except with the annealing temperature raised to 55°C.  RT-
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PCR amplification products were analyzed by agarose gel electrophoresis in 1% agarose 
and stained with ethidium bromide. 
 
3.7  TABLES AND FIGURES 
Table 3.1  PCR Results With Plasmid-Safe DNase Treated Plasmid DNA.  Hospital 1 is Carle Foundation 
Hospital, Hospital 2 is Delnor Community Hospital, Hospital 3 is Memorial Medical Center, NARSA is 
Network on Antimicrobial Resistance in Staphylococcus aureus.  
 
                                 Plasmid Stability Systems                                                    
Isolate ω/ε/ζ axe-txe par parDE ccd mazEF relBE higBA vagCD phd-doc 
Hospital 1 
C1   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C2   (-) (-) (-) (-) (+) (+) (-) (-) (-) (-) 
C3   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C4   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C5   (-) (-) (-) (-) (+) (+) (-) (-) (-) (-) 
C6   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C7   (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
C8   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C9   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C10   (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
C11   (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
C12   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C13   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C14   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C15   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
C16   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C17   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
C18   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C19   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
C20   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
C21   (-) (-) (-) (-) (+) (+) (-) (-) (-) (-) 
  
Hospital 2 
G1   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G2   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
G3   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
G4   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G5   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
G6   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
G7   (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) 
G8   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
G9   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G10   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G11   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G12   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
G13   (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
G14   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
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 Table 3.1 (cont.) 
 
                                 Plasmid Stability Systems                                                    
Isolate ω/ε/ζ axe-txe par parDE ccd mazEF relBE higBA vagCD phd-doc 
Hospital 3 
S1   (-) (-) (-) (-) (-) (-) (+) (-) (-) (-) 
S2   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S3   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S4   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S5   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S6   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S7   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S8   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S9   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S10   (-) (-) (-) (-) (-) (+) (-) (-) (-) (-) 
S11   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S12   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S13   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S14   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S15   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S16   (-) (-) (-) (-) (+) (-) (+) (-) (-) (-) 
S17   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S18   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S19   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S20   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S21   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S22   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S23   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S24   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
S25   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
S26   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
  
NARSA 
NRS3   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
NRS4   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS17   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS18   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS21   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS22   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS23   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS24   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
NRS26   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS27   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS28   (-) (-) (-) (-) (-) (+) (+) (-) (-) (-) 
NRS29   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS51   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS68   (-) (-) (-) (-) (+) (+) (-) (-) (-) (-) 
NRS73   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS74   (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
NRS76   (-) (-) (-) (-) (+) (-) (-) (-) (-) (-) 
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Table 3.2  PCR Results With Total Genomic DNA.  Hospital 1 is Carle Foundation Hospital, Hospital 2 is 
Delnor Community Hospital, Hospital 3 is Memorial Medical Center, NARSA is Network on 
Antimicrobial Resistance in Staphylococcus aureus.  
 
                                 Toxin-Antitoxin Systems                                                       
Isolate ω/ε/ζ axe-txe par parDE ccd mazEF mazEFSa relBE higBA vagCD phd-doc 
Hospital 1 
C1 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C2 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C3 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C4 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C5 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C6 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C7 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C8 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C9 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C10 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C11 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C12 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C13 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C14 (+) (+) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
C15 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C16 (+) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C17 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C18 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C19 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
C20 (-) (-) (-) (-) (+) (-) (+) (+) (-) (-) (-) 
C21 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
  
Hospital 2 
G1 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G2 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G3 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G4 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G5 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G6 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G7 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G8 (-) (-) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
G9 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G10 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G11 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G12 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G13 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
G14 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
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Table 3.2 (cont.) 
 
                                 Toxin-Antitoxin Systems                                                       
Isolate ω/ε/ζ axe-txe par parDE ccd mazEF mazEFSa relBE higBA vagCD phd-doc 
Hospital 3 
S1 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S2 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S3 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S4 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S5 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S6 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S7 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S8 (+) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S9 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S10 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S11 (-) (+) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
S12 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S13 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S14 (+) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S15 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S16 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S17 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S18 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S19 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S20 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S21 (-) (+) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
S22 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S23 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S24 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S25 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
S26 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
  
NARSA 
NRS3 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS4 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS17 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS18 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS21 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS22 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS23 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS24 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS26 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS27 (-) (+) (-) (-) (-) (+) (+) (+) (-) (-) (-) 
NRS28 (-) (+) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS29 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS51 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS68 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS73 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS74 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
NRS76 (-) (-) (-) (-) (+) (+) (+) (+) (-) (-) (-) 
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CHAPTER 4 
IDENTIFICATION OF DISRUPTORS OF RELBE 
 
4.1  INTRODUCTION  
The E. coli RelBE toxin-antitoxin (TA) system is one of the most extensively 
characterized TA systems.  First reported by Gotfredsen and Gerdes in 1998 [9], the 
RelBE pair was shown to possess the characteristic features of a TA system:  relE 
encodes a toxin that inhibits the growth of cells; relB encodes an antitoxin that neutralizes 
the inhibitory effect of the RelE toxin; when cloned onto an unstable plasmid, the relBE 
genes stabilize the plasmid; and transcription of the relBE operon is autoregulated (see 
Chapter 1, Section 1.5.1 for a more detailed description of the characteristics of the 
RelBE system) [7, 9, 14, 19, 20, 22].        
Database searching has revealed many homologs of the RelBE system in both 
bacteria and archaea and the RelE toxin belongs to a superfamily of toxins (accession 
number cl11422) that includes the toxin proteins YoeB, ParE, HigB, YafQ, YhaV, StbE, 
RegB, and Txe [2, 10, 11, 13, 17, 18, 21, 23].  Additionally, the PCR screen described in 
Chapter 2 of this thesis found the genes for the E. coli relBE system to be prevalent in 
clinical isolates of vancomycin-resistant enterococci [16].  The wealth of genetic and 
biochemical knowledge of the RelBE TA system and the widespread occurrence of 
RelBE and its homologs in prokaryotes, including pathogenic bacterial species, make 
RelBE an attractive TA system to pursue as the target of an antimicrobial strategy aimed 
at selective activation of the toxin.      
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4.2  CELL-BASED HIGH-THROUGHPUT SCREEN FOR RELE-DEPENDENT CELL 
DEATH 
 
4.2.1  Cloning, Expression and Purification of RelBE 
 The relBE genes were initially amplified from the chromosomal DNA of E. coli 
K12 and cloned into the pCR2.1-TOPO vector.  However, pCR2.1 is a cloning vector, so 
to facilitate over-expression and purification of the RelBE proteins,  the relBE genes were 
cloned into vector pET28a with an N-terminal His6-tag.  Inspection of the pET28a-His6-
relBE DNA sequence revealed it to be correct and in-frame, but the His6-RelBE proteins 
could not be detected by SDS-PAGE analysis of pilot expressions or nickel-
nitrilotriacetic acid (Ni-NTA) metal-affinity chromatography fractions.  Thus, the cloning 
was redesigned to allow over-expression and purification of the RelBE proteins with a C-
terminal His6-tag from pET28a.  The DNA sequence of pET28a-relBE-His6 (clone #3-1) 
was found to be correct and in-frame and selected for further experiments (Figure 4.1).  
To determine if the C-terminal His6-tagged version of RelBE could be 
successfully over-expressed and purified, a plasmid DNA preparation of pET28a-relBE-
His6 was transformed into E. coli BL21 (DE3).  Expression was carried out under 
standard conditions at 37°C and induced with 0.5 mM IPTG.  Purification of the RelBE-
His6 protein complex was performed under native conditions using Ni-NTA agarose 
metal-affinity chromatography (with buffers previously reported for the purification of an 
archaeal homolog of RelBE [25]).  As seen in Lane 7 of Figure 4.2, the RelBE proteins 
were eluted from the Ni-NTA matrix with high yield and purity. 
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Figure 4.1  Nucelotide sequence of pET28a-relBE-His6.  The relBE sequence was cloned into pET28a 
between the NcoI and HindIII restriction enzyme sites to allow fusion of a C-terminal His6-tag to RelE. 
 
   
 
Figure 4.2  15% SDS-PAGE analysis of RelBE-His6 native purification fractions.  For lanes 2-6, 10 µL of 
each purification fraction (cell pellet, supernatant, initial flowthrough, binding buffer flowthrough, wash 
buffer flowthrough) was analyzed.  For lane 7, the elution flowthrough was concentrated 10-fold and 10 µg 
of protein was analyzed.  Lane 1 is Full-range marker (Bio-Rad). Expected size of RelB = 9.1 kDa.  
Expected size of RelE-His6 = 12.7 kDa.   
 
rbs
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80 
GAAGGAGATA TACCATGGGA ACAATGGGTA GCATTAACCT GCGTATTGAC GATGAACTTA AAGCGCGTTC TTACGCCGCG 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160 
CTTGAAAAAA TGGGTGTAAC TCCTTCTGAA GCGCTTCGTC TCATGCTCGA GTATATCGCT GACAATGAAC GCTTGCCGTT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240 
CAAACAGACA CTCCTGAGTG ATGAAGATGC TGAACTTGTG GAGATAGTGA AAGAACGGCT TCGTAATCCT AAGCCAGTAC 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
250        260        270        280        290        300        310        320 
GTGTGACGCT GGATGAACTC TGATGGCGTA TTTTCTGGAT TTTGACGAGC GGGCACTAAA GGAATGGCGA AAGCTGGGCT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
330        340        350        360        370        380        390        400 
CGACGGTACG TGAACAGTTG AAAAAGAAGC TGGTTGAAGT ACTTGAGTCA CCCCGGATTG AAGCAAACAA GCTCCGTGGT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
410        420        430        440        450        460        470        480 
ATGCCTGATT GTTACAAGAT TAAGCTCCGG TCTTCAGGCT ATCGCCTTGT ATACCAGGTT ATAGACGAGA AAGTTGTCGT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
490        500        510        520        530        540        550        560 
TTTCGTGATT TCTGTTGGGA AAAGAGAACG CTCGGAAGTA TATAGCGAGG CGGTCAAACG CATTCTCGGA ACCAAGCTTG 
....|....| ....|....| ....|....| ....|
570        580        590
CGGCCGCAC TCGAGCACCA CCACCACCAC CACTGA
relB startNco I
relB stop/relE start
relE no stop Hind III
His6-tag stop
17 kDa
12 kDa
1          2           3           4          5           6          7
RelE-His6
RelB
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4.2.2  RelBE Polyclonal Antibodies 
 As mentioned in Chapter 2, Section 2.5, anti-RelBE polyclonal antibodies were 
generated at the University of Illinois Immunological Resource Center to facilitate the 
detection of the RelBE proteins in clinical isolates as well as in laboratory expression 
strains.  To evaluate the activity of the RelBE antibodies, Western blots were performed 
with purified RelBE-His6 using crude serum collected prior to the rabbits being injected 
with the RelBE antigen (pre-immune), and crude serum collected one week after the last 
RelBE injection (1st bleed).  The pre-immune crude serum samples of two rabbits (7-8 
and 7-9) showed no prior immunity to RelBE (Figure 4.3 A-B) while the 1st bleed serum 
from both rabbits was immunologically active against the RelBE proteins (Figure 4.3 C-
D).  A third, unexpected band above the 12.7 kDa RelE-His6 band was visible by Western 
blot and was not investigated further as later crude serum bleeds detected only the RelB 
and RelE bands (Figure 4.3 E).  
 
Figure 4.3  Western blot to evaluate the RelBE antibody.  (A) and (B) Western blot (10 second exposure) 
of 500 ng and 1 µg RelBE-His6 with pre-immune serum from rabbits 7-8 and 7-9.  (C) and (D) Western 
blot (10 second exposure) of 500 ng and 1 µg RelBE-His6 with 1st bleed crude serum from rabbits 7-8 and 
7-9.  (E) Western blot (10 second exposure) of 100 ng and 500 ng RelBE-His6 with 2nd bleed crude serum 
from rabbit 7-8. 
A B
15 kDa
10 kDa
7-8 pre-immune 7-9 pre-immune
E
12 kDa
7-8 2nd bleed
C D
7-8 1st bleed 7-9 1st bleed
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 Once it was established that the RelBE polyclonal antibodies were active and 
selective, they were used to compare the endogenous levels of RelBE expression with 
that of the over-expression strain in E. coli BL21 (DE3).  E. coli BL21 (DE3) carrying 
the empty pET28a vector would be used in a counter-screen for compounds identified 
from a high-throughput cell-based screen for RelE-dependent cell death to determine if 
hit compounds possessed general or selective antimicrobial properties.  Thus, the levels 
of endogenous RelBE protein expression would need to be significantly lower in E. coli 
BL21 (DE3) compared to the overexpression strain carrying the pET28a-relBE-His6 
construct.  E. coli BL21 (DE3) cultures carrying pET28a or pET28a-relBE-His6 were 
grown simultaneously, induced with 0.5 mM IPTG and harvested for SDS-PAGE and 
Western blot analysis.  Shown in Figure 4.4, the results of both the Coomassie-stained 
gel and RelBE-probed Western blot suggest that low levels of RelB (9.0 kDa) and RelE 
(11.2 kDa or 12.7 kDa with the C-terminal His6 tag) are endogenously expressed in E. 
coli BL21 (DE3).  Thus, this system was used for the cell-based screen and counter-
screen described in the following sections.      
 
Figure 4.4  RelBE protein levels in E. coli BL21 (DE3).    (A)  Coomassie-stained gel  and (B) Western 
blot of 10 µL lysed cells of pET28a and pET28a-relBE-His6 in E. coli BL21 (DE3).  The Coomassie-
stained gel was stained for two hours before destaining overnight.  The Western blot was exposed to 
autoradiography film for 1 minute to develop the image.   
15 kDa
10 kDa
A B
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4.2.3  High-Throughput Screen Development 
 A cell-based screen was developed to identify small molecules in a 165,000-
member compound library that could cause RelE-dependent cell death in E. coli BL21 
(DE3) expressing RelBE- His6 (Figure 4.5).  Since the compound library at Urbana-
Champaign (UIUC) High-Throughput Screening Facility (HTSF) is maintained in 384-
well plates, conditions first were needed to uniformly grow bacteria in 384-well plates to 
an optical density (OD) at which cell growth inhibition could be easily distinguished 
from untreated control cells.   
 
Figure 4.5  Toxin-dependent cell death by a small molecule. 
 
 Cultures of BL21 (DE3) expressing RelBE-His6 were grown in Luria broth with 
50 µg/mL kanamycin (LBkan50) in 384-well plates with plastic lids at 37°C for 24 hours 
and the uniformity of growth across the plate was determined.  Columns 1, 2 and 23 in 
the plate served as negative controls for uninhibited growth and cultures in column 24 
represented positive controls for no detectable growth (see Figure 4.6A). Under these 
conditions, it was discovered that the level of growth varied significantly from well-to-
well and considerable evaporation occurred in the outer wells, resulting in artificially 
high OD values for the positive controls (Figure 4.6B).  To reduce evaporation occurring 
174 
 
at the outer wells of the plate, stacks of 4 plates were each wrapped in plastic-wrap and 
incubated at 37°C for 24 hours.  While this drastically reduced evaporation, the growth 
from well-to-well remained extremely variable (Figure 4.6C).  Thus, to achieve a more 
uniform growth rate across the plate, cultures were incubated for 24 hours at room 
temperature in plastic-wrapped stacks of 4 plates with the hope that slowing down the 
growth rate of the bacteria would reduce the variability observed.  As shown in Figure 
4.6D, this method produced consistent growth across the plate and eliminated the 
occurrence of false-positives.  Accordingly, this method was used for the screen. 
 
Figure 4.6  Optimization of cell-based high-throughput screening method.  (A) 384-well plate set-up.  (B-
D) Percent growth inhibition based on optical density under different incubation conditions: (B) 24 hours at 
37°C with no plastic wrap, (C) 24 hours at 37°C with plastic wrap, (D) 24 hours at room temperature with 
plastic wrap. 
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4.2.4  Screening Results 
Using the method described above, approximately 165,000 compounds were 
screened for growth inhibition properties at a concentration of 25 µg/mL against BL21 
(DE3) expressing RelBE- His6.  The threshold for a compound to be designated as a “hit” 
was determined by setting up a “mock” screening plate in which two wells contained 
ampicillin at 200 µg/mL and 20 µg/mL, while all other wells received an equal volume of 
DMSO.  As shown in Figure 4.7, a potent antibacterial compound such as ampicillin 
could be detected and would be expected to cause 40% growth inhibition at a 
concentration near the one to be used in the screen.  Thus, compounds were considered 
hits if the percent growth inhibition exceeded 40%.  
 
Figure 4.7  Activity of ampicillin in the cell-based screening method.  Ampicillin was added to wells C5 
and F13 at 200 and 20 µg/mL, respectively, and tested against E. coli BL21 (DE3) expressing RelBE-His6.  
Results are graphed as percent growth inhibition. 
 
 Of the approximately 165,000 compounds examined, 335 caused 40% or greater 
growth inhibition in the high-throughput screen.  All 335 compounds were “cherry-
2 3 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 21 22 23 24
4
20
1
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picked” from the HTSF compound library plates, retested against BL21 (DE3) expressing 
RelBE-His6 and counter-screened against BL21 (DE3) carrying the empty pET28a 
vector.  This counter-screen served to verify that compounds identified as hits in the 
high-throughput screen were not false-positives as well as to identify compounds that 
selectively cause RelE-dependent cell death instead of general antimicrobial activity.  
Retesting was performed under conditions identical to the screen, except that 25 µL 
culture volumes were used instead of 50 µL per well to reduce the amount of compound 
needed.  Upon retesting, 123 compounds caused less than 20% growth inhibition and 
were therefore no longer pursued.  The remaining 212 compounds were divided into three 
general categories:  91 compounds showed general antimicrobial activity and 
significantly inhibited the growth of BL21 (DE3) carrying empty vector and expressing 
RelBE-His6; 118 compounds possessed either weak (20-40% growth inhibition) activity 
against both strains or mild selective inhibition of BL21 (DE3) expressing RelBE-His6; 
and 3 compounds caused greater than 40% growth inhibition of the RelBE-expressing 
strain but did not significantly inhibit the growth of BL21 (DE3) carrying empty vector.  
The chemical structures of the 3 hit compounds are shown in Figure 4.8. 
Retests with compound 46-B8/7118462 (from here-on referred to as “711”) 
showed 47% growth inhibition with BL21 (DE3) expressing RelBE-His6 and 17% 
growth inhibition with the empty vector at 25 µg/mL.  Compound 276-I11/5488185 
(“5488”) caused 44% growth inhibition in the RelBE-expressing strain and no detectable 
growth inhibition when the empty vector was present.  Finally, compound 306-
F4/5791573 (“579”) was the most promising hit identified in the screen as it caused 89% 
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growth inhibition of the RelBE-expressing strain and 18% growth inhibition with the 
empty vector in the retest experiments. 
 
Figure 4.8  Chemical structures of 3 hit compounds identified in the cell-based high-throughput screen for 
RelE-dependent cell death.  Listed below each structure is the plate and well number in the UIUC HTSF 
compound library and the Chembridge Corporation compound ID number. 
 
4.2.5  Investigation of Compounds 579, 5488 and 711   
 Following the retest experiments, the three hit compounds were assessed in an 
extensive battery of dose-dependent growth inhibition assays against E. coli BL21 (DE3) 
carrying a variety of genetic constructs to better determine the potency and selectivity of 
the compounds.  In order to have sufficient quantities of each hit for further testing, the 
compounds were purchased from ChemBridge Corporation. 
 
46-B8
#7118462
“711”
276-I11
#5488185
“5488”
306-F4
#5791573
“579”
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4.2.5a  Growth inhibition assays 
 Growth inhibition assays were carried out to determine if compounds 579, 711, 
and 5488 selectively inhibited the growth of E. coli BL21 (DE3) expressing RelBE-His6 
compared to the empty vector due to the burden imposed on the cells by protein over-
expression instead of in a RelE-dependent manner.  To better evaluate the nature of the 
effect of the compounds in E. coli, a relBE mutant known to have reduced toxicity was 
constructed by changing the arginine residue at position 81 in RelE to alanine [15, 19].  
Mutant pET28a-relBER81A-His6 was created by site-directed mutagenesis of the pET28a-
relBE-His6 construct (Figure 4.9).    
 
Figure 4.9  Nucelotide sequence of clone pET28a-relBER81A-His6.  The wild-type relBE sequence was 
originally cloned into pET28a between the NcoI and HindIII restriction enzyme sites to allow addition of a 
C-terminal His6-tag on relE.  Using site-directed mutagenesis, the arginine residue at position 81 (AGA) 
was changed to alanine (GCA) to create a low-toxicity mutant (mutation is highlighted in green). 
 
rbs relB startNco I
relB stop/relE start
relE no stop Hind III
stop
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80 
GAAGGAGATA TACCATGGGA ACAATGGGTA GCATTAACCT GCGTATTGAC GATGAACTTA AAGCGCGTTC TTACGCCGCG 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160 
CTTGAAAAAA TGGGTGTAAC TCCTTCTGAA GCGCTTCGTC TCATGCTCGA GTATATCGCT GACAATGAAC GCTTGCCGTT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240 
CAAACAGACA CTCCTGAGTG ATGAAGATGC TGAACTTGTG GAGATAGTGA AAGAACGGCT TCGTAATCCT AAGCCAGTAC 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
250        260        270        280        290        300        310        320 
GTGTGACGCT GGATGAACTC TGATGGCGTA TTTTCTGGAT TTTGACGAGC GGGCACTAAA GGAATGGCGA AAGCTGGGCT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
330        340        350        360        370        380        390        400 
CGACGGTACG TGAACAGTTG AAAAAGAAGC TGGTTGAAGT ACTTGAGTCA CCCCGGATTG AAGCAAACAA GCTCCGTGGT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
410        420        430        440        450        460        470        480 
ATGCCTGATT GTTACAAGAT TAAGCTCCGG TCTTCAGGCT ATCGCCTTGT ATACCAGGTT ATAGACGAGA AAGTTGTCGT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
490        500        510        520        530        540        550        560 
TTTCGTGATT TCTGTTGGGA AAGCAGAACG CTCGGAAGTA TATAGCGAGG CGGTCAAACG CATTCTCGGA ACCAAGCTTG 
....|....| ....|....| ....|....| ....| 
570        580        590                    
CGGCCGCACT CGAGCACCAC CACCACCACC ACTGA
R81A
His6-tag
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 To determine if the R81A mutant version of RelBE  was expressed at comparable 
levels to wild-type (wt) RelBE-His6, plasmid DNA preparations of the pET28a-relBE-
His6 and pET28a-relBER81A-His6 constructs were transformed into BL21 (DE3).  
Expression was carried out using a 384-well plate using the conditions described for 
retesting compounds identified in the cell-based high-throughput screen.  After 
incubation overnight at room temperature, approximately 500 µL of each culture was 
collected from the wells, pelleted by centrifugation, and subjected to Western blot 
analysis with the anti-RelBE antibody.  As seen in Figure 4.10A, the mutant and wt 
proteins were expressed at similar levels.  Therefore, growth inhibition assays were set-
up with increasing compound concentrations (10, 50 and 100 µM) using the retesting 
conditions described above.  At the three concentrations tested, compounds 711 and 5488 
showed selective growth inhibition of the wt RelBE-His6 expressing strain compared to 
the mutant in which growth inhibition did not exceed 5% (Figure 4.10B, C, and E).  In 
contrast, compound 579 caused appreciable growth inhibition of BL21 (DE3) expressing 
wt and mutant RelBE-His6 (Figure 4.10D and E).  This suggested that compound 579 
caused growth inhibition in cells burdened with protein over-expression.  Additionally, 
the results with compounds 5488 and 711 proved difficult to repeat.  Often, the 
compounds were not selective and the level of growth inhibition was similar between 
BL21 (DE3) expressing wt RelBE-His6 and the low-toxicity mutant.   
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Figure 4.10  Evaluation of hit compounds against wt and mutant RelBE-His6.  (A)  Western blot of 500 µL 
E. coli BL21 (DE3) pET28a-relBE-His6 and pET28a-relBER81A-His6 cultures with anti-RelBE serum after a 
1 second exposure.  (B, C, D, and E)    Activity of compounds 711, 5488, and 579 in the 384-well plate 
retesting assay.  Compounds were added to wells (n = 5) at 10, 50 and 100 µM and tested against BL21 
(DE3) expressing wt and mutant RelBE-His6.  Results are reported as percent growth inhibition. 
 
To further examine the inhibitory activity of the compounds against E. coli BL21 
(DE3) when over-expressing protein, another TA system, CcdAB, was tested in the 
growth inhibition assays.  The ccdAB construct was cloned by another member of the 
Hergenrother lab, Manuel Rodriguez, and expressed at a similar level to the RelBE-His6 
complex.  Growth inhibition assays with BL21 (DE3) expressing CcdAB-His6  and wt 
RelBE-His6 were set-up at increasing compound concentrations (10, 50 and 100 µM) 
using the retesting conditions as before.  At the three concentration tested, compounds 
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711 and 5488 showed selective growth inhibition of the wt RelBE-His6 expressing strain 
compared to the CcdAB-His6 expressing strain in which growth inhibition did not exceed 
5% (Figure 4.11A, C, and D).  Compound 579 showed selective growth inhibition of the 
RelBE-expressing strain to a lesser degree than compounds 711 and 5488 (Figure 4.11B 
and D). However, like the growth inhibition assays with RelBE-His6 mutant R81A, these 
results proved difficult to repeat for all three compounds and selective growth inhibition 
was not observed with additional replicates.   
 
Figure 4.11  Evaluation of hit compounds against wild-type RelBE-His6 and CcdAB.  Activity of 
compounds 711 (A), 579, (B), and 5488 (C) in the 384-well plate retesting assay.  Compounds were added 
to wells (n = 4) at 10, 50 and 100 µM and tested against E. coli BL21 (DE3) expressing wt RelBE-His6 and 
CcdAB-His6.  Results are reported as percent growth inhibition. 
 
Two of the hit compounds, 711 and 5488, were also tested against two clinical 
isolates of VRE that were shown by PCR analysis to carry the relBE genes, one VRE 
isolate that was negative for relBE by PCR (see Chapter 2), an enterococcal laboratory 
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strain, BM4105-RF, that does not carry the relBE genes, and 10 MRSA clinical isolates 
initially thought to carry the relBE genes but later confirmed by PCR to be negative 
(Chapter 3).  Compound 579 was only tested against the four enterococcal strains and not 
investigated further since data from the growth inhibition assays suggested it did no 
induce RelE-dependent growth inhibition.  Growth inhibition assays with the 
enterococcal and MRSA strains were carried out according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines to determine the minimum inhibitory concentration 
(MIC) of each compound.  The MIC values for each compound against the different 
strains was considered the lowest concentration at which 50% (MIC50) or 90% (MIC90) 
growth inhibition was observed.  A summary of the results is displayed in Table 4.1. 
As expected, compound 579 equally inhibited the growth of enterococcal strains 
with and without the relBE genes, supporting previous MIC assay results suggesting that 
it was not selective.  In contrast, MIC assay results with compounds 711 and 5488 
showed 2-16-fold lower MIC50 values with VRE strains carrying the relBE genes 
compared to strains negative by PCR for relBE.  However, with compound 5488, MIC90 
values were only 2-fold lower and lab strain BM4105-RF was killed at 64 µg/mL, 
suggesting that the compound is toxic to cells at higher concentrations in a RelE-
independent manner.     
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  relBE PCR 711 579 5488 
Enterococci         
SL756 (+) MIC50 = 4   MIC90 = 32 
MIC50 = 2   
MIC90 > 64 
MIC50 = 2   
MIC90 = 32 
S34 (+) MIC50 = 8   MIC90 = 32 
MIC50 = 16   
MIC90 > 64 
MIC50 = 8   
MIC90 = 32 
SL278 (-) MIC50 = 32   MIC90 > 64 
MIC50 > 64   
MIC90 > 64 
MIC50 = 16  
MIC90 > 64 
BM4105-RF (-) MIC50 = 64   MIC90 > 64 
MIC50 = 16   
MIC90 > 64 
MIC50 = 32  
MIC90 = 64 
MRSA 
C15 (-) MIC50 >128   MIC90 > 128 
N/D MIC50 = 16   MIC90 = 32 
G7 (-) MIC50 >128   MIC90 > 128 
N/D MIC50 = 16   MIC90 = 16 
C6 (-) MIC50 >128   MIC90 > 128 
N/D MIC50 = 8   MIC90 = 32 
S11 (-) MIC50 >128   MIC90 > 128 
N/D MIC50 = 4   MIC90 = 16 
S8 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 16   MIC90 = 32 
S25 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 32   MIC90 = 64 
NRS4 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 32  MIC90 = 32 
G14 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 32  MIC90 = 32 
C9 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 16   MIC90 = 16 
C20 (-) MIC50 > 64   MIC90 > 64 
N/D MIC50 = 16   MIC90 = 32 
 
Table 4.1  Evaluation of hit compounds against enterococci and MRSA.  MIC assays were conducted in 
100 µL volumes following CLSI guidelines.  Compounds were added to wells (n = 3) at 1, 2, 4, 8, 16, 32, 
64 and 128 µg/mL, though for several isolates the compounds were insoluble at 128 µg/mL.  All MIC 
values listed in the table are in µg/mL.  N/D = not determined. 
 
   
 MIC determinations with the MRSA strains showed compound 5488 to be 
modestly active against all 10 isolates, but since a S. aureus strain carrying the relBE 
genes was not available it is unknown whether these MIC values would support selective 
or non-selective growth inhibition.  Unlike 5488, compound 711 was inactive against all 
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10 MRSA isolates, causing no detectable growth inhibition at the highest concentrations 
tested.  At first glance, these results with compound 711 appeared to support a RelE-
dependent mechanism of growth inhibition; however, these MIC determinations marked 
the beginning in which compound 711 failed to inhibit bacterial growth.   
Every sample of 711 from this point forward, whether ordered from ChemBridge 
Corporation or synthesized in the Hergenrother lab, showed no significant growth 
inhibition in all bacterial strains tested.  The samples of compound 711 all had the correct 
mass and existed as powders ranging in color from white to slightly yellow/tan.  When 
dissolved in DMSO at 6.4 mg/mL or lower, the solutions always appeared clear in color.  
Additionally, the sequences of the pET28a-relBE-His6 and pET28a-relBER81A-His6 
constructs were confirmed by DNA sequencing and to be correct.  It remains unknown 
why the initial samples of 711 from the UIUC HTSF and Chembridge Corporation 
inhibited the growth of BL21 (DE3) expressing wt RelBE-His6 and later samples ordered 
and synthesized in-house were not active in growth inhibition assays.      
Since initial growth inhibition assays with compounds 711 and 5488 against 
BL21 (DE3) expressing wt RelBE-His6, mutant R81A, and CcdAB-His6 were 
inconclusive at the three concentrations tested, MIC assays were performed with BL21 
(DE3) harboring various constructs according to CLSI guidelines except that LB with 50 
µg/mL kanamycin was used instead of Mueller-Hinton broth to facilitate protein 
expression.  Included in the MIC assays was a BL21 (DE3) strain expressing only the 
antitoxin, RelB.  The relB gene was amplified from the plasmid DNA of pET28a-relBE-
His6 and cloned into pET28a with a C-terminal His6-tag (Figure 4.12).  Like the wt 
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RelBE-His6 complex, the RelB-His6 protein was expressed at high levels in BL21 (DE3) 
and could be purified by Ni-NTA metal-affinity chromatography. 
 
Figure 4.12  Nucelotide sequence of clone pET28a-relB-His6.  The relB sequence was cloned into pET28a 
between the NcoI and HindIII restriction enzyme sites to allow addition of a C-terminal His6-tag on RelB.   
 
 In addition to the parent compound, 711, four derivatives were ordered from 
ChemBridge Corporation and Enamine Ltd. to investigate the structure-activity 
relationship of the compound.  Compounds 711-a, b and c were ordered from 
Chembridge Corporation (compound ID numbers 7956465, 5556650, and 9038593, 
respectively) and Compound 711-d was ordered from Enamine Ltd. (compound ID 
number T739716).  The results of MIC assays with 711 (inactive sample) and the 
commercially available derivatives are listed in Table 4.2.  Of the four commercially 
available derivatives, compounds 711-a and 711-c showed modest activity against E. coli 
BL21 (DE3) expressing wild-type RelBE-His6 and limited growth inhibition with the 
remaining strains.  Unfortunately, neither compound was as potent as the parent 
compound was initially (MIC50 = 16 µg/mL).     
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80 
GAAGGAGATA TACCATGGGA ACAATGGGTA GCATTAACCT GCGTATTGAC GATGAACTTA AAGCGCGTTC TTACGCCGCG 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160 
CTTGAAAAAA TGGGTGTAAC TCCTTCTGAA GCGCTTCGTC TCATGCTCGA GTATATCGCT GACAATGAAC GCTTGCCGTT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240 
CAAACAGACA CTCCTGAGTG ATGAAGATGC TGAACTTGTG GAGATAGTGA AAGAACGGCT TCGTAATCCT AAGCCAGTAC 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
250        260        270        280        290        300        310
GTGTGACGCT GGATGAACTC GGATGGAAGC TTGCGGCCGC ACTCGAGCAC CACCACCACC ACCACTGA
rbs relB startNco I
relB no stop Hind III 6xHis-tag stop
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Table 4.2  Determination of MIC values with 711 and commercially available derivatives.  MIC50 and 
MIC90 values (n = 3) were determined using standard MIC conditions except that bacteria were grown in 
LB with 50 µg/mL kanamycin.  RelBE is E. coli BL21 (DE3) expressing wt RelBE-His6.  R81A is BL21 
(DE3) expressing RelBER81A-His6.  RelB is BL21 (DE3) expressing RelB-His6.  Vector is BL21 (DE3) 
carrying empty pET28a.  All MIC values listed are in µg/mL.  N/D = not determined. 
 
 An undergraduate member of the Hergenrother lab, Clint Holaday, synthesized 
three additional derivatives of compound 711:  711-e, 711-h, and 711-i.  These 
compounds were also tested against BL21 (DE3) expressing wt RelBE-His6, mutant 
R81A, RelB-His6, and empty vector under the standard MIC conditions described above 
(see Table 4.3).  Two of the deriviates, 711-h and 711-i, did not cause any detectable 
growth inhibition up to their solubility limit against the four BL21 (DE3) strains.  
Compound 711-e, however, resembled compounds 711-a and 711-c by showing modest 
activity against E. coli BL21 (DE3) expressing wt RelBE-His6 and limited growth 
inhibition with the remaining strains.   
711(µg/mL) 711-a 711-b 711-c 711-d
RelBE
vector
128
>128
128
>128
32
>64
N/D
N/D
>64
>64
N/D
N/D
32
128
64
128
>64
>64
N/D
N/D
>128
>128
>64
>64
>64
>64
64
>128
>64
>64
R81A
RelB
>128
>128
>64
>64
>64
>64
128
>128
>64
>64
MIC50
MIC90
MIC50
MIC90
MIC50
MIC90
MIC50
MIC90
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Table 4.3  Determination of MIC values with derivatives of 711.  MIC50 and MIC90 values (n = 3) were 
determined using standard MIC conditions except that bacteria were grown in LB with 50 µg/mL 
kanamycin.  RelBE is E. coli BL21 (DE3) expressing wt RelBE-His6.  R81A is BL21 (DE3) expressing 
mutant RelBER81A-His6.  RelB is BL21 (DE3) expressing the antitoxin, RelB-His6.  Vector is BL21 (DE3) 
carrying empty pET28a.  All MIC values listed are in µg/mL.  N/D = not determined. 
 
 After analyzing compound 711 and the initial seven derivatives in the MIC 
assays, it was decided to further explore the structure-activity relationship of 711 and to 
attempt to identify a derivative that would show the same potency and selectivity as the 
original parent compound.  Therefore, Seok-Ho Kim, a postdoctoral research fellow in 
the Hergenrother lab, synthesized 28 additional derivatives of 711, focusing on 
modifications to the phenol (Figure 4.13) and pyridine rings (Figure 4.14) of the 
compound.  Due to the large number of compounds, these derivatives were tested in MIC 
assays against E. coli BL21 (DE3) expressing wt RelBE-His6 to determine their activity 
and either RelB-His6 or empty vector for selectivity.  Listed in Figures 4.13 and 4.14 are 
the MIC50 values of each compound against BL21 (DE3) expressing wt RelBE-His6 and 
states if the compound exhibited selective inhibition in a RelE-dependent manner.     
711-e(µg/mL) 711-h 711-i
RelBE
vector
32
>128
64
>128
>64
>64
>64
>64
>64
>64
>64
>64
128
>128
N/D
N/D
N/D
N/D
R81A
RelB
128
>128
>64
>64
>64
>64
MIC50
MIC90
MIC50
MIC90
MIC50
MIC90
MIC50
MIC90
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Figure 4.13  Potency and selectivity of derivatives with modifications to the phenol ring of 711.  MIC50 
values (n = 3) were determined using standard MIC conditions except that bacteria were grown in LB with 
50 µg/mL kanamycin.  The compound name is displayed above each structure.  The MIC50 value listed 
under each compound refers to the activity of the compound against BL21 (DE3) expressing wt RelBE-
His6.  Selectivity was determined by comparing the MIC50 values of the compound against wt RelBE-His6 
and either BL21 (DE3) expressing only the antitoxin or carrying empty pET28a.  All MIC values listed are 
in µg/mL.   
 
ksh-1-259 ksh-1-261 ksh-1-265 ksh-1-271 ksh-1-275
ksh-1-277
MIC50 = 64-128 MIC50 = 128 MIC50 = 128 MIC50 = 128 MIC50 = 128
ksh-1-283 ksh-1-285 ksh-1-287 ksh-1-291
MIC50 = 128 MIC50 = 128 MIC50 > 128 MIC50 > 128 MIC50 > 128
ksh-1-293
MIC50 > 128
Not selective Not selective Not selective Not selective Not selective
Not selective Not selective Not selective Not selective Not selective
Not selective
ksh-2-001
MIC50 > 128
Not selective
ksh-2-003
MIC50 = 128
Not selective
ksh-2-005
MIC50 > 128
Not selective
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Figure 4.14  Potency and selectivity of derivatives with modifications to the pyridine ring of 711.  MIC50 
values (n = 3) were determined using standard MIC conditions except that bacteria were grown in LB with 
50 µg/mL kanamycin.  The compound name is displayed above each structure.  The MIC50 value listed 
under each compound refers to the activity of the compound against BL21 (DE3) expressing wt RelBE-
His6.  Selectivity was determined by comparing the MIC50 values of the compound against wt RelBE-His6 
and either BL21 (DE3) expressing only the antitoxin or carrying empty pET28a vector.  All MIC values 
listed are in µg/mL.   
 
 Analysis of the antimicrobial activity and selectivity of all the derivatives of 711 
tested in the MIC assays allowed a limited determination of the structure-activity 
relationship of the compound (summarized in Figure 4.15).  Unfortunately, most 
derivatives were inactive and the few compounds found to be mildly selective for cells 
expressing RelBE-His6 had MIC50 values greater than 32 µg/mL.   For example, moving 
the nitrogen to the ortho position of the pyridine ring reduced the potency to 32 µg/mL 
and retained modest selectivity (MIC50 ≥ 64 µg/mL against the vector only strain).  
Similar results were seen when the nitrogen was deleted from the pyridine ring in 
combination with saponification at the para position or loss of aromaticity.  In 
ksh-2-019 ksh-2-035 ksh-2-037 ksh-2-041 ksh-2-045
ksh-2-047
MIC50 = 64-128 MIC50 = 128 MIC50 = 64 MIC50 = 128 MIC50 = 128
ksh-2-053 ksh-2-055 ksh-2-067 ksh-2-069
MIC50 = 32 MIC50 = 64 MIC50 = 128 MIC50 = 32 MIC50 = 32
ksh-2-071
MIC50 = 32
Not selective Not selective Not selective Not selective Not selective
2-fold selectivity Not selective Not selective Not selective 2-fold selectivity
Not selective
ksh-2-081
MIC50 = 32
Not selective
ksh-2-087
MIC50 = 32
Not selective
ksh-2-091
MIC50 = 128
Not selective
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comparison, the parent compound, 711, initially had an MIC50 = 16 µg/mL against BL21 
(DE3) expressing wt RelBE-His6 and an MIC50 = 128 µg/mL or greater against all other 
BL21 (DE3) strains before becoming inactive.  Thus, 711 and structurally related 
compounds did not seem promising as RelBE-specific inducers of growth inhibition in 
bacteria.   
 
Figure 4.15  Structure-activity relationship analysis for compound 711.  MICs were determined for 35 
derivatives that had modifications to the phenol ring or pyridine ring of the parent structure.  Most 
compounds were inactive or had reduced potency and were no longer selective.  Only three derivatives 
showed modest activity and selectively. 
 
Fewer derivatives of 5488 were commercially available, including one compound 
with a single modification to the parent structure and two compounds with changes to the 
guanidine moiety.  Thus, these three compounds were purchased from ChemBridge 
Corporation; 5488-a (compound ID 5805043), 5488-b (compound ID 5803981), and 
5488-c (compound ID 7608945).  Additionally, Seok-Ho Kim synthesized three 
derivatives with changes to the left-side ring of 5488; ksh-2-009, ksh-2-013, and ksh-2-
029.  Figure 4.16 shows the structures of the six derivatives of 5488 and the MIC50 
values and selectivity of each compound for BL21 (DE3) expressing wt RelBE-His6.     
All changes made to hydroxy 
phenyl ring abolish activity
Changes to pyridine 
ring reduce potency
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Figure 4.16  Potency and selectivity of derivatives of 5488.  MIC50 values (n = 3) were determined using 
standard MIC conditions except that bacteria were grown in LB with 50 µg/mL kanamycin.  Listed are the 
MIC50 values of each compound against BL21 (DE3) expressing wt RelBE-His6.  Selectivity was 
determined by comparing the MIC50 of the compound against wt RelBE-His6 and either BL21 (DE3) 
expressing only the antitoxin or carrying empty pET28a.  All MIC values listed are in µg/mL.   
 
 
Due to the small number of derivatives of 5488 tested in the MIC assays, the 
structure-activity relationship of the compound could not be confidently determined. 
Compound 5488 caused growth inhibition of BL21 (DE3) expressing wt RelBE-His6 at 
an MIC50 of 16 µg/mL compared to an MIC50 of 32-64 µg/mL with BL21 (DE3) 
expressing mutant RelBER81A-His6, RelB-His6 and empty vector.  Most of the derivatives 
were inactive or had MIC50 values greater than 32 µg/mL.  Only derivative 5488-a was as 
potent as 5488 against RelBE-expressing cells, however, it inhibited the growth of all 
other strains equally as well and appeared to have general antimicrobial properties.  This 
was concerning, as the only structural difference between 5488 and 5488-a was the 
addition of a methyl group to the left-side ring system and called into question the 
5488-a 5488-b 5488-c
ksh-2-009
MIC50 = 8-16 MIC50 = 64 MIC50 > 64
ksh-2-013 ksh-2-029
MIC50 = 32 MIC50 > 64 MIC50 = 32
Not selective Not selective Not selective 
Not selective Not selective Not selective
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selectivity of 5488 for RelBE-expressing cells.  Thus, a number of secondary assays were 
explored to determine if the activity of the hit compounds was RelE-dependent.   
 
4.2.5b  [3H]-Leucine incorporation assays 
 The RelE toxin inhibits protein synthesis by cleaving mRNA positioned in the A-
site of the ribosome.  Thus, a compound that causes RelE-dependent growth inhibition 
would be expected to induce protein synthesis inhibition in the cell.  To further 
investigate 5488 and 711,  3H-leucine radiolabel incorporation assays with BL21 (DE3) 
expression strains were performed in the presence or absence of compound.  In addition 
to the pET28a-relBE-His6 and pET28a-relB-His6 constructs, the relE gene was also 
cloned into pET28a.  Both the wt and R81A mutant forms of relE were cloned into 
pET28a with a C-terminal His6-tag; however, expression of the RelE-His6 protein was 
not observed with either construct by SDS-PAGE and Western blot analysis.  A variety 
of expression and purification conditions were attempted without success, so secondary 
assays, such as the radiolabel incorporation assay, were pushed forward without this 
control.      
 Compound 5488 was tested against BL21 (DE3) expressing RelB-His6 or RelBE-
His6 at the MIC50 value (16 µg/mL) in the 3H-leucine incorporation assay.  As shown in 
Figure 4.17, compound 5488 does not affect the level of protein synthesis in BL21 (DE3) 
expressing RelB-His6.  In cells expressing RelBE-His6, compound 5488 caused a slight 
decrease in the level of protein synthesis compared to cells receiving only DMSO, but 
this decrease was far less than that observed when 32 µg/mL of erythromycin was added.  
P-values were calculated for the counts per minute (cpm) measured from RelBE-
193 
 
expressing cells in the presence of DMSO compared to compound 5488 at 30 and 60 
minutes after IPTG induction.  At 30 minutes, the p-value = 0.167 and at 60 minutes the 
p-value = 0.045.  Thus, only at 60 minutes post-induction does compound 5488 appear to 
significantly inhibit protein synthesis in cells expressing RelBE-His6.     
 
Figure 4.17  The effect of compound 5488 on protein synthesis.  Levels of 3H-leucine incorporation were 
monitored in BL21 (DE3) cells expressing RelB-His6 or RelBE-His6 in the presence of 16 µg/mL 5488, 32 
µg/mL erythromycin, or an equal volume of DMSO.  Cpms were measured with a scintiallation counter.  
Results are the average of 3 or more separate experiments.  Error bars represent the standard deviation from 
the mean and p represents the statistical significance between bracketed groups.   
 
 
Compound 711 was also tested in the 3H-leucine incorporation assay with BL21 
(DE3) expressing RelBE-His6 at concentrations of 32 and 64 µg/mL.  As shown in 
Figure 4.18, levels of 3H-leucine incorporation were similar between cells treated with 
compound 711 and those receiving only DMSO.  The same result was observed when 64 
µg/mL of 711 was used (data not shown). P-values for the cpms measured from RelBE-
expressing cells in the presence of DMSO compared to compound 711 were above 0.2 at 
all timepoints.  Thus, compound 711 does not affect the level of protein synthesis in cells 
expressing RelBE-His6.   
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Figure 4.18  The effect of compound 711 on protein synthesis.  Levels of 3H-leucine incorporation were 
monitored in BL21 (DE3) cells expressing RelBE-His6 in the presence of 32 µg/mL 711 or an equal 
volume of DMSO.  Cpms were measured with a scintillation counter.  Results are the average of 3 or more 
separate experiments.  Error bars represent the standard deviation from the mean and p represents the 
statistical significance between bracketed groups.   
 
4.2.5c  Hemolysis assays 
 Compounds 5488 and 711-e, a modestly active and selective derivative of 711, 
were examined for their ability to lyse human erythrocytes as a measure of their toxicity.  
Human blood was purchased through Bioreclamation Inc. and used within days of arrival 
to avoid increased susceptibility of the cells to lysis over time.  Assays were performed in 
triplicate over three days with freshly prepared erythrocytes at compound concentrations 
used in the MIC assays (Figure 4.19).  Hemolysis generally did not exceed 5% at even 
the highest concentrations tested, which is in accordance with clinically used antibacterial 
compounds.  Thus, compounds 5488 and 711-e are not significantly hemolytic to human 
erythrocytes. 
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Figure 4.19  Hemolytic activity of compounds 5488 and 711-e.  The level of hemolysis was measured with 
human red blood cells in the presence of 1, 2, 4, 8, 16, 32, and 64 µg/mL of 5488 and 711-e, an equal 
volume of DMSO as the negative control (no hemolysis), and DMSO with dH2O instead of buffer as the 
positive control (100% hemolysis).  Hemolysis was measured as the absorbance at 540 nm.  Results are the 
average of 3 separate experiments.  Error bars represent the standard deviation from the mean. 
 
4.2.5d  Native gel electrophoresis analysis 
 In order to evaluate a compound’s ability to bind the RelBE proteins and prevent 
or disrupt complex formation, the RelB and RelE proteins must be purified separately for 
in vitro analysis.  While RelB can be expressed and purified alone, RelE, as mentioned 
above, does not express in a pET28a construct.  However, small amounts of the untagged 
RelB protein and C-terminal His6-tagged RelE protein could be purified separately from 
the RelBE-His6 complex by extensive dialysis in buffer containing 8 M urea or 6 M 
guanidine hydrochloride followed by Ni-NTA metal-affinity chromatography under 
denaturing conditions (Figure 4.20A).  The pure RelB and RelE-His6 proteins were then 
refolded by extensive dialysis according to a previously published protocol [22]. 
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 Native gel electrophoresis with the RelB and RelE-His6 proteins was used to 
evaluate the ability of compound 711-c, another modestly active and selective derivative 
of 711, to prevent the formation of the RelBE-His6 complex.  The RelB (1.5 µg, 16.5 
µM) and RelE-His6 (0.3 µg, 1 µM)  proteins were incubated together in the presence of 
640 µg/mL (2.8 mM) 711-c or an equal volume of DMSO for up to 48 hours at 4°C.  
Samples were analyzed by Native-PAGE for the formation of the RelBE-His6 complex.  
As seen in Figure 4.20B, RelB (pI = 4.81) appears as a single band half-way down the 
gel, while RelE-His6 (pI = 9.64) is unable to enter the gel alone under the buffer 
conditions used.  When RelB and RelE-His6 were incubated together, a new band is 
visible in addition to the RelB band that most likely corresponds to the RelBE-His6 
complex as it runs in the gel to a similar position as the purified RelBE-His6 complex.  
Finally, when RelB and RelE-His6 were incubated together in the presence of 711-c, no 
difference was observed compared to the untreated sample.  Thus, it did not appear that 
711-c prevented the formation of the RelBE-His6 complex to any significant degree.    
 
Figure 4.20  Native gel electrophoresis with RelBE-His6 and compound 711-c.  (A)  15% SDS-PAGE 
analysis of RelB (“B”) and RelE-His6 (“E”) proteins purified separately from the RelBE-His6 (“BE”) 
complex by dialysis and Ni-NTA affinity chromatography under denaturing conditions.  (B)  15% Native 
PAGE analysis of RelBE-His6 complex formation in the presence or absence of 640 µg/mL 711-c after 
incubation at 4°C for 48 hours.  Gels stained with SYPRO Ruby Protein Gel stain.  
15 kDa
10 kDa
A B
197 
 
4.2.5e  Photonic crystal biosensor assays 
 Native gel electrophoresis conditions that would allow visualization of both the 
RelB and RelE-His proteins proved difficult to optimize, thus a different assay using 
photonic crystal (PC) biosensor technology was employed to analyze the effect of the hit 
compounds on RelBE-His6 complex formation.  When illuminated with white light, the 
surface of a PC biosensor reflects a single wavelength that is modulated by the density of 
biomolecules binding to the sensor surface.  Thus, PC biosensor technology can be used 
to detect and measure protein-protein interactions based on changes in the peak 
reflectance of the sensor, or peak wavelength value shift (PWV) [3, 12].   
A PC biosensor sheet coated with streptavidin and attached to a bottomless 384-
well plate was purchased from SRU Biosystems.  Individual wells of the streptavidin-
coated biosensor plate were incubated with  a D-biotin-tris-NTA hybrid compound 
(BTN) and charged with Ni2+ to serve as a linkage between the biosensor surface and a 
His6-tagged protein.  RelE-His6  protein, isolated under denaturing conditions as 
described previously, was successfully bound to the BTN-functionalized PC biosensor 
surface causing an increase in PWV of 0.7 nm (Figure 4.21A).  However, when RelB 
was added to the wells and incubated for up to 48 hours at 4°C, the net PWV was the 
same for wells with or without RelE-His6 bound (Figure 4.21B).  This suggests that RelB 
is able to interact with the PC biosensor surface nonspecifically and complex formation 
with RelE-His6 could not be detected.  Thus, hit compounds could not be tested for 
preventing RelBE-His6 complex formation with this technology.  However, disruption of 
the preformed RelBE-His6 complex could still be examined.   
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Figure 4.21  Analysis of the RelBE-His6 protein complex using PC biosensor technology.  A)  RelE-His6 ( 
“E-His”) bound to the PC biosensor surface caused a PWV shift of 0.7 nm.  B)  Addition of RelB (“B”) to 
wells with or without RelE-His6 caused a PWV shift of 0.5 nm.  C)  RelBE-His6 (“BE-His”) bound to the 
PC biosensor surface caused a PWV shift of 1.6 nm.  D)  Addition of compound 711-c to wells with 
RelBE-His6 caused a decrease in the PWV shift that is not significantly different than wells treated with 
DMSO only.     
 
 Purified RelBE-His6 was successfully bound to the BTN-functionalized 
PC biosensor surface with an PWV increase of 1.6 nm (Figure 4.21C).  Compound 711-c 
or an equal volume of DMSO was then added to wells and incubated for 24 hours at 4°C.  
The PWV shift observed when compound 711-c was incubated with RelBE-His6 was 0.2 
nm lower than the DMSO control wells (Figure 4.21D).  However, this decrease in the 
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PWV shift generated is not outside the  noise of the experiment, so disruption of the 
RelBE-His6 complex by 711-c is not apparent.  Thus, after counter-screening against a 
variety of strains in MIC assays and mechanistic studies via a battery of secondary 
assays, it was concluded that the hit compounds and their derivatives did not cause RelE-
dependent cell death with great enough potency to be viable drug candidates.   
4.3  PEPTIDE ANALYSIS 
To better characterize the interactions involved in the RelBE complex, a series of 
peptides spanning the RelB protein sequence were evaluated for their ability to bind 
RelE-His6 in vitro using native gel electrophoresis.  Further analysis of the RelB peptide 
fragments as well as investigation of a series of RelE peptide fragments using in vitro 
assays is being carried out by another member of the Hergenrother lab, Julia Williams.  
These experiments have been designed to test for the ability of a peptide to either disrupt 
the RelBE protein complex or prevent its formation, thus freeing the RelE toxin from the 
antitoxin’s neutralizing effects. 
4.3.1  RelB Peptides 
 The RelB protein sequence was divided into 11 fragments, each 30 amino acids in 
length and overlapping by 5 residues (see Figure 4.22).  The 11 RelB peptide fragments 
were ordered from GenScript as 4 mg of crude preparations (50-60% purity) lyophilized 
to a powder.  Peptides spanning residues 1-30, 6-35, 16-45, 21-50, 36-65, 41-70, and 46-
75 were dissolved in dH2O at a concentration of 1 mg/mL.  Peptides spanning residues 
11-40, 26-55, 31-60, and 51-80 were insoluble in dH2O and were dissolved in 20-50% 
solutions of acetonitrile.   
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Figure 4.22  RelB peptide fragments.  The full-length sequence of RelB is shown in blue (* indicates the 
stop codon of the sequence).  Peptide fragments were each 30 amino acids in length, overlapped by 5 
amino acid residues and spanned the entire RelB sequence.   
 
 The solutions of the RelB peptide crude preparations were diluted to 10 µM in 
dH2O and submitted for low-resolution matrix-assisted laser desorption ionization 
(MALDI) analysis at the Mass Spectrometry Laboratory at the University of Illinois at 
Urbana-Champaign.  The spectra of the crude preparations of the 11 RelB peptides are 
shown in Figures 4.24-4.34 at the end of the chapter.  A few of the peptides appeared 
quite pure with a major peak at the expected mass of the full-length peptide.  The 
remaining peptides contained numerous peaks at masses that did not correspond with the 
mass of the full-length peptide or other charge states.  High performance liquid 
chromatography (HPLC) was used to desalt and isolate the full-length versions of the 11 
RelB peptides.  Approximately 1 mg of crude peptide for each RelB fragment was 
purified using reverse-phase HPLC on a Beckman analytical n-butyl (C4) column using 
acetonitrile and dH20.  Fraction were collected based on the absorbance at 220 nm and 
the major peak for each peptide was analyzed by MALDI analysis.  The spectra of the 
HPLC-purified RelB peptides are shown in Figures 4.35-4.44.  For almost all of the 
RelB peptides, the major species detected by MALDI had a mass close to the expected 
mass of the full-length peptide (Table 4.4).  Two exceptions were peptides 1-30 and 46-
75.  The major peak observed in the MALDI spectra of the crude and HPLC-purified 
MGSINLRIDDELKARSYAALEKMGVTPSEALRLMLEYIADNERLPFKQTLLSDEDAELVEIVKERLRNPKPVRVTLDEL*
1‐30       MGSINLRIDDELKARSYAALEKMGVTPSEA
6‐35                   LRIDDELKARSYAALEKMGVTPSEALRLML               
11‐40                            ELKARSYAALEKMGVTPSEALRLMLEYIAD
16‐45                                       SYAALEKMGVTPSEALRLMLEYIADNERLP
21‐50                                                  EKMGVTPSEALRLMLEYIADNERLPFKQTL
26‐55                                                               TPSEALRLMLEYIADNERLPFKQTLLSDED
31‐60                                                                          LRLMLEYIADNERLPFKQTLLSDEDAELVE
36‐65                                                                                      EYIADNERLPFKQTLLSDEDAELVEIVKER
41‐70                                                                                                NERLPFKQTLLSDEDAELVEIVKERLRNPK
46‐75                                                                                                            FKQTLLSDEDAELVEIVKERLRNPKPVRVT
51‐80                                                                                                                       LSDEDAELVEIVKERLRNPKPVRVTLDEL
RelB
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preparations of RelB peptide 1-30 was m/z 3291, while the expected mass at m/z 3266 
was not detected by MALDI.  RelB peptide 46-75, despite HPLC-purification, remained 
contaminated with peptides of lower molecular weight than the full-length peptide.  Most 
likely, peptide 46-75 contains truncated peptide species that cannot be separated from the 
full-length peptide by HPLC.  RelB peptide 31-60 was not recovered from the analytical 
HPLC column due to an instrument malfunction and so was not included in further 
experiments.  
RelB 
Peptide 
Expected 
Mass 
Crude Peptide 
Mass by MALDI 
HPLC-purified Peptide 
Mass by MALDI 
Amount 
recovered 
(mg) 
1-30 3266.72 3291.72 3291.94 0.386 
6-35 3390.99 3390.47 3392.49 0.012 
11-40 3369.92 3385.51, 3369.26 3370.57 0.023 
16-45 3381.89 3381.98 3383.16 0.127 
21-50 3494.06 3494.48 3493.65 0.113 
26-55 3508.92 3511.21 3508.59 0.415 
31-60 3565.03 3564.81 N/A N/A 
36-65 3563.93 3563.55 3564.65 0.256 
41-70 3581.06 3581.43 3581.85 0.423 
46-75 3524.05 3524.39 3524.26 0.429 
51-80 3376.83 3377.31 3376.93 0.224 
 
Table 4.4  MALDI analysis and amount recovered after HPLC-purification of 11 RelB peptide fragments. 
N/A = not available.     
 
 To determine the amount of purified peptide recovered from the 1 mg injected 
onto the analytical HPLC C4 column, fractions found to contain full-length peptide at its 
greatest purity were lyophilized and weighed.  The amount recovered for each peptide is 
listed in Table 4.4.  Most peptides were recovered in modest yields, however an error 
with the injection loop on the analytical HPLC resulted in extremely low recoveries for a 
few of the peptides.  The lyophilized samples were stored at -20°C under dry conditions.  
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4.3.2  Native Gel Electrophoresis Analysis 
 As discussed in Chapter 1, section 1.5.1, peptides spanning the C-terminal region 
of RelB from residues 36-79, 47-79, and 52-79 have been shown to bind and inhibit the 
activity of RelE [4, 15, 19].  Thus, the RelB peptides designed in this study that 
corresponded to the C-terminal half of RelB, peptides 41-70 and 51-80, were analyzed by 
native gel electrophoresis for binding to RelE-His6.  RelB peptide 46-75 was not included 
because it contained a greater number of impurities than the other HPLC-purified 
peptides. 
 RelB peptides 41-70 and 51-80 were dissolved to 1 µg/µL in the same buffer that 
RelB and RelE-His6 are refolded in by dialysis (polymix buffer containing 20% glycerol) 
[22].  Approxmiately 30 µg of the peptides were initially analyzed by SDS-PAGE gel and 
visualized with Deep Purple Total Protein stain; lower amounts of peptide could not be 
detected (Figure 4.23A).  The modest intensity of the peptide bands when stained with 
Deep Purple Total Protein stain suggests that the actual amounts of peptide recovered are 
much less than what was calculated after weighing.  Without knowledge of the true 
concentration of the RelB peptides 41-70 and 51-80, 15 µL of each were incubated with 
refolded RelE-His6 (0.2 µg) or an equal amount of polymix buffer containing 20% 
glycerol for 18 hours at 4°C.  Refolded RelB (1.5 µg) was also incubated with refolded 
RelE-His6 alongside the peptide binding reactions.  Samples were analyzed by Native-
PAGE in the same manner as before (see Section 4.2.5d) to assess the formation of the 
RelBE-His6 complex and peptide binding to RelE-His6.  As seen in Figure 4.23B, RelB 
appears, as expected, as a single band half-way down the gel, while RelE-His6  is unable 
to enter the gel.  However, in this experiment, when RelB and RelE-His6 were incubated 
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together, a new band representing the RelBE-His6 complex was not detected.  When the 
RelB peptides 41-70 (pI = 5.15) and 51-80 (pI = 4.56) were run alone or after incubation 
with RelE-His6, no bands were visible.  The failure to observe binding between RelE-
His6 and RelB or the peptides could be due to the difficulty of detecting unknown low 
concentrations of the peptides as well as the instability and low yield of refolded RelE-
His6.   
 
Figure 4.23  SDS-PAGE and Native-PAGE analysis of RelB peptides 41-70 and 51-80.  A)  15% SDS-
PAGE stained with Deep Purple Total Protein stain.  The expected sizes of RelB peptides 41-70 and 51-80 
are 3.3 kDa and 3.5 kDa, respectively.  B)  15% Native PAGE analysis of RelBE-His6 complex formation 
and RelE-His6 binding to RelB peptides 41-70 and 51-80 after incubation at 4°C for 18 hours.  Gel stained 
with SYPRO Ruby Protein Gel stain. 
 
The project is currently being carried further by Julia Williams in the 
Hergenrother lab using PC biosensor technology in addition to native gel electrophoresis 
to investigate the ability of both RelB and RelE peptide fragments to bind natively folded 
RelBE.   
 
 
 
10 kDa
A B
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4.4  CONCLUSIONS 
 Originally discovered on the E. coli chromosome in 1998, RelBE is one of the 
most well-studied TA systems [9].  The RelE toxin belongs to the RelE/StbE/ParE 
superfamily of toxins and homologs of the RelBE system have been found on the 
genomes of a wide variety of bacteria and archaea, including vancomycin-resistant 
enterococci [2, 10, 11, 13, 16-18, 21, 23].  While the role of the chromosomal RelBE 
system as a modulator of the bacterial stress response is debated, on plasmids, the relBE 
genes lead to stabilization of the plasmid through postsegregational killing of plasmid-
free daughter cells (as discussed in Chapter 1).  Thus, it has been proposed that activation 
of a TA system, like RelBE, could be an attractive antibacterial target, as a small 
molecule that releases the toxin from the complex would kill the host bacterial cell from 
within [1, 5, 6, 8, 26].  With the discovery that the relBE genes were prevalent in clinical 
isolates of vancomycin-resistant enterococci [16], this system was selected for further 
investigation in hopes of developing an antimicrobial strategy through selective 
activation of the RelE toxin.  
 This thesis research led to the successful expression and purification of the RelBE 
proteins as a complex with both the wt and mutant R81A relE encoded.  Additionally, it 
was possible to express and purify the RelB antitoxin without RelE present.  In contrast, 
the RelE protein was never able to be expressed without RelB present, even with the 
R81A mutation, despite numerous optimization attempts.  Using the wild-type pET28a-
relBE-His6 construct, polyclonal antibodies were generated to the RelBE-His6 complex 
and a cell-based high-throughput screen was developed to identify small molecules that 
could cause cell death in E. coli expressing RelBE-His6 in a RelE-dependent manner. 
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 The major findings of the cell-based high-throughput screen were as follows: (i)  
Of the approximately 165,000 compounds examined in the screen, 335 caused 40% or 
greater growth inhibition; (ii) retesting identified 3 compounds that selectively inhibited 
the growth of the RelBE-expressing strain compared to the vector-only strain; (iii) 
secondary assays determined that the 3 hit compounds and derivatives either did not 
cause RelE-dependent cell death or had very low potency.  Specifically, compound 579 
was found to cause growth inhibition in E. coli BL21 (DE3) overexpressing any protein, 
not just RelBE-His6.  Compound 5488 appeared to selectively inhibit the growth of BL21 
(DE3) expressing RelBE-His6 (MIC50 = 16 µg/mL).  However secondary assays 
suggested it was not acting in a RelE-dependent manner.  Derivatives of 5488 were either 
completely inactive or active but not selective.  Compound 711 was the most promising 
hit identified in the screen and appeared both mildly potent (MIC50 = 16 µg/mL) and 
selective.  However, subsequent samples of 711, whether ordered from ChemBridge 
Corporation or synthesized in the Hegenrother lab, did not cause growth inhibition 
against any bacterial strain tested.  A few derivatives of 711 showed modest activity 
against BL21 (DE3) expressing wt RelBE-His6 and limited growth inhibition with other 
strains, but none were as potent as the parent compound was initially.  Additionally, 
secondary assays with derivative 711-c did not support any direct effect of the compound 
on the RelBE proteins. 
 Due to the difficulty encountered with identifying compounds that cause growth 
inhibition in a RelE-dependent manner, studies were refocused to better characterize and 
understand the interactions of the RelBE protein complex.  Peptides spanning the RelB 
protein have been designed and purified by analytical HPLC; two C-terminal peptide 
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fragments, 41-70 and 51-80, have been further evaluated by SDS-PAGE and Native-
PAGE analysis.  As mentioned earlier, further analysis of the RelB peptides is being 
carried out by Julia Williams in the Hergenrother lab.  RelB and RelE peptide fragments 
are being investigated for the ability to disrupt or prevent the formation of the RelBE 
protein complex using PC biosensor technology.  It is hoped that these studies will lead to 
the identification of key residues/segments in the RelBE complex and facilitate a more 
targeted approach to identify molecules that can activate the RelE toxin and kill the 
bacterial cell from within. 
 
4.5  MATERIALS AND METHODS 
Plasmids constructed.  To construct plasmid pCR2.1-TOPO-relBE (clone #3), 
the relBE genes were PCR-amplified from a total DNA preparation of E. coli K12 with 
primers relE-HindIII, 5’GTC AAG CTT TGG TTC AGA GAA TGC3’ and relB-NdeI, 
5’GAG GCA TAT GAC ATG GGT AGC3’.  After amplification, 3’-adenine overhangs 
were added by incubating with 1 U of Taq polymerase at 72°C for 10 minutes. The PCR 
product was then cloned into pCR2.1-TOPO with the TOPO TA Cloning Kit for 
subcloning following the manufactuer’s instructions (Invitrogen).     
To construct plasmid pET28a-His6-relBE (clone #2c1QC), pCR2.1-TOPO-relBE 
was digested with NdeI and HindIII and inserted into pET28a (Novagen) digested with 
NdeI and HindIII.  Site-directed mutagenesis was performed with plasmid DNA of 
pET28a-His6-relBE using primers pET-rel-qc-f, 5’CGG CAG CCA TAT GAC AAT 
GGG TAG CAT TAA C3’ and pET-rel-qc-r, 5’GTT AAT GCT ACC CAT TGT CAT 
ATG GCT GCC G3’ to insert an adenine between the NdeI restriction site and ATG start 
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codon of relBE to correct the reading frame.  pET28a-His6-relBE encodes for an N-
terminal His6-tag fused to RelB but fails to express His6-RelBE upon addition of IPTG to 
E. coli BL21 (DE3). 
To construct plasmid pET28a-relBE-His6 (clone #3-1), relBE was amplified by 
PCR from pET28a-His6-relBE plasmid DNA with primers relB-NcoI, 5’CAG CCA TGG 
GAA CAA TGG GTA GC3’ and relE-HindIII-nostop, 5’CGC AAG CTT GGT TCC GAG 
AAT GC3’.  The PCR product was digested with NcoI and HindIII and inserted into 
pET28a digested with NcoI and HindIII.  pET28a-relBE-His6 produces RelBE-His6 upon 
addition of IPTG to E. coli BL21 (DE3). 
To construct plasmid pET28a-relBER81A-His6, site-directed mutagenesis was 
performed with the plasmid DNA of pET28a-relBE-His6 using primers relER81A-41F, 
5’GTG ATT TCT GTT GGG AAA GCA GAA CGC TCG GAA GTA TAT AG3’ and 
relER81A-41R, 5’CTA TAT ACT TCC GAG CGT TCT GCT TTC CCA ACA GAA 
ATC AC3’ to change alanine (GCA) to arginine (AGA) at position 81.  pET28a-
relBER81A-His6 produces mutant RelBER81A-His6 upon addition of IPTG to BL21 (DE3).  
To construct plasmid pET28a-relB-His6, relB was amplified by PCR from 
pET28a-relBE-His6 plasmid DNA with primers relB-NcoI-F2, 5’GGA GAT ATA CCA 
TGG GAA CAA TGG3’ and relB-HindIII-R, 5’CCA GAA AAG CTT CCA TCC GAG 
TTC3’.  The PCR product was digested with NcoI and HindIII and inserted into pET28a 
treated with NcoI and HindIII.  pET28a-relBE produces RelB-His6 upon addition of 
IPTG to BL21 (DE3). 
RelBE Expression and Purification.  Expression of RelBE-His6 was performed 
in E. coli BL21 (DE3) cells.  A 15 mL overnight culture of BL21 (DE3) carrying the 
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pET28a-relBE-His6 plasmid was used to inoculate 1.5 L of LB containing kanamycin (50 
µg/mL) and shaken at 37°C until the OD600 was 0.4-0.6.  Expression was induced by 
addition of 0.5 mM IPTG and further incubation with shaking at 37°C for 3  hours.  Cells 
were pelleted by centrifugation and stored at -80°C. 
 RelBE-His6 was purified under native conditions in a similar manner to the 
purification of the archaeal homolog of RelBE and the QIAexpressionist protocol for 
batch purification of His6-tagged proteins (Qiagen) [25].  The cell pellet was thawed on 
ice and resuspended in cold RelBE-binding buffer (20 mM Tris-HCl, pH 7.9, 0.5 M 
NaCl).  The cell suspension was lysed by pulsing sonication on ice for 5 minutes and then 
centrifuged at 35,000 × g, 4°C for 30 minutes.  The cleared cell lysate was mixed with 1 
mL Ni-NTA agarose resin (Qiagen) at 4°C for 1 hour and then loaded onto an empty 
column fitted with a bottom cap.  Once the Ni-NTA resin was loosely packed at the 
bottom of the column, the cap was removed and any material not bound to the Ni-NTA 
resin was allowed to flow through.  The column was washed with 10 mL cold RelBE-
binding buffer followed by 10 mL cold RelBE-wash buffer (20 mM Tris-HCl, pH 7.9, 0.5 
M NaCl, 60 mM imidazole).  To elute the His-tagged RelBE protein complex, 10 mL 
cold RelBE-elution buffer (20 mM Tris-HCl, pH 7.9, 0.5 M NaCl, 0.5 M imidazole) was 
flowed over the column.  The eluate was collected and stored at 4°C.   
 To separately purify the RelB and RelE-His6 proteins, the RelBE complex was 
purified under native conditions as above.  The eluate was concentrated to a volume of 
1.5 mL and then dialyzed in 1 L denaturing buffer B (100 mM Na2HPO4, 10 mM Tris, 
pH 8.0, 8 M urea, filter sterilized; all denaturing buffers recipes were obtained from the 
Qiagen QIAexpressionist manual) at room temperature for at least 24 hours.  The volume 
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of the dialyzed sample was brought up to 5 mL with denaturing buffer B and mixed with 
1 mL Ni-NTA agarose resin at room temperature for 1 - 4 hours and then loaded onto an 
empty column with the bottom cap still attached.  Once the Ni-NTA resin was loosely 
packed at the bottom of the column, the cap was removed and any RelB protein not 
bound to RelE-His6 and the Ni-NTA resin was collected in the flow-through.  The 
column was washed with 5 mL denaturing buffer B (the flow-through of which may also 
contain free RelB), followed by 5 mL denaturing buffer C (100 mM Na2HPO4, 10 mM 
Tris, pH 6.3, 8 M urea, filter sterilized).  To elute the His-tagged RelE protein (and any 
intact RelBE-His6 complex), 4 mL denaturing buffer D (100 mM Na2HPO4, 10 mM Tris, 
pH 5.9, 8 M urea, filter sterilized) and 4 mL denaturing buffer E (100 mM Na2HPO4, 10 
mM Tris, pH 4.5, 8 M urea, filter sterilized) were flowed over the column.  Fractions 
were collected and analyzed by SDS-PAGE for the presence of free RelB, RelE-His6 and 
RelBE-His6 complex.   
Because oftentimes the eluate still contained RelB with RelE-His6, the flow-
through from denaturing buffers D and E (and sometimes C) were dialyzed in 1 L 
denaturing buffer A (100 mM Na2HPO4, 10 mM Tris, pH 8.0, 6 M GuHCl, filter 
sterilized) at room temperature for at least 24 hours.  The dialyzed sample was then 
mixed with 0.5 mL Ni-NTA agarose resin at room temperature for 1 hour and loaded 
onto an empty column as before.  Any RelB protein not bound to RelE-His6 and the Ni-
NTA resin was again allowed to flow through and collected.  The column was washed 
twice with 10 mL denaturing buffer B, followed by 5 mL each denaturing buffers C, D, 
and E.  Fractions were analyzed by SDS-PAGE for the presence of free RelB, RelE-His6 
and RelBE-His6 complex. 
210 
 
To refold free RelB and RelE-His6 purified under denaturing conditions, an 
extensive dialysis scheme was used as described previously in the literature comprised of 
dialysis into four different buffers for 10 -16 hours at 4°C each [22].  Dialysis buffer I 
contained phosphate-buffered saline (PBS), pH 7.4, 0.1% Triton X-100, and 5 mM 
dithiothreitol (DTT).  Dialysis buffer II contained PBS, pH 7.4, and 5 mM DTT.  Dialysis 
buffer III contained 1X polymix (5 mM Mg(C2H3O2)2, 5 mM NH4Cl, 95 mM KCl, 0.5 
mM CaCl2, 5 mM K2HPO4, pH 7.4, 1 mM DTT).  Dialysis buffer IV contained 1X 
polymix and 20% glyercol.  All buffers were chilled to 4°C before use.         
Western Blot Analysis with RelBE Polyclonal Antibodies.  RelBE 
immunodetection was carried out in a nearly identical manner to the  method described in 
Section 2.7 of Chapter 2.  As before, protein samples were separated by SDS-PAGE and 
transferred to an Immobilon-P PVDF membrane (Millipore) in cold Towbin Transfer 
buffer for 2 hours at 45-60 V.  Prior to probing, membranes were blocked with PBS 
containing 5% nonfat dried milk or 1% bovine serum albumin overnight with gentle 
shaking at 4°C.  The next day, membranes were washed three times with PBS at room 
temperature and then probed with anti-RelBE serum at a 1:500 or 1:1000 dilution in PBS, 
followed by mouse anti-rabbit IgG-horseradish peroxidase conjugated antibody at a 
1:20,000 dilution (Pierce) in PBS with or without 5% nonfat dried milk.  Antibody 
binding was detected with Supersignal West Pico Chemiluminescent substrate according 
to the manufacturer’s instruction (Pierce), followed by exposure to autoradiography film 
and developed using a Future 2000 K automatic x-ray film processor (Fisher Scientific).   
High-Throughput Screening Conditions.  E. coli BL21 (DE3) carrying 
pET28a-relBE-His6 was first grown in LB with 50 µg/mL kanamycin to an OD600 
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between 0.4-0.6.  The culture was diluted approximately 16-fold into LB with 50 µg/mL 
kanamycin and 1 mM IPTG, and 22.5 µL was added to individual wells containing 25 µL 
LB with 50 µg/mL kanamycin and 2.5 µL DMSO or 500 ng/µL compound dissolved in 
DMSO (final concentration is 25 ng/µL).  Wells in column 24 of the 384-well plate 
served as the positive control for no growth and received 22.5 µL LB with 50 µg/mL 
kanamycin and 1 mM IPTG instead of the diluted culture.  Plates were incubated 
overnight under a variety of conditions, as described in Section 4.2.3 of this chapter.  
Growth was evaluated by measuring the OD600 with a SpectraMax Plus384 High-
Throughput Microplate Spectrophotometer (Molecular Devices) and graphed as the 
percent of growth inhibition compared to the average OD600 of wells in columns 1, 2, and 
23 (negative control wells for uninhibited growth) after subtracting the background OD600 
of uninoculated media in column 24. 
Retesting and Growth Inhibition Assay Conditions.  Initial retesting of 
compounds identified in the high-throughput screen was performed in a similar manner to 
the screening conditions described above.  E. coli BL21 (DE3) carrying pET28a-relBE-
His6 or empty vector were grown in LB with 50 µg/mL kanamycin to an OD600 between 
0.4-0.6 and then diluted approximately 16-fold into LB with 50 µg/mL kanamycin and 1 
mM IPTG.  Individual wells of a 384-well plate contained 11.25 µL diluted culture, 12.5 
µL LB with 50 µg/mL kanamycin, and 1.25 µL DMSO or 500 µg/mL compound 
dissolved in DMSO (final concentration is 25 µg/mL).  Plates were wrapped in plastic 
wrap and kept at room temperature for 24 hours before determining the percent of growth 
inhibition. 
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 Growth inhibition assays with hit compounds 711, 5488 and 579 were performed 
using the retesting conditions described above, but with a variety of E. coli BL21 (DE3) 
expressing strains and compound concentrations.  The same ratios of diluted culture, 
media and DMSO or compound dissolved in DMSO were used.  
MIC Assays with Clinical Isolates.  The susceptibility of clinical isolates to hit 
compounds 711, 5488, and 579 was performed using the microdilution broth method as 
outlined by the Clinical and Laboratory Standards Institute (CLSI) [24].  Clinical isolates 
were inoculated into cation-adjusted Mueller-Hinton (MH) II broth (BBL) and incubated 
at 37°C until the culture reached a turbidity equal to 1 x 108 – 2 x 108 cfu/mL.  Individual 
wells of a 96-well round-bottom plate contained 93 µL MH broth, 5 µL culture, and 2 µL 
DMSO or compound dissolved in DMSO.  Final compound concentrations were 1, 2, 4, 
8, 16, 32, 64 and 128 µg/mL.  Wells that served as the positive control for no detectable 
growth received 5 µL uninoculated MH broth instead of the bacterial culture.  Plates were 
incubated at 37°C for 18-20 hours before determining the MIC.  MIC50 and MIC90 values 
were defined as the lowest concentrations of each compound that resulted in ≥ 50% and 
90% reductions in growth, respectively.    
MIC Assays with E. coli BL21 (DE3) Expression Strains.  MIC assays were 
performed as described for susceptibility testing with the clinical isolates with minor 
modifications.  Bacterial cultures were grown in LB with 50 µg/mL kanamycin instead of 
MH broth and MIC assays contained 1 mM IPTG to induce expression. 
3H-Leucine Incorporation Assay.  For each strain tested, a 5 mL overnight 
culture grown in LB with 50 µg/mL kanamycin was used to seed 10 mL filter-sterilized 
M9 broth (42 mM Na2HPO4, 24 mM KH2PO4, 9 mM NaCl, 19 mM NH4Cl, 0.2% 
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glucose, all amino acids except leucine at 50 µg/mL) and shaken at 37°C until the OD600 
was 0.2.  Tritiated leucine (L-[3, 4, 5-3H(N)]-Leucine, PerkinElmer) was added to the 10 
mL culture at a final concentration of 2 µCi/mL and shaken at 37°C for 5 minutes.  
Before inducing expression, 0.5 mL was taken from the culture and added to 1 mL cold 
15% TCA, inverted once, and placed on ice for at least 30 minutes to TCA-precipitate all 
macromolecules in the cell.  The remaining culture was split into two separate tubes; one 
tube received 2 mM IPTG and DMSO and the other received 2 mM IPTG and compound 
dissolved in DMSO.  The cultures were returned to shaking at 37°C and 0.5 mL aliquots 
were TCA-precipitated, as above, at 5, 15, 30 and 60 minutes after IPTG was added.  
After 30 minutes on ice, precipitates were filtered on a glass microfiber disk (Whatman), 
washed twice by filtering 1 mL cold 100% ethanol over the disk, and then allowed to dry.  
Disks were placed in 5 mL ScintiSafe Econo 1 scintillation fluid (Fisher Scientific) and 
the counts per minute (cpm) were measured on a LS 6500 Multi-Purpose Scintillation 
Counter (Beckman Coulter).   
P-values were calculated in Microsoft Excel with results from three or more 
separate experiments. Each timepoint for each strain was evaluated using the TTEST 
function: array 1 was the cpm values measured for the strain with DMSO, array 2 was the 
cpm values measured for the strain with compound present, tails was set to 2 for a two-
tailed distribution, and type was set to 2 for a two-sample equal variance (homoscedastic) 
t-test.  
Hemolysis Assay.  Human whole blood was purchased from Bioreclamation Inc. 
and stored at 4°C upon arrival.  To prepare erythrocytes for testing, 0.5 mL of blood was 
centrifuged at 10,000 × g for 2 minutes at room temperature.  The supernatant was 
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discarded and the cell pellet resuspended by inversion in 0.5 mL saline solution (0.9% 
NaCl in dH2O, filter-sterilized).  The suspension was centrifuged at 10,000 × g for 2 
minutes at room temperature and the supernatant discarded; cells were resuspended in 
saline solution and pelleted three more times.  After the final saline wash the cells were 
resuspended in 0.5 mL RBC buffer (10 mM Na2HPO4, 150 mM NaCl, 1 mM MgCl2, pH 
7.4, filter-sterilized). 
 Compounds to be tested in the hemolysis assay were first dissolved in DMSO at 
concentrations of 0.05 – 6.4 mg/mL and 20 µL of each concentrated compound stock 
solution was added to 980 µL RBC buffer to achieve a final concentration of 1 – 128 
µg/mL.  To prepare the negative control (no hemolysis), 20 µL DMSO was added to 980 
µL RBC buffer, and for the positive control (100% hemolysis), 20 µL DMSO was added 
to 980 µL dH2O.  Next, 25 µL of the prepared erythrocytes were added to the compound-
containing samples and positive and negative controls, mixed by inversion and incubated 
at 37°C for 2 hours.  After incubation, the samples were centrifuged at 10,000 × g for 2 
minutes at room temperature and 100 µL of supernatant from each sample was 
transferred to a 96-well plate.  To assess the degree of hemolysis, the absorbance at 540 
nm was measured and the percent hemolysis was calculated as follows:  % ݄݁݉݋݈ݕݏ݅ݏ ൌ
 100 ݔ ቀ ஺ହସ଴ሺ௦௔௠௣௟௘ሻି ஺ହସ଴ሺ௡௘௚௔௧௜௩௘ ௖௢௡௧௥௢௟ሻ
஺ହସ଴ሺ௣௢௦௜௧௜௩௘ ௖௢௡௧௥௢௟ሻି ஺ହସ଴ሺ௡௘௚௔௧௜௩௘ ௖௢௡௧௥௢௟ሻ
ቁ 
Native Gel Electrophoresis Analysis.  The RelBE proteins, compound 711-c, 
and RelB peptides were combined as desired and kept at 4°C for up to 48 hours to allow 
binding.  Next, 20 µL native gel sample buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 
0.1 % bromophenol blue, prepared fresh and chilled to 4°C) was added to each sample 
and loaded onto a 15% polyacrylamide precast gel (Bio-Rad).  Native gel electrophoresis 
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was run in cold 1X native gel buffer (25 mM Tris-HCl, pH 7.4, 192 mM glycine) on ice 
at 110 V for 3 hours.  Gels were stained with SYPRO Ruby Protein Gel stain (Invitrogen) 
according to the manufacturer’s instructions. 
PC Biosensor Analysis.  To prepare the 384-well PC biosensor plate for His6–
tagged protein binding, individual wells were washed five times with 40 µL assay buffer 
(10 mM HEPES, pH 7.4, 150 mM NaCl, 20 µM EDTA, 0.005% Tween-20).  Wells were 
then incubated with 10 µM D-biotin-tris-NTA hybrid compound (BTN) in assay buffer 
overnight at 4°C.  The next day, the wells were washed as before and charged with Ni2+ 
by incubating with 40 µL charging buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 20 
µM EDTA, 0.005% Tween-20, 500 µM NiCl2 ) for at least 2 minutes at room 
temperature to allow for His6-tag protein binding.  Wells were washed with assay buffer 
three times before adding either 40 µL RelE-His6 in dialysis buffer IV or dialysis buffer 
IV alone and incubating at room temperature 10 minutes.  Wells were again washed with 
assay buffer three times and the PWV shift measured with a BIND plate-based reader 
(SRU Biosystems).  Next, 40 µL RelB in dialysis buffer IV or dialysis buffer IV alone 
was added and incubated at 4°C up to 48 hours.  Wells were washed with assay buffer 
three times and the PWV shift measured as before.   
To assess compound disruption of RelBE-His6, RelBE-His6 was immobilized to 
the PC biosensor surface; wells were washed with assay buffer three times before adding 
either 40 µL RelBE-His6 in assay buffer or assay buffer alone and incubating at room 
temperature 10 minutes.  Wells were again washed with assay buffer three times and the 
PWV shift measured.  Next, 128 µg/mL compound 711-c or an equivalent amount of 
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DMSO in assay buffer was added and incubated at 4°C up to 24 hours.  Wells were 
washed with assay buffer three times and the PWV shift measured.   
RelB Peptide HPLC-Purification.  Reverse-phase HPLC was performed on a 
Beckman analytical n-butyl (C4) column housed in the van der Donk laboratory to purify 
the RelB peptides.  The “A” line of the HPLC contained dH2O and 0.1% trifluoroacetic 
acid (TFA) and the “B” line contained 80% acetonitrile and 0.086% TFA.  Before 
subjecting a peptide to HPLC-purification, the A and B pumps were first primed with 
their respective solutions.  Next, 100% of the B solution was flowed through the C4 
column at a flow-rate of 1 mL/minute for 5 minutes, followed by 2% B/98% A for at 
least 5 minutes at 1 mL/minute to equilibrate the column.  A “blank” was then run to 
examine the baseline absorbance at 220 nm.  The blank program used an acetonitrile 
gradient with the following steps:  Minutes 1-21 increase from 2% B/98% A to 100% B, 
minutes 21-26 hold at 100% B, minutes 26-31 decrease from 100% B to 2% B/98% A.  
After the blank was run, the column was again equilibrated with 2% B/98% A for 8-10 
minutes at 1 mL/minute. 
 Approximately 1 mg of crude peptide was resuspended in 1 mL dH2O and 500 – 
700 µL was injected onto the HPLC.  The program for an acetonitrile gradient on the C4 
column consisted of the following steps:  Minutes 1-46 increase from 2% B/98% A to 
100% B, minutes 46-51 hold at 100% B, minutes 51-56 decrease from 100% B to 2% 
B/98% A, minutes 56-66 hold at 2% B/98% A.  After running peptide over the column, 
the blank program was repeated, followed by flowing a 50% acetonitrile solution through 
the column for 15 minutes at 1 mL/minute and priming pumps A and B again.   
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4.6  FIGURES 
 
 
Figure 4.24  MALDI spectra of the crude preparation of RelB peptide 1-30.   
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Figure 4.25  MALDI spectra of the crude preparation of RelB peptide 6-35. 
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Figure 4.26  MALDI spectra of the crude preparation of RelB peptide 11-40. 
 
220 
 
 
Figure 4.27  MALDI spectra of the crude preparation of RelB peptide 16-45. 
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Figure 4.28  MALDI spectra of the crude preparation of RelB peptide 21-50. 
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Figure 4.29  MALDI spectra of the crude preparation of RelB peptide 26-55. 
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Figure 4.30  MALDI spectra of the crude preparation of RelB peptide 31-60. 
 
 
224 
 
 
Figure 4.31  MALDI spectra of the crude preparation of RelB peptide 36-65. 
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Figure 4.32  MALDI spectra of the crude preparation of RelB peptide 41-70. 
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Figure 4.33  MALDI spectra of the crude preparation of RelB peptide 46-75. 
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Figure 4.34  MALDI spectra of the crude preparation of RelB peptide 51-80. 
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Figure 4.35  MALDI spectra of the HPLC-purified RelB peptide 1-30. 
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Figure 4.36  MALDI spectra of the HPLC-purified RelB peptide 6-35. 
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Figure 4.37  MALDI spectra of the HPLC-purified RelB peptide 11-40. 
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Figure 4.38  MALDI spectra of the HPLC-purified RelB peptide 16-45. 
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Figure 4.39  MALDI spectra of the HPLC-purified RelB peptide 21-50. 
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Figure 4.40  MALDI spectra of the HPLC-purified RelB peptide 26-55. 
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Figure 4.41  MALDI spectra of the HPLC-purified RelB peptide 36-65. 
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Figure 4.42  MALDI spectra of the HPLC-purified RelB peptide 41-70. 
 
236 
 
 
Figure 4.43  MALDI spectra of the HPLC-purified RelB peptide 46-75. 
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Figure 4.44  MALDI spectra of the HPLC-purified RelB peptide 51-80. 
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CHAPTER 5 
CHARACTERIZATION OF THE AXE-TXE TOXIN-ANTITOXIN SYSTEM 
 
5.1  INTRODUCTION 
 As previously discussed in Chapters 1 and 2, the genes for the axe-txe toxin-
antitoxin (TA) system were first reported on a 24.8-kb nonconjugative plasmid, pRUM, 
in a multidrug resistant clinical isolate of E. faecium.  Antibiotic resistance to 
chloramphenicol, erythromycin, streptomycin, and streptothricin was encoded on pRUM, 
while a second 60-kb conjugative plasmid conferred vancomycin resistance [9].  
Recently, an investigation of a collection of 93 E. faecium strains suggested that a genetic 
linkage exists between the axe-txe genes and pRUM-replicon type plasmids [18].  
Additionally, as discussed in Chapter 2, a survey of 75 vancomycin-resistant enterococci 
(VRE) showed that the axe-txe genes were frequently present on plasmids isolated from 
VRE (appearing in 75% of the isolates), and in most cases, the genes resided on the same 
plasmid as the vancomycin resistance determinant [16].  Thus, the Axe-Txe TA system 
appears to be a common feature on enterococcal plasmids and may play a role in the 
persistence and stability of plasmid-encoded antibiotic resistance in clinical isolates of 
VRE.   
 Despite the prevalence of the axe-txe genes in enterococci, little is known about 
the Axe and Txe proteins, including the biological target of Txe toxin activity.  Txe 
shares significant sequence similarity with the toxin of the E. coli YefM-YoeB TA 
system, and Axe shares limited homology with the YefM and Phd antitoxins [9].  The 
YoeB toxin has been shown to inhibit protein synthesis through mRNA cleavage and is 
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part of the RelE toxin superfamily (see Chapters 1 and 4 for more information) [11].  
Given the extensive sequence homology between the YoeB and Txe proteins, mRNA 
cleavage may be the target of Txe, though not all members of the RelE toxin superfamily 
act as ribonucleases (for example, the ParE toxin inhibits DNA gyrase) [10].  Therefore, 
studies were undertaken to better characterize the Axe and Txe proteins and to identify 
the biological target of the Txe toxin.         
 
5.2  EXPRESSION AND PURIFICATION OF AXE AND TXE  
 
5.2.1  Axe Cloning, Expression, and Purification 
The axe gene was amplified from the plasmid DNA of VRE isolate U275 and 
cloned into the pACYCDuet-1 vector with an N-terminal His6-tag to facilitate over-
expression and purification of the Axe protein.  Additionally, the pACYCDuet-1 vector 
carries the P15A replicon and is compatible with plasmids carrying the ColE1 replicon 
found in most pET vectors.  Inspection of the pACYCDuet1-His6-axe DNA sequence 
(clone #6) revealed it to be correct and in-frame and was selected for further experiments 
(Figure 5.1). 
The axe gene was also cloned into vector pET21a (Novagen) to create a C-
terminal His6-tagged version of Axe for over-expression and purification.  The DNA 
sequence of pET21a-axe-His6 (clone #1-4) was found to be correct and in-frame and was 
also selected for further analysis (Figure 5.2).  
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Figure 5.1  Nucelotide sequence of clone pACYCDuet1-His6-axe.  The axe sequence was cloned into 
pACYCDuet-1 between the EcoRI and SalI restriction enzyme sites to allow addition of a N-terminal His6-
tag on axe. 
 
 
Figure 5.2  Nucelotide sequence of clone pET21a-axe-His6.  The axe sequence was cloned into pET21a 
between the NdeI and XhoI restriction enzyme sites to allow addition of a C-terminal His6-tag on axe. 
 
 To determine if the C-terminal and N-terminal His6-tagged versions of Axe could 
be successfully over-expressed and purified, plasmid DNA preparations of 
pACYCDuet1-His6-axe and pET21a-axe-His6 were each transformed into E. coli BL21 
(DE3).  Expression was carried out under standard conditions at 37°C and induced with 
0.5 mM IPTG.  Purification of Axe was initially performed under native conditions using 
standard buffers for Ni-NTA agarose metal-affinity chromatography.  As seen in Figure 
5.3A and 5.3C, Axe was eluted from the Ni-NTA matrix in very low yields for the both 
rbs axe startEcoR I
Hind III
His6-tag
stop
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80 
AAGGAGATAT ACCATGGGCA GCAGCCATCA CCATCATCAC CACAGCCAGG ATCCGAATTC AATGGAAGCA GTAGCTTATT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160 
CAAATTTCCG CCAAAATTTA CGTAGTTATA TGAAACAAGT TAATGAGGAT GCTGAAACAC TTATTGTAAC AAGTAAAGAT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240 
GTAGAAGATA CAGTTGTTGT ATTATCAAAA AGAGATTATG ATTCTATGCA AGAAACGTTG AGAACACTTT CTAATAATTA 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
250        260        270        280        290        300        310        320 
CGTCATGGAA AAAATTCGTC GAGGAGATGA ACAATTCTCC AAAGGTGCAT TTAAAACACA TGACTTAATC GAGGTTGAAT 
....|....| ....|....|
330        340
CTGATGATTA AGTCGAC...
rbs axe startNde I
Xho I stop
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80 
AAGGAGATAT ACATATGATG GAAGCAGTAG CTTATTCAAA TTTCCGCCAA AATTTACGTA GTTATATGAA ACAAGTTAAT 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160 
GAGGATGCTG AAACACTTAT TGTAACAAGT AAAGATGTAG AAGATACAGT TGTTGTATTA TCAAAAAGAG ATTATGATTC 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240 
TATGCAAGAA ACGTTGAGAA CACTTTCTAA TAATTACGTC ATGGAAAAAA TTCGTCGAGG AGATGAACAA TTCTCCAAAG 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
250        260        270        280        290        300        310        320 
GTGCATTTAA AACACATGAC TTAATCGAGG TTGAATCTGA TGATGAAGTC CTCGAGCACC ACCACCACCA CCACTGA... 
no stop His6-tag
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the N-terminal and C-terminal His6-tagged versions.  Under native purification 
conditions, most of the His6-tagged protein was either insoluble and remained in the 
pellet after lysis or did not bind the Ni-NTA matrix and was collected in the initial 
flowthrough fraction.  When Axe was purified by Ni-NTA affinity chromatography under 
denaturing conditions, large amounts of denatured Axe was eluted from the Ni-NTA 
matrix with several higher molecular weight contaminants (see Figure 5.3B and 5.3D). 
 
Figure 5.3  SDS-PAGE analysis of Axe purification fractions.  A and C)  For each native purification, 30 
µL of the initial flowthrough (Flow), binding buffer flowthrough (BB), wash buffer flowthrough (WB) and 
elution buffer flowthrough (EB) were analyzed by 15% SDS-PAGE.  B and D)  For each denaturing 
purification, 30 µL of the initial flowthrough, buffer “B” flowthrough, buffer “C” flowthrough, buffer “D” 
flowthrough, and buffer “E” flowthrough were analyzed by 15% SDS-PAGE.  Expected size for His6-Axe 
= 12.2 kDa.  Expected size for Axe-His6 = 11.6 kDa.   
M      P    Flow  BB   WB     EB
M      Flow     BB      WB        EB
M    Flow   B      C       D E
M     Flow     B        C         D       E
A B
C D
15 kDa
10 kDa
15 kDa
10 kDa
15 kDa
10 kDa
15 kDa
10 kDa
His6-Axe His6-Axe
Axe-His6 Axe-His6
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Various refolding conditions were tested to renature Axe, including the extensive 
dialysis scheme used with the RelB and RelE-His6 proteins (see Chapter 4) and dialysis 
conditions reported for other TA systems [8, 12, 14, 20].  However, Axe was extremely 
unstable upon removal of the denaturing agent and frequently precipitated out of solution 
during dialysis. Fortunately, it was found that both the N-terminal and C-terminal His6-
tagged versions of Axe could be further purified and stably refolded in solution when 
immobilized on the Ni-NTA matrix using a stepwise 8 M to zero urea gradient. 
 As mentioned above, small amounts of natively folded His6-Axe and Axe-His6 
were present in the eluate of native purifications.  Thus, a limited amount of natively 
folded Axe could be isolated from the soluble fraction of the expression culture cleared 
lysate.  Since the lysate supernatant contained many proteins besides Axe, the protein 
mixture was first filtered through a centrifugal filter device with a nominal molecular 
weight limit of 50 kDa.  The filtrate was then applied to a gravity-flow size-exclusion 
chromatography (SEC) column to isolate Axe (Figure 5.4).  When purified in this 
manner, Axe was generally free of contaminating proteins and stable in solution at 4°C. 
 
Figure 5.4  Axe-His6 SEC Purification.  A) The SEC elution was collected in 1-1.5 mL aliquots and the 
absorbance at 220 nm was measured for each fraction.  B)  For each 1-1.5 mL sample collected, 30 µL was 
analyzed by 15% SDS-PAGE.  Lane M = Protein standards marker.  Lane 1 = Soluble, filtered Axe-His6, 
Lanes 2-6  = fractions at 3.5, 4.5, 6, 7, and 8.25 mL elution volumes, respectively. Expected size for Axe-
His6 = 11.6 kDa. 
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5.2.2  Txe Cloning, Expression, and Purification   
 The txe gene was initially amplified from the plasmid DNA of VRE isolate S34 
and cloned into the pBAD22 vector as well as the pET200/D-TOPO vector with an N-
terminal His6-tag to facilitate over-expression and purification of the Txe protein.  
Inspection of the pBAD22-txe and pET200-His6-txe DNA sequences revealed both 
constructs to be correct and in-frame, but analysis of pilot expressions and Ni-NTA metal 
affinity chromatography purification fractions (for the His6-tagged version only) failed to 
detect Txe.  Additionally, if pET200-His6-txe or pBAD22-txe plasmid DNA was co-
transformed into E. coli BL21 (DE3) with pACYCDuet1-His6-axe, only His6-Axe was 
observed in the purification fractions.      
Because Txe is presumed to be a toxin and its expression may be detrimental to 
the cell, the txe gene was also cloned into the pET200/D-TOPO and pET28a vectors as 
part of the axe-txe gene cassette with an N-terminal His6-tag on the antitoxin.  Inspection 
of the DNA sequence of several pET200-His6-axetxe and pET28a-His6-axetxe clones 
revealed nonsense mutations present in the sequence of txe.  The stop codon mutations in 
the txe sequence occurred at either codon 5 (TGG to TAG) or codon 16 (TGG to TAG).  
Since the sequence of the template axe-txe genes used for cloning did not contain any 
premature stop codons in txe, only those clones encoding truncated Txe appear to have 
been selected for during culturing.  Multiple attempts to correct the sequence of txe by 
site-directed mutagenesis were unsuccessful.  
 Upon closer examination of the natural txe gene sequence, it was discovered that 
the occurrence of rare codons was great enough to possibly lower the protein expression 
potential of a Txe over-expression system.  Thus, all of the constructs described above 
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were transformed into E. coli Rosetta (DE3) cells and examined for expression of the Txe 
protein.  The Rosetta (DE3) expression strain carries the pRARE plasmid, which supplies 
tRNAs for six codons rarely used in E. coli (AGG, AGA, AUA, CUA, CCC, and GGA) 
to enhance the expression of proteins with these codons.  Of the 85 codons in the txe 
sequence, AGA is used 4 times, AUA is used 4 times, GGA is used 4 times, and CCC is 
used once.  Unfortunately, expression in Rosetta (DE3) cells only mildly increased the 
amount of Txe protein that was made, so codon optimization was next employed to 
increase protein expression levels.   
 The sequence manipulation software Gene Designer (DNA 2.0) was used to 
optimize the codon usage of the txe sequence for protein expression in E. coli by 
adjusting the codon bias and reducing the occurrence of rare codons.  Figure 5.5 shows 
the natural and codon-optimized sequences of txe.  The optimized txe gene, synthesized 
by DNA 2.0, was subcloned into vector pET28a with an N-terminal His6-tag.  However, 
as before, the level of Txe expression observed was very low; thus, codon optimization 
did not appear to significantly improve Txe expression and purification in E. coli.   
 
Figure 5.5  Natural and codon optimized sequences of txe.  The txe sequence was optimized for codon bias 
and frequency of rare codons using Gene Designer software and synthesized by DNA 2.0.   
5’ATGATTAAGGCTTGGTCTGATGATGCTTGGGATGATTATCTTTATTGGCATGAGCAAGGAAACAAAAGC3’
5’ATGATTAAAGCGTGGTCTGATGATGCATGGGACGATTACCTGTACTGGCATGAGCAGGGCAACAAATCC3’
5’AATATAAAAAAGATTAACAAGTTAATAAAAGATATCGATCGTTCCCCCTTTGCTGGATTAGGAAAACCT3’
5’AACATTAAGAAAATTAACAAGCTGATTAAAGACATCGATCGTTCTCCGTTCGCTGGCCTGGGTAAACCG3’
5’GAGCCATTAAAGCATGATTTATCTGGAAAATGGTCCAGAAGAATTACAGATGAACATAGACTGATATAT3’
5’GAGCCGCTGAAACACGACCTGAGCGGCAAATGGAGCCGTCGTATCACCGATGAACACCGCCTGATCTAC3’
5’AGAGTTGAAAATGAAACGATATTTATTTATTCTGCAAAAGATCACTATTAA3’
5’CGTGTTGAAAACGAAACCATTTTCATTTACAGCGCCAAAGACCACTATTAA3’
natural
optimized
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 Up to this point, all txe constructs created for expression were designed to yield 
Txe with an N-terminal His6-tag or no affinity tag present.  Thus, the cloning was 
redesigned to allow over-expression and purification of the Txe protein with a C-terminal 
His6-tag from the pET21a vector.  The DNA sequence of pET21a-txe-His6 (clone #2e) 
contained the natural sequence of the txe gene and was found to be correct and in-frame 
(Figure 5.6). 
 
Figure 5.6  Nucelotide sequence of clone pET21a-txe-His6.  The txe sequence was cloned into pET21a 
between the NheI and XhoI restriction enzyme sites to allow addition of a C-terminal His6-tag on txe. 
 
To determine if the C-terminal His6-tagged version of Txe could be successfully 
over-expressed and purified, pET21a-txe-His6 plasmid DNA was transformed into E. coli 
BL21 (DE3) and Rosetta (DE3) cells.  Analysis of pilot expressions revealed that Txe-
His6 was expressed in Rosetta (DE3), but not BL21 (DE3) cells.  Therefore, expression 
was carried out in Rosetta (DE3) under standard conditions at 37°C and induced with 0.5 
mM IPTG.  Purification of the Txe-His6 protein was initially performed under denaturing 
conditions using buffers containing 8 M urea by Ni-NTA agarose metal-affinity 
chromatography.  As seen in Figure 5.7A, the Txe-His6 protein was eluted from the Ni-
NTA matrix in low yield and contained several higher molecular weight contaminants.  
When the Txe-His6 protein was purified by Ni-NTA affinity chromatography under 
rbs txe startNhe I
Xho I stopno stop
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
10         20         30         40         50         60         70         80
AAGGAGATAT ACATATGGCT AGCATGATTA AGGCTTGGTC TGATGATGCT TGGGATGATT ATCTTTATTG GCATGAGCAA 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
90        100        110        120        130        140        150        160
GGAAACAAAA GCAATATAAA AAAGATTAAC AAGTTAATAA AAGATATCGA TCGTTCCCCC TTTGCTGGAT TAGGAAAACC 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
170        180        190        200        210        220        230        240
TGAGCCATTA AAGCATGATT TATCTGGAAA ATGGTCCAGA AGAATTACAG ATGAACATAG ACTGATATAT AGAGTTGAAA 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
250        260        270        280        290        300        310           
ATGAAACGAT ATTTATTTAT TCTGCAAAAG ATCACTATGA ACTCGAGCAC CACCACCACC ACCACTGA..
His6-tag
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native conditions, a similarly small amount of protein was eluted from the Ni-NTA 
matrix along with several contaminants (see Figure 5.7B).  It appeared that under native 
conditions, most of the tagged protein was soluble after lysis but did not bind the Ni-NTA 
matrix and was collected in the initial flowthrough fraction.   
 
Figure 5.7  SDS-PAGE analysis of Txe-His6 purification fractions.  A)  For denaturing purification, 30 µL 
of the initial flowthrough (Flow), buffer “B” flowthrough, buffer “C” flowthrough, buffer “D” flowthrough, 
and buffer “E” flowthrough were analyzed by 15% SDS-PAGE.  B)  For native purification, 30 µL of the 
lysed pellet (P), lysate supernatant (S), initial flowthrough (Flow), binding buffer flowthrough (BB), wash 
buffer flowthrough (WB) and elution (E) were analyzed by 15% SDS-PAGE.  Expected size for Txe-His6 = 
11.4 kDa.   
 
Since natively folded Txe-His6 failed to bind the Ni-NTA matrix with high 
affinity, Txe-His6 was directly isolated from the soluble fraction of the expression culture 
cleared lystate.  As described earlier for the purification of Axe, the lysate supernatant of 
a Txe-His6 expression culture contained many other proteins so the cleared lysate was 
filtered through a centrifugal filter device with a nominal molecular weight limit of 50 
kDa.  The filtrate was then applied to a gravity-flow SEC column to selectively purify the 
Txe protein (Figure 5.8).  When isolated in this manner, Txe-His6 was generally free of 
contaminating proteins and stable in solution at 4°C.    
M   Flow  B     C     D      EA B
15 kDa
10 kDa
15 kDa
10 kDa
M      P      S    Flow   BB   WB     E
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Figure 5.8  Txe-His6 SEC Analysis.  A) The SEC elution was collected in 1-1.25 mL aliquots and the 
absorbance at 220 nm was measured for each fraction.  B)  For each 1-1.25 mL sample collected, 30 µL 
was analyzed by 15% SDS-PAGE.  Lane M = Protein standards marker.  Lane 1 = Soluble, filtered Txe-
His6, Lane 2 = fraction at 5.25 mL elution volume, Lane 3 = fraction at 6.25 mL elution volume, Lane 4 = 
fraction at 7.25 mL elution volume, Lane 5 = fraction at 8.25 mL elution volume, Lane 6 = fraction at 9.5 
mL elution volume, Lane 7 = fraction at 10.5 mL elution volume, Lane 8 = fraction at 11.5 mL elution 
volume, Lane 9 = 12.5 mL elution volume.  Expected size for Txe-His6 = 11.4 kDa. 
 
5.3  CHARACTERIZATION OF AXE AND TXE 
 
5.3.1  RT-PCR Analysis 
 To determine if the mRNA transcript coding for the Axe-Txe proteins is produced 
in VRE strains previously shown by PCR to carry the axe-txe genes (see Chapter 2), RT-
PCR was performed from total mRNA isolated from six VRE clinical isolates.  As shown 
in Figure 5.9A, all six isolates (C29113, S34, S177, SL242, SL266, and SL745) produce 
the axe-txe transcript, as assessed by RT-PCR.  RT-PCR analysis was also performed on 
the total RNA isolated from the plasmid-free E. faecium strain BM4105-RF, which does 
not contain the axe-txe genes, and no axe-txe transcript was detected (Figure 5.9A).  To 
ensure that the observed RT-PCR products were not due to DNA contamination, controls 
were performed in which the reverse transcriptase enzyme was not added, but all other 
components (including thermostable DNA polymerase and primers for axe-txe) were 
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added.  As shown in Figure 5.9B, no amplification product is observed under these 
conditions, confirming that the products seen by RT-PCR were due to the presence of 
transcript and not DNA contamination.  Finally, RT-PCR with primers for the 
enterococcal elongation factor tuf gave the expected positive result for all seven strains 
examined (Figure 5.9C) [7].  Thus, RT-PCR analysis demonstrated that the axe-txe 
transcript is made in VRE clinical isolates carrying the axe-txe genes.   
  
Figure 5.9  RT-PCR analysis of 6 VRE isolates and a plasmid-free enterococcal strain (BM4105-RF).  The 
isolates tested were C29113, S34, S177, SL242, SL266, and SL745.  (A) RT-PCR with primers 
complementary to axe-txe (product size = 447 bp).  (B)  Controls for DNA contamination, in which reverse 
transcriptase was omitted from the reaction mix.  (C)  RT-PCR with primers complementary to the 
enterococci tuf gene (product size = 112 bp).  Lane M contains the 100-bp DNA ladder.  
 
5.3.2  Axe-DNA Binding Activity 
 Proteic TA systems have been shown to be autoregulated at the level of 
transcription by binding of the antitoxin to palindromic sequences in the operator-
promoter region of the operon [6, 12, 15, 19].  In most cases, the antitoxin acts as the 
C29113 S34 S177 SL242
500 bp
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primary repressor and the toxin is a co-repressor that enhances antitoxin binding.  Thus, 
using electrophoretic mobility shift assays (EMSAs) and photonic crystal (PC) biosensor 
technology, Axe was assessed for DNA binding activity to the region directly upstream 
of the axe-txe genes on the pRUM sequence. 
  
Figure 5.10  DNA sequence directly upstream of the axe-txe genes.  Highlighted in red is an imperfect 
palindromic sequence containing paired paired TGTACA motifs present in the possible axe-txe operator-
promoter region. 
 
The axe-txe operator-promoter region has not been defined, so a 342 bp sequence 
directly upstream of the axe-txe genes that contains a palindromic sequence was 
amplified by PCR with a 5’ biotinylated forward primer (see Figure 5.10).  The labeled 
DNA fragment was incubated with increasing concentrations of either His6-Axe or Axe-
His6, subjected to 7.5% polyacrylamide gel electrophoresis and detected by Western blot 
with an anti-biotin horseradish peroxidase (HRP)-conjugated antibody.  At concentrations 
as high as 8 µM Axe, the antitoxin did not cause retardation of 0.1 nM of the labeled 
DNA fragment (Figure 5.11A). 
5’-AGGGTTATTTCGATGAAAGGAGAGAGTACTAATGCCAATTGCAATAGGAAATAAACG
GTTACCCGTTACGTTGGATGAAAAGAGACAAAAAGAATTGCAGCAACTAAAGCAGAA
GTACGGCAAAAGTGAATCCAGGATTATGTGTATTGCGTTAGATTTATTGATTGCCCAA
GAAAAAGCAGGATTTGAGGTACCAGCACTCAAAAAGTGACGTCACTTTTTATCCTAAA
AACTAAAAGTGATAGCACTTTTAATTATAAGAAGTTAGAATATTAATCATTTGCTTAAT
TGTACAATATAATGTACAATTGTTTTATAGAAATAAATAAGGGGTGAAAGGA-3’
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Figure 5.11  Evaluation of Axe-DNA binding activity by EMSA and PC biosensor technology.  A)  0.1 nM 
of a 342 bp labeled DNA fragment hypothesized to contain the axe-txe operator-promoter was incubated 
with increasing concentrations of Axe-His6 and analyzed by polyacrylamide gel electrophoresis and 
Western blot.  B)  1 µM Biotin-labeled DNA fragments corresponding to the 342 bp sequence upstream of 
the axe-txe genes and the 24 bp palindromic sequence within the upstream region were bound to the PC 
biosensor surface.  Addition of 8 µM His6-Axe did not cause a significant increase in the net PWV.  Black 
line, His6-Axe added with no DNA bound; Orange line, 24 bp DNA fragment with no His6-Axe added; Red 
line, 24 bp DNA fragment with His6-Axe added; Green line, 342 bp DNA fragment with no His6-Axe 
added; Blue line, 342 bp DNA fragment with His6-Axe added.         
 
PC biosensor technology was also employed to detect Axe-DNA binding (see 
Chapter 4, section 4.25 for a description of PC biosensor technology).  The 5’ 
biotinylated 342 bp upstream sequence and 24 bp palindromic sequence were bound to 
individual wells of a streptavidin-coated biosensor plate and incubated with purified His6-
Axe.  Binding of His6-Axe to the labeled DNA fragments should result in an increase in 
the net peak wavelength value shift (PWV).  However, when His6-Axe was added to the 
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wells, no net PWV increase was observed compared to wells without His6-Axe added 
(Figure 5.11B).  These results, along with the EMSA results, suggest that Axe is unable 
to bind the DNA sequence directly upstream of the axe-txe genes that mostly likely 
contains the axe-txe operator-promoter region.  This could be due to an inherent property 
of Axe that differs from most antitoxins or interference from the His6-tag fused to Axe.  
Future studies to assess the DNA binding activity of Axe may require untagged Axe and 
the addition of Txe to facilitate DNA binding. 
 
5.3.3  Txe Mechanism of Action 
The biological target of Txe is currently unknown; however, Txe shares 
significant sequence similarity with the toxin of the E. coli YefM-YoeB TA system [9].  
As mentioned earlier, the YoeB toxin has been shown to inhibit protein synthesis through 
mRNA cleavage and is part of the RelE toxin superfamily, which includes several other 
toxins that act as ribonucleases to inhibit protein synthesis [11].  Therefore, mRNA 
cleavage may also be the intracellular target of Txe toxin activity.  However, some 
members of the RelE toxin superfamily are not ribonucleases and inhibit the growth of 
cells through an entirely different mechanism, such as DNA gyrase inhibition [10].  
Therefore, studies were undertaken to identify the biological target of Txe toxin activity.         
 
5.3.3a  Macromolecular synthesis assays 
 Determination of the mechanism of action of Txe toxicity began with assessing 
the toxin’s effect on global biosynthetic pathways in the cell.  Using a radiolabeled 
precursor incorporation assay, the rates of protein, DNA, and RNA synthesis were 
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measured upon induction of Txe-His6 expression with IPTG in E. coli.  The amount of 
IPTG added to cells was up to 10-fold lower than the concentration used for protein 
expression and purification due to the growth inhibitory effects of IPTG alone.  As shown 
in Figure 5.12A, the inhibitory effect of 0.05 mM IPTG on cellular protein synthesis 
levels was much less than that observed with 0.5 mM IPTG in cells expressing the 
antitoxin, Axe-His6, which is presumably non-toxic, while still inducing adequate T7-
driven protein over-expression  In cells expressing Txe-His6, the difference in protein 
synthesis levels between induced and uninduced cultures was more pronounced, likely 
due to the additional inhibitory effect of expressing a toxic protein (Figure 5.12B). 
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Figure 5.12  Effect of IPTG concentration on protein synthesis.  A and B) Graphs of the percent [3H]-
leucine incorporation (relative to the amount of [3H]-leucine incorporation at time of IPTG addition) 
following addition of 0, 0.05, 0.1, or 0.5 mM IPTG to E. coli Rosetta cells carrying the pET21a-axe-His6 
plasmid (A) or the pET21a-txe-His6 plasmid (B).  Also shown are Western blots with HisProbe-HRP of 1 
mL samples of E. coli Rosetta with pET21a-axe-His6 (A) or pET21a-txe-His6 (B) following IPTG addition.  
For both Western blots:  Lane M = protein standards marker, Lane 1 = 1 hour, no IPTG, Lane 2 = 1 hour, 
0.05 mM IPTG, Lane 3 = 1 hour, 0.1 mM IPTG, Lane 4 = 2 hours, no IPTG, Lane 5 = 2 hours, 0.05 mM 
IPTG, Lane 6 = 2 hours, 0.1 mM IPTG, Lane 7 = 3 hours, no IPTG, Lane 8 = 3 hours, 0.05 mM IPTG, 
Lane 9 = 0.1 mM IPTG.  Expected size for Axe-His6 = 11.6 kDa.  Expected size for Txe-His6 = 11.4 kDa. 
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 Radiolabel incorporation assays were carried out with [3H]-leucine to measure 
protein synthesis, [3H]-uridine to measure RNA synthesis, and [3H]-thymidine to measure 
DNA synthesis in Rosetta cells expressing Txe-His6.  As shown in Figures 5.13A and 
5.13B, the levels of DNA and RNA synthesis were not inhibited by the expression of 
Txe-His6 in Rosetta (DE3). 
 
Figure 5.13  DNA and RNA synthesis following Txe-His6 induction.  A and B) Counts per minute 
measured for [3H]-thymidine incorporation (A) and [3H]-uridine incorporation (B) immediately before and 
following addition of 0 or 0.05 mM IPTG to E. coli Rosetta (DE3) carrying the pET21a-txe-His6 plasmid.  
Results are the average of three separate experiments.  Error bars represent the standard deviation from the 
mean and p represents the statistical significance between bracketed groups.   
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In cells expressing Txe-His6, the level of DNA synthesis at 1 hour post-induction 
was comparable to uninduced cultures not expressing Txe-His6.  Interestingly, at 2 and 3 
hours post-induction, cells expressing Txe-His6 had significantly greater levels of [3H]-
thymidine incorporation compared to the uninduced culture.  When [3H]-uridine 
incorporation was measured in cells expressing Txe-His6, the level of RNA synthesis was 
similar to uninduced cultures at all timepoints post-induction.  P-values were calculated 
in Microsoft Excel using the TTEST function for the counts per minute (cpm) measured 
from Rosetta (DE3) carrying the pET21a-txe-His6 plasmid at 0, 60, 120 and 180 minutes 
after addition of 0 or 0.05 mM IPTG.  Thus, expression of Txe-His6 does not appear to 
significantly inhibit DNA and RNA synthesis in E. coli Rosetta (DE3).  
 In contrast, the level of protein synthesis was significantly inhibited by the 
expression of Txe-6xHis in Rosetta (DE3) (Figure 5.14A).  By two hours post-induction, 
the amount [3H]-leucine incorporation measured was greatly reduced in cells receiving 
0.05 mM IPTG compared to cells that did not receive IPTG.  Shorter timepoints (5, 10, 
15, and 30 minutes) were also investigated to determine how quickly expression of Txe-
His6 inhibited protein synthesis; however, differences in [3H]-leucine incorporation were 
not observed until 60 minutes post-induction (Figure 5.14B).  P-values were calculated 
in Microsoft Excel using the TTEST function as described above.  
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Figure 5.14  Protein synthesis following Txe-His6 induction.  A and B) Counts per minute measured for 
[3H]-leucine incorporation immediately before and following addition of 0 or 0.05 mM IPTG to E. coli 
Rosetta cells carrying the pET21a-txe-His6 plasmid.  Results are the average of three separate experiments.  
Error bars represent the standard deviation from the mean and p represents the statistical significance 
between bracketed groups.   
 
 Next, it was investigated if the inhibition of protein synthesis observed upon 
IPTG-induction of Rosetta (DE3) carrying the pET21a-txe-His6 plasmid was specific for 
the expression of Txe-His6 or an artifact of the system used.  Radiolabel incorporation 
assays were performed with [3H]-leucine to measure protein synthesis as a function of 
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time and IPTG concentration in Rosetta (DE3) carrying the pET21a-axe-His6 plasmid or 
the empty pET21a vector.  As shown in Figures 5.15A and 5.15B, the level of protein 
synthesis was not inhibited by the expression of Axe-His6 in Rosetta (DE3) or when 
IPTG was added to cells carrying the empty vector. 
 
Figure 5.15  Protein synthesis following IPTG induction of Axe-His6 and empty pET21a vector.  A and B) 
Counts per minute measured for [3H]-leucine incorporation immediately before and following addition of 0 
or 0.05 mM IPTG to Rosetta (DE3) carrying the pET21a-axe-His6 plasmid (A) or the pET21a plasmid (B).  
Results are the average of three separate experiments.  Error bars represent the standard deviation from the 
mean and p represents the statistical significance between bracketed groups.   
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 When the levels of [3H]-leucine incorporation following addition of 0.05 mM 
IPTG to Rosetta with pET21a, pET21a-axe-His6, and pET21a-txe-His6 are graphed 
alongside each other at the various timepoints examined, the inhibition of protein 
synthesis by Txe-His6 becomes even clearer (Figure 5.16). 
 
Figure 5.16  Protein synthesis following IPTG induction of Txe-His6, Axe-His6 and empty pET21a vector.  
A) Counts per minute measured for [3H]-leucine incorporation immediately before and following addition 
of 0.05 mM IPTG to Rosetta (DE3) carrying pET21a, pET21a-txe-His6, or pET21a-axe-His6.  Results are 
the average of three separate experiments.  Error bars represent the standard deviation from the mean and p 
represents the statistical significance between bracketed groups.   
 
5.3.3b  Cell-free protein synthesis assays 
 A cell-free system was used to further examine the inhibitory effect of Txe-His6 
on protein synthesis.  An E. coli T7 S30 extract system was preincubated with the 
pET21a-txe-His6 plasmid for 20 minutes to begin synthesis of the Txe-His6 protein.  The 
plasmid pET28a-relB-His6 was then added to allow synthesis of RelB-His6, the antitoxin 
of the RelBE TA system, for 1 hour.  The pET28a-relB-His6 construct was used due to its 
robust expression of the RelB-His6 antitoxin, which is not expected to bind toxins from 
other TA systems.   
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As expected, Txe-His6 inhibited the synthesis of RelB-His6 (Figure 5.17A, Lane 
3).  Txe-His6 also inhibited the synthesis of the major lipoprotein, Lpp, of the E. coli 
outer membrane, expressed from the plasmid pRSF-1b-His6-lpp (Figure 5.17B, Lane 3).  
When His6-Axe or Axe-His6 was synthesized instead of Txe-His6, protein synthesis of 
RelB-His6 and His6-Lpp was not inhibited, as would be expected for the antitoxin 
component of a TA system (Figures 5.17A-B, Lane 4).  Unfortunately, both tagged 
versions of the antitoxin were unable to prevent protein synthesis inhibition by Txe-His6 
(Figures 5.17A-B, Lane 5).  This may be the result of Txe-His6 inhibiting the protein 
synthesis of the antitoxin as well as RelB-His6 and His6-Lpp, or interference of the His6-
tag on Axe with its ability to bind the toxin.  When purified Txe-His6 or Axe-His6 
proteins were used instead of synthesizing the proteins in the cell-free system, the toxin 
did not inhibit protein synthesis and the antitoxin did not prevent protein synthesis 
inhibition by Txe-His6 expressed in the cell (Figure 5.17C, Lane 3, and Figure 5.17D, 
Lane 5).  Interestingly, Western blots for the His6-tag did not detect the Txe-His6 and 
Axe-His6 proteins when added exogenously to the cell-free system (up to 190 pmoles 
added), suggesting that the purified proteins were unstable and degraded in the cell-free 
system.   
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Figure 5.17  Effect of Txe-His6, Axe-His6, His6-Axe on cell-free protein synthesis.  A) Western blot with 
HisProbe-HRP of cell-free protein synthesis reactions with no DNA added (Lane 1), pET28a-relB-His6 
DNA added (Lane 2), pET28a-relB-His6 and pET21a-txe-His6 DNA added (Lane 3), pET28a-relB-His6 and 
pET21a-axe-His6 DNA added (Lane 4), and pET28a-relB-His6, pET21a-txe-His6, and pET21a-axe-His6 
DNA added (Lane 5).  B)  Western blot with HisProbe-HRP of cell-free protein synthesis reactions with no 
DNA added (Lane 1), pRSF1b-His6-lpp DNA added (Lane 2), pRSF1b-His6-lpp and pET21a-txe-His6 DNA 
added (Lane 3), pRSF1b-His6-lpp and pACYCDuet1-His6-axe DNA added (Lane 4), and pRSF1b-His6-lpp, 
pET21a-txe-His6, and pACYCDuet1-His6-axe DNA added (Lane 5).  C)  Western blot with HisProbe-HRP 
of cell-free protein synthesis reactions with no DNA added (Lane 1), pET28a-relB-His6 DNA added (Lane 
2), pET28a-relB-His6 DNA and Txe-His6 protein added (Lane 3), and pET28a-relB-His6 and pET21a-txe-
His6 DNA added (Lane 4).  D)  Western blot with HisProbe-HRP of cell-free protein synthesis reactions 
with no DNA added (Lane 1), pET28a-relB-His6 DNA added (Lane 2), pET28a-relB-His6 DNA and 
pET21a-txe-His6 DNA added (Lane 3), pET28a-relB-His6 DNA and Axe-His6 protein added (Lane 4), and 
pET28a-relB-His6 DNA, pET21a-txe-His6 DNA, and Axe-His6 protein added (Lane 5).        
 
The protein synthesis inhibition observed with Txe-His6 in the cell-free system 
support the results of the macromolecular synthesis assays in that Txe toxicity is derived 
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from its ability to inhibit protein synthesis.  As mentioned in this chapter and Chapter 1, 
Txe shares extensive sequence homology with the YoeB toxin, which has been shown to 
inhibit protein synthesis through mRNA cleavage and is part of the RelE toxin 
superfamily [9, 11].  Therefore, protein synthesis inhibition through mRNA cleavage may 
also be the intracellular target of Txe.  However, two mechanisms of mRNA cleavage 
have been described for the toxins of TA systems; the RelE toxin, and possibly the YoeB 
toxin, cleaves mRNA only when it is associated with the ribosomal A-site, while the 
MazF toxin is a ribosome-independent endoribonuclease [2, 3, 17, 22].  Thus, further 
experiments were performed to determine if the mechanism of Txe-induced protein 
synthesis inhibition involved mRNA cleavage and if this cleavage could occur 
independent of the ribosome. 
 
5.3.3c  In vitro assays 
 Before examining the ability of Txe-His6 to cleave mRNA, an in vitro gyrase 
cleavage assay was used to verify that Txe is not a gyrase poison like the toxins of the 
CcdAB and ParDE TA systems [1, 5, 10].  Txe-His6 or ciprofloxacin were incubated with 
supercoiled pBR322 plasmid DNA and E. coli DNA gyrase, followed by treatment with 
SDS and proteinase K to release cleaved DNA bound by gyrase.  DNA was extracted 
from the samples, subjected to 1% agarose gel electrophoresis and visualized with 
ethidium bromide.     
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Figure 5.18  In vitro gyrase cleavage assay with Txe-His6.  Lane 1, supercoiled pBR322 plasmid DNA; 
Lane 2, supercoiled pBR322 and E. coli DNA gyrase; Lane 3, gyrase and supercoiled pBR322 incubated 
with 1µg Txe-His6; Lane 4, gyrase and supercoiled pBR322 incubated with ciprofloxacin.  Samples were 
analyzed on a 1% agarose gel stained with ethidum bromide.  OC, open circle; L, linear; SC, supercoiled. 
 
As shown in Figure 5.18, treatment with ciprofloxacin caused double-stranded 
breaks in the supercoiled pBR322 plasmid DNA, resulting in an increase of the linear 
form.  When Txe-His6 was added to pBR322, no visible increase in the linear form of 
pBR322 plasmid DNA was observed.  These results suggest that Txe-His6 does not 
poison DNA gyrase in vitro, which is in agreement with the results of the 
macromolecular synthesis assays that showed DNA synthesis was not affected by Txe-
His6 expression. 
Next, purified Txe-His6 was evaluated for its ability to cleave mRNA not 
associated with the ribosome in vitro, in a similar manner to that of the toxin of the 
MazEF system [22].  To determine if mRNA can be cleaved by Txe-His6 in vitro, E. coli 
lpp and mouse β-actin mRNAs were generated with an in vitro T7 transcription kit and 
incubated with up to 50 pmoles purified Txe-His6.  RNA was extracted from the samples, 
subjected to 5% polyacrylamide TBE-urea gel electrophoresis, and stained with ethidium 
bromide to detect mRNA digestion. 
1           2           3          4
OC
SC
L
266 
 
 
Figure 5.19  In vitro mRNA cleavage assay with Txe-His6.  A) Txe-His6 was incubated with mouse β-actin 
mRNA and analyzed on a 5% polyacrylamide TBE-urea gel stained with ethidum bromide.  Lane 1, β-actin 
mRNA with no Txe-His6 added; Lane 2, β-actin mRNA with 15 pmoles Txe-His6; Lane 3, β-actin mRNA 
with 30 pmoles Txe-His6; Lane 4, β-actin mRNA with 45 pmoles Txe-His6; Lane 5, β-actin mRNA with 1 
µg RNase A.  B)  Txe-His6 was incubated with lpp mRNA and analyzed on a 5% polyacrylamide TBE-urea 
gel stained with ethidum bromide.  Lane 1, lpp mRNA with no Txe-His6 added; Lane 2, lpp mRNA with 50 
pmoles Txe-His6; Lane 3, lpp mRNA with 1 µg RNase A.   
 
As shown in Figure 5.19, the E. coli lpp and mouse β-actin mRNAs were not 
digested by Txe-His6 after 2 hours incubation together.  These results suggest that Txe-
His6 cannot cleave mRNA in vitro and/or may require mRNA to be associated with the 
ribosome to cause cleavage and, consequently, protein synthesis inhibition.  However, it 
was unknown if Txe-His6 was enzymatically active in vitro after native purification and, 
without knowledge of the toxin’s mechanism of action, binding studies with Axe provide 
the best method to determine if Txe-His6 is correctly folded.   
Photonic crystal (PC) biosensor assays were attempted in the same manner as 
described in Chapter 4 for RelB and RelE-His6 to detect Axe-Txe-His6 complex 
formation.  Unfortunately, natively purified Txe-His6 did not bind the D-biotin-tris-NTA-
functionalized PC biosensor surface.  This is not surprising given that Txe-His6 does not 
bind the Ni-NTA matrix under native purification conditions either.  Since Txe-His6 
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could not be immobilized for binding studies with Axe, native gel electrophoresis was 
used to evaluate the ability of Txe-His6 and Axe (both His6-tagged and untagged 
versions) to bind each other.  Native gel electrophoresis conditions similar to those used 
for RelB and RelE-His6 were tested (see Chapter 4); however, visualization of both the 
Axe and Txe proteins proved difficult.  Thus, it remains to be determined if Txe-His6 is 
correctly folded in vitro and able to interact with Axe and current studies are underway to 
optimize native gel electrophoresis conditions.    
 
5.3.3d  In vivo primer extension analysis 
As discussed previously, the toxins of several TA systems have been shown to 
inhibit protein synthesis through mRNA cleavage, including YoeB, which shares 
extensive sequence homology with Txe  [2, 3, 9, 11, 17, 22].  Therefore, in vivo primer 
extension analysis was used to determine if Txe-induced protein synthesis inhibition 
involves mRNA cleavage in the cell.  Cleavage of the 5’ end of lpp mRNA was chosen 
for analysis due to its frequent use as an RNA substrate for both Northern blot analysis 
and primer extension analysis of the mechanism of other TA system toxins [2-4, 21].   
To perform primer extension analysis in vivo, RNA was isolated from E. coli 
Rosetta (DE3) cultures before and after induction of txe and lpp expression by IPTG.  As 
shown in Figure 5.20, induction of Txe-His6 expression led to the disappearance of full-
length lpp mRNA product (Figure 5.20A-B, Lane 1) and the appearance of cleavage 
products as early as 30 minutes post-induction. 
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Figure 5.20  Primer extension analysis of lpp mRNA cleavage by Txe-His6.  Expression of Txe-His6 and 
His6-Lpp in E. coli Rosetta (DE3) was induced by 0.5 mM IPTG.  Total RNA was extracted immediately 
before induction and at 30, 60, and 120 minutes post-induction (Lanes 1-4, respectively).  Primer extension 
was carried out with a 32P-labeled primer for lpp and products were analyzed on a 10% polyacrylamide 
TBE-urea gel.  A) Gel image of primer extension products with the 32P-labeled ladder shown (Low 
Molecular Weight DNA Ladder, NEB).  B)  Due to washout of the lanes containing primer extension 
samples by the 32P-labeled ladder, the primer extension products were also imaged without the ladder for 
stronger detection. Full-length lpp product size = 213 bp.   
 
These results suggest that Txe-His6 cleaves mRNA in vivo and that this 
ribonuclease activity leads to the protein synthesis inhibition observed upon induction of 
Txe-His6 expression in the macromolecular synthesis assays and cell-free protein 
synthesis assays.  On-going studies aim to determine the Txe-His6-specific cleavage sites 
in mRNA in vivo and if Txe-His6 requires mRNA to be associated with the ribosome to 
induce cleavage. 
 
5.4  CONCLUSIONS 
 The Axe-Txe TA system was first discovered on a multidrug-resistant plasmid, 
pRUM, in a vancomycin-resistant E. facium clinical isolate.  Preliminary analysis of Axe-
Txe demonstrated it functions as a characteristic TA system: expression of Txe is toxic to 
cells, expression of Axe alleviates Txe-induced toxicity, and Axe-Txe increases the 
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segregational stability of plasmids [9].  Due to the prevalence of the axe-txe genes 
encoded on plasmids in enterococcal isolates, activation of Txe presents an attractive 
antimicrobial strategy [16, 18].  However, a lack of biochemical characterization of the 
Axe-Txe proteins, including no knowledge of the biological target or mechanism of 
action of Txe, hampers exploration of Axe-Txe as an antimicrobial target.  Thus, the 
Axe-Txe TA system was selected for further investigation in hopes of better 
characterizing the Axe-Txe interaction and identifying the mechanism of toxicity of Txe.    
 This thesis research led to the successful expression and purification of the Axe 
and Txe proteins from separate constructs.  The Axe protein could be expressed at high 
yields with either an N- or C-terminal His6-tag in both E. coli BL21 (DE3) and Rosetta 
(DE3).  In contrast, the Txe protein could only be expressed with an N-terminal His6-tag 
in E. coli Rosetta (DE3).  Attempts to express Txe with Axe from a single operon 
resulted in nonsense mutations present in the txe sequence.  Thus, expression of the toxin 
may require provisions to be made for the occurrence of rare codons in the txe sequence, 
and N-terminal modifications of the protein may facilitate expression in the absence of 
the antitoxin.  
 With the ability to isolate the Axe and Txe proteins in good yield and high purity, 
it is now possible to generate antibodies to Axe and Txe.  RT-PCR analysis of six VRE 
clinical isolates showed that the axe-txe transcript is made; thus, antibodies could be used 
to verify that the Axe-Txe proteins are made in VRE as well.  In conjunction with more 
in-depth RT-PCR analysis, antibodies to Axe-Txe could help quantify the levels of Txe 
expressed in the cell under various growth stages and conditions. 
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 The biochemical characterization of the Axe-Txe system was approached from 
two directions:  the DNA-binding activity of Axe and the mechanism of action of Txe 
toxicity.  Unfortunately, DNA binding studies with Axe using EMSAs and PC biosensor 
technology failed to detect binding of the antitoxin to a 342 bp region directly upstream 
of the axe-txe genes on the pRUM sequence or to a 24 bp palindromic sequence 
contained within that region.  As mentioned earlier, it is possible that Axe, unlike most 
other antitoxins, does not bind the DNA sequence upstream of the toxin-antitoxin genes.  
However, further examination of the sequence upstream of the axe-txe genes to identify 
the operator-promoter region may be needed before resuming investigation of the DNA-
binding activity of Axe.  Futhermore, the addition of Txe in the DNA-binding assays and 
isolation of an untagged version of Axe may also be necessary. 
As mentioned throughout this chapter and Chapter 1, Txe shares significant 
sequence similarity with the YoeB toxin, which has been shown to inhibit protein 
synthesis through mRNA cleavage [9, 11].  Thus, it was hypothesized that mRNA 
cleavage may also be the biological target of Txe toxicity.  The results of the 
macromolecular synthesis assays and cell-free protein synthesis assays showed that, 
indeed, expression of Txe-His6 causes significant protein synthesis inhibition.  While in 
vitro assays with purified Txe-His6 failed to demonstrate any activity, assays in which the 
Txe-His6 protein was expressed provide the opportunity for future mutagenesis studies of 
the toxin.  Site-directed mutagenesis and alanine-scanning mutagenesis using the 
pET21a-txe-His6 construct could be performed and protein synthesis inhibition by the 
mutants could be assessed by the macromolecular synthesis assay or cell-free protein 
synthesis assay.  In this way, residues important for Txe toxicity could be identified.    
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Finally, the results of primer extension analysis suggest that Txe-His6 cleaves 
mRNA, which is characteristic of several toxins belonging to the RelE toxin superfamily, 
and is most likely the mechanism by which Txe causes protein synthesis inhibition (see 
Figure 5.21) [11].  Current studies aim to identify the Txe-His6-specific cleavage sites in 
mRNA in vivo using primer extension analysis and a DNA sequencing ladder.  It remains 
to be determined if Txe-His6 cleaves mRNA only when it is associated with the 
ribosome.  Since in vitro mRNA cleavage analysis with purified Txe-His6 did not detect 
any ribonuclease activity, in vivo primer extension analysis comparing cleavage patterns 
of a mRNA substrate with a functional or mutated start codon can be used to determine if 
Txe cleaves mRNA in vivo only when it is translated [3].  Additionally, future 
experiments may require further optimization of the purification of Axe and Txe such 
that Txe activity can be studied in vitro and the protein-protein interactions of the Axe-
Txe complex can be characterized.    
 
Figure 5.21  Three known mechanisms of action for toxins of TA systems. Representative toxins are 
shown in red. 
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5.5  MATERIALS AND METHODS 
Plasmids constructed.  To construct plasmid pACYCDuet1-His6-axe (clone #6), 
the axe gene was PCR-amplified from a plasmid DNA preparation of VRE isolate U275 
with primers axe-start-EcoRI, 5’GGG TGA ATT CAA TGG AAG CA3’ and axe-stop-
SalI, 5’TCA GAC TGC GAC TTA ATC ATC3’.  The PCR product was digested with 
EcoRI and SalI and inserted into pACYCDuet1 (Novagen) digested with EcoRI and SalI.  
His6-Axe is expressed from pACYCDuet1-His6-axe upon addition of IPTG to E. coli 
BL21 (DE3) or Rosetta (DE3).    
 To construct plasmid pET21a-axe-His6 (clone #1-4), the axe gene was amplified 
by PCR from pACYCDuet1-His6-axe plasmid DNA with primers axe-cterm-F1, 5’CCA 
GGA TCC GCA TAT GAT GGA AGC3’ and axe-XhoI-R, 5’CAA GCT CGA GGA CTT 
CAT CAT C3’.  The PCR product was digested with NdeI and XhoI and inserted into 
pET21a (Novagen) digested with NdeI and XhoI.  Axe-His6 is expressed from pET21a-
axe-His6 upon addition of IPTG to E. coli BL21 (DE3) or Rosetta (DE3).    
 To construct plasmid pET200-His6-txe, the txe gene was amplified by PCR from a 
plasmid DNA preparation of VRE isolate S34 with primers Nterminal-txe, 5’CAC CAT 
GAT TAA GGC TTG G3’ and Cterminal-txe, 5’TGG TTA ATA GTG ATC TTT TGC 
AGA3’.  The PCR product was cloned into pET200/D-TOPO with the Champion pET200 
Directional TOPO Expression Kit following the manufactuer’s instructions (Invitrogen).  
pET200-His6-txe encodes an N-terminal His6-tag fused to Txe but fails to express His6-
Txe upon addition of IPTG to E. coli BL21 (DE3) or Rosetta (DE3).     
To construct plasmid pBAD22-txe, the txe gene was amplified by PCR from a 
plasmid DNA preparation of  VRE isolate S226 with primers txe-start-EcoRI, 5’CGA 
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GGT TGA ATT CGA TGA TTA AG3’ and txe-stop-SalI, 5’ACT TCC GTC GAC TTA 
ATA GTG3’.  The PCR product was digested with EcoRI and SalI and inserted into 
pBAD22 (ATCC) digested with EcoRI and NdeI.  pBAD22-txe fails to express Txe upon 
addition of L-arabinose to E. coli TOP10 (Invitrogen).    
To construct plasmid pET28a-His6-txe, a codon-optimized version of the txe gene 
was amplified by PCR from a plasmid DNA preparation of E. coli DH10B carrying 
pJ201:txe-optimization-gene (as provided by DNA 2.0) with primers pJ201-txe-F, 5’GGT 
CGC GGA TCC GAA TTC ATG3’ and pJ201-txe-R, 5’TGG CGC CTC GAG GAA TTC 
TC3’.  The PCR product was digested with BamHI and XhoI and inserted into pET28a 
(Novagen) digested with BamHI and XhoI.  pET28a-His6-txe encodes an N-terminal His6-
tag fused to Txe but fails to express His6-Txe upon addition of IPTG to E. coli BL21 
(DE3) or Rosetta (DE3).    
To construct plasmid pET21a-txe-His6, the txe gene was amplified by PCR from 
pET200-His6-txe plasmid DNA with primers txe-NheI-F, 5’CAT CCC GCT AGC ATG 
ATT AAG G3’ and txe-XhoI-R, 5’CGC CCT CGA GTT CAT AGT G3’.  The PCR product 
was digested with NheI and XhoI and inserted into pET21a (Novagen) digested with NheI 
and XhoI.  His6-Txe is expressed from pET21a-txe-His6 upon addition of IPTG to E. coli 
Rosetta (DE3), but not to E. coli BL21 (DE3).    
To construct plasmid pET200-His6-axetxe, the axe-txe genes were amplified by 
PCR from a plasmid DNA preparation of VRE isolate S34 with primers Nterminal-axe, 
5’CAC CAT GGA AGC AGT AGC TTA T3’ and Cterminal-txe, 5’TGG TTA ATA GTG 
ATC TTT TGC AGA3’.  The PCR product was cloned into pET200/D-TOPO with the 
Champion pET200 Directional TOPO Expression Kit following the manufactuer’s 
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instructions (Invitrogen).  pET200-His6-axetxe encodes for an N-terminal His6-tag fused 
to Axe followed by an untagged Txe that contains a nonsense mutation. 
 To construct plasmid pET28a-His6-axetxe, the axe-txe genes were amplified by 
PCR from a plasmid DNA preparation of VRE isolate U275 with primers axe-NdeI-R, 
5’GAC TCG CAT ATG ATG GAA GCA GTA GC3’ and txe-HindIII-F, 5’GCA GTC 
AAG CTT CTT CCG ATT GG3’.  The PCR product was digested with NdeI and HindIII 
and inserted into pET28a (Novagen) digested with NdeI and HindIII.  pET28a-His6-
axetxe encodes an N-terminal His6-tag fused to Axe followed by an untagged Txe that 
contains a nonsense mutation. 
Axe Expression and Purification.  Expression of Axe-His6 and His6-Axe was 
performed in E. coli BL21 (DE3) cells.  A 15 mL overnight culture of BL21 (DE3) 
carrying pET21a-axe-His6 or pACYCDuet1-His6-axe was used to inoculate 1.5 L of LB 
containing ampicillin (100 µg/mL) or chloramphenicol (20 µg/mL), respectively, and 
shaken at 37°C until the OD600 was 0.4-0.6.  Expression was induced by addition of 0.5 
mM IPTG and further incubation with shaking at 37°C for 3 hours.  Cells were pelleted 
by centrifugation and stored at -80°C. 
Purification of Axe-His6 and His6-Axe under native conditions was carried out 
according to the QIAexpressionist protocol for batch purification of His6-tagged proteins 
(Qiagen).  The cell pellet was thawed on ice, resuspended in cold lysis buffer (50 mM 
Tris-HCl, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mg/mL lysozyme), and kept on ice 
for 30 minutes.  The cell suspension was lysed by pulsing sonication on ice for 5 minutes 
and then centrifuged (35,000 × g, 4°C) for 30 minutes.  The cleared cell lysate was mixed 
with 1 mL Ni-NTA agarose resin (Qiagen) at 4°C for 1 hour and then loaded onto an 
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empty column fitted with a bottom cap.  Once the Ni-NTA resin was loosely packed at 
the bottom of the column, the cap was removed and any material not bound to the Ni-
NTA resin was allowed to flow through.  The column was washed with 10 mL cold lysis 
buffer without lysozyme added followed by 10 mL cold wash buffer (50 mM Tris-HCl, 
pH 8.0, 300 mM NaCl, 20 mM imidazole).  To elute the His-tagged Axe protein, 10 mL 
cold elution buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 250 mM imidazole) was 
flowed over the column.  The eluate was collected and stored at 4°C.   
Purification of Axe-His6 and His6-Axe under denaturing conditions was carried 
out according to the QIAexpressionist protocol for batch purification of His6-tagged 
proteins (Qiagen) with some modifications.  The cell pellet was thawed on ice and 
resuspended in buffer B (100 mM Na2HPO4, 10 mM Tris-HCl, pH 8.0, 8 M urea).  The 
cell suspension was lysed by shaking at room temperature for 60 minutes and then 
centrifuged at 35,000 × g for 30 minutes.  The cleared cell lysate was mixed with 1 mL 
Ni-NTA agarose resin (Qiagen) at room temperature for 1 hour and then loaded onto an 
empty column fitted with a bottom cap.  Once the Ni-NTA resin was loosely packed at 
the bottom of the column, the cap was removed and any material not bound to the Ni-
NTA resin was allowed to flow through.  The column was washed with 10 mL buffer B 
followed by 10 mL denaturing buffer C (100 mM Na2HPO4, 10 mM Tris, pH 6.3, 8 M 
urea).  To elute the His-tagged Axe protein, 5 mL buffer D (100 mM Na2HPO4, 10 mM 
Tris, pH 5.9, 8 M urea) and 5 mL denaturing buffer E (100 mM Na2HPO4, 10 mM Tris, 
pH 4.5, 8 M urea) were flowed over the column.  The eluate was collected and stored at 
room temperature.   
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To refold His6-tagged Axe purified under denaturing conditions, a stepwise urea 
gradient was used as recommended in the QIAexpressionist handbook (Qiagen).  The pH 
of the denatured Axe eluate was adjusted to 8.0 and mixed with 1 mL Ni-NTA agarose 
resin at room temperature for 1 hour and then loaded onto an empty column fitted with a 
bottom cap.  Once the Ni-NTA resin was loosely packed at the bottom of the column, the 
cap was removed and any material not bound to the Ni-NTA resin was allowed to flow 
through.  The column was washed with an 8 M to zero urea gradient in 100 mM 
Na2HPO4, 10 mM Tris, pH 8.0, by flowing over 10 mL volumes of buffer decreasing by 
1 M urea each time.  Once the urea was removed, the column was washed in a manner 
identical to that used for native purifications with cold lysis, wash, and elution buffers.  
The eluate contained refolded His6-tagged Axe and was stored at 4°C.   
Purification of Axe-His6 and His6-Axe under native conditions by size-exclusion 
chromatograpy began by obtaining cleared cell lysate as described above for batch 
purification of His6-tagged Axe except that lysis buffer did not contain imidazole.  The 
cleared cell lysate was filtered by centrifugation at 4°C through an Amicon Ultra-4 
centrifugal filter device with a nominal molecular weight limit of 50 kDa (Millipore).   
The size-exclusion chromatography (SEC) column was prepared by first 
hydrating Bio-Gel P-100 media (Bio-Rad) in binding buffer (50 mM Tris-HCl, pH 8.0, 
300 mM NaCl) for 12-16 hours at room temperature.  After hydration was complete, the 
P-100 media was degassed on ice under vacuum for at least 30 minutes before pouring 
into a glass column with a 1 cm diameter.  A 12.5 cm bed was allowed to form and pack 
overnight at 4°C by gravity.  The column was equilibrated before use by passing 1.5 bed 
volumes of cold binding buffer by gravity flow (flow rate was approximately 0.03 
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mL/minute) at 4°C.  The buffer was allowed to drain down to the level of the gel bed 
before applying 1 mL of the filtered and cleared cell lysate sample onto the bed surface.  
The sample was allowed to drain into the bed and then was followed with 1.5 bed 
volumes of cold binding buffer.  Fractions were collected immediately after the sample 
was applied to the column in 1-1.5 mL volumes and analyzed by their absorbance at 220 
nm and by SDS-PAGE. 
Txe Expression and Purification.  Expression of Txe-His6 was performed in E. 
coli Rosetta (DE3) cells.  A 15 mL overnight culture of Rosetta (DE3) carrying pET21a-
txe-His6 was used to inoculate 1.5 L of LB containing ampicillin (100 µg/mL) and shaken 
at 37°C until the OD600 was 0.4-0.6.  Expression was induced by addition of 0.5 mM 
IPTG and further incubation with shaking at 37°C for 3  hours.  Cells were pelleted by 
centrifugation and stored at -80°C. 
Purification of Txe-His6 under denaturing or native conditions was carried out 
according to the QIAexpressionist protocol for batch purification of His6-tagged proteins 
(Qiagen) with the same modifications as described above for denaturing and native 
purification of His6-tagged Axe.  Purification of Txe-His6 under native conditions by 
size-exclusion chromatograpy was also carried out in a manner identical to that described 
above for the purification of His6-tagged Axe.  
Electrophoretic Mobility Shift Assays (EMSAs).  The DNA substrate for 
EMSAs was obtained by PCR from a plasmid DNA preparation of VRE isolate S177 
with primers Biotin-Promoter-PstI-F, 5’Biotin GGG TTA CTG CAG TGA AAG GAG 
AG3’ and Promoter-EcoRI-R, 5’CCT TTC ACC CCG AAT TCA TTT CTA3’.  This 
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substrate consisted of a 5’-biotinylated double-stranded 342 bp DNA fragment containing 
the sequence directly upstream of the axe-txe genes.   
Reactions were assembled with 0.1 nM of biotin-labeled DNA and 0, 2, 4 or 8 
µM His6-tagged Axe in binding buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM 
MgCl2, 1mM DTT, 1 mg herring sperm DNA, 2.5% glycerol) and incubated for 20 
minutes at room temperature.  Samples were electrophoresed on 7.5% native 
polyacrylamide gels in 0.5× Tris borate-EDTA (TBE) buffer at 80 V for 90 minutes at 
room temperature.  The DNA was transferred to positively charged nylon membranes by 
electroblotting at 45 V for 3 hours in cold 0.5× TBE buffer and immobilized onto the 
membrane by ultraviolet (254 nm) cross-linking for 1 minute.  Prior to probing, 
membranes were blocked with PBS containing 0.1% Tween-20 and 5% bovine serum 
albumin (BSA) overnight with gentle shaking at 4°C.  The next day, membranes were 
washed three times with PBS at room temperature and then probed with anti-biotin HRP-
conjugated antibody (Cell Signaling Technology) at a 1:2000 dilution in PBS containing 
0.1% Tween-20 and 5% BSA.  Antibody binding was detected with Supersignal West 
Pico Chemiluminescent substrate according to the manufacturer’s instruction (Pierce), 
followed by exposure to autoradiography film, and developed using a Future 2000 K 
automatic x-ray film processor (Fisher Scientific).    
PC Biosensor Analysis of DNA binding.  The DNA substrates consisted of a 5’-
biotinylated double-stranded 24 bp DNA fragment containing an imperfect palindrome 
found directly upstream of the axe-txe genes and the 5’-biotinylated double-stranded 342 
bp DNA fragment used for EMSAs described above.  The 24 bp DNA fragment was 
obtained by PCR from a plasmid DNA preparation of VRE isolate S177 with primers 
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biotin-axe-palindrome-F, 5’Biotin GCT TAA TTG TAC AAT ATA ATG TAC AAT 
TGT TT3’ and axe-palindrome-R, 5’AAA CAA TTG TAC ATT ATA TTG TAC AAT 
TAA GC3’. 
To prepare the 384-well PC biosensor plate for biotin-labeled DNA binding, 
individual wells were washed five times with 40 µL assay buffer (10 mM HEPES, pH 
7.4, 150 mM NaCl, 20 µM EDTA, 0.005% Tween-20).  Wells were then incubated with 
1 µM of the 342 bp or 24 bp DNA fragments in assay buffer or assay buffer with no 
DNA overnight at 4°C.  The next day, the wells were washed with assay buffer three 
times before adding either 8 µM His6-Axe in PBS, pH 7.4 with 10 mM BME or buffer 
alone and incubating at room temperature for 20 minutes.  Wells were again washed with 
assay buffer three times and the PWV shift measured with a BIND plate reader (SRU 
Biosystems).     
Macromolecular Synthesis Assays.  For each strain tested, a 5 mL overnight 
culture grown in LB with 100 µg/mL ampicillin was used to seed 10 mL filter-sterilized 
M9 broth (42 mM Na2HPO4, 24 mM KH2PO4, 9 mM NaCl, 19 mM NH4Cl, 0.5% 
glucose, 1% casamino acids) and shaken at 37°C until the OD600 was 0.3.  To measure 
protein synthesis, [3H]-leucine (L-[3, 4, 5-3H(N)]-Leucine, PerkinElmer) was added to 
the 10 mL culture at a final concentration of 2 µCi/mL and shaken at 37°C for 5 minutes.  
To measure DNA synthesis, [3H]-thymidine ([6-3H]-Thymidine, PerkinElmer) was added 
to the the 10 mL culture at a final concentration of 0.1 µCi/mL and shaken at 37°C for 1 
minute.  To measure RNA synthesis, [3H]-uridine ([5,6-3H]-Uridine, PerkinElmer) was 
added to the the 10 mL culture at a final concentration of 0.1 µCi/mL and shaken at 37°C 
for 1 minute.   
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Before inducing expression, 0.5 mL was taken from the culture and added to 1 
mL cold 15% trichloroacetic acid (TCA), inverted once, and placed on ice for at least 30 
minutes to TCA-precipitate all macromolecules in the cell.  The remaining culture was 
split into two separate tubes; one tube received 0.05 mM IPTG and the other received no 
IPTG.  The cultures were returned to shaking at 37°C and 0.5 mL aliquots were TCA-
precipitated, as above, at 60, 120 and 180 minutes after IPTG was added.  After 30 
minutes on ice, precipitates were filtered on a glass microfiber disk (Whatman or Fisher 
Scientific), washed twice by filtering 1 mL cold 100% ethanol over the disk, and then 
allowed to dry overnight.  Disks were placed in 5 mL ScintiSafe Econo 1 scintillation 
fluid (Fisher Scientific) and the counts per minute (cpm) were measured on a LS 6500 
Multi-Purpose Scintillation Counter (Beckman Coulter).   
P-values were calculated in Microsoft Excel with results from three or more 
independent experiments. Each timepoint for each strain was evaluated using the TTEST 
function: array 1 was the cpm values measured for the strain with no IPTG added, array 2 
was the cpm values measured for the strain with 0.05 mM IPTG added, “tails” was set to 
2 for a two-tailed distribution, and “type” was set to 2 for a two-sample equal variance 
(homoscedastic) t-test.  
Cell-Free Protein Synthesis Assays.  The S30 T7 High-Yield Protein Expression 
System (Promega) was used for cell-free protein synthesis according to the 
manufacturer’s protocol with some modifications.  Before the DNA template was added, 
reactions were set up with 10 µL S30 Premix Plus, 9 µL T7 S30 Extract, and the protein 
or construct to be tested and shaken at 37°C for 20 minutes.  Proteins tested included up 
to 190 pmoles Txe-His6 or Axe-His6 in 50 mM Tris-HCl, pH 8.0, 300 mM NaCl.  
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Constructs tested included 100 ng pET21-txe-His6, 100 ng pET21a-axe-His6, and 50 ng 
pACYCDuet1-His6-axe in 10 mM Tris-HCl, pH 7.5.  Controls for inhibited and 
uninhibited protein synthesis received an equal volume of buffer instead of the protein or 
construct tested.  After the initial 20 minute incubation, 300 ng of DNA template 
(pET28a-relB-His6 or pRSF1b-His6-lpp) and 10 mM Tris-HCl, pH 8.0 to 25 µL total was 
added and shaken at 37°C for 1 hour.  (No template DNA was added to the control for 
inhibited protein synthesis.)  Reactions were stopped by placing the tubes on ice for 5 
minutes, followed by the addition of 1 µg RNase A to each tube and incubating at room 
temperature for 5 minutes.   
 Next, TCA precipitation was used to isolate protein from each reaction.  Sample 
volumes were increased to 100 µL with dH2O and 100 µL cold 10% TCA was added.  
Samples were vortexed vigorously and kept on ice for 20 minutes before centrifuging at 
maximum speed for 15 minutes at room temperature.  Pellets were washed with 100 µL 
cold 100% ethanol, centrifuged at maximum speed for 5 minutes at room temperature, 
and allowed to air-dry.  Pellets were resuspended in 30 µL 50 mM Tris-HCl, pH 8.0, 300 
mM NaCl and 20 µL 6x SDS loading dye and heated at 95°C for 5 minutes.  For each 
sample, the entire volume was run on a 15% polyacyrlamide Tris-HCl precast gel (Bio-
Rad) for approximately 1.25 hours at 120V.  After SDS-PAGE, proteins were transferred 
to an Immobilon-P PVDF membrane (Millipore) in cold Towbin Transfer buffer as 
described in Section 2.7 of Chapter 2.  Before probing, membranes were blocked with 
PBS containing 5% BSA and 0.05% Tween-20 overnight with gentle shaking at 4°C.  
Membranes were probed with HisProbe-HRP (Pierce) at 1 µg/mL in PBS with 0.05% 
Tween-20 for 1 hour at room temperature.  Antibody binding was detected with 
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Supersignal West Pico Chemiluminescent substrate (Pierce), followed by exposure to 
autoradiography film, and developed using a Future 2000 K automatic x-ray film 
processor (Fisher Scientific).  
Gyrase Cleavage Assay.  Cleavage reactions contained 1 µg supercoiled pBR322 
plasmid DNA, 2.5 U E. coli DNA gyrase (New England Biolabs or Inspiralis), 5× assay 
buffer (35 mM Tris-HCl, pH 7.5, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.75 mM ATP, 
5 mM spermidine, 0.1 mg/mL BSA, 6.5% glyercol), and 1 µg Txe-His6 or 25 µM 
ciprofloxacin in 30 µL total volumes.  Additionally, 1 µg supercoiled pBR322 plasmid 
DNA was added to 5× assay buffer with or without 2.5 U E. coli DNA gyrase, and dH2O 
to 30 µL.  All samples were incubated at 37°C for 1 hour, followed by the addition of 0.6 
µL 10% SDS and 0.3 µL 10 mg/mL proteinase K and incubated again at 37°C for 1 hour.  
Reactions were stopped by adding 3 µL 0.5 mM EDTA.  Plasmid DNA was isolated 
using the QIAquick PCR Purification Kit (Qiagen) before analyzing samples by 1% 
agarose gel electrophoresis and staining with ethidium bromide. 
In vitro mRNA Cleavage Assay.  mRNA substrates were synthesized using the 
Maxiscript T7 in vitro transcription kit (Ambion) according to the manufacturer’s 
protocol.  Transcription reactions contained 1 µg plasmid DNA substrate (pTRI-Actin-
Mouse supplied with the kit or pGEM3z-lpp [3]), 0.5 mM dNTPs, 10× transcription 
buffer, 30 U T7 RNA polymerase, and dH2O to 30 µL.  Reactions were incubated at 37°C 
for 1 hour, followed by the addition of 2 U TURBO DNase and incubated again at 37°C 
for 30 minutes. 
 To assay for Txe-induced mRNA cleavage, 15-50 pmoles of Txe-His6 in 50 mM 
Tris-HCl, pH 8.0, 300 mM NaCl or buffer alone were added to the in vitro transcribed 
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mRNA samples and incubated at 37°C for 2 hours.  RNA was isolated using the RNeasy 
RNA cleanup kit (Qiagen) and eluted with dH2O.  An equal volume of 2× acrylamide gel 
loading buffer (95% formamide, 18 mM EDTA, 0.025% SDS, 0.025% bromophenol 
blue) was added to each sample and heated at 95°C for 3 minutes.  Samples were 
electrophoresed on 5% polyacrylamide TBE-urea precast gels (Bio-Rad) in 1× TBE 
buffer at 120 V.  To detect RNA, gels were stained with ethidium bromide. 
RNA Extraction and RT-PCR Analysis.  Total RNA from enterococci was 
isolated in a manner identical to the extraction method described in Chapter 2 [16].  
Intragenic primers used for axe-txe RT-PCR analysis were designed from the sequence of 
the plasmid pRUM.  The primers used were axe-txe-RT-F, 5’CAG TAG CTT ATT CAA 
ATT TCC GCC3’ and axe-txe-RT-R, 5’GTT CAT CTG TAA TTC TTC TGG ACC3’.  
Control primers were based on the tuf gene specific to enterococcal species [7].  The 
primers used were Ent-tuf F, 5’TAC TGA CAA ACC ATT CAT GAT G3’ and Ent-tuf R, 
5’AAC TTC GTC ACC AAC GCG AAC3’.  RT-PCR and PCR for DNA contamination 
were performed using the SuperScript One-Step RT-PCR with Platinum Taq kit 
(Invitrogen) as described in Chapter 2 [16].  RT-PCR amplification products were 
analyzed by agarose gel electrophoresis in 1% agarose and stained with ethidium 
bromide.   
Primer Extension Analysis.  Primer lpp 21 (5’CTG AAC GTC AGA AGA CAG 
CTG ATC G3’) [4] was 5’-end-labeled with [γ-32P]ATP according to a previously 
reported protocol with some modifications [13].  In a 10 µL reaction volume, 10 pmoles 
of the lpp 21 primer was mixed with 1 µL 10× T4 polynucleotide kinase (PNK) reaction 
buffer (NEB), 1 µL 10 U/mL T4 PNK (NEB), and 3 µL [γ-32P]ATP (6000 Ci/mmol, 10 
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mCi/mL, or adjusted appropriately for decay).  The reaction mixture was incubated at 
37°C for 30 minutes followed by 2 minutes at 90°C to inactivate the enzyme.  The 
volume of the reaction was increased to 50 µL with RNase-free dH2O and unincorporated 
nucleotides were removed with a NucAway Spin column according to the manufacturer’s 
directions (Ambion).  The final concentration of the end-labeled primer was adjusted to 
100 fmol/µL by adding more RNase-free dH2O.  To 5’-end-label the Low Molecular 
Weight DNA ladder (NEB) with [γ-32P]ATP, the same reaction method was used with 1 
µg of ladder in a 20 µL reaction volume.  After labeling, the reaction mixture was not 
cleaned up and 30 µL Stop Solution (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol FF) (Affymetrix) and 40 µL dH2O were added. 
 E. coli Rosetta (DE3) carrying plasmids pET21-txe-His6 and pRSF1b-lpp-His6 
was grown in LB containing 100 µg/mL ampicillin and 50 µg/mL kanamycin to an OD600 
of 0.3.  Before adding 0.5 mM IPTG, a 1 mL aliquot was taken, centrifuged for 5 minutes 
at room temperature and the pellet frozen at -80°C.  Following addition of IPTG, 1 mL 
aliquots were also taken at 30, 60, and 120 minutes post-induction and the pellets frozen 
at -80°C.  RNA was extracted using the RNeasy Mini Kit for Isolation of Total RNA 
from Bacteria and treated with RNase-Free DNase (Qiagen).  The 32P-labeled lpp 21 
primer was hybridized with 5 µg total RNA from each timepoint according to a 
previously reported protocol with some modifications [13].  In a 20 µL reaction volume, 
5 µg total RNA, 100 fmoles 32P-labeled lpp 21 primer, 2 µL 10× Avian Myeloblastosis 
Virus Reverse Transcriptase (AMV RT) reaction buffer (NEB), and 2 µL 10× dNTP 
solution (10 mM each dNTP) were added together.  The reaction mixture was heated at 
90°C for 2 minutes and then incubated at 58°C overnight (18-20 hours). 
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 The next day, 10 µL of a primer extension mastermix (consisting of 3 µL 10× 
AMV RT reaction buffer, 3 µL 10× dNTP solution, 2.1 µL 40 mM sodium 
pyrophosphate, 0.9 µL dH20, and 1 µL 10U/µL AMV RT) was added to each 
hybridization reaction, mixed gently, and incubated at 42°C for 1 hour.  Each reaction 
then received 1 µL 10 mg/mL RNase A and was incubated at 37°C for 30 minutes.  After 
RNase A treatment, reaction volumes were increased to 100 µL with dH2O and extracted 
twice with phenol/chloroform/isoamyl alcohol.  DNA was precipitated by adding 0.1 
volumes 3M sodium acetate, pH 5.5, and 2.5 volumes 70% ethanol and incubating at -
80°C for 30 minutes.  The DNA precipitation was centrifuged at room temperature for 15 
minutes, washed with 70% ethanol and centrifuged again at room temperature for 5 
minutes.  The DNA pellet was allowed to air-dry before resuspending in 10 µL Stop 
Solution. 
 Gel analysis was performed with a 10% polyacrylamide TBE-urea precast Ready 
gel (Bio-Rad).  The gel was pre-electrophoresed at 100 V in 1× TBE buffer for 30 
minutes.  Primer extension samples and the 32P-labeled ladder were heated at 90°C for 5 
minutes before loading 5 µL of each primer extension sample and 2 µL of the ladder onto 
the gel.  The gel was run at 100 V for approximately 1 hour and then rinsed in 100 mL 
15% MeOH/5% acetic acid before drying under vacuum on a Model 583 gel dryer (Bio-
Rad) at 80°C for 35 minutes.  The gel was cooled before exposing to a storage phosphor 
screen cassette (Molecular Dynamics) at room temperature overnight.  Primer extension 
products and the ladder were detected using the Storm PhosphorImager (Molecular 
Dyanmics/GE Lifesciences).     
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CHAPTER 6 
CONCLUSIONS 
 
6.1  CONCLUSIONS 
Many antibiotics in clinical use today exploit only a handful of biological targets, 
such as the ribosome, DNA gyrase, and macromolecules involved in cell wall synthesis 
[21].  This is, in part, because the majority of antibiotics approved in the last twenty years 
are derivatives of existing antibiotic scaffolds.  As drug resistance to all classes of 
antibiotics continues to increase, the need for new antibacterial targets and novel classes 
of antibiotics becomes greater.  In the search for new targets, such as those involving 
virulence and plasmid-based gene products, exploitation of toxin-antitoxin (TA) systems 
are also being considered as a novel antimicrobial strategy [1, 2, 5, 6, 8, 10, 12, 19, 20, 
22].  TA systems are a potentially attractive target for antibacterial therapy because 
artificial disturbance of the TA interaction could allow the freed toxin to kill the bacterial 
cell.  However, the identity and prevalence of TA systems in pathogenic bacteria must be 
defined before TA systems can be realized as a novel opportunity for antibacterial 
therapy.  Thus, this thesis research aimed, in part, to validate TA systems as an 
antimicrobial target by determining the prevalence of genes for TA systems in VRE and 
MRSA clinical isolates.   
As discussed in Chapter 2, a PCR-based survey was performed to define the 
presence of TA systems on plasmids isolated from VRE strains obtained from 75 
different patients.  Two major findings of the survey were that genes encoding TA 
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systems are ubiquitous in plasmids isolated from VRE and that, in particular, the genes 
for the mazEF, axe-txe, relBE, and ω−ε−ζ TA systems are common in plasmids from 
VRE isolates.  RT-PCR analysis performed with 10 of the isolates positive for the mazEF 
genes by PCR revealed that the mazEF transcript is made.  Additionally, the results of 
plasmid stability assays with the mazEF loci from VRE suggest that mazEF is capable of 
acting as a functional TA system in enterococci [14, 17].   
Analysis of the flanking regions of several axe-txe and mazEF genes from the 
VRE isolates revealed the surrounding sequence to match that of plasmid pRUM, on 
which axe-txe was first discovered.  Interestingly, another recent PCR-based survey of 93 
E. faecium strains reported a genetic linkage between pRUM-replicon type plasmids and 
the axe-txe genes [16].  Thus, the axe-txe genes may be an important feature of pRUM-
like plasmids in enterococci and may contribute to the stability and persistence of 
plasmid-encoded multidrug resistance in enterococcal isolates.  
To determine if other pathogenic bacteria harbor the genes for TA systems, a 
PCR-based survey was also performed with 78 MRSA clinical isolates (see Chapter 3).  
In the collection of MRSA strains, it was discovered that the mazEFSa genes were present 
in all isolates and that the mazEFSa transcript was made in nine isolates analyzed by RT-
PCR.  Further PCR analysis of the regions flanking the mazEFSa genes revealed that the 
mazEFSa loci is located on the chromosome between the rbsU and alr genes in all of the 
MRSA isolates.  Sequence analysis of the flanking regions from 8 of the MRSA isolates 
showed the surrounding sequence to match the sequences flanking the mazEFSa genes in 
16 S. aureus genomes in the NCBI database.    Although the role of chromosomally-
encoded TA systems remains unclear, recent work on the MazEFSa system showed it to 
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be co-transcribed with the alternative transcription factor, σΒ, under certain stress 
conditions [7, 9, 18].  Thus, the discovery that the genes for the MazEFSa TA system are 
prevalent in MRSA and possibly linked to the stress-response system in staphylococci 
supports further investigation of this TA system as a novel S. aureus-specific 
antibacterial strategy.  
This thesis project also further investigated two of the TA systems found to be 
prevalent in the VRE and MRSA strains surveyed, RelBE and Axe-Txe.  As described in 
Chapter 4, a cell-based high-throughput screen was developed to identify small molecules 
that could cause RelE-dependent cell death in E. coli expressing RelBE-His6.  After 
testing approximately 165,000 compounds in the screen, 3 compounds appeared to 
selectively inhibit the growth of the RelBE-expressing strain compared to the vector-only 
strain.  However, a battery of secondary assays determined that the three hit compounds 
either did not induce RelE-dependent cell death or had very low potency that could not be 
improved by derivatization. 
Due to the difficulty encountered with identifying small molecules that cause 
growth inhibition in a RelE-dependent manner, efforts have been refocused on peptide 
fragment analysis of RelBE.   It is hoped that by evaluating peptides spanning the RelB 
and RelE protein sequences, key residues or segments of the RelBE complex will be 
identified.  A better understanding of the minimal interactions of the RelBE TA system 
may lead to the identification of peptidic disruptors of the RelBE complex and, possibly, 
facilitate a more targeted approach to identify small molecules that can activate RelE, 
inducing bacterial cell death.  
 
291 
 
The second TA system investigated as part of this thesis project was Axe-Txe, the 
genes for which were found to be particularly prevalent and transcribed in the collection 
of VRE isolates.  As discussed in Chapter 5, the mechanism of action of Txe was 
unknown and the interactions of the Axe-Txe system poorly understood.  Thus, efforts 
were focused on isolating and characterizing the Axe-Txe system. 
Two approaches were pursued in the biochemical characterization of the Axe-Txe 
system:  the DNA-binding activity of Axe and the mechanism of action of Txe toxicity.  
DNA binding studies performed with purified Axe using EMSAs and PC biosensor 
technology failed to detect binding of the antitoxin to DNA sequences encoded directly 
upstream of the axe-txe genes on pRUM.  Additionally, in vitro assays to detect Axe-Txe 
complex formation were unsuccessful.  Thus, further optimization of the isolation and 
assay conditions for the purified proteins will be necessary to characterize the Axe-Txe 
system in vitro.  
To identify the biological process targeted by Txe, macromolecular synthesis 
assays were performed to evaluate the toxin’s effect on global biosynthetic pathways in 
the cell.  Txe shares significant sequence similarity with the YoeB toxin, which has been 
shown to inhibit protein synthesis through mRNA cleavage; therefore, it was 
hypothesized that Txe also inhibited protein sythesis [11, 13].  As expected, the results of 
the macromolecular synthesis assays showed that expression of Txe-His6 caused 
significant protein synthesis inhibition.  In agreement with these results, expression of 
Txe-His6 also potently inhibited protein synthesis in a cell-free protein synthesis assay.  
The results of primer extension analysis suggest that the mechanism by which Txe 
inhibits protein synthesis involves mRNA cleavage, a mechanism of action employed by 
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toxins from several other TA systems [3, 4, 11, 13, 15, 23].  Ongoing studies aim to 
identify the Txe-His6-specific cleavage sites in mRNA and to determine if Txe-His6 
cleaves mRNA only when it is associated with the ribosome.         
In summary, this thesis project defined the prevalence of the genes for TA 
systems in two clinically important bacterial pathogens, VRE and MRSA.  Furthermore, 
a high-throughput cell-based screen was developed to identify small molecules that cause 
RelE-dependent cell death and peptide fragment analysis of RelBE was begun.  Finally, 
further characterization of the biochemistry of the Axe-Txe system was performed and 
the mechanism of action of Txe determined.  A better understanding of the TA systems 
most prevalent in pathogenic bacteria and the development of a high-throughput 
screening method accomplished by this thesis research will facilitate the validation of TA 
systems as novel antimicrobial targets and enable the identification of molecules capable 
of toxin activation. 
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